International Cancer Genome Consortium
Us Cohort
Powered by SNPnexus
Overview
Help
Sex
Survival Status
Age at Diagnosis
Loading...
Cancer Genome Interpreter (CGI) help
| Gene | Protein Alteration | Alteration Match | Drug | Effect | Tumour | Evidence |
|---|---|---|---|---|---|---|
| PIK3CA | PIK3CA MUT (H1047R) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (H1047R) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (H1047R) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (H1047R) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (H1047R) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (H1047R) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (H1047R) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| NTRK1 | NTRK1 MUT* (P695P) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Case report |
| NTRK1 | NTRK1 MUT* (P695P) | Different Alteration | Pan-TKR inhibitor | Responsive | CANCER | Early trials |
| NTRK1 | NTRK1 MUT* (P695P) | Different Alteration | Pan-TK inhibitor | Responsive | LUAD | Pre-clinical |
| NTRK1 | NTRK1 MUT* (P695P) | Different Alteration | Pan-TK inhibitor | Responsive | COREAD | Case report |
| KRAS | KRAS MUT (G12V) | Complete Match | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | FDA guidelines |
| KRAS | KRAS MUT (G12V) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | FDA guidelines |
| KRAS | KRAS MUT (G12V) | Different Mutation | Cetuximab (EGFR mAb inhibitor) | No Responsive | COREAD | Late trials |
| KRAS | KRAS MUT (G12V) | Complete Match | MEK inhibitor | Responsive | ALL | Pre-clinical |
| KRAS | KRAS MUT (G12V) | Complete Match | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Resistant | GIST | Case report |
| KRAS | KRAS MUT (G12V) | Complete Match | MEK inhibitor | Responsive | OV, CER, AML | Pre-clinical |
| KRAS | KRAS MUT (G12V) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Responsive | L | Early trials |
| KRAS | KRAS MUT (G12V) | Complete Match | MEK inhibitor;PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | KRAS MUT (G12V) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | NCCN guidelines |
| KRAS | KRAS MUT (G12V) | Complete Match | Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) | Responsive | HC | Early trials |
| KRAS | KRAS MUT (G12V) | Complete Match | EGFR inhibitor | Resistant | L | NCCN guidelines |
| KRAS | KRAS MUT (G12V) | Complete Match | CDK4 inhibitor | Responsive | L | Pre-clinical |
| KRAS | KRAS MUT (G12V) | Complete Match | Selumetinib (MEK inhibitor) | Responsive | NSCLC | Early trials |
| KRAS | KRAS MUT (G12V) | Complete Match | BET inhibitor | Responsive | L | Pre-clinical |
| KRAS | KRAS MUT (G12V) | Complete Match | Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) | Responsive | OV | Pre-clinical |
| KRAS | KRAS MUT (G12V) | Complete Match | FAK inhibitor | Responsive | L | Pre-clinical |
| KRAS | KRAS MUT (G12V) | Complete Match | EGFR inhibitor | Resistant | NSCLC | Pre-clinical |
| KRAS | KRAS MUT (G12V) | Complete Match | EZH2 inhibitor | Resistant | CANCER | Pre-clinical |
| KRAS | KRAS MUT (G12V) | Complete Match | MEK inhibitor | Responsive | BT, L | Early trials |
| KRAS | KRAS MUT (G12V) | Complete Match | MEK inhibitor;IGF1R inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | KRAS MUT (G12V) | Complete Match | MTOR inhibitor;BH3 mimetics | Responsive | COREAD | Pre-clinical |
| KRAS | KRAS MUT (G12V) | Complete Match | EGFR mAb inhibitor;MEK inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | KRAS MUT (G12V) | Complete Match | pan-RAF inhibitor | Responsive | ED | Case report |
| KRAS | KRAS MUT (G12V) | Complete Match | EGFR mAb inhibitor | Resistant | ST | Pre-clinical |
| KRAS | KRAS MUT (G12V) | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | L | Early trials |
| KRAS | KRAS MUT (G12V) | Complete Match | Selumetinib (MEK inhibitor) | No Responsive | L | Early trials |
| KRAS | KRAS MUT (G12V) | Complete Match | CDK4/6 inhibitor;MEK inhibitor | Responsive | L | Early trials |
| KRAS | KRAS MUT (G12V) | Complete Match | Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) | Responsive | LUAD | Pre-clinical |
| KRAS | KRAS MUT (G12V) | Complete Match | Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) | Resistant | COREAD | Late trials |
| KRAS | KRAS MUT (G12V) | Complete Match | pan-RAF inhibitor | Responsive | L | Early trials |
| KRAS | KRAS MUT (G12V) | Complete Match | JAK/TBK1/IKKε inhibitor | Responsive | L | Pre-clinical |
| KRAS | KRAS MUT (G12V) | Complete Match | FAS inhibitor | Responsive | L | Case report |
| KRAS | KRAS MUT (G12V) | Complete Match | HSP90 inhibitor | Responsive | L | Pre-clinical |
| KRAS | KRAS MUT (G12V) | Complete Match | ERK inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | KRAS MUT (G12V) | Complete Match | PI3K pathway inhibitor;MEK inhibitor | No Responsive | PA | Early trials |
| KRAS | KRAS MUT (G12V) | Complete Match | MEK inhibitor;BCL-XL inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | KRAS MUT (G12V) | Complete Match | Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) | Responsive | PA | Early trials |
| KRAS | KRAS MUT (G12V) | Complete Match | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | NCCN guidelines |
| KRAS | KRAS MUT (G12V) | Complete Match | PI3K pathway inhibitor | Resistant | ED | Pre-clinical |
| KRAS | KRAS MUT (G12V) | Complete Match | CDK4/6 inhibitor;MEK inhibitor | Responsive | CESC | Pre-clinical |
| KRAS | KRAS MUT (G12V) | Different Alteration | BRAF inhibitor;MEK inhibitor | Resistant | COREAD | Case report |
| KRAS | KRAS MUT (G12V) | Different Alteration | BRAF inhibitor;EGFR mAb inhibitor | Resistant | COREAD | Case report |
| TP53 | TP53 MUT (R175H) | Complete Match | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (R175H) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (R175H) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (R175H) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (R175H) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (R175H) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (R175H) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R175H) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R175H) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (R175H) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (R175H) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R175H) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (R175H) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (R175H) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (R175H) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| PIK3CA | PIK3CA MUT (E545A) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (E545A) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (E545A) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (E545A) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (E545A) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (E545A) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (E545A) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (E545A) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (E545A) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (E545A) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (E545A) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (E545A) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (E545A) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (E545A) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| FGFR2 | FGFR2 MUT (N550K) | Different Alteration | FGFR inhibitor | Resistant | CH | Early trials |
| FGFR2 | FGFR2 MUT (N550K) | Different Mutation | FGFR inhibitor | Responsive | LUSC | Pre-clinical |
| FGFR2 | FGFR2 MUT (N550K) | Complete Match | Dovitinib (FGFR inhibitor) | Resistant | ED | Pre-clinical |
| FGFR2 | FGFR2 MUT (N550K) | Complete Match | Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) | Responsive | ED | Pre-clinical |
| FGFR2 | FGFR2 MUT (N550K) | Complete Match | FGFR inhibitor | Responsive | ED | Pre-clinical |
| FGFR2 | FGFR2 MUT (N550K) | Different Mutation | FGFR inhibitor | Responsive | L | Pre-clinical |
| FGFR2 | FGFR2 MUT (N550K) | Different Mutation | FGFR inhibitor | Responsive | ED | Pre-clinical |
| FGFR2 | FGFR2 MUT (N550K) | Different Mutation | FGFR inhibitor | Responsive | BT | Case report |
| FGFR2 | FGFR2 MUT (N550K) | Different Alteration | FGFR inhibitor | Responsive | ST | Early trials |
| FGFR2 | FGFR2 MUT (N550K) | Different Alteration | FGFR inhibitor | Responsive | BRCA | Case report |
| FGFR2 | FGFR2 MUT (N550K) | Different Alteration | FGFR inhibitor | Responsive | COREAD | Early trials |
| FGFR2 | FGFR2 MUT (N550K) | Different Alteration | FGFR inhibitor | Responsive | BT | Early trials |
| TP53 | TP53 MUT (splice_acceptor_variant) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (splice_acceptor_variant) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (splice_acceptor_variant) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (splice_acceptor_variant) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (splice_acceptor_variant) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (splice_acceptor_variant) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (splice_acceptor_variant) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (splice_acceptor_variant) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (splice_acceptor_variant) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (splice_acceptor_variant) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (splice_acceptor_variant) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (splice_acceptor_variant) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (splice_acceptor_variant) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (splice_acceptor_variant) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (splice_acceptor_variant) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| NTRK3 | NTRK3 MUT* (L827F) | Different Alteration | IGF1R inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK3 | NTRK3 MUT* (L827F) | Different Alteration | PI3K pathway inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK3 | NTRK3 MUT* (L827F) | Different Alteration | Midostaurin (Pan-TK inhibitor) | Responsive | BRCA | Pre-clinical |
| ROS1 | ROS1 MUT* (T1735T) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | IM | Case report |
| ROS1 | ROS1 MUT* (T1735T) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ROS1 | ROS1 MUT* (T1735T) | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Case report |
| ROS1 | ROS1 MUT* (T1735T) | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Pre-clinical |
| ROS1 | ROS1 MUT* (T1735T) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Early trials |
| AKT1 | AKT1 MUT (E17K) | Complete Match | BRAF inhibitor | Resistant | CM | Case report |
| AKT1 | AKT1 MUT (E17K) | Complete Match | allosteric AKT inhibitor | Responsive | CANCER | Early trials |
| AKT1 | AKT1 MUT (E17K) | Complete Match | non-allosteric AKT inhibitor | Responsive | CANCER | Early trials |
| AKT1 | AKT1 MUT (E17K) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| AKT1 | AKT1 MUT (E17K) | Complete Match | Temsirolimus (MTOR inhibitor) | Responsive | ED | Early trials |
| AKT1 | AKT1 MUT (E17K) | Complete Match | AKT inhibitor | Responsive | CANCER | Pre-clinical |
| AKT1 | AKT1 MUT (E17K) | Different Mutation | Everolimus (MTOR inhibitor) | Responsive | FH | Case report |
| ERBB2 | ERBB2 MUT (V777L) | Different Alteration | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | ERBB2 MUT (V777L) | Different Alteration | Lapatinib (ERBB2 inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | ERBB2 MUT (V777L) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | ST, BRCA, GEJA | FDA guidelines |
| ERBB2 | ERBB2 MUT (V777L) | Different Alteration | Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | ERBB2 MUT (V777L) | Different Alteration | MK2206;Trastuzumab (allosteric AKT inhibitor;ERBB2 mAb inhibitor) | Responsive | SOLID | Early trials |
| ERBB2 | ERBB2 MUT (V777L) | Complete Match | Lapatinib (ERBB2 inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (V777L) | Complete Match | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (V777L) | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | CANCER, BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (V777L) | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | CANCER | Early trials |
| ERBB2 | ERBB2 MUT (V777L) | Complete Match | Neratinib (ERBB2 inhibitor) | Responsive | CANCER | Early trials |
| ERBB2 | ERBB2 MUT (V777L) | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Case report |
| ERBB2 | ERBB2 MUT (V777L) | Different Mutation | Lapatinib (ERBB2 inhibitor) | Responsive | BRCA, LUAD | Case report |
| ERBB2 | ERBB2 MUT (V777L) | Different Mutation | Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) | Responsive | L | Early trials |
| ERBB2 | ERBB2 MUT (V777L) | Different Mutation | Neratinib (ERBB2 inhibitor) | Resistant | BRCA | Case report |
| ERBB2 | ERBB2 MUT (V777L) | Different Mutation | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (V777L) | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | LUAD | Case report |
| ERBB2 | ERBB2 MUT (V777L) | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (V777L) | Different Mutation | Lapatinib (ERBB2 inhibitor) | Resistant | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (V777L) | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | CANCER | Pre-clinical |
| ERBB2 | ERBB2 MUT (V777L) | Complete Match | Temsirolimus (MTOR inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (V777L) | Complete Match | Dacomitinib (Pan ERBB inhibitor) | Responsive | NSCLC | Early trials |
| ERBB2 | ERBB2 MUT (V777L) | Complete Match | Neratinib (ERBB2 inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (V777L) | Different Mutation | ERBB2 inhibitor | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (V777L) | Different Mutation | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (V777L) | Different Mutation | ERBB2 mAb inhibitor | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (V777L) | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (V777L) | Different Mutation | Lapatinib (ERBB2 inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (V777L) | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (V777L) | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BRCA | Late trials |
| ERBB2 | ERBB2 MUT (V777L) | Different Alteration | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | BT | Early trials |
| ERBB2 | ERBB2 MUT (V777L) | Different Alteration | Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) | Responsive | COREAD | Late trials |
| ERBB2 | ERBB2 MUT (V777L) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | OV | Early trials |
| ERBB2 | ERBB2 MUT (V777L) | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BLCA | Case report |
| ERBB2 | ERBB2 MUT (V777L) | Different Alteration | Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) | Responsive | COREAD | Case report |
| ERBB2 | ERBB2 MUT (V777L) | Different Alteration | Rociletinib (EGFR inhibitor) | Resistant | LUAD | Case report |
| ERBB2 | ERBB2 MUT (V777L) | Different Alteration | Osimertinib (EGFR inhibitor) | Resistant | LUAD | Case report |
| ERBB2 | ERBB2 MUT (V777L) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | BT | Early trials |
| ERBB2 | ERBB2 MUT (V777L) | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Early trials |
| ERBB2 | ERBB2 MUT (V777L) | Different Alteration | Lapatinib (ERBB2 inhibitor) | Responsive | BT | Early trials |
| ERBB2 | ERBB2 MUT (V777L) | Different Alteration | Trastuzumab;HSP90 inhibitor (ERBB2 mAb inhibitor;HSP90 inhibitor) | Responsive | BRCA | Early trials |
| ERBB2 | ERBB2 MUT (V777L) | Different Alteration | HER2 inhibitor;CDK4/6 inhibitor | Responsive | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (V777L) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | ERBB2 MUT (V777L) | Different Alteration | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | ST | Early trials |
| ERBB2 | ERBB2 MUT (V777L) | Different Alteration | Trastuzumab;Everolimus;Chemotherapy (ERBB2 mAb inhibitor;MTOR inhibitor;Chemotherapy) | Responsive | BRCA | Early trials |
| ERBB2 | ERBB2 MUT (V777L) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | ST, GEJA | FDA guidelines |
| ERBB2 | ERBB2 MUT (V777L) | Different Alteration | ERBB2 inhibitor;CDK4/6 inhibitor | Responsive | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (V777L) | Different Alteration | Ado-Trastuzumab Emtansine (EGFR mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | ERBB2 MUT (V777L) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | HNC | Case report |
| ERBB2 | ERBB2 MUT (V777L) | Different Alteration | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Late trials |
| ERBB2 | ERBB2 MUT (V777L) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | No Responsive | ED | Early trials |
| ERBB2 | ERBB2 MUT (V777L) | Different Alteration | Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) | Responsive | ED | Pre-clinical |
| ERBB2 | ERBB2 MUT (V777L) | Different Alteration | Lapatinib;Chemotherapy (ERBB2 inhibitor;Chemotherapy) | Responsive | ST | Early trials |
| ERBB2 | ERBB2 MUT (V777L) | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | ST | Case report |
| ERBB2 | ERBB2 MUT (V777L) | Different Alteration | EGFR inhibitor | Resistant | LUAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (E545K) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (E545K) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (E545K) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (E545K) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (E545K) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (E545K) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (E545K) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (E545K) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (E545K) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (E545K) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (E545K) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (E545K) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (E545K) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (E545K) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| STAG2 | STAG2 MUT (R1045*) | Complete Match | PARP inhibitor | Responsive | G | Pre-clinical |
| PTEN | PTEN MUT (K128N) | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | PTEN MUT (K128N) | Different Mutation | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | PTEN MUT (K128N) | Different Mutation | BYL719 (PIK3CA inhibitor) | Resistant | BRCA | Case report |
| PTEN | PTEN MUT (K128N) | Complete Match | ATM inhibitor | Responsive | BRCA | Pre-clinical |
| PTEN | PTEN MUT (K128N) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA, ED, TH, CANCER, L, G, OV | Pre-clinical |
| PTEN | PTEN MUT (K128N) | Complete Match | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | PTEN MUT (K128N) | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | PTEN MUT (K128N) | Complete Match | PARP inhibitor | Responsive | ED | Case report |
| PTEN | PTEN MUT (K128N) | Complete Match | PD1 Ab inhibitor | Resistant | CM | Early trials |
| PTEN | PTEN MUT (K128N) | Complete Match | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | PTEN MUT (K128N) | Complete Match | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | PTEN MUT (K128N) | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| PTEN | PTEN MUT (K128N) | Complete Match | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | PTEN MUT (K128N) | Complete Match | AKT inhibitor | Responsive | PA | Case report |
| PTEN | PTEN MUT (K128N) | Complete Match | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | PTEN MUT (K128N) | Different Alteration | PI3K pathway inhibitor | Responsive | L, BRCA, CANCER, G, ED, TH, OV | Pre-clinical |
| PTEN | PTEN MUT (K128N) | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | PTEN MUT (K128N) | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | PTEN MUT (K128N) | Different Alteration | PARP inhibitor | Responsive | ED | Case report |
| PTEN | PTEN MUT (K128N) | Different Alteration | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | PTEN MUT (K128N) | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | PTEN MUT (K128N) | Different Alteration | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | PTEN MUT (K128N) | Different Alteration | AKT inhibitor | Responsive | PA | Case report |
| PTEN | PTEN MUT (K128N) | Different Alteration | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | PTEN MUT (K128N) | Different Alteration | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| EZH2 | EZH2 MUT (S639*) | Different Mutation | EZH2 inhibitor | Responsive | LY | Pre-clinical |
| EZH2 | EZH2 MUT (S639*) | Different Mutation | EZH2 inhibitor | Responsive | LY | Early trials |
| PML | PML MUT* (P419P) | Different Alteration | Volasertib (PLK1 inhibitor) | Responsive | AML | Early trials |
| PML | PML MUT* (P419P) | Different Alteration | Tretinoin (Retinoid) | Responsive | APML | FDA guidelines |
| PML | PML MUT* (P419P) | Different Alteration | Tretinoin;Arsenic Trioxide (Retinoid;Chemotherapy) | Responsive | AML | FDA guidelines |
| AKT3 | AKT3 MUT* (G265R) | Different Alteration | ATP competitive AKT inhibitor | Responsive | BRCA | Pre-clinical |
| EGFR | EGFR MUT (T847K) | Different Alteration | Cetuximab (EGFR mAb inhibitor) | Responsive | COREAD | FDA guidelines |
| EGFR | EGFR MUT (T847K) | Different Alteration | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | FDA guidelines |
| EGFR | EGFR MUT (T847K) | Different Mutation | Rindopepimut (Vaccine) | Responsive | GB | Late trials |
| EGFR | EGFR MUT (T847K) | Different Mutation | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | NSCLC | FDA guidelines |
| EGFR | EGFR MUT (T847K) | Different Mutation | Gefitinib (EGFR inhibitor) | Responsive | NSCLC | FDA guidelines |
| EGFR | EGFR MUT (T847K) | Different Mutation | HSP90 inhibitor | Responsive | L | Early trials |
| EGFR | EGFR MUT (T847K) | Different Mutation | Afatinib;Cetuximab (ERBB2 & EGFR inhibitor;EGFR mAb inhibitor) | Responsive | L | Early trials |
| EGFR | EGFR MUT (T847K) | Different Mutation | MEK inhibitor | Responsive | L | Pre-clinical |
| EGFR | EGFR MUT (T847K) | Different Mutation | EGFR TK inhibitor | Responsive | L | Late trials |
| EGFR | EGFR MUT (T847K) | Different Mutation | Erlotinib (EGFR inhibitor) | Responsive | NSCLC | NCCN guidelines |
| EGFR | EGFR MUT (T847K) | Different Mutation | Osimertinib (EGFR inhibitor) | Resistant | L | Early trials |
| EGFR | EGFR MUT (T847K) | Different Mutation | EGFR-TKI's (EGFR inhibitor) | Resistant | L | Late trials |
| EGFR | EGFR MUT (T847K) | Different Mutation | HSP90 inhibitor | Responsive | L | Case report |
| EGFR | EGFR MUT (T847K) | Different Mutation | EGFR inhibitor | Resistant | L | Late trials |
| EGFR | EGFR MUT (T847K) | Different Mutation | Poziotinib (EGFR inhibitor) | Responsive | L | Early trials |
| EGFR | EGFR MUT (T847K) | Different Mutation | Osimertinib (EGFR inhibitor) | Responsive | L | Pre-clinical |
| EGFR | EGFR MUT (T847K) | Different Mutation | HSP90 inhibitor (HSP90 inhibitor) | Responsive | L | Early trials |
| EGFR | EGFR MUT (T847K) | Different Mutation | Erlotinib (EGFR inhibitor) | Responsive | G | Pre-clinical |
| EGFR | EGFR MUT (T847K) | Different Mutation | Erlotinib (EGFR inhibitor) | Responsive | NSCLC | FDA guidelines |
| EGFR | EGFR MUT (T847K) | Different Mutation | Osimertinib (EGFR inhibitor) | Responsive | L | Early trials |
| EGFR | EGFR MUT (T847K) | Different Mutation | Rociletinib (EGFR inhibitor) | Resistant | LUAD | Case report |
| EGFR | EGFR MUT (T847K) | Different Mutation | Panitumumab (EGFR mAb inhibitor) | Responsive | COREAD | Case report |
| EGFR | EGFR MUT (T847K) | Different Mutation | novel EGFR mAb inhibitor | Responsive | COREAD | Early trials |
| EGFR | EGFR MUT (T847K) | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| EGFR | EGFR MUT (T847K) | Different Mutation | Cetuximab;Sirolimus (EGFR mAb inhibitor;MTOR inhibitor) | Responsive | HNC | Case report |
| EGFR | EGFR MUT (T847K) | Different Mutation | Erlotinib (EGFR inhibitor) | Responsive | L | Case report |
| EGFR | EGFR MUT (T847K) | Different Mutation | Gefitinib (EGFR inhibitor) | No Responsive | HNC | Case report |
| EGFR | EGFR MUT (T847K) | Different Mutation | EGFR inhibitor | Responsive | L | Early trials |
| EGFR | EGFR MUT (T847K) | Different Mutation | Erlotinib (EGFR inhibitor) | Resistant | L | NCCN/CAP guidelines |
| EGFR | EGFR MUT (T847K) | Different Mutation | Osimertinib (EGFR inhibitor) | Responsive | NSCLC | FDA guidelines |
| EGFR | EGFR MUT (T847K) | Different Mutation | EGFR inhibitor | Responsive | NSCLC | Late trials |
| EGFR | EGFR MUT (T847K) | Different Mutation | Afatinib;Nimotuzumab (ERBB2 & EGFR inhibitor;EGFR mAb inhibitor) | Responsive | L | Early trials |
| EGFR | EGFR MUT (T847K) | Different Mutation | Afatinib (ERBB2 & EGFR inhibitor) | Resistant | L | NCCN/CAP guidelines |
| EGFR | EGFR MUT (T847K) | Different Mutation | Erlotinib (EGFR inhibitor) | Responsive | L | Early trials |
| EGFR | EGFR MUT (T847K) | Different Mutation | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | L | Late trials |
| EGFR | EGFR MUT (T847K) | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Pre-clinical |
| EGFR | EGFR MUT (T847K) | Different Mutation | Erlotinib (EGFR inhibitor) | No Responsive | L | Case report |
| EGFR | EGFR MUT (T847K) | Different Mutation | Lapatinib (ERBB2 inhibitor) | Responsive | ED | Case report |
| EGFR | EGFR MUT (T847K) | Different Mutation | EGFR inhibitor | No Responsive | G | Early trials |
| EGFR | EGFR MUT (T847K) | Different Mutation | EGFR inhibitor | Resistant | NSCLC | Case report |
| EGFR | EGFR MUT (T847K) | Different Mutation | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| EGFR | EGFR MUT (T847K) | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant;Resistant | COREAD | Pre-clinical;Case report |
| EGFR | EGFR MUT (T847K) | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Responsive | HNC | Case report |
| EGFR | EGFR MUT (T847K) | Different Alteration | Gefitinib (EGFR inhibitor) | Responsive | ED | Late trials |
| EGFR | EGFR MUT (T847K) | Different Alteration | Gefitinib (EGFR inhibitor) | No Responsive | HNC | Early trials |
| EGFR | EGFR MUT (T847K) | Different Alteration | EGFR inhibitor | Responsive | HNSC | Case report |
| EGFR | EGFR MUT (T847K) | Different Alteration | EGFR inhibitor | No Responsive | G | Early trials |
| EGFR | EGFR MUT (T847K) | Different Alteration | Erlotinib (EGFR inhibitor) | No Responsive | L | Early trials |
| EGFR | EGFR MUT (T847K) | Different Alteration | EGFR mAb inhibitor | Responsive | COREAD | Late trials |
| EGFR | EGFR MUT (T847K) | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | L | Case report |
| EGFR | EGFR MUT (T847K) | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | NSCLC | Case report |
| TP53 | TP53 MUT (C141R) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (C141R) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (C141R) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (C141R) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (C141R) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (C141R) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (C141R) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (C141R) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (C141R) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (C141R) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (C141R) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (C141R) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (C141R) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (C141R) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (C141R) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| PML | PML MUT* (intron_variant) | Different Alteration | Volasertib (PLK1 inhibitor) | Responsive | AML | Early trials |
| PML | PML MUT* (intron_variant) | Different Alteration | Tretinoin (Retinoid) | Responsive | APML | FDA guidelines |
| PML | PML MUT* (intron_variant) | Different Alteration | Tretinoin;Arsenic Trioxide (Retinoid;Chemotherapy) | Responsive | AML | FDA guidelines |
| ALK | ALK MUT* (I1194I) | Different Alteration | ALK inhibitor;SRC inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (I1194I) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | GB, LY | Early trials |
| ALK | ALK MUT* (I1194I) | Different Alteration | Lorlatinib (ALK&ROS1 inhibitor) | Responsive | NSCLC | Early trials |
| ALK | ALK MUT* (I1194I) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | THCA, IM | Case report |
| ALK | ALK MUT* (I1194I) | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (I1194I) | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | ALK MUT* (I1194I) | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | IM, COREAD | Case report |
| ALK | ALK MUT* (I1194I) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | ALK MUT* (I1194I) | Different Alteration | Brigatinib (Pan-TK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | ALK MUT* (I1194I) | Different Alteration | Entrictinib (Pan-TK inhibitor) | Responsive | COREAD | Case report |
| ALK | ALK MUT* (I1194I) | Different Alteration | Alectinib (ALK inhibitor) | Responsive | LUAD | FDA guidelines |
| ALK | ALK MUT* (I1194I) | Different Alteration | HSP90 inhibitor (HSP90 inhibitor) | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (I1194I) | Different Alteration | ALK inhibitor;IGF1R inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (I1194I) | Different Alteration | ALK inhibitor;MEK inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (I1194I) | Different Alteration | novel ALK inhibitor | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (I1194I) | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | HEMATO | Early trials |
| ALK | ALK MUT* (I1194I) | Different Alteration | ALK inhibitor | Responsive | COREAD | Case report |
| ALK | ALK MUT* (I1194I) | Different Alteration | Alectinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | ALK MUT* (I1194I) | Different Alteration | MEK inhibitor (ALK inhibitor;MEK inhibitor) | Responsive | LUAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (H1047L) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (H1047L) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (H1047L) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (H1047L) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (H1047L) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (H1047L) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (H1047L) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (H1047L) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (H1047L) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (H1047L) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (H1047L) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (H1047L) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (H1047L) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (H1047L) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| MET | MET MUT* (G1364G) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | G | Case report |
| TP53 | TP53 MUT (L194R) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (L194R) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (L194R) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (L194R) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (L194R) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (L194R) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (L194R) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (L194R) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (L194R) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (L194R) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (L194R) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (L194R) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (L194R) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (L194R) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (L194R) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| ERBB3 | ERBB3 MUT (D297Y) | Different Mutation | PI3K pathway inhibitor;MEK inhibitor | Responsive | CANCER | Pre-clinical |
| ERBB3 | ERBB3 MUT (D297Y) | Different Mutation | Lapatinib (ERBB2 inhibitor) | Responsive | CANCER | Pre-clinical |
| ERBB3 | ERBB3 MUT (D297Y) | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | CANCER | Pre-clinical |
| ERBB3 | ERBB3 MUT (D297Y) | Different Mutation | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BLCA | Case report |
| ERBB3 | ERBB3 MUT (D297Y) | Different Mutation | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | CANCER | Pre-clinical |
| ERBB3 | ERBB3 MUT (D297Y) | Different Mutation | ERBB3 mAb inhibitor | Responsive | CANCER | Pre-clinical |
| ERBB3 | ERBB3 MUT (D297Y) | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Early trials |
| ARID1A | ARID1A MUT (Q723*) | Complete Match | EZH2 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | ARID1A MUT (Q723*) | Complete Match | PD1 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | ARID1A MUT (Q723*) | Complete Match | PARP inhibitor | Responsive | CANCER | Pre-clinical |
| ARID1A | ARID1A MUT (Q723*) | Complete Match | ATR inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (R196*) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (R196*) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (R196*) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (R196*) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (R196*) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (R196*) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (R196*) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R196*) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R196*) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (R196*) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (R196*) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R196*) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (R196*) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (R196*) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (R196*) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (R273L) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (R273L) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (R273L) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (R273L) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (R273L) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (R273L) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (R273L) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R273L) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R273L) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (R273L) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (R273L) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R273L) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (R273L) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (R273L) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (R273L) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| CDH1 | CDH1 MUT (Q255*) | Complete Match | Bicalutamide (AR inhibitor) | Responsive | BRCA | Pre-clinical |
| ARID1A | ARID1A MUT (S711*) | Complete Match | EZH2 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | ARID1A MUT (S711*) | Complete Match | PD1 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | ARID1A MUT (S711*) | Complete Match | PARP inhibitor | Responsive | CANCER | Pre-clinical |
| ARID1A | ARID1A MUT (S711*) | Complete Match | ATR inhibitor | Responsive | CANCER | Pre-clinical |
| CDKN1A | CDKN1A MUT (S98*) | Complete Match | CDK2/4 inhibitor | Responsive | CANCER | Pre-clinical |
| CDKN1A | CDKN1A MUT (S98*) | Different Alteration | CDK2/4 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (I255F) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (I255F) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (I255F) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (I255F) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (I255F) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (I255F) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (I255F) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (I255F) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (I255F) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (I255F) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (I255F) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (I255F) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (I255F) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (I255F) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (I255F) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| KMT2A | MLL MUT* (I1401F) | Different Alteration | EPZ-5676 (DOT1L inhibitor) | Responsive | ALL, MDS, AML | Early trials |
| KMT2A | MLL MUT* (I1401F) | Different Alteration | BET inhibitor | Responsive | ALL | Pre-clinical |
| KMT2A | MLL MUT* (I1401F) | Different Alteration | BET inhibitor | Responsive | AML | Pre-clinical |
| KMT2A | MLL MUT* (I1401F) | Different Alteration | Daunorubicin (Chemotherapy) | Responsive | AML | FDA guidelines |
| KMT2A | MLL MUT* (I1401F) | Different Alteration | Belinostat (HDAC inhibitor) | Responsive | AML | Early trials |
| KMT2A | MLL MUT* (I1401F) | Different Alteration | DOT1L inhibitor | Responsive | AML | Early trials |
| CDH1 | CDH1 MUT (Q673*) | Complete Match | Bicalutamide (AR inhibitor) | Responsive | BRCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (G118D) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (G118D) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (G118D) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (G118D) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (G118D) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (G118D) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (G118D) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (G118D) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (G118D) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (G118D) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (G118D) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (G118D) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (G118D) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (G118D) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| BAP1 | BAP1 MUT (Y627*) | Complete Match | EZH2 inhibitor | Responsive | MESO | Pre-clinical |
| BAP1 | BAP1 MUT (Y627*) | Complete Match | PARP inhibitor | Responsive | R, CANCER | Pre-clinical |
| BAP1 | BAP1 MUT (Y627*) | Complete Match | HDAC inhibitor | Responsive | CM | Pre-clinical |
| BAP1 | BAP1 MUT (Y627*) | Different Alteration | PARP inhibitor | Responsive | CANCER, R | Pre-clinical |
| BAP1 | BAP1 MUT (Y627*) | Different Alteration | EZH2 inhibitor | Responsive | MESO | Pre-clinical |
| BAP1 | BAP1 MUT (Y627*) | Different Alteration | HDAC inhibitor | Responsive | CM | Pre-clinical |
| PTPRD | PTPRD MUT (G574*) | Complete Match | IGF1R inhibitor | Responsive | S | Case report |
| TP53 | TP53 MUT (V272M) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (V272M) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (V272M) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (V272M) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (V272M) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (V272M) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (V272M) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (V272M) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (V272M) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (V272M) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (V272M) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (V272M) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (V272M) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (V272M) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (V272M) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| ATM | ATM MUT (Q2800*) | Different Mutation | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| ATM | ATM MUT (Q2800*) | Complete Match | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| ATM | ATM MUT (Q2800*) | Complete Match | Olaparib (PARP inhibitor) | Responsive | ST, PRAD | Early trials |
| ATM | ATM MUT (Q2800*) | Complete Match | PARP inhibitor | Responsive | ST | Early trials |
| ATM | ATM MUT (Q2800*) | Complete Match | ATR inhibitor | Responsive | COREAD | Case report |
| ATM | ATM MUT (Q2800*) | Complete Match | DNA-PKc inhibitor | Responsive | LY | Pre-clinical |
| ATM | ATM MUT (Q2800*) | Complete Match | Temozolomide (Chemotherapy) | Responsive | G | Pre-clinical |
| ATM | ATM MUT (Q2800*) | Complete Match | PD1/PDL1 inhibitor | Responsive | UTH | Early trials |
| ATM | ATM MUT (Q2800*) | Different Alteration | PD1/PDL1 inhibitor | Responsive | UTH | Early trials |
| ATM | ATM MUT (Q2800*) | Different Alteration | DNA-PKc inhibitor | Responsive | LY | Pre-clinical |
| ATM | ATM MUT (Q2800*) | Different Alteration | PARP inhibitor | Responsive | ST | Early trials |
| ATM | ATM MUT (Q2800*) | Different Alteration | ATR inhibitor | Responsive | COREAD | Case report |
| ATM | ATM MUT (Q2800*) | Different Alteration | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| MET | MET MUT* (D127N) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | G | Case report |
| BRCA1 | BRCA1 MUT (Q1408*) | Complete Match | Chemotherapy (PARP inhibitor;Chemotherapy) | Responsive | OV | Early trials |
| BRCA1 | BRCA1 MUT (Q1408*) | Complete Match | PARP inhibitor | Responsive | BRCA | Early trials |
| BRCA1 | BRCA1 MUT (Q1408*) | Complete Match | PARP inhibitor;Chemotherapy | Responsive | OV | Early trials |
| BRCA1 | BRCA1 MUT (Q1408*) | Complete Match | Rucaparib (PARP inhibitor) | Responsive | OV | FDA guidelines |
| BRCA1 | BRCA1 MUT (Q1408*) | Complete Match | Platinum Agent (Chemotherapy) | Responsive | BRCA | Early trials |
| BRCA1 | BRCA1 MUT (Q1408*) | Complete Match | WEE1 inhibitor | Responsive | CANCER | Case report |
| BRCA1 | BRCA1 MUT (Q1408*) | Complete Match | Platinum Agent (Chemotherapy) | Responsive | OV | Late trials |
| BRCA1 | BRCA1 MUT (Q1408*) | Complete Match | Olaparib (PARP inhibitor) | Responsive | PRAD | Early trials |
| BRCA1 | BRCA1 MUT (Q1408*) | Complete Match | Veliparib;Cisplatin (PARP inhibitor;Chemotherapy) | Responsive | BRCA | Early trials |
| BRCA1 | BRCA1 MUT (Q1408*) | Complete Match | PARP inhibitor | Responsive | PA | Case report |
| BRCA1 | BRCA1 MUT (Q1408*) | Complete Match | Olaparib (PARP inhibitor) | Responsive | OV | FDA guidelines |
| BRCA1 | BRCA1 MUT (Q1408*) | Different Alteration | PARP inhibitor | Responsive | OV | Pre-clinical |
| NRG1 | NRG1 MUT* (A547T) | Different Alteration | Lapatinib (ERBB2 inhibitor) | Responsive | LUAD | Pre-clinical |
| NRG1 | NRG1 MUT* (A547T) | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | LUAD | Case report |
| HRAS | HRAS MUT (G12D) | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | CER | Pre-clinical |
| HRAS | HRAS MUT (G12D) | Complete Match | MEK inhibitor +/- MTOR inhibitor | Responsive | AML | Pre-clinical |
| HRAS | HRAS MUT (G12D) | Complete Match | MTOR inhibitor | Responsive | CESC | Pre-clinical |
| HRAS | HRAS MUT (G12D) | Complete Match | Tipifarnib (Farnesyltransferase inhibitor) | Responsive | CANCER | Early trials |
| TP53 | TP53 MUT (R273H) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (R273H) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (R273H) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (R273H) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (R273H) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (R273H) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (R273H) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R273H) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R273H) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (R273H) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (R273H) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R273H) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (R273H) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (R273H) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (R273H) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (G245D) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (G245D) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (G245D) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (G245D) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (G245D) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (G245D) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (G245D) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (G245D) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (G245D) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (G245D) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (G245D) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (G245D) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (G245D) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (G245D) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (G245D) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| PTEN | PTEN MUT (A126G) | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | PTEN MUT (A126G) | Different Mutation | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | PTEN MUT (A126G) | Different Mutation | BYL719 (PIK3CA inhibitor) | Resistant | BRCA | Case report |
| PTEN | PTEN MUT (A126G) | Complete Match | ATM inhibitor | Responsive | BRCA | Pre-clinical |
| PTEN | PTEN MUT (A126G) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA, ED, TH, CANCER, L, G, OV | Pre-clinical |
| PTEN | PTEN MUT (A126G) | Complete Match | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | PTEN MUT (A126G) | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | PTEN MUT (A126G) | Complete Match | PARP inhibitor | Responsive | ED | Case report |
| PTEN | PTEN MUT (A126G) | Complete Match | PD1 Ab inhibitor | Resistant | CM | Early trials |
| PTEN | PTEN MUT (A126G) | Complete Match | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | PTEN MUT (A126G) | Complete Match | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | PTEN MUT (A126G) | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| PTEN | PTEN MUT (A126G) | Complete Match | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | PTEN MUT (A126G) | Complete Match | AKT inhibitor | Responsive | PA | Case report |
| PTEN | PTEN MUT (A126G) | Complete Match | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | PTEN MUT (A126G) | Different Alteration | PI3K pathway inhibitor | Responsive | L, BRCA, CANCER, G, ED, TH, OV | Pre-clinical |
| PTEN | PTEN MUT (A126G) | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | PTEN MUT (A126G) | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | PTEN MUT (A126G) | Different Alteration | PARP inhibitor | Responsive | ED | Case report |
| PTEN | PTEN MUT (A126G) | Different Alteration | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | PTEN MUT (A126G) | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | PTEN MUT (A126G) | Different Alteration | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | PTEN MUT (A126G) | Different Alteration | AKT inhibitor | Responsive | PA | Case report |
| PTEN | PTEN MUT (A126G) | Different Alteration | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | PTEN MUT (A126G) | Different Alteration | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| TP53 | TP53 MUT (R280K) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (R280K) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (R280K) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (R280K) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (R280K) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (R280K) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (R280K) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R280K) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R280K) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (R280K) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (R280K) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R280K) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (R280K) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (R280K) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (R280K) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| CDH1 | CDH1 MUT (E494*) | Complete Match | Bicalutamide (AR inhibitor) | Responsive | BRCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (E542K) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (E542K) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (E542K) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (E542K) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (E542K) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (E542K) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (E542K) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (E542K) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (E542K) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (E542K) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (E542K) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (E542K) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (E542K) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (E542K) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| CDH1 | CDH1 MUT (Q23*) | Complete Match | Bicalutamide (AR inhibitor) | Responsive | BRCA | Pre-clinical |
| TP53 | TP53 MUT (R306*) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (R306*) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (R306*) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (R306*) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (R306*) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (R306*) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (R306*) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R306*) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R306*) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (R306*) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (R306*) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R306*) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (R306*) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (R306*) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (R306*) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| PIK3CA | PIK3CA MUT (N345K) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (N345K) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (N345K) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (N345K) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (N345K) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (N345K) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (N345K) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (N345K) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (N345K) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (N345K) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (N345K) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (N345K) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (N345K) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (N345K) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| NOTCH2 | NOTCH2 MUT* (5-UTRSNV) | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| NRG1 | NRG1 MUT* (V322V) | Different Alteration | Lapatinib (ERBB2 inhibitor) | Responsive | LUAD | Pre-clinical |
| NRG1 | NRG1 MUT* (V322V) | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | LUAD | Case report |
| TP53 | TP53 MUT (E294*) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (E294*) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (E294*) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (E294*) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (E294*) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (E294*) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (E294*) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (E294*) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (E294*) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (E294*) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (E294*) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (E294*) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (E294*) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (E294*) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (E294*) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| SETD2 | SETD2 MUT (R2077*) | Complete Match | WEE1 inhibitor | Responsive | CANCER | Pre-clinical |
| SETD2 | SETD2 MUT (R2077*) | Different Alteration | WEE1 inhibitor | Responsive | CANCER | Pre-clinical |
| ERBB4 | ERBB4 MUT* (3-UTRSNV) | Different Alteration | Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) | Responsive | LUAD | Pre-clinical |
| NOTCH2 | NOTCH2 MUT* (S1388T) | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (E545K), PIK3CA MUT (E545G) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (E545K), PIK3CA MUT (E545G) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (E545K), PIK3CA MUT (E545G) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (E545K), PIK3CA MUT (E545G) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (E545K), PIK3CA MUT (E545G) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (E545K), PIK3CA MUT (E545G) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (E545K), PIK3CA MUT (E545G) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (E545K), PIK3CA MUT (E545G) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (E545K), PIK3CA MUT (E545G) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (E545K), PIK3CA MUT (E545G) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (E545K), PIK3CA MUT (E545G) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (E545K), PIK3CA MUT (E545G) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (E545K), PIK3CA MUT (E545G) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (E545K), PIK3CA MUT (E545G) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| TP53 | TP53 MUT (I195T) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (I195T) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (I195T) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (I195T) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (I195T) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (I195T) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (I195T) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (I195T) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (I195T) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (I195T) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (I195T) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (I195T) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (I195T) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (I195T) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (I195T) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (H179R) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (H179R) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (H179R) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (H179R) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (H179R) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (H179R) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (H179R) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (H179R) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (H179R) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (H179R) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (H179R) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (H179R) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (H179R) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (H179R) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (H179R) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (P250L) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (P250L) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (P250L) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (P250L) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (P250L) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (P250L) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (P250L) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (P250L) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (P250L) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (P250L) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (P250L) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (P250L) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (P250L) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (P250L) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (P250L) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| EGFR | EGFR MUT* (A147T) | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | L | Case report |
| EGFR | EGFR MUT* (A147T) | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | NSCLC | Case report |
| RAF1 | RAF1 MUT* (S605F) | Different Alteration | Sorafenib (Pan-TK inhibitor) | Responsive | PRAD | Pre-clinical |
| RAF1 | RAF1 MUT* (S605F) | Different Alteration | Pan-RAF inhibitor | Responsive | PRAD | Pre-clinical |
| RAF1 | RAF1 MUT* (S605F) | Different Alteration | U0126 (MEK inhibitor) | Responsive | PRAD | Pre-clinical |
| SF3B1 | SF3B1 MUT (K666N) | Complete Match | Spliceosome inhibitor | Responsive | CANCER | Pre-clinical |
| PIK3CA | PIK3CA MUT (C420R), PIK3CA MUT (E545K) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (C420R), PIK3CA MUT (E545K) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (C420R), PIK3CA MUT (E545K) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (C420R), PIK3CA MUT (E545K) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (C420R), PIK3CA MUT (E545K) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (C420R), PIK3CA MUT (E545K) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (C420R), PIK3CA MUT (E545K) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (C420R), PIK3CA MUT (E545K) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (C420R), PIK3CA MUT (E545K) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (C420R), PIK3CA MUT (E545K) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (C420R), PIK3CA MUT (E545K) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (C420R), PIK3CA MUT (E545K) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (C420R), PIK3CA MUT (E545K) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (C420R), PIK3CA MUT (E545K) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| KMT2A | MLL MUT* (R442Q) | Different Alteration | EPZ-5676 (DOT1L inhibitor) | Responsive | ALL, MDS, AML | Early trials |
| KMT2A | MLL MUT* (R442Q) | Different Alteration | BET inhibitor | Responsive | ALL | Pre-clinical |
| KMT2A | MLL MUT* (R442Q) | Different Alteration | BET inhibitor | Responsive | AML | Pre-clinical |
| KMT2A | MLL MUT* (R442Q) | Different Alteration | Daunorubicin (Chemotherapy) | Responsive | AML | FDA guidelines |
| KMT2A | MLL MUT* (R442Q) | Different Alteration | Belinostat (HDAC inhibitor) | Responsive | AML | Early trials |
| KMT2A | MLL MUT* (R442Q) | Different Alteration | DOT1L inhibitor | Responsive | AML | Early trials |
| FBXW7 | FBXW7 MUT (R465C) | Complete Match | Steroid | Responsive | ALL | Late trials |
| FBXW7 | FBXW7 MUT (R465C) | Complete Match | Tubulin inhibitor | Resistant | CANCER | Pre-clinical |
| FBXW7 | FBXW7 MUT (R465C) | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | COREAD | Pre-clinical |
| FBXW7 | FBXW7 MUT (R465C) | Different Alteration | Tubulin inhibitor | Resistant | CANCER | Pre-clinical |
| TP53 | TP53 MUT (R248Q) | Complete Match | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (R248Q) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (R248Q) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (R248Q) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (R248Q) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (R248Q) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (R248Q) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R248Q) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R248Q) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (R248Q) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (R248Q) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R248Q) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (R248Q) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (R248Q) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (R248Q) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| EGFR | EGFR MUT* (E928V) | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | L | Case report |
| EGFR | EGFR MUT* (E928V) | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | NSCLC | Case report |
| TP53 | TP53 MUT (Q52*) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (Q52*) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (Q52*) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (Q52*) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (Q52*) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (Q52*) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (Q52*) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Q52*) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Q52*) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (Q52*) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (Q52*) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Q52*) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (Q52*) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (Q52*) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (Q52*) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| ESR1 | ESR1 MUT* (K472K) | Different Alteration | ESR1 inhibitor | Resistant | BRCA | Pre-clinical |
| ALK | ALK MUT* (E780D) | Different Alteration | ALK inhibitor;SRC inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (E780D) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | GB, LY | Early trials |
| ALK | ALK MUT* (E780D) | Different Alteration | Lorlatinib (ALK&ROS1 inhibitor) | Responsive | NSCLC | Early trials |
| ALK | ALK MUT* (E780D) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | THCA, IM | Case report |
| ALK | ALK MUT* (E780D) | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (E780D) | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | ALK MUT* (E780D) | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | IM, COREAD | Case report |
| ALK | ALK MUT* (E780D) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | ALK MUT* (E780D) | Different Alteration | Brigatinib (Pan-TK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | ALK MUT* (E780D) | Different Alteration | Entrictinib (Pan-TK inhibitor) | Responsive | COREAD | Case report |
| ALK | ALK MUT* (E780D) | Different Alteration | Alectinib (ALK inhibitor) | Responsive | LUAD | FDA guidelines |
| ALK | ALK MUT* (E780D) | Different Alteration | HSP90 inhibitor (HSP90 inhibitor) | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (E780D) | Different Alteration | ALK inhibitor;IGF1R inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (E780D) | Different Alteration | ALK inhibitor;MEK inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (E780D) | Different Alteration | novel ALK inhibitor | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (E780D) | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | HEMATO | Early trials |
| ALK | ALK MUT* (E780D) | Different Alteration | ALK inhibitor | Responsive | COREAD | Case report |
| ALK | ALK MUT* (E780D) | Different Alteration | Alectinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | ALK MUT* (E780D) | Different Alteration | MEK inhibitor (ALK inhibitor;MEK inhibitor) | Responsive | LUAD | Pre-clinical |
| PTEN | PTEN MUT (splice_acceptor_variant) | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | PTEN MUT (splice_acceptor_variant) | Different Mutation | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | PTEN MUT (splice_acceptor_variant) | Different Mutation | BYL719 (PIK3CA inhibitor) | Resistant | BRCA | Case report |
| PTEN | PTEN MUT (splice_acceptor_variant) | Complete Match | ATM inhibitor | Responsive | BRCA | Pre-clinical |
| PTEN | PTEN MUT (splice_acceptor_variant) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA, ED, TH, CANCER, L, G, OV | Pre-clinical |
| PTEN | PTEN MUT (splice_acceptor_variant) | Complete Match | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | PTEN MUT (splice_acceptor_variant) | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | PTEN MUT (splice_acceptor_variant) | Complete Match | PARP inhibitor | Responsive | ED | Case report |
| PTEN | PTEN MUT (splice_acceptor_variant) | Complete Match | PD1 Ab inhibitor | Resistant | CM | Early trials |
| PTEN | PTEN MUT (splice_acceptor_variant) | Complete Match | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | PTEN MUT (splice_acceptor_variant) | Complete Match | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | PTEN MUT (splice_acceptor_variant) | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| PTEN | PTEN MUT (splice_acceptor_variant) | Complete Match | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | PTEN MUT (splice_acceptor_variant) | Complete Match | AKT inhibitor | Responsive | PA | Case report |
| PTEN | PTEN MUT (splice_acceptor_variant) | Complete Match | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | PTEN MUT (splice_acceptor_variant) | Different Alteration | PI3K pathway inhibitor | Responsive | L, BRCA, CANCER, G, ED, TH, OV | Pre-clinical |
| PTEN | PTEN MUT (splice_acceptor_variant) | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | PTEN MUT (splice_acceptor_variant) | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | PTEN MUT (splice_acceptor_variant) | Different Alteration | PARP inhibitor | Responsive | ED | Case report |
| PTEN | PTEN MUT (splice_acceptor_variant) | Different Alteration | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | PTEN MUT (splice_acceptor_variant) | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | PTEN MUT (splice_acceptor_variant) | Different Alteration | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | PTEN MUT (splice_acceptor_variant) | Different Alteration | AKT inhibitor | Responsive | PA | Case report |
| PTEN | PTEN MUT (splice_acceptor_variant) | Different Alteration | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | PTEN MUT (splice_acceptor_variant) | Different Alteration | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| KMT2A | MLL MUT* (P654P) | Different Alteration | EPZ-5676 (DOT1L inhibitor) | Responsive | ALL, MDS, AML | Early trials |
| KMT2A | MLL MUT* (P654P) | Different Alteration | BET inhibitor | Responsive | ALL | Pre-clinical |
| KMT2A | MLL MUT* (P654P) | Different Alteration | BET inhibitor | Responsive | AML | Pre-clinical |
| KMT2A | MLL MUT* (P654P) | Different Alteration | Daunorubicin (Chemotherapy) | Responsive | AML | FDA guidelines |
| KMT2A | MLL MUT* (P654P) | Different Alteration | Belinostat (HDAC inhibitor) | Responsive | AML | Early trials |
| KMT2A | MLL MUT* (P654P) | Different Alteration | DOT1L inhibitor | Responsive | AML | Early trials |
| NOTCH2 | NOTCH2 MUT* (V1015A) | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| EGFR | EGFR MUT* (S246S) | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | L | Case report |
| EGFR | EGFR MUT* (S246S) | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | NSCLC | Case report |
| ROS1 | ROS1 MUT* (L567L), ROS1 MUT* (I745I), ROS1 MUT* (3-UTRSNV) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | IM | Case report |
| ROS1 | ROS1 MUT* (L567L), ROS1 MUT* (I745I), ROS1 MUT* (3-UTRSNV) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ROS1 | ROS1 MUT* (L567L), ROS1 MUT* (I745I), ROS1 MUT* (3-UTRSNV) | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Case report |
| ROS1 | ROS1 MUT* (L567L), ROS1 MUT* (I745I), ROS1 MUT* (3-UTRSNV) | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Pre-clinical |
| ROS1 | ROS1 MUT* (L567L), ROS1 MUT* (I745I), ROS1 MUT* (3-UTRSNV) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Early trials |
| MET | MET MUT* (P485L) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | G | Case report |
| ERBB4 | ERBB4 MUT (splice_acceptor_variant) | Different Mutation | Lapatinib (ERBB2 inhibitor) | Responsive | CM | Pre-clinical |
| ERBB4 | ERBB4 MUT (splice_acceptor_variant) | Different Mutation | ERBB2 inhibitor | Resistant | BRCA | Case report |
| ERBB4 | ERBB4 MUT (splice_acceptor_variant) | Different Alteration | Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) | Responsive | LUAD | Pre-clinical |
| CDH1 | CDH1 MUT (splice_donor_variant) | Complete Match | Bicalutamide (AR inhibitor) | Responsive | BRCA | Pre-clinical |
| RAF1 | RAF1 MUT* (3-UTRSNV) | Different Alteration | Sorafenib (Pan-TK inhibitor) | Responsive | PRAD | Pre-clinical |
| RAF1 | RAF1 MUT* (3-UTRSNV) | Different Alteration | Pan-RAF inhibitor | Responsive | PRAD | Pre-clinical |
| RAF1 | RAF1 MUT* (3-UTRSNV) | Different Alteration | U0126 (MEK inhibitor) | Responsive | PRAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (C420R) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (C420R) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (C420R) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (C420R) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (C420R) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (C420R) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (C420R) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (C420R) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (C420R) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (C420R) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (C420R) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (C420R) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (C420R) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (C420R) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| TP53 | TP53 MUT (E258Q) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (E258Q) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (E258Q) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (E258Q) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (E258Q) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (E258Q) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (E258Q) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (E258Q) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (E258Q) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (E258Q) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (E258Q) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (E258Q) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (E258Q) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (E258Q) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (E258Q) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| NTRK3 | NTRK3 MUT* (R683S) | Different Alteration | IGF1R inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK3 | NTRK3 MUT* (R683S) | Different Alteration | PI3K pathway inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK3 | NTRK3 MUT* (R683S) | Different Alteration | Midostaurin (Pan-TK inhibitor) | Responsive | BRCA | Pre-clinical |
| NOTCH2 | NOTCH2 MUT* (Q921Q) | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| NF1 | NF1 MUT (W1048*), NF1 MUT (Q554*) | Complete Match | Vemurafenib (BRAF inhibitor) | Resistant | CM | Pre-clinical |
| NF1 | NF1 MUT (W1048*), NF1 MUT (Q554*) | Different Mutation | Everolimus (MTOR inhibitor) | Responsive | HNC | Case report |
| NF1 | NF1 MUT (W1048*), NF1 MUT (Q554*) | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (W1048*), NF1 MUT (Q554*) | Complete Match | Vinblastine (Chemotherapy) | Responsive | G | Early trials |
| NF1 | NF1 MUT (W1048*), NF1 MUT (Q554*) | Complete Match | KIT inhibitor;MTOR inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (W1048*), NF1 MUT (Q554*) | Complete Match | Tamoxifen (Hormonal therapy) | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (W1048*), NF1 MUT (Q554*) | Complete Match | Bevacizumab (VEGFR mAb inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (W1048*), NF1 MUT (Q554*) | Complete Match | Retinoic Acid | Resistant | NB | Pre-clinical |
| NF1 | NF1 MUT (W1048*), NF1 MUT (Q554*) | Complete Match | Everolimus (MTOR inhibitor) | Responsive | NF | Late trials |
| NF1 | NF1 MUT (W1048*), NF1 MUT (Q554*) | Complete Match | Trametinib (MEK inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (W1048*), NF1 MUT (Q554*) | Complete Match | Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (W1048*), NF1 MUT (Q554*) | Complete Match | Nilotinib (BCR-ABL inhibitor) | Responsive | MPN, PLEN | Pre-clinical |
| NF1 | NF1 MUT (W1048*), NF1 MUT (Q554*) | Complete Match | MEK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (W1048*), NF1 MUT (Q554*) | Complete Match | Everolimus (MTOR inhibitor) | Responsive | HNC, SG | Case report |
| NF1 | NF1 MUT (W1048*), NF1 MUT (Q554*) | Complete Match | Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) | No Responsive | MPN | Early trials |
| NF1 | NF1 MUT (W1048*), NF1 MUT (Q554*) | Complete Match | PLX3397 (Pan-TK inhibitor) | Responsive | PLEN | Pre-clinical |
| NF1 | NF1 MUT (W1048*), NF1 MUT (Q554*) | Complete Match | MEK inhibitor | Responsive | LK, G | Pre-clinical |
| NF1 | NF1 MUT (W1048*), NF1 MUT (Q554*) | Complete Match | Pan-RAF inhibitor;MEK inhibitor | Responsive | CM | Pre-clinical |
| NF1 | NF1 MUT (W1048*), NF1 MUT (Q554*) | Complete Match | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (W1048*), NF1 MUT (Q554*) | Complete Match | AURK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (W1048*), NF1 MUT (Q554*) | Complete Match | MTOR inhibitor | Responsive | LK, G, MPN | Pre-clinical |
| NF1 | NF1 MUT (W1048*), NF1 MUT (Q554*) | Complete Match | Dasatinib (BCR-ABL inhibitor) | Resistant | L | Pre-clinical |
| NF1 | NF1 MUT (W1048*), NF1 MUT (Q554*) | Complete Match | Everolimus;Pazopanib (MTOR inhibitor;VEGFR inhibitor) | Responsive | HC | Case report |
| NF1 | NF1 MUT (W1048*), NF1 MUT (Q554*) | Complete Match | Everolimus (MTOR inhibitor) | No Responsive | MPN | Early trials |
| NF1 | NF1 MUT (W1048*), NF1 MUT (Q554*) | Complete Match | Cediranib (ALK inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (W1048*), NF1 MUT (Q554*) | Complete Match | PD1 Ab inhibitor | Responsive | CM | Early trials |
| NF1 | NF1 MUT (W1048*), NF1 MUT (Q554*) | Complete Match | Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (W1048*), NF1 MUT (Q554*) | Complete Match | Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (W1048*), NF1 MUT (Q554*) | Complete Match | Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | No Responsive | G | Case report |
| NF1 | NF1 MUT (W1048*), NF1 MUT (Q554*) | Complete Match | BRD4 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (W1048*), NF1 MUT (Q554*) | Complete Match | Tipifarnib (Farnesyltransferase inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (W1048*), NF1 MUT (Q554*) | Complete Match | Selumetinib (MEK inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (W1048*), NF1 MUT (Q554*) | Complete Match | MTOR inhibitor;HSP90 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (W1048*), NF1 MUT (Q554*) | Complete Match | Trametinib (MEK inhibitor) | Responsive | CM | Pre-clinical |
| NF1 | NF1 MUT (W1048*), NF1 MUT (Q554*) | Complete Match | Erlotinib (EGFR inhibitor) | Resistant | L | Pre-clinical |
| NF1 | NF1 MUT (W1048*), NF1 MUT (Q554*) | Complete Match | Trametinib (MEK inhibitor) | No Responsive | OS | Case report |
| NF1 | NF1 MUT (W1048*), NF1 MUT (Q554*) | Different Alteration | MTOR inhibitor | Responsive | MPN, G, LK | Pre-clinical |
| NF1 | NF1 MUT (W1048*), NF1 MUT (Q554*) | Different Alteration | PLX3397 (Pan-TK inhibitor) | Responsive | PLEN | Pre-clinical |
| NF1 | NF1 MUT (W1048*), NF1 MUT (Q554*) | Different Alteration | Erlotinib (EGFR inhibitor) | Resistant | L | Pre-clinical |
| NF1 | NF1 MUT (W1048*), NF1 MUT (Q554*) | Different Alteration | Trametinib (MEK inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (W1048*), NF1 MUT (Q554*) | Different Alteration | BRD4 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (W1048*), NF1 MUT (Q554*) | Different Alteration | Trametinib (MEK inhibitor) | No Responsive | OS | Case report |
| NF1 | NF1 MUT (W1048*), NF1 MUT (Q554*) | Different Alteration | Cediranib (ALK inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (W1048*), NF1 MUT (Q554*) | Different Alteration | Bevacizumab (VEGFR mAb inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (W1048*), NF1 MUT (Q554*) | Different Alteration | MEK inhibitor | Responsive | G, LK | Pre-clinical |
| NF1 | NF1 MUT (W1048*), NF1 MUT (Q554*) | Different Alteration | Vinblastine (Chemotherapy) | Responsive | G | Early trials |
| NF1 | NF1 MUT (W1048*), NF1 MUT (Q554*) | Different Alteration | Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (W1048*), NF1 MUT (Q554*) | Different Alteration | Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) | No Responsive | MPN | Early trials |
| NF1 | NF1 MUT (W1048*), NF1 MUT (Q554*) | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Resistant | L | Pre-clinical |
| NF1 | NF1 MUT (W1048*), NF1 MUT (Q554*) | Different Alteration | MTOR inhibitor;HSP90 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (W1048*), NF1 MUT (Q554*) | Different Alteration | Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (W1048*), NF1 MUT (Q554*) | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (W1048*), NF1 MUT (Q554*) | Different Alteration | Tamoxifen (Hormonal therapy) | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (W1048*), NF1 MUT (Q554*) | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | SG, HNC | Case report |
| NF1 | NF1 MUT (W1048*), NF1 MUT (Q554*) | Different Alteration | Pan-RAF inhibitor;MEK inhibitor | Responsive | CM | Pre-clinical |
| NF1 | NF1 MUT (W1048*), NF1 MUT (Q554*) | Different Alteration | Tipifarnib (Farnesyltransferase inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (W1048*), NF1 MUT (Q554*) | Different Alteration | Selumetinib (MEK inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (W1048*), NF1 MUT (Q554*) | Different Alteration | Retinoic Acid | Resistant | NB | Pre-clinical |
| NF1 | NF1 MUT (W1048*), NF1 MUT (Q554*) | Different Alteration | Everolimus (MTOR inhibitor) | No Responsive | MPN | Early trials |
| NF1 | NF1 MUT (W1048*), NF1 MUT (Q554*) | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (W1048*), NF1 MUT (Q554*) | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | PLEN, MPN | Pre-clinical |
| NF1 | NF1 MUT (W1048*), NF1 MUT (Q554*) | Different Alteration | Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (W1048*), NF1 MUT (Q554*) | Different Alteration | Trametinib (MEK inhibitor) | Responsive | CM | Pre-clinical |
| NF1 | NF1 MUT (W1048*), NF1 MUT (Q554*) | Different Alteration | AURK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (W1048*), NF1 MUT (Q554*) | Different Alteration | Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | No Responsive | G | Case report |
| NF1 | NF1 MUT (W1048*), NF1 MUT (Q554*) | Different Alteration | PD1 Ab inhibitor | Responsive | CM | Early trials |
| NF1 | NF1 MUT (W1048*), NF1 MUT (Q554*) | Different Alteration | MEK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (W1048*), NF1 MUT (Q554*) | Different Alteration | KIT inhibitor;MTOR inhibitor | Responsive | MPN | Pre-clinical |
| TP53 | TP53 MUT (R248W) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (R248W) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (R248W) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (R248W) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (R248W) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (R248W) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (R248W) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R248W) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R248W) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (R248W) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (R248W) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R248W) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (R248W) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (R248W) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (R248W) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (V274F) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (V274F) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (V274F) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (V274F) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (V274F) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (V274F) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (V274F) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (V274F) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (V274F) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (V274F) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (V274F) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (V274F) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (V274F) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (V274F) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (V274F) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| RET | RET MUT* (T636T) | Different Alteration | Nintedanib (Pan-TK inhibitor) | Responsive | LUAD | Case report |
| RET | RET MUT* (T636T) | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Early trials |
| RET | RET MUT* (T636T) | Different Alteration | RET inhibitor | Responsive | LUAD | Pre-clinical |
| RET | RET MUT* (T636T) | Different Alteration | Vandetanib (Pan-TK inhibitor) | Responsive | LUAD | Early trials |
| RET | RET MUT* (T636T) | Different Alteration | Sunitinib (Pan-TK inhibitor) | Responsive | LUAD | Early trials |
| RET | RET MUT* (T636T) | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | THCA | Pre-clinical |
| RET | RET MUT* (T636T) | Different Alteration | Vandetanib (Pan-TK inhibitor) | Responsive | THCA | Pre-clinical |
| RET | RET MUT* (T636T) | Different Alteration | Sunitinib (Pan-TK inhibitor) | Responsive | THCA | Pre-clinical |
| RET | RET MUT* (T636T) | Different Alteration | RET inhibitor | Responsive | TH | Pre-clinical |
| PIK3CA | PIK3CA MUT (Q546P) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (Q546P) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (Q546P) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (Q546P) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (Q546P) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (Q546P) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (Q546P) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (Q546P) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (Q546P) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (Q546P) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (Q546P) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (Q546P) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (Q546P) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (Q546P) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| JAK2 | JAK2 MUT* (Y44*) | Different Alteration | Ruxolitinib (JAK inhibitor) | Responsive | ALL | Pre-clinical |
| ROS1 | ROS1 MUT* (R1182S) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | IM | Case report |
| ROS1 | ROS1 MUT* (R1182S) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ROS1 | ROS1 MUT* (R1182S) | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Case report |
| ROS1 | ROS1 MUT* (R1182S) | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Pre-clinical |
| ROS1 | ROS1 MUT* (R1182S) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Early trials |
| TP53 | TP53 MUT (G199V) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (G199V) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (G199V) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (G199V) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (G199V) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (G199V) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (G199V) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (G199V) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (G199V) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (G199V) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (G199V) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (G199V) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (G199V) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (G199V) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (G199V) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (C141Y) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (C141Y) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (C141Y) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (C141Y) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (C141Y) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (C141Y) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (C141Y) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (C141Y) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (C141Y) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (C141Y) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (C141Y) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (C141Y) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (C141Y) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (C141Y) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (C141Y) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| NF1 | NF1 MUT (W571*) | Different Mutation | Vemurafenib (BRAF inhibitor) | Resistant | CM | Pre-clinical |
| NF1 | NF1 MUT (W571*) | Different Mutation | Everolimus (MTOR inhibitor) | Responsive | HNC | Case report |
| NF1 | NF1 MUT (W571*) | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (W571*) | Complete Match | Vinblastine (Chemotherapy) | Responsive | G | Early trials |
| NF1 | NF1 MUT (W571*) | Complete Match | KIT inhibitor;MTOR inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (W571*) | Complete Match | Tamoxifen (Hormonal therapy) | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (W571*) | Complete Match | Bevacizumab (VEGFR mAb inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (W571*) | Complete Match | Retinoic Acid | Resistant | NB | Pre-clinical |
| NF1 | NF1 MUT (W571*) | Complete Match | Everolimus (MTOR inhibitor) | Responsive | NF | Late trials |
| NF1 | NF1 MUT (W571*) | Complete Match | Trametinib (MEK inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (W571*) | Complete Match | Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (W571*) | Complete Match | Nilotinib (BCR-ABL inhibitor) | Responsive | MPN, PLEN | Pre-clinical |
| NF1 | NF1 MUT (W571*) | Complete Match | MEK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (W571*) | Complete Match | Everolimus (MTOR inhibitor) | Responsive | HNC, SG | Case report |
| NF1 | NF1 MUT (W571*) | Complete Match | Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) | No Responsive | MPN | Early trials |
| NF1 | NF1 MUT (W571*) | Complete Match | PLX3397 (Pan-TK inhibitor) | Responsive | PLEN | Pre-clinical |
| NF1 | NF1 MUT (W571*) | Complete Match | MEK inhibitor | Responsive | LK, G | Pre-clinical |
| NF1 | NF1 MUT (W571*) | Complete Match | Pan-RAF inhibitor;MEK inhibitor | Responsive | CM | Pre-clinical |
| NF1 | NF1 MUT (W571*) | Complete Match | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (W571*) | Complete Match | AURK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (W571*) | Complete Match | MTOR inhibitor | Responsive | LK, G, MPN | Pre-clinical |
| NF1 | NF1 MUT (W571*) | Complete Match | Dasatinib (BCR-ABL inhibitor) | Resistant | L | Pre-clinical |
| NF1 | NF1 MUT (W571*) | Complete Match | Everolimus;Pazopanib (MTOR inhibitor;VEGFR inhibitor) | Responsive | HC | Case report |
| NF1 | NF1 MUT (W571*) | Complete Match | Everolimus (MTOR inhibitor) | No Responsive | MPN | Early trials |
| NF1 | NF1 MUT (W571*) | Complete Match | Cediranib (ALK inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (W571*) | Complete Match | PD1 Ab inhibitor | Responsive | CM | Early trials |
| NF1 | NF1 MUT (W571*) | Complete Match | Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (W571*) | Complete Match | Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (W571*) | Complete Match | Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | No Responsive | G | Case report |
| NF1 | NF1 MUT (W571*) | Complete Match | BRD4 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (W571*) | Complete Match | Tipifarnib (Farnesyltransferase inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (W571*) | Complete Match | Selumetinib (MEK inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (W571*) | Complete Match | MTOR inhibitor;HSP90 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (W571*) | Complete Match | Trametinib (MEK inhibitor) | Responsive | CM | Pre-clinical |
| NF1 | NF1 MUT (W571*) | Complete Match | Erlotinib (EGFR inhibitor) | Resistant | L | Pre-clinical |
| NF1 | NF1 MUT (W571*) | Complete Match | Trametinib (MEK inhibitor) | No Responsive | OS | Case report |
| NF1 | NF1 MUT (W571*) | Different Alteration | MTOR inhibitor | Responsive | MPN, G, LK | Pre-clinical |
| NF1 | NF1 MUT (W571*) | Different Alteration | PLX3397 (Pan-TK inhibitor) | Responsive | PLEN | Pre-clinical |
| NF1 | NF1 MUT (W571*) | Different Alteration | Erlotinib (EGFR inhibitor) | Resistant | L | Pre-clinical |
| NF1 | NF1 MUT (W571*) | Different Alteration | Trametinib (MEK inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (W571*) | Different Alteration | BRD4 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (W571*) | Different Alteration | Trametinib (MEK inhibitor) | No Responsive | OS | Case report |
| NF1 | NF1 MUT (W571*) | Different Alteration | Cediranib (ALK inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (W571*) | Different Alteration | Bevacizumab (VEGFR mAb inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (W571*) | Different Alteration | MEK inhibitor | Responsive | G, LK | Pre-clinical |
| NF1 | NF1 MUT (W571*) | Different Alteration | Vinblastine (Chemotherapy) | Responsive | G | Early trials |
| NF1 | NF1 MUT (W571*) | Different Alteration | Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (W571*) | Different Alteration | Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) | No Responsive | MPN | Early trials |
| NF1 | NF1 MUT (W571*) | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Resistant | L | Pre-clinical |
| NF1 | NF1 MUT (W571*) | Different Alteration | MTOR inhibitor;HSP90 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (W571*) | Different Alteration | Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (W571*) | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (W571*) | Different Alteration | Tamoxifen (Hormonal therapy) | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (W571*) | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | SG, HNC | Case report |
| NF1 | NF1 MUT (W571*) | Different Alteration | Pan-RAF inhibitor;MEK inhibitor | Responsive | CM | Pre-clinical |
| NF1 | NF1 MUT (W571*) | Different Alteration | Tipifarnib (Farnesyltransferase inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (W571*) | Different Alteration | Selumetinib (MEK inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (W571*) | Different Alteration | Retinoic Acid | Resistant | NB | Pre-clinical |
| NF1 | NF1 MUT (W571*) | Different Alteration | Everolimus (MTOR inhibitor) | No Responsive | MPN | Early trials |
| NF1 | NF1 MUT (W571*) | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (W571*) | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | PLEN, MPN | Pre-clinical |
| NF1 | NF1 MUT (W571*) | Different Alteration | Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (W571*) | Different Alteration | Trametinib (MEK inhibitor) | Responsive | CM | Pre-clinical |
| NF1 | NF1 MUT (W571*) | Different Alteration | AURK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (W571*) | Different Alteration | Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | No Responsive | G | Case report |
| NF1 | NF1 MUT (W571*) | Different Alteration | PD1 Ab inhibitor | Responsive | CM | Early trials |
| NF1 | NF1 MUT (W571*) | Different Alteration | MEK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (W571*) | Different Alteration | KIT inhibitor;MTOR inhibitor | Responsive | MPN | Pre-clinical |
| SETD2 | SETD2 MUT (S180*) | Complete Match | WEE1 inhibitor | Responsive | CANCER | Pre-clinical |
| SETD2 | SETD2 MUT (S180*) | Different Alteration | WEE1 inhibitor | Responsive | CANCER | Pre-clinical |
| KMT2A | MLL MUT* (Q900*) | Different Alteration | EPZ-5676 (DOT1L inhibitor) | Responsive | ALL, MDS, AML | Early trials |
| KMT2A | MLL MUT* (Q900*) | Different Alteration | BET inhibitor | Responsive | ALL | Pre-clinical |
| KMT2A | MLL MUT* (Q900*) | Different Alteration | BET inhibitor | Responsive | AML | Pre-clinical |
| KMT2A | MLL MUT* (Q900*) | Different Alteration | Daunorubicin (Chemotherapy) | Responsive | AML | FDA guidelines |
| KMT2A | MLL MUT* (Q900*) | Different Alteration | Belinostat (HDAC inhibitor) | Responsive | AML | Early trials |
| KMT2A | MLL MUT* (Q900*) | Different Alteration | DOT1L inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (Y205C) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (Y205C) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (Y205C) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (Y205C) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (Y205C) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (Y205C) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (Y205C) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Y205C) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Y205C) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (Y205C) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (Y205C) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Y205C) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (Y205C) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (Y205C) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (Y205C) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| FBXW7 | FBXW7 MUT (R479Q) | Complete Match | Steroid | Responsive | ALL | Late trials |
| FBXW7 | FBXW7 MUT (R479Q) | Complete Match | Tubulin inhibitor | Resistant | CANCER | Pre-clinical |
| FBXW7 | FBXW7 MUT (R479Q) | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | COREAD | Pre-clinical |
| FBXW7 | FBXW7 MUT (R479Q) | Different Alteration | Tubulin inhibitor | Resistant | CANCER | Pre-clinical |
| JAK2 | JAK2 MUT* (I77I) | Different Alteration | Ruxolitinib (JAK inhibitor) | Responsive | ALL | Pre-clinical |
| SMARCA1 | SMARCA1 MUT (splice_acceptor_variant) | Complete Match | EZH2 inhibitor | Responsive | CANCER | Pre-clinical |
| PIK3CA | PIK3CA MUT (M1004I), PIK3CA MUT (E545K), PIK3CA MUT (E726K) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (M1004I), PIK3CA MUT (E545K), PIK3CA MUT (E726K) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (M1004I), PIK3CA MUT (E545K), PIK3CA MUT (E726K) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (M1004I), PIK3CA MUT (E545K), PIK3CA MUT (E726K) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (M1004I), PIK3CA MUT (E545K), PIK3CA MUT (E726K) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (M1004I), PIK3CA MUT (E545K), PIK3CA MUT (E726K) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (M1004I), PIK3CA MUT (E545K), PIK3CA MUT (E726K) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (M1004I), PIK3CA MUT (E545K), PIK3CA MUT (E726K) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (M1004I), PIK3CA MUT (E545K), PIK3CA MUT (E726K) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (M1004I), PIK3CA MUT (E545K), PIK3CA MUT (E726K) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (M1004I), PIK3CA MUT (E545K), PIK3CA MUT (E726K) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (M1004I), PIK3CA MUT (E545K), PIK3CA MUT (E726K) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (M1004I), PIK3CA MUT (E545K), PIK3CA MUT (E726K) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (M1004I), PIK3CA MUT (E545K), PIK3CA MUT (E726K) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| TP53 | TP53 MUT (E287D), TP53 MUT (R280T) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (E287D), TP53 MUT (R280T) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (E287D), TP53 MUT (R280T) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (E287D), TP53 MUT (R280T) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (E287D), TP53 MUT (R280T) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (E287D), TP53 MUT (R280T) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (E287D), TP53 MUT (R280T) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (E287D), TP53 MUT (R280T) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (E287D), TP53 MUT (R280T) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (E287D), TP53 MUT (R280T) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (E287D), TP53 MUT (R280T) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (E287D), TP53 MUT (R280T) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (E287D), TP53 MUT (R280T) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (E287D), TP53 MUT (R280T) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (E287D), TP53 MUT (R280T) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| BRCA1 | BRCA1 MUT (G1788V) | Complete Match | Chemotherapy (PARP inhibitor;Chemotherapy) | Responsive | OV | Early trials |
| BRCA1 | BRCA1 MUT (G1788V) | Complete Match | PARP inhibitor | Responsive | BRCA | Early trials |
| BRCA1 | BRCA1 MUT (G1788V) | Complete Match | PARP inhibitor;Chemotherapy | Responsive | OV | Early trials |
| BRCA1 | BRCA1 MUT (G1788V) | Complete Match | Rucaparib (PARP inhibitor) | Responsive | OV | FDA guidelines |
| BRCA1 | BRCA1 MUT (G1788V) | Complete Match | Platinum Agent (Chemotherapy) | Responsive | BRCA | Early trials |
| BRCA1 | BRCA1 MUT (G1788V) | Complete Match | WEE1 inhibitor | Responsive | CANCER | Case report |
| BRCA1 | BRCA1 MUT (G1788V) | Complete Match | Platinum Agent (Chemotherapy) | Responsive | OV | Late trials |
| BRCA1 | BRCA1 MUT (G1788V) | Complete Match | Olaparib (PARP inhibitor) | Responsive | PRAD | Early trials |
| BRCA1 | BRCA1 MUT (G1788V) | Complete Match | Veliparib;Cisplatin (PARP inhibitor;Chemotherapy) | Responsive | BRCA | Early trials |
| BRCA1 | BRCA1 MUT (G1788V) | Complete Match | PARP inhibitor | Responsive | PA | Case report |
| BRCA1 | BRCA1 MUT (G1788V) | Complete Match | Olaparib (PARP inhibitor) | Responsive | OV | FDA guidelines |
| BRCA1 | BRCA1 MUT (G1788V) | Different Alteration | PARP inhibitor | Responsive | OV | Pre-clinical |
| PTEN | PTEN MUT (C124S) | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | PTEN MUT (C124S) | Different Mutation | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | PTEN MUT (C124S) | Different Mutation | BYL719 (PIK3CA inhibitor) | Resistant | BRCA | Case report |
| PTEN | PTEN MUT (C124S) | Complete Match | ATM inhibitor | Responsive | BRCA | Pre-clinical |
| PTEN | PTEN MUT (C124S) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA, ED, TH, CANCER, L, G, OV | Pre-clinical |
| PTEN | PTEN MUT (C124S) | Complete Match | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | PTEN MUT (C124S) | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | PTEN MUT (C124S) | Complete Match | PARP inhibitor | Responsive | ED | Case report |
| PTEN | PTEN MUT (C124S) | Complete Match | PD1 Ab inhibitor | Resistant | CM | Early trials |
| PTEN | PTEN MUT (C124S) | Complete Match | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | PTEN MUT (C124S) | Complete Match | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | PTEN MUT (C124S) | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| PTEN | PTEN MUT (C124S) | Complete Match | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | PTEN MUT (C124S) | Complete Match | AKT inhibitor | Responsive | PA | Case report |
| PTEN | PTEN MUT (C124S) | Complete Match | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | PTEN MUT (C124S) | Different Alteration | PI3K pathway inhibitor | Responsive | L, BRCA, CANCER, G, ED, TH, OV | Pre-clinical |
| PTEN | PTEN MUT (C124S) | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | PTEN MUT (C124S) | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | PTEN MUT (C124S) | Different Alteration | PARP inhibitor | Responsive | ED | Case report |
| PTEN | PTEN MUT (C124S) | Different Alteration | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | PTEN MUT (C124S) | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | PTEN MUT (C124S) | Different Alteration | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | PTEN MUT (C124S) | Different Alteration | AKT inhibitor | Responsive | PA | Case report |
| PTEN | PTEN MUT (C124S) | Different Alteration | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | PTEN MUT (C124S) | Different Alteration | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| CDH1 | CDH1 MUT (splice_acceptor_variant) | Complete Match | Bicalutamide (AR inhibitor) | Responsive | BRCA | Pre-clinical |
| PTEN | PTEN MUT (splice_donor_variant) | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | PTEN MUT (splice_donor_variant) | Different Mutation | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | PTEN MUT (splice_donor_variant) | Different Mutation | BYL719 (PIK3CA inhibitor) | Resistant | BRCA | Case report |
| PTEN | PTEN MUT (splice_donor_variant) | Complete Match | ATM inhibitor | Responsive | BRCA | Pre-clinical |
| PTEN | PTEN MUT (splice_donor_variant) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA, ED, TH, CANCER, L, G, OV | Pre-clinical |
| PTEN | PTEN MUT (splice_donor_variant) | Complete Match | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | PTEN MUT (splice_donor_variant) | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | PTEN MUT (splice_donor_variant) | Complete Match | PARP inhibitor | Responsive | ED | Case report |
| PTEN | PTEN MUT (splice_donor_variant) | Complete Match | PD1 Ab inhibitor | Resistant | CM | Early trials |
| PTEN | PTEN MUT (splice_donor_variant) | Complete Match | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | PTEN MUT (splice_donor_variant) | Complete Match | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | PTEN MUT (splice_donor_variant) | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| PTEN | PTEN MUT (splice_donor_variant) | Complete Match | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | PTEN MUT (splice_donor_variant) | Complete Match | AKT inhibitor | Responsive | PA | Case report |
| PTEN | PTEN MUT (splice_donor_variant) | Complete Match | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | PTEN MUT (splice_donor_variant) | Different Alteration | PI3K pathway inhibitor | Responsive | L, BRCA, CANCER, G, ED, TH, OV | Pre-clinical |
| PTEN | PTEN MUT (splice_donor_variant) | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | PTEN MUT (splice_donor_variant) | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | PTEN MUT (splice_donor_variant) | Different Alteration | PARP inhibitor | Responsive | ED | Case report |
| PTEN | PTEN MUT (splice_donor_variant) | Different Alteration | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | PTEN MUT (splice_donor_variant) | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | PTEN MUT (splice_donor_variant) | Different Alteration | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | PTEN MUT (splice_donor_variant) | Different Alteration | AKT inhibitor | Responsive | PA | Case report |
| PTEN | PTEN MUT (splice_donor_variant) | Different Alteration | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | PTEN MUT (splice_donor_variant) | Different Alteration | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| ERBB4 | ERBB4 MUT* (L1008L) | Different Alteration | Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) | Responsive | LUAD | Pre-clinical |
| SF3B1 | SF3B1 MUT (K666E) | Different Mutation | Spliceosome inhibitor | Responsive | CANCER | Pre-clinical |
| KMT2A | MLL MUT* (R613Q), MLL MUT* (S2170N) | Different Alteration | EPZ-5676 (DOT1L inhibitor) | Responsive | ALL, MDS, AML | Early trials |
| KMT2A | MLL MUT* (R613Q), MLL MUT* (S2170N) | Different Alteration | BET inhibitor | Responsive | ALL | Pre-clinical |
| KMT2A | MLL MUT* (R613Q), MLL MUT* (S2170N) | Different Alteration | BET inhibitor | Responsive | AML | Pre-clinical |
| KMT2A | MLL MUT* (R613Q), MLL MUT* (S2170N) | Different Alteration | Daunorubicin (Chemotherapy) | Responsive | AML | FDA guidelines |
| KMT2A | MLL MUT* (R613Q), MLL MUT* (S2170N) | Different Alteration | Belinostat (HDAC inhibitor) | Responsive | AML | Early trials |
| KMT2A | MLL MUT* (R613Q), MLL MUT* (S2170N) | Different Alteration | DOT1L inhibitor | Responsive | AML | Early trials |
| NOTCH2 | NOTCH2 MUT* (A422T) | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| ROS1 | ROS1 MUT* (3-UTRSNV) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | IM | Case report |
| ROS1 | ROS1 MUT* (3-UTRSNV) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ROS1 | ROS1 MUT* (3-UTRSNV) | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Case report |
| ROS1 | ROS1 MUT* (3-UTRSNV) | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Pre-clinical |
| ROS1 | ROS1 MUT* (3-UTRSNV) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (P213L) | Different Alteration | ALK inhibitor;SRC inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (P213L) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | GB, LY | Early trials |
| ALK | ALK MUT* (P213L) | Different Alteration | Lorlatinib (ALK&ROS1 inhibitor) | Responsive | NSCLC | Early trials |
| ALK | ALK MUT* (P213L) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | THCA, IM | Case report |
| ALK | ALK MUT* (P213L) | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (P213L) | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | ALK MUT* (P213L) | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | IM, COREAD | Case report |
| ALK | ALK MUT* (P213L) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | ALK MUT* (P213L) | Different Alteration | Brigatinib (Pan-TK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | ALK MUT* (P213L) | Different Alteration | Entrictinib (Pan-TK inhibitor) | Responsive | COREAD | Case report |
| ALK | ALK MUT* (P213L) | Different Alteration | Alectinib (ALK inhibitor) | Responsive | LUAD | FDA guidelines |
| ALK | ALK MUT* (P213L) | Different Alteration | HSP90 inhibitor (HSP90 inhibitor) | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (P213L) | Different Alteration | ALK inhibitor;IGF1R inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (P213L) | Different Alteration | ALK inhibitor;MEK inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (P213L) | Different Alteration | novel ALK inhibitor | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (P213L) | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | HEMATO | Early trials |
| ALK | ALK MUT* (P213L) | Different Alteration | ALK inhibitor | Responsive | COREAD | Case report |
| ALK | ALK MUT* (P213L) | Different Alteration | Alectinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | ALK MUT* (P213L) | Different Alteration | MEK inhibitor (ALK inhibitor;MEK inhibitor) | Responsive | LUAD | Pre-clinical |
| PDGFRA | PDGFRA MUT* (intron_variant) | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | MDPS, MDS, ECL, HES | FDA guidelines |
| TP53 | TP53 MUT (C176F) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (C176F) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (C176F) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (C176F) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (C176F) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (C176F) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (C176F) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (C176F) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (C176F) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (C176F) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (C176F) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (C176F) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (C176F) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (C176F) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (C176F) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| SF3B1 | SF3B1 MUT (N626D) | Different Mutation | Spliceosome inhibitor | Responsive | CANCER | Pre-clinical |
| DNMT3A | DNMT3A MUT (R882H) | Complete Match | Daunorubicin (Chemotherapy) | Responsive | AML | FDA guidelines |
| RB1 | RB1 MUT (S829*) | Different Alteration | Palbociclib (CDK4/6 inhibitor) | Responsive | PRAD | Pre-clinical |
| RB1 | RB1 MUT (S829*) | Complete Match | MDM2/MDMX inhibitor | Responsive | RB | Pre-clinical |
| RB1 | RB1 MUT (S829*) | Complete Match | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| RB1 | RB1 MUT (S829*) | Complete Match | HDAC inhibitor | Responsive | RB | Pre-clinical |
| RB1 | RB1 MUT (S829*) | Different Alteration | MDM2/MDMX inhibitor | Responsive | RB | Pre-clinical |
| RB1 | RB1 MUT (S829*) | Different Alteration | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| RB1 | RB1 MUT (S829*) | Different Alteration | HDAC inhibitor | Responsive | RB | Pre-clinical |
| NF1 | NF1 MUT (Q209*) | Different Mutation | Vemurafenib (BRAF inhibitor) | Resistant | CM | Pre-clinical |
| NF1 | NF1 MUT (Q209*) | Different Mutation | Everolimus (MTOR inhibitor) | Responsive | HNC | Case report |
| NF1 | NF1 MUT (Q209*) | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (Q209*) | Complete Match | Vinblastine (Chemotherapy) | Responsive | G | Early trials |
| NF1 | NF1 MUT (Q209*) | Complete Match | KIT inhibitor;MTOR inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (Q209*) | Complete Match | Tamoxifen (Hormonal therapy) | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (Q209*) | Complete Match | Bevacizumab (VEGFR mAb inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (Q209*) | Complete Match | Retinoic Acid | Resistant | NB | Pre-clinical |
| NF1 | NF1 MUT (Q209*) | Complete Match | Everolimus (MTOR inhibitor) | Responsive | NF | Late trials |
| NF1 | NF1 MUT (Q209*) | Complete Match | Trametinib (MEK inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (Q209*) | Complete Match | Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (Q209*) | Complete Match | Nilotinib (BCR-ABL inhibitor) | Responsive | MPN, PLEN | Pre-clinical |
| NF1 | NF1 MUT (Q209*) | Complete Match | MEK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (Q209*) | Complete Match | Everolimus (MTOR inhibitor) | Responsive | HNC, SG | Case report |
| NF1 | NF1 MUT (Q209*) | Complete Match | Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) | No Responsive | MPN | Early trials |
| NF1 | NF1 MUT (Q209*) | Complete Match | PLX3397 (Pan-TK inhibitor) | Responsive | PLEN | Pre-clinical |
| NF1 | NF1 MUT (Q209*) | Complete Match | MEK inhibitor | Responsive | LK, G | Pre-clinical |
| NF1 | NF1 MUT (Q209*) | Complete Match | Pan-RAF inhibitor;MEK inhibitor | Responsive | CM | Pre-clinical |
| NF1 | NF1 MUT (Q209*) | Complete Match | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (Q209*) | Complete Match | AURK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (Q209*) | Complete Match | MTOR inhibitor | Responsive | LK, G, MPN | Pre-clinical |
| NF1 | NF1 MUT (Q209*) | Complete Match | Dasatinib (BCR-ABL inhibitor) | Resistant | L | Pre-clinical |
| NF1 | NF1 MUT (Q209*) | Complete Match | Everolimus;Pazopanib (MTOR inhibitor;VEGFR inhibitor) | Responsive | HC | Case report |
| NF1 | NF1 MUT (Q209*) | Complete Match | Everolimus (MTOR inhibitor) | No Responsive | MPN | Early trials |
| NF1 | NF1 MUT (Q209*) | Complete Match | Cediranib (ALK inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (Q209*) | Complete Match | PD1 Ab inhibitor | Responsive | CM | Early trials |
| NF1 | NF1 MUT (Q209*) | Complete Match | Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (Q209*) | Complete Match | Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (Q209*) | Complete Match | Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | No Responsive | G | Case report |
| NF1 | NF1 MUT (Q209*) | Complete Match | BRD4 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (Q209*) | Complete Match | Tipifarnib (Farnesyltransferase inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (Q209*) | Complete Match | Selumetinib (MEK inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (Q209*) | Complete Match | MTOR inhibitor;HSP90 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (Q209*) | Complete Match | Trametinib (MEK inhibitor) | Responsive | CM | Pre-clinical |
| NF1 | NF1 MUT (Q209*) | Complete Match | Erlotinib (EGFR inhibitor) | Resistant | L | Pre-clinical |
| NF1 | NF1 MUT (Q209*) | Complete Match | Trametinib (MEK inhibitor) | No Responsive | OS | Case report |
| NF1 | NF1 MUT (Q209*) | Different Alteration | MTOR inhibitor | Responsive | MPN, G, LK | Pre-clinical |
| NF1 | NF1 MUT (Q209*) | Different Alteration | PLX3397 (Pan-TK inhibitor) | Responsive | PLEN | Pre-clinical |
| NF1 | NF1 MUT (Q209*) | Different Alteration | Erlotinib (EGFR inhibitor) | Resistant | L | Pre-clinical |
| NF1 | NF1 MUT (Q209*) | Different Alteration | Trametinib (MEK inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (Q209*) | Different Alteration | BRD4 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (Q209*) | Different Alteration | Trametinib (MEK inhibitor) | No Responsive | OS | Case report |
| NF1 | NF1 MUT (Q209*) | Different Alteration | Cediranib (ALK inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (Q209*) | Different Alteration | Bevacizumab (VEGFR mAb inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (Q209*) | Different Alteration | MEK inhibitor | Responsive | G, LK | Pre-clinical |
| NF1 | NF1 MUT (Q209*) | Different Alteration | Vinblastine (Chemotherapy) | Responsive | G | Early trials |
| NF1 | NF1 MUT (Q209*) | Different Alteration | Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (Q209*) | Different Alteration | Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) | No Responsive | MPN | Early trials |
| NF1 | NF1 MUT (Q209*) | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Resistant | L | Pre-clinical |
| NF1 | NF1 MUT (Q209*) | Different Alteration | MTOR inhibitor;HSP90 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (Q209*) | Different Alteration | Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (Q209*) | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (Q209*) | Different Alteration | Tamoxifen (Hormonal therapy) | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (Q209*) | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | SG, HNC | Case report |
| NF1 | NF1 MUT (Q209*) | Different Alteration | Pan-RAF inhibitor;MEK inhibitor | Responsive | CM | Pre-clinical |
| NF1 | NF1 MUT (Q209*) | Different Alteration | Tipifarnib (Farnesyltransferase inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (Q209*) | Different Alteration | Selumetinib (MEK inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (Q209*) | Different Alteration | Retinoic Acid | Resistant | NB | Pre-clinical |
| NF1 | NF1 MUT (Q209*) | Different Alteration | Everolimus (MTOR inhibitor) | No Responsive | MPN | Early trials |
| NF1 | NF1 MUT (Q209*) | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (Q209*) | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | PLEN, MPN | Pre-clinical |
| NF1 | NF1 MUT (Q209*) | Different Alteration | Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (Q209*) | Different Alteration | Trametinib (MEK inhibitor) | Responsive | CM | Pre-clinical |
| NF1 | NF1 MUT (Q209*) | Different Alteration | AURK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (Q209*) | Different Alteration | Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | No Responsive | G | Case report |
| NF1 | NF1 MUT (Q209*) | Different Alteration | PD1 Ab inhibitor | Responsive | CM | Early trials |
| NF1 | NF1 MUT (Q209*) | Different Alteration | MEK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (Q209*) | Different Alteration | KIT inhibitor;MTOR inhibitor | Responsive | MPN | Pre-clinical |
| PIK3CA | PIK3CA MUT (E726K), PIK3CA MUT (H1047R) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (E726K), PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (E726K), PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (E726K), PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (E726K), PIK3CA MUT (H1047R) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (E726K), PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (E726K), PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (E726K), PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (E726K), PIK3CA MUT (H1047R) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (E726K), PIK3CA MUT (H1047R) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (E726K), PIK3CA MUT (H1047R) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (E726K), PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (E726K), PIK3CA MUT (H1047R) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (E726K), PIK3CA MUT (H1047R) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| ATM | ATM MUT (Q2269*) | Different Mutation | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| ATM | ATM MUT (Q2269*) | Complete Match | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| ATM | ATM MUT (Q2269*) | Complete Match | Olaparib (PARP inhibitor) | Responsive | ST, PRAD | Early trials |
| ATM | ATM MUT (Q2269*) | Complete Match | PARP inhibitor | Responsive | ST | Early trials |
| ATM | ATM MUT (Q2269*) | Complete Match | ATR inhibitor | Responsive | COREAD | Case report |
| ATM | ATM MUT (Q2269*) | Complete Match | DNA-PKc inhibitor | Responsive | LY | Pre-clinical |
| ATM | ATM MUT (Q2269*) | Complete Match | Temozolomide (Chemotherapy) | Responsive | G | Pre-clinical |
| ATM | ATM MUT (Q2269*) | Complete Match | PD1/PDL1 inhibitor | Responsive | UTH | Early trials |
| ATM | ATM MUT (Q2269*) | Different Alteration | PD1/PDL1 inhibitor | Responsive | UTH | Early trials |
| ATM | ATM MUT (Q2269*) | Different Alteration | DNA-PKc inhibitor | Responsive | LY | Pre-clinical |
| ATM | ATM MUT (Q2269*) | Different Alteration | PARP inhibitor | Responsive | ST | Early trials |
| ATM | ATM MUT (Q2269*) | Different Alteration | ATR inhibitor | Responsive | COREAD | Case report |
| ATM | ATM MUT (Q2269*) | Different Alteration | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| ALK | ALK MUT* (N1544N) | Different Alteration | ALK inhibitor;SRC inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (N1544N) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | GB, LY | Early trials |
| ALK | ALK MUT* (N1544N) | Different Alteration | Lorlatinib (ALK&ROS1 inhibitor) | Responsive | NSCLC | Early trials |
| ALK | ALK MUT* (N1544N) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | THCA, IM | Case report |
| ALK | ALK MUT* (N1544N) | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (N1544N) | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | ALK MUT* (N1544N) | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | IM, COREAD | Case report |
| ALK | ALK MUT* (N1544N) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | ALK MUT* (N1544N) | Different Alteration | Brigatinib (Pan-TK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | ALK MUT* (N1544N) | Different Alteration | Entrictinib (Pan-TK inhibitor) | Responsive | COREAD | Case report |
| ALK | ALK MUT* (N1544N) | Different Alteration | Alectinib (ALK inhibitor) | Responsive | LUAD | FDA guidelines |
| ALK | ALK MUT* (N1544N) | Different Alteration | HSP90 inhibitor (HSP90 inhibitor) | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (N1544N) | Different Alteration | ALK inhibitor;IGF1R inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (N1544N) | Different Alteration | ALK inhibitor;MEK inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (N1544N) | Different Alteration | novel ALK inhibitor | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (N1544N) | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | HEMATO | Early trials |
| ALK | ALK MUT* (N1544N) | Different Alteration | ALK inhibitor | Responsive | COREAD | Case report |
| ALK | ALK MUT* (N1544N) | Different Alteration | Alectinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | ALK MUT* (N1544N) | Different Alteration | MEK inhibitor (ALK inhibitor;MEK inhibitor) | Responsive | LUAD | Pre-clinical |
| TP53 | TP53 MUT (Y126C) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (Y126C) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (Y126C) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (Y126C) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (Y126C) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (Y126C) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (Y126C) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Y126C) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Y126C) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (Y126C) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (Y126C) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Y126C) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (Y126C) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (Y126C) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (Y126C) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| RB1 | RB1 MUT (S215*) | Different Alteration | Palbociclib (CDK4/6 inhibitor) | Responsive | PRAD | Pre-clinical |
| RB1 | RB1 MUT (S215*) | Complete Match | MDM2/MDMX inhibitor | Responsive | RB | Pre-clinical |
| RB1 | RB1 MUT (S215*) | Complete Match | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| RB1 | RB1 MUT (S215*) | Complete Match | HDAC inhibitor | Responsive | RB | Pre-clinical |
| RB1 | RB1 MUT (S215*) | Different Alteration | MDM2/MDMX inhibitor | Responsive | RB | Pre-clinical |
| RB1 | RB1 MUT (S215*) | Different Alteration | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| RB1 | RB1 MUT (S215*) | Different Alteration | HDAC inhibitor | Responsive | RB | Pre-clinical |
| CDH1 | CDH1 MUT (W103*) | Complete Match | Bicalutamide (AR inhibitor) | Responsive | BRCA | Pre-clinical |
| BRCA1 | BRCA1 MUT (E720*) | Complete Match | Chemotherapy (PARP inhibitor;Chemotherapy) | Responsive | OV | Early trials |
| BRCA1 | BRCA1 MUT (E720*) | Complete Match | PARP inhibitor | Responsive | BRCA | Early trials |
| BRCA1 | BRCA1 MUT (E720*) | Complete Match | PARP inhibitor;Chemotherapy | Responsive | OV | Early trials |
| BRCA1 | BRCA1 MUT (E720*) | Complete Match | Rucaparib (PARP inhibitor) | Responsive | OV | FDA guidelines |
| BRCA1 | BRCA1 MUT (E720*) | Complete Match | Platinum Agent (Chemotherapy) | Responsive | BRCA | Early trials |
| BRCA1 | BRCA1 MUT (E720*) | Complete Match | WEE1 inhibitor | Responsive | CANCER | Case report |
| BRCA1 | BRCA1 MUT (E720*) | Complete Match | Platinum Agent (Chemotherapy) | Responsive | OV | Late trials |
| BRCA1 | BRCA1 MUT (E720*) | Complete Match | Olaparib (PARP inhibitor) | Responsive | PRAD | Early trials |
| BRCA1 | BRCA1 MUT (E720*) | Complete Match | Veliparib;Cisplatin (PARP inhibitor;Chemotherapy) | Responsive | BRCA | Early trials |
| BRCA1 | BRCA1 MUT (E720*) | Complete Match | PARP inhibitor | Responsive | PA | Case report |
| BRCA1 | BRCA1 MUT (E720*) | Complete Match | Olaparib (PARP inhibitor) | Responsive | OV | FDA guidelines |
| BRCA1 | BRCA1 MUT (E720*) | Different Alteration | PARP inhibitor | Responsive | OV | Pre-clinical |
| PTEN | PTEN MUT (K266*) | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | PTEN MUT (K266*) | Different Mutation | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | PTEN MUT (K266*) | Different Mutation | BYL719 (PIK3CA inhibitor) | Resistant | BRCA | Case report |
| PTEN | PTEN MUT (K266*) | Complete Match | ATM inhibitor | Responsive | BRCA | Pre-clinical |
| PTEN | PTEN MUT (K266*) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA, ED, TH, CANCER, L, G, OV | Pre-clinical |
| PTEN | PTEN MUT (K266*) | Complete Match | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | PTEN MUT (K266*) | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | PTEN MUT (K266*) | Complete Match | PARP inhibitor | Responsive | ED | Case report |
| PTEN | PTEN MUT (K266*) | Complete Match | PD1 Ab inhibitor | Resistant | CM | Early trials |
| PTEN | PTEN MUT (K266*) | Complete Match | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | PTEN MUT (K266*) | Complete Match | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | PTEN MUT (K266*) | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| PTEN | PTEN MUT (K266*) | Complete Match | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | PTEN MUT (K266*) | Complete Match | AKT inhibitor | Responsive | PA | Case report |
| PTEN | PTEN MUT (K266*) | Complete Match | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | PTEN MUT (K266*) | Different Alteration | PI3K pathway inhibitor | Responsive | L, BRCA, CANCER, G, ED, TH, OV | Pre-clinical |
| PTEN | PTEN MUT (K266*) | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | PTEN MUT (K266*) | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | PTEN MUT (K266*) | Different Alteration | PARP inhibitor | Responsive | ED | Case report |
| PTEN | PTEN MUT (K266*) | Different Alteration | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | PTEN MUT (K266*) | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | PTEN MUT (K266*) | Different Alteration | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | PTEN MUT (K266*) | Different Alteration | AKT inhibitor | Responsive | PA | Case report |
| PTEN | PTEN MUT (K266*) | Different Alteration | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | PTEN MUT (K266*) | Different Alteration | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| EGFR | EGFR MUT* (V1200V) | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | L | Case report |
| EGFR | EGFR MUT* (V1200V) | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | NSCLC | Case report |
| PIK3CA | PIK3CA MUT (P539R) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (P539R) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (P539R) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (P539R) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (P539R) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (P539R) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (P539R) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (P539R) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (P539R) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (P539R) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (P539R) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (P539R) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (P539R) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (P539R) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| TP53 | TP53 MUT (R273C) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (R273C) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (R273C) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (R273C) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (R273C) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (R273C) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (R273C) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R273C) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R273C) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (R273C) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (R273C) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R273C) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (R273C) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (R273C) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (R273C) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| BRD4 | BRD4 MUT* (3-UTRSNV) | Different Alteration | BET inhibitor | Responsive | NMC | Case report |
| TP53 | TP53 MUT (D281V) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (D281V) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (D281V) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (D281V) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (D281V) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (D281V) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (D281V) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (D281V) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (D281V) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (D281V) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (D281V) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (D281V) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (D281V) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (D281V) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (D281V) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| ERBB2 | ERBB2 MUT (D769Y) | Different Alteration | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | ERBB2 MUT (D769Y) | Different Alteration | Lapatinib (ERBB2 inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | ERBB2 MUT (D769Y) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | ST, BRCA, GEJA | FDA guidelines |
| ERBB2 | ERBB2 MUT (D769Y) | Different Alteration | Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | ERBB2 MUT (D769Y) | Different Alteration | MK2206;Trastuzumab (allosteric AKT inhibitor;ERBB2 mAb inhibitor) | Responsive | SOLID | Early trials |
| ERBB2 | ERBB2 MUT (D769Y) | Complete Match | Lapatinib (ERBB2 inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (D769Y) | Complete Match | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (D769Y) | Complete Match | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | CANCER, BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (D769Y) | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | CANCER | Early trials |
| ERBB2 | ERBB2 MUT (D769Y) | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Case report |
| ERBB2 | ERBB2 MUT (D769Y) | Different Mutation | Lapatinib (ERBB2 inhibitor) | Responsive | BRCA, LUAD | Case report |
| ERBB2 | ERBB2 MUT (D769Y) | Different Mutation | Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) | Responsive | L | Early trials |
| ERBB2 | ERBB2 MUT (D769Y) | Different Mutation | Neratinib (ERBB2 inhibitor) | Resistant | BRCA | Case report |
| ERBB2 | ERBB2 MUT (D769Y) | Different Mutation | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (D769Y) | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | LUAD | Case report |
| ERBB2 | ERBB2 MUT (D769Y) | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (D769Y) | Different Mutation | Lapatinib (ERBB2 inhibitor) | Resistant | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (D769Y) | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | CANCER | Pre-clinical |
| ERBB2 | ERBB2 MUT (D769Y) | Complete Match | Temsirolimus (MTOR inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (D769Y) | Complete Match | Dacomitinib (Pan ERBB inhibitor) | Responsive | NSCLC | Early trials |
| ERBB2 | ERBB2 MUT (D769Y) | Complete Match | Neratinib (ERBB2 inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (D769Y) | Different Mutation | ERBB2 inhibitor | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (D769Y) | Different Mutation | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (D769Y) | Different Mutation | ERBB2 mAb inhibitor | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (D769Y) | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (D769Y) | Different Mutation | Lapatinib (ERBB2 inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (D769Y) | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (D769Y) | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BRCA | Late trials |
| ERBB2 | ERBB2 MUT (D769Y) | Different Alteration | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | BT | Early trials |
| ERBB2 | ERBB2 MUT (D769Y) | Different Alteration | Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) | Responsive | COREAD | Late trials |
| ERBB2 | ERBB2 MUT (D769Y) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | OV | Early trials |
| ERBB2 | ERBB2 MUT (D769Y) | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BLCA | Case report |
| ERBB2 | ERBB2 MUT (D769Y) | Different Alteration | Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) | Responsive | COREAD | Case report |
| ERBB2 | ERBB2 MUT (D769Y) | Different Alteration | Rociletinib (EGFR inhibitor) | Resistant | LUAD | Case report |
| ERBB2 | ERBB2 MUT (D769Y) | Different Alteration | Osimertinib (EGFR inhibitor) | Resistant | LUAD | Case report |
| ERBB2 | ERBB2 MUT (D769Y) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | BT | Early trials |
| ERBB2 | ERBB2 MUT (D769Y) | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Early trials |
| ERBB2 | ERBB2 MUT (D769Y) | Different Alteration | Lapatinib (ERBB2 inhibitor) | Responsive | BT | Early trials |
| ERBB2 | ERBB2 MUT (D769Y) | Different Alteration | Trastuzumab;HSP90 inhibitor (ERBB2 mAb inhibitor;HSP90 inhibitor) | Responsive | BRCA | Early trials |
| ERBB2 | ERBB2 MUT (D769Y) | Different Alteration | HER2 inhibitor;CDK4/6 inhibitor | Responsive | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (D769Y) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | ERBB2 MUT (D769Y) | Different Alteration | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | ST | Early trials |
| ERBB2 | ERBB2 MUT (D769Y) | Different Alteration | Trastuzumab;Everolimus;Chemotherapy (ERBB2 mAb inhibitor;MTOR inhibitor;Chemotherapy) | Responsive | BRCA | Early trials |
| ERBB2 | ERBB2 MUT (D769Y) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | ST, GEJA | FDA guidelines |
| ERBB2 | ERBB2 MUT (D769Y) | Different Alteration | ERBB2 inhibitor;CDK4/6 inhibitor | Responsive | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (D769Y) | Different Alteration | Ado-Trastuzumab Emtansine (EGFR mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | ERBB2 MUT (D769Y) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | HNC | Case report |
| ERBB2 | ERBB2 MUT (D769Y) | Different Alteration | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Late trials |
| ERBB2 | ERBB2 MUT (D769Y) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | No Responsive | ED | Early trials |
| ERBB2 | ERBB2 MUT (D769Y) | Different Alteration | Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) | Responsive | ED | Pre-clinical |
| ERBB2 | ERBB2 MUT (D769Y) | Different Alteration | Lapatinib;Chemotherapy (ERBB2 inhibitor;Chemotherapy) | Responsive | ST | Early trials |
| ERBB2 | ERBB2 MUT (D769Y) | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | ST | Case report |
| ERBB2 | ERBB2 MUT (D769Y) | Different Alteration | EGFR inhibitor | Resistant | LUAD | Pre-clinical |
| TP53 | TP53 MUT (Q192*) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (Q192*) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (Q192*) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (Q192*) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (Q192*) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (Q192*) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (Q192*) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Q192*) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Q192*) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (Q192*) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (Q192*) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Q192*) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (Q192*) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (Q192*) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (Q192*) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| PIK3CA | PIK3CA MUT (Q546R) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (Q546R) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (Q546R) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (Q546R) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (Q546R) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (Q546R) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (Q546R) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (Q546R) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (Q546R) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (Q546R) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (Q546R) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (Q546R) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (Q546R) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (Q546R) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| PDGFB | PDGFB MUT* (intron_variant) | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | DFS | FDA guidelines |
| RAF1 | RAF1 MUT* (I122V) | Different Alteration | Sorafenib (Pan-TK inhibitor) | Responsive | PRAD | Pre-clinical |
| RAF1 | RAF1 MUT* (I122V) | Different Alteration | Pan-RAF inhibitor | Responsive | PRAD | Pre-clinical |
| RAF1 | RAF1 MUT* (I122V) | Different Alteration | U0126 (MEK inhibitor) | Responsive | PRAD | Pre-clinical |
| RB1 | RB1 MUT (Y606*) | Different Alteration | Palbociclib (CDK4/6 inhibitor) | Responsive | PRAD | Pre-clinical |
| RB1 | RB1 MUT (Y606*) | Complete Match | MDM2/MDMX inhibitor | Responsive | RB | Pre-clinical |
| RB1 | RB1 MUT (Y606*) | Complete Match | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| RB1 | RB1 MUT (Y606*) | Complete Match | HDAC inhibitor | Responsive | RB | Pre-clinical |
| RB1 | RB1 MUT (Y606*) | Different Alteration | MDM2/MDMX inhibitor | Responsive | RB | Pre-clinical |
| RB1 | RB1 MUT (Y606*) | Different Alteration | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| RB1 | RB1 MUT (Y606*) | Different Alteration | HDAC inhibitor | Responsive | RB | Pre-clinical |
| ERCC1 | ERCC1 MUT (S80*) | Different Alteration | Cisplatin (Chemotherapy) | Resistant | BLCA | Pre-clinical |
| ERCC1 | ERCC1 MUT (S80*) | Complete Match | PARP inhibitor | Responsive | L | Pre-clinical |
| ERCC1 | ERCC1 MUT (S80*) | Complete Match | Cisplatin (Chemotherapy) | Responsive | L | Pre-clinical |
| ERCC1 | ERCC1 MUT (S80*) | Different Alteration | PARP inhibitor | Responsive | L | Pre-clinical |
| ERCC1 | ERCC1 MUT (S80*) | Different Alteration | Cisplatin (Chemotherapy) | Responsive | L | Pre-clinical |
| PTEN | PTEN MUT (R130*) | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | PTEN MUT (R130*) | Different Mutation | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | PTEN MUT (R130*) | Different Mutation | BYL719 (PIK3CA inhibitor) | Resistant | BRCA | Case report |
| PTEN | PTEN MUT (R130*) | Complete Match | ATM inhibitor | Responsive | BRCA | Pre-clinical |
| PTEN | PTEN MUT (R130*) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA, ED, TH, CANCER, L, G, OV | Pre-clinical |
| PTEN | PTEN MUT (R130*) | Complete Match | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | PTEN MUT (R130*) | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | PTEN MUT (R130*) | Complete Match | PARP inhibitor | Responsive | ED | Case report |
| PTEN | PTEN MUT (R130*) | Complete Match | PD1 Ab inhibitor | Resistant | CM | Early trials |
| PTEN | PTEN MUT (R130*) | Complete Match | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | PTEN MUT (R130*) | Complete Match | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | PTEN MUT (R130*) | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| PTEN | PTEN MUT (R130*) | Complete Match | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | PTEN MUT (R130*) | Complete Match | AKT inhibitor | Responsive | PA | Case report |
| PTEN | PTEN MUT (R130*) | Complete Match | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | PTEN MUT (R130*) | Different Alteration | PI3K pathway inhibitor | Responsive | L, BRCA, CANCER, G, ED, TH, OV | Pre-clinical |
| PTEN | PTEN MUT (R130*) | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | PTEN MUT (R130*) | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | PTEN MUT (R130*) | Different Alteration | PARP inhibitor | Responsive | ED | Case report |
| PTEN | PTEN MUT (R130*) | Different Alteration | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | PTEN MUT (R130*) | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | PTEN MUT (R130*) | Different Alteration | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | PTEN MUT (R130*) | Different Alteration | AKT inhibitor | Responsive | PA | Case report |
| PTEN | PTEN MUT (R130*) | Different Alteration | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | PTEN MUT (R130*) | Different Alteration | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| TP53 | TP53 MUT (P278T) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (P278T) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (P278T) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (P278T) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (P278T) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (P278T) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (P278T) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (P278T) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (P278T) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (P278T) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (P278T) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (P278T) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (P278T) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (P278T) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (P278T) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| ERBB4 | ERBB4 MUT* (E1205K) | Different Alteration | Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) | Responsive | LUAD | Pre-clinical |
| TP53 | TP53 MUT (G266E) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (G266E) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (G266E) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (G266E) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (G266E) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (G266E) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (G266E) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (G266E) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (G266E) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (G266E) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (G266E) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (G266E) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (G266E) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (G266E) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (G266E) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (D281E) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (D281E) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (D281E) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (D281E) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (D281E) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (D281E) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (D281E) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (D281E) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (D281E) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (D281E) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (D281E) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (D281E) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (D281E) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (D281E) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (D281E) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| FGFR2 | FGFR2 MUT* (E367Q) | Different Alteration | FGFR inhibitor | Responsive | COREAD | Early trials |
| FGFR2 | FGFR2 MUT* (E367Q) | Different Alteration | FGFR inhibitor | Responsive | BT | Early trials |
| RET | RET MUT* (I625M) | Different Alteration | Nintedanib (Pan-TK inhibitor) | Responsive | LUAD | Case report |
| RET | RET MUT* (I625M) | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Early trials |
| RET | RET MUT* (I625M) | Different Alteration | RET inhibitor | Responsive | LUAD | Pre-clinical |
| RET | RET MUT* (I625M) | Different Alteration | Vandetanib (Pan-TK inhibitor) | Responsive | LUAD | Early trials |
| RET | RET MUT* (I625M) | Different Alteration | Sunitinib (Pan-TK inhibitor) | Responsive | LUAD | Early trials |
| RET | RET MUT* (I625M) | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | THCA | Pre-clinical |
| RET | RET MUT* (I625M) | Different Alteration | Vandetanib (Pan-TK inhibitor) | Responsive | THCA | Pre-clinical |
| RET | RET MUT* (I625M) | Different Alteration | Sunitinib (Pan-TK inhibitor) | Responsive | THCA | Pre-clinical |
| RET | RET MUT* (I625M) | Different Alteration | RET inhibitor | Responsive | TH | Pre-clinical |
| SETD2 | SETD2 MUT (S618*) | Complete Match | WEE1 inhibitor | Responsive | CANCER | Pre-clinical |
| SETD2 | SETD2 MUT (S618*) | Different Alteration | WEE1 inhibitor | Responsive | CANCER | Pre-clinical |
| PML | PML MUT* (P410A) | Different Alteration | Volasertib (PLK1 inhibitor) | Responsive | AML | Early trials |
| PML | PML MUT* (P410A) | Different Alteration | Tretinoin (Retinoid) | Responsive | APML | FDA guidelines |
| PML | PML MUT* (P410A) | Different Alteration | Tretinoin;Arsenic Trioxide (Retinoid;Chemotherapy) | Responsive | AML | FDA guidelines |
| JAK2 | JAK2 MUT* (C75F) | Different Alteration | Ruxolitinib (JAK inhibitor) | Responsive | ALL | Pre-clinical |
| TP53 | TP53 MUT (Y220C) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (Y220C) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (Y220C) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (Y220C) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (Y220C) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (Y220C) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (Y220C) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Y220C) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Y220C) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (Y220C) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (Y220C) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Y220C) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (Y220C) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (Y220C) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (Y220C) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (V216M) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (V216M) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (V216M) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (V216M) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (V216M) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (V216M) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (V216M) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (V216M) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (V216M) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (V216M) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (V216M) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (V216M) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (V216M) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (V216M) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (V216M) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| MAP2K1 | MAP2K1 MUT (E203K) | Different Mutation | MEK inhibitor | Resistant | CANCER | Pre-clinical |
| MAP2K1 | MAP2K1 MUT (E203K) | Different Mutation | novel MEK inhibitor | Responsive | CM | Pre-clinical |
| MAP2K1 | MAP2K1 MUT (E203K) | Different Mutation | MEK inhibitor | Resistant | CM | Case report |
| MAP2K1 | MAP2K1 MUT (E203K) | Different Mutation | ERK inhibitor | Responsive | CANCER | Pre-clinical |
| MAP2K1 | MAP2K1 MUT (E203K) | Complete Match | Vemurafenib (BRAF inhibitor) | Resistant | CM | Case report |
| MAP2K1 | MAP2K1 MUT (E203K) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| MAP2K1 | MAP2K1 MUT (E203K) | Different Mutation | Trametinib (MEK inhibitor) | Responsive | CANCER | Pre-clinical |
| MAP2K1 | MAP2K1 MUT (E203K) | Different Mutation | Panitumumab;Trametinib (EGFR mAb inhibitor;MEK inhibitor) | Responsive | COREAD | Case report |
| MAP2K1 | MAP2K1 MUT (E203K) | Different Mutation | Selumetinib (MEK inhibitor) | Responsive | OV | Case report |
| MAP2K1 | MAP2K1 MUT (E203K) | Different Mutation | BRAF inhibitor | Resistant | CM | Early trials |
| MAP2K1 | MAP2K1 MUT (E203K) | Different Mutation | ERK inhibitor | Responsive | CM | Pre-clinical |
| MAP2K1 | MAP2K1 MUT (E203K) | Complete Match | EGFR mAb inhibitor | Resistant | COREAD | Case report |
| PIK3CA | PIK3CA MUT (E542G), PIK3CA MUT (E542K) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (E542G), PIK3CA MUT (E542K) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (E542G), PIK3CA MUT (E542K) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (E542G), PIK3CA MUT (E542K) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (E542G), PIK3CA MUT (E542K) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (E542G), PIK3CA MUT (E542K) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (E542G), PIK3CA MUT (E542K) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (E542G), PIK3CA MUT (E542K) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (E542G), PIK3CA MUT (E542K) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (E542G), PIK3CA MUT (E542K) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (E542G), PIK3CA MUT (E542K) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (E542G), PIK3CA MUT (E542K) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (E542G), PIK3CA MUT (E542K) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (E542G), PIK3CA MUT (E542K) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| GNAS | GNAS MUT (R201C) | Complete Match | JAK inhibitor | Responsive | CANCER | Pre-clinical |
| FGFR2 | FGFR2 MUT* (V633I) | Different Alteration | FGFR inhibitor | Responsive | COREAD | Early trials |
| FGFR2 | FGFR2 MUT* (V633I) | Different Alteration | FGFR inhibitor | Responsive | BT | Early trials |
| PTEN | PTEN MUT (N48I) | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | PTEN MUT (N48I) | Different Mutation | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | PTEN MUT (N48I) | Different Mutation | BYL719 (PIK3CA inhibitor) | Resistant | BRCA | Case report |
| PTEN | PTEN MUT (N48I) | Complete Match | ATM inhibitor | Responsive | BRCA | Pre-clinical |
| PTEN | PTEN MUT (N48I) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA, ED, TH, CANCER, L, G, OV | Pre-clinical |
| PTEN | PTEN MUT (N48I) | Complete Match | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | PTEN MUT (N48I) | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | PTEN MUT (N48I) | Complete Match | PARP inhibitor | Responsive | ED | Case report |
| PTEN | PTEN MUT (N48I) | Complete Match | PD1 Ab inhibitor | Resistant | CM | Early trials |
| PTEN | PTEN MUT (N48I) | Complete Match | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | PTEN MUT (N48I) | Complete Match | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | PTEN MUT (N48I) | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| PTEN | PTEN MUT (N48I) | Complete Match | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | PTEN MUT (N48I) | Complete Match | AKT inhibitor | Responsive | PA | Case report |
| PTEN | PTEN MUT (N48I) | Complete Match | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | PTEN MUT (N48I) | Different Alteration | PI3K pathway inhibitor | Responsive | L, BRCA, CANCER, G, ED, TH, OV | Pre-clinical |
| PTEN | PTEN MUT (N48I) | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | PTEN MUT (N48I) | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | PTEN MUT (N48I) | Different Alteration | PARP inhibitor | Responsive | ED | Case report |
| PTEN | PTEN MUT (N48I) | Different Alteration | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | PTEN MUT (N48I) | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | PTEN MUT (N48I) | Different Alteration | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | PTEN MUT (N48I) | Different Alteration | AKT inhibitor | Responsive | PA | Case report |
| PTEN | PTEN MUT (N48I) | Different Alteration | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | PTEN MUT (N48I) | Different Alteration | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| ESR1 | ESR1 MUT* (L370F) | Different Alteration | ESR1 inhibitor | Resistant | BRCA | Pre-clinical |
| NOTCH2 | NOTCH2 MUT (R2400*) | Complete Match | Mk-0752 (Gamma secretase inhibitor) | Responsive | ALL, AML, BRCA | Early trials |
| NOTCH2 | NOTCH2 MUT (R2400*) | Complete Match | OMP-59R5 (NOTCH2 inhibitor) | Responsive | SOLID | Early trials |
| NOTCH2 | NOTCH2 MUT (R2400*) | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| TP53 | TP53 MUT (R282W) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (R282W) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (R282W) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (R282W) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (R282W) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (R282W) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (R282W) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R282W) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R282W) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (R282W) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (R282W) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R282W) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (R282W) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (R282W) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (R282W) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| SF3B1 | SF3B1 MUT (K700E) | Complete Match | Spliceosome inhibitor | Responsive | CANCER | Pre-clinical |
| CDH1 | CDH1 MUT (R63*) | Complete Match | Bicalutamide (AR inhibitor) | Responsive | BRCA | Pre-clinical |
| NTRK3 | NTRK3 MUT* (L824L) | Different Alteration | IGF1R inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK3 | NTRK3 MUT* (L824L) | Different Alteration | PI3K pathway inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK3 | NTRK3 MUT* (L824L) | Different Alteration | Midostaurin (Pan-TK inhibitor) | Responsive | BRCA | Pre-clinical |
| TP53 | TP53 MUT (S241C) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (S241C) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (S241C) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (S241C) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (S241C) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (S241C) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (S241C) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (S241C) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (S241C) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (S241C) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (S241C) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (S241C) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (S241C) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (S241C) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (S241C) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| BRCA1 | BRCA1 MUT (splice_acceptor_variant) | Complete Match | Chemotherapy (PARP inhibitor;Chemotherapy) | Responsive | OV | Early trials |
| BRCA1 | BRCA1 MUT (splice_acceptor_variant) | Complete Match | PARP inhibitor | Responsive | BRCA | Early trials |
| BRCA1 | BRCA1 MUT (splice_acceptor_variant) | Complete Match | PARP inhibitor;Chemotherapy | Responsive | OV | Early trials |
| BRCA1 | BRCA1 MUT (splice_acceptor_variant) | Complete Match | Rucaparib (PARP inhibitor) | Responsive | OV | FDA guidelines |
| BRCA1 | BRCA1 MUT (splice_acceptor_variant) | Complete Match | Platinum Agent (Chemotherapy) | Responsive | BRCA | Early trials |
| BRCA1 | BRCA1 MUT (splice_acceptor_variant) | Complete Match | WEE1 inhibitor | Responsive | CANCER | Case report |
| BRCA1 | BRCA1 MUT (splice_acceptor_variant) | Complete Match | Platinum Agent (Chemotherapy) | Responsive | OV | Late trials |
| BRCA1 | BRCA1 MUT (splice_acceptor_variant) | Complete Match | Olaparib (PARP inhibitor) | Responsive | PRAD | Early trials |
| BRCA1 | BRCA1 MUT (splice_acceptor_variant) | Complete Match | Veliparib;Cisplatin (PARP inhibitor;Chemotherapy) | Responsive | BRCA | Early trials |
| BRCA1 | BRCA1 MUT (splice_acceptor_variant) | Complete Match | PARP inhibitor | Responsive | PA | Case report |
| BRCA1 | BRCA1 MUT (splice_acceptor_variant) | Complete Match | Olaparib (PARP inhibitor) | Responsive | OV | FDA guidelines |
| BRCA1 | BRCA1 MUT (splice_acceptor_variant) | Different Alteration | PARP inhibitor | Responsive | OV | Pre-clinical |
| NTRK3 | NTRK3 MUT* (S359S) | Different Alteration | IGF1R inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK3 | NTRK3 MUT* (S359S) | Different Alteration | PI3K pathway inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK3 | NTRK3 MUT* (S359S) | Different Alteration | Midostaurin (Pan-TK inhibitor) | Responsive | BRCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (E81K) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (E81K) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (E81K) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (E81K) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (E81K) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (E81K) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (E81K) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (E81K) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (E81K) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (E81K) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (E81K) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (E81K) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (E81K) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (E81K) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| FGFR2 | FGFR2 MUT* (L262P) | Different Alteration | FGFR inhibitor | Responsive | COREAD | Early trials |
| FGFR2 | FGFR2 MUT* (L262P) | Different Alteration | FGFR inhibitor | Responsive | BT | Early trials |
| FGFR3 | FGFR3 MUT* (H711H) | Different Alteration | FGFR inhibitor | Responsive | BLCA | Case report |
| FGFR3 | FGFR3 MUT* (H711H) | Different Alteration | FGFR inhibitor | Responsive | G | Early trials |
| FGFR3 | FGFR3 MUT* (H711H) | Different Alteration | FGFR inhibitor | Responsive | NSCLC | Pre-clinical |
| TP53 | TP53 MUT (L114*), TP53 MUT (R248W) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (L114*), TP53 MUT (R248W) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (L114*), TP53 MUT (R248W) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (L114*), TP53 MUT (R248W) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (L114*), TP53 MUT (R248W) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (L114*), TP53 MUT (R248W) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (L114*), TP53 MUT (R248W) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (L114*), TP53 MUT (R248W) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (L114*), TP53 MUT (R248W) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (L114*), TP53 MUT (R248W) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (L114*), TP53 MUT (R248W) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (L114*), TP53 MUT (R248W) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (L114*), TP53 MUT (R248W) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (L114*), TP53 MUT (R248W) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (L114*), TP53 MUT (R248W) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (H193L) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (H193L) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (H193L) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (H193L) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (H193L) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (H193L) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (H193L) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (H193L) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (H193L) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (H193L) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (H193L) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (H193L) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (H193L) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (H193L) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (H193L) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| IDH1 | IDH1 MUT (R132C) | Complete Match | Venetoclax (BCL2 inhibitor) | Responsive | AML | Early trials |
| IDH1 | IDH1 MUT (R132C) | Complete Match | IDH1 inhibitor | Responsive | AML | Early trials |
| IDH1 | IDH1 MUT (R132C) | Complete Match | AG-120 (IDH1 inhibitor) | Responsive | G | Early trials |
| IDH1 | IDH1 MUT (R132C) | Complete Match | Dasatinib (BCR-ABL inhibitor) | Responsive | CH | Early trials |
| IDH1 | IDH1 MUT (R132C) | Complete Match | Ivosidenib (IDH1 inhibitor) | Responsive | AML | Early trials |
| IDH1 | IDH1 MUT (R132C) | Complete Match | BCL2 inhibitor | Responsive | AML | Pre-clinical |
| IDH1 | IDH1 MUT (R132C) | Complete Match | BCL2 inhibitor (BCL2 inhibitor) | Responsive | AML | Pre-clinical |
| IDH1 | IDH1 MUT (R132C) | Complete Match | Dasatinib (BCR-ABL inhibitor) | Responsive | BT | Pre-clinical |
| IDH1 | IDH1 MUT (R132C) | Complete Match | PARP inhibitor | Responsive | CANCER | Pre-clinical |
| ROS1 | ROS1 MUT* (R1311Q) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | IM | Case report |
| ROS1 | ROS1 MUT* (R1311Q) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ROS1 | ROS1 MUT* (R1311Q) | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Case report |
| ROS1 | ROS1 MUT* (R1311Q) | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Pre-clinical |
| ROS1 | ROS1 MUT* (R1311Q) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Early trials |
| NF1 | NF1 MUT (Q682*) | Different Mutation | Vemurafenib (BRAF inhibitor) | Resistant | CM | Pre-clinical |
| NF1 | NF1 MUT (Q682*) | Different Mutation | Everolimus (MTOR inhibitor) | Responsive | HNC | Case report |
| NF1 | NF1 MUT (Q682*) | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (Q682*) | Complete Match | Vinblastine (Chemotherapy) | Responsive | G | Early trials |
| NF1 | NF1 MUT (Q682*) | Complete Match | KIT inhibitor;MTOR inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (Q682*) | Complete Match | Tamoxifen (Hormonal therapy) | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (Q682*) | Complete Match | Bevacizumab (VEGFR mAb inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (Q682*) | Complete Match | Retinoic Acid | Resistant | NB | Pre-clinical |
| NF1 | NF1 MUT (Q682*) | Complete Match | Everolimus (MTOR inhibitor) | Responsive | NF | Late trials |
| NF1 | NF1 MUT (Q682*) | Complete Match | Trametinib (MEK inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (Q682*) | Complete Match | Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (Q682*) | Complete Match | Nilotinib (BCR-ABL inhibitor) | Responsive | MPN, PLEN | Pre-clinical |
| NF1 | NF1 MUT (Q682*) | Complete Match | MEK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (Q682*) | Complete Match | Everolimus (MTOR inhibitor) | Responsive | HNC, SG | Case report |
| NF1 | NF1 MUT (Q682*) | Complete Match | Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) | No Responsive | MPN | Early trials |
| NF1 | NF1 MUT (Q682*) | Complete Match | PLX3397 (Pan-TK inhibitor) | Responsive | PLEN | Pre-clinical |
| NF1 | NF1 MUT (Q682*) | Complete Match | MEK inhibitor | Responsive | LK, G | Pre-clinical |
| NF1 | NF1 MUT (Q682*) | Complete Match | Pan-RAF inhibitor;MEK inhibitor | Responsive | CM | Pre-clinical |
| NF1 | NF1 MUT (Q682*) | Complete Match | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (Q682*) | Complete Match | AURK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (Q682*) | Complete Match | MTOR inhibitor | Responsive | LK, G, MPN | Pre-clinical |
| NF1 | NF1 MUT (Q682*) | Complete Match | Dasatinib (BCR-ABL inhibitor) | Resistant | L | Pre-clinical |
| NF1 | NF1 MUT (Q682*) | Complete Match | Everolimus;Pazopanib (MTOR inhibitor;VEGFR inhibitor) | Responsive | HC | Case report |
| NF1 | NF1 MUT (Q682*) | Complete Match | Everolimus (MTOR inhibitor) | No Responsive | MPN | Early trials |
| NF1 | NF1 MUT (Q682*) | Complete Match | Cediranib (ALK inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (Q682*) | Complete Match | PD1 Ab inhibitor | Responsive | CM | Early trials |
| NF1 | NF1 MUT (Q682*) | Complete Match | Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (Q682*) | Complete Match | Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (Q682*) | Complete Match | Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | No Responsive | G | Case report |
| NF1 | NF1 MUT (Q682*) | Complete Match | BRD4 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (Q682*) | Complete Match | Tipifarnib (Farnesyltransferase inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (Q682*) | Complete Match | Selumetinib (MEK inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (Q682*) | Complete Match | MTOR inhibitor;HSP90 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (Q682*) | Complete Match | Trametinib (MEK inhibitor) | Responsive | CM | Pre-clinical |
| NF1 | NF1 MUT (Q682*) | Complete Match | Erlotinib (EGFR inhibitor) | Resistant | L | Pre-clinical |
| NF1 | NF1 MUT (Q682*) | Complete Match | Trametinib (MEK inhibitor) | No Responsive | OS | Case report |
| NF1 | NF1 MUT (Q682*) | Different Alteration | MTOR inhibitor | Responsive | MPN, G, LK | Pre-clinical |
| NF1 | NF1 MUT (Q682*) | Different Alteration | PLX3397 (Pan-TK inhibitor) | Responsive | PLEN | Pre-clinical |
| NF1 | NF1 MUT (Q682*) | Different Alteration | Erlotinib (EGFR inhibitor) | Resistant | L | Pre-clinical |
| NF1 | NF1 MUT (Q682*) | Different Alteration | Trametinib (MEK inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (Q682*) | Different Alteration | BRD4 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (Q682*) | Different Alteration | Trametinib (MEK inhibitor) | No Responsive | OS | Case report |
| NF1 | NF1 MUT (Q682*) | Different Alteration | Cediranib (ALK inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (Q682*) | Different Alteration | Bevacizumab (VEGFR mAb inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (Q682*) | Different Alteration | MEK inhibitor | Responsive | G, LK | Pre-clinical |
| NF1 | NF1 MUT (Q682*) | Different Alteration | Vinblastine (Chemotherapy) | Responsive | G | Early trials |
| NF1 | NF1 MUT (Q682*) | Different Alteration | Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (Q682*) | Different Alteration | Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) | No Responsive | MPN | Early trials |
| NF1 | NF1 MUT (Q682*) | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Resistant | L | Pre-clinical |
| NF1 | NF1 MUT (Q682*) | Different Alteration | MTOR inhibitor;HSP90 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (Q682*) | Different Alteration | Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (Q682*) | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (Q682*) | Different Alteration | Tamoxifen (Hormonal therapy) | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (Q682*) | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | SG, HNC | Case report |
| NF1 | NF1 MUT (Q682*) | Different Alteration | Pan-RAF inhibitor;MEK inhibitor | Responsive | CM | Pre-clinical |
| NF1 | NF1 MUT (Q682*) | Different Alteration | Tipifarnib (Farnesyltransferase inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (Q682*) | Different Alteration | Selumetinib (MEK inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (Q682*) | Different Alteration | Retinoic Acid | Resistant | NB | Pre-clinical |
| NF1 | NF1 MUT (Q682*) | Different Alteration | Everolimus (MTOR inhibitor) | No Responsive | MPN | Early trials |
| NF1 | NF1 MUT (Q682*) | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (Q682*) | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | PLEN, MPN | Pre-clinical |
| NF1 | NF1 MUT (Q682*) | Different Alteration | Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (Q682*) | Different Alteration | Trametinib (MEK inhibitor) | Responsive | CM | Pre-clinical |
| NF1 | NF1 MUT (Q682*) | Different Alteration | AURK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (Q682*) | Different Alteration | Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | No Responsive | G | Case report |
| NF1 | NF1 MUT (Q682*) | Different Alteration | PD1 Ab inhibitor | Responsive | CM | Early trials |
| NF1 | NF1 MUT (Q682*) | Different Alteration | MEK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (Q682*) | Different Alteration | KIT inhibitor;MTOR inhibitor | Responsive | MPN | Pre-clinical |
| ROS1 | ROS1 MUT* (S551F) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | IM | Case report |
| ROS1 | ROS1 MUT* (S551F) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ROS1 | ROS1 MUT* (S551F) | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Case report |
| ROS1 | ROS1 MUT* (S551F) | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Pre-clinical |
| ROS1 | ROS1 MUT* (S551F) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Early trials |
| AKT3 | AKT3 MUT* (P310A) | Different Alteration | ATP competitive AKT inhibitor | Responsive | BRCA | Pre-clinical |
| NF2 | NF2 MUT (S265*) | Complete Match | AR42 (HDAC inhibitor) | Responsive | SCHW | Pre-clinical |
| NF2 | NF2 MUT (S265*) | Complete Match | AR42 (HDAC inhibitor) | Responsive | MEN | Early trials |
| NF2 | NF2 MUT (S265*) | Complete Match | HSP90 inhibitor | Responsive | MEN | Pre-clinical |
| NF2 | NF2 MUT (S265*) | Complete Match | Everolimus;Octreotide (MTOR inhibitor;Somatostatin analog) | Responsive | MEN | Pre-clinical |
| NF2 | NF2 MUT (S265*) | Complete Match | MTOR inhibitor | Responsive | MEN | Pre-clinical |
| NF2 | NF2 MUT (S265*) | Complete Match | Lapatinib (ERBB2 inhibitor) | Responsive | NF, SCHW | Early trials |
| NF2 | NF2 MUT (S265*) | Complete Match | Everolimus (MTOR inhibitor) | Responsive | SCHW | Early trials |
| NF2 | NF2 MUT (S265*) | Complete Match | Erlotinib (EGFR inhibitor) | No Responsive | SCHW | Early trials |
| NF2 | NF2 MUT (S265*) | Complete Match | FAK inhibitor | Responsive | OV | Pre-clinical |
| NF2 | NF2 MUT (S265*) | Complete Match | Temsirolimus;Chemotherapy (MTOR inhibitor;Chemotherapy) | Responsive | BRCA | Case report |
| NF2 | NF2 MUT (S265*) | Complete Match | MEK inhibitor | Responsive | TH | Pre-clinical |
| NF2 | NF2 MUT (S265*) | Complete Match | PAK inhibitor | Responsive | SCHW, MEN | Pre-clinical |
| NF2 | NF2 MUT (S265*) | Complete Match | PDK1 inhibitor | Responsive | SCHW | Pre-clinical |
| NF2 | NF2 MUT (S265*) | Complete Match | FAK inhibitor | Responsive;Responsive | MESO | Early trials;Pre-clinical |
| NF2 | NF2 MUT (S265*) | Complete Match | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | SCHW | Pre-clinical |
| NF2 | NF2 MUT (S265*) | Complete Match | Bevacizumab (VEGFR mAb inhibitor) | Responsive | SCHW | Early trials |
| NF2 | NF2 MUT (S265*) | Different Alteration | FAK inhibitor | Responsive | OV | Pre-clinical |
| NF2 | NF2 MUT (S265*) | Different Alteration | MEK inhibitor | Responsive | TH | Pre-clinical |
| NF2 | NF2 MUT (S265*) | Different Alteration | Erlotinib (EGFR inhibitor) | No Responsive | SCHW | Early trials |
| NF2 | NF2 MUT (S265*) | Different Alteration | Everolimus;Octreotide (MTOR inhibitor;Somatostatin analog) | Responsive | MEN | Pre-clinical |
| NF2 | NF2 MUT (S265*) | Different Alteration | PDK1 inhibitor | Responsive | SCHW | Pre-clinical |
| NF2 | NF2 MUT (S265*) | Different Alteration | PAK inhibitor | Responsive | SCHW, MEN | Pre-clinical |
| NF2 | NF2 MUT (S265*) | Different Alteration | AR42 (HDAC inhibitor) | Responsive | SCHW | Pre-clinical |
| NF2 | NF2 MUT (S265*) | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | SCHW | Pre-clinical |
| NF2 | NF2 MUT (S265*) | Different Alteration | Temsirolimus;Chemotherapy (MTOR inhibitor;Chemotherapy) | Responsive | BRCA | Case report |
| NF2 | NF2 MUT (S265*) | Different Alteration | AR42 (HDAC inhibitor) | Responsive | MEN | Early trials |
| NF2 | NF2 MUT (S265*) | Different Alteration | FAK inhibitor | Responsive;Responsive | MESO | Early trials;Pre-clinical |
| NF2 | NF2 MUT (S265*) | Different Alteration | Bevacizumab (VEGFR mAb inhibitor) | Responsive | SCHW | Early trials |
| NF2 | NF2 MUT (S265*) | Different Alteration | Lapatinib (ERBB2 inhibitor) | Responsive | SCHW, NF | Early trials |
| NF2 | NF2 MUT (S265*) | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | SCHW | Early trials |
| NF2 | NF2 MUT (S265*) | Different Alteration | HSP90 inhibitor | Responsive | MEN | Pre-clinical |
| NF2 | NF2 MUT (S265*) | Different Alteration | MTOR inhibitor | Responsive | MEN | Pre-clinical |
| TP53 | TP53 MUT (splice_donor_variant) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (splice_donor_variant) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (splice_donor_variant) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (splice_donor_variant) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (splice_donor_variant) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (splice_donor_variant) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (splice_donor_variant) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (splice_donor_variant) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (splice_donor_variant) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (splice_donor_variant) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (splice_donor_variant) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (splice_donor_variant) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (splice_donor_variant) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (splice_donor_variant) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (splice_donor_variant) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| BAP1 | BAP1 MUT (T93A) | Complete Match | EZH2 inhibitor | Responsive | MESO | Pre-clinical |
| BAP1 | BAP1 MUT (T93A) | Complete Match | PARP inhibitor | Responsive | R, CANCER | Pre-clinical |
| BAP1 | BAP1 MUT (T93A) | Complete Match | HDAC inhibitor | Responsive | CM | Pre-clinical |
| BAP1 | BAP1 MUT (T93A) | Different Alteration | PARP inhibitor | Responsive | CANCER, R | Pre-clinical |
| BAP1 | BAP1 MUT (T93A) | Different Alteration | EZH2 inhibitor | Responsive | MESO | Pre-clinical |
| BAP1 | BAP1 MUT (T93A) | Different Alteration | HDAC inhibitor | Responsive | CM | Pre-clinical |
| CDH1 | CDH1 MUT (Y835*) | Complete Match | Bicalutamide (AR inhibitor) | Responsive | BRCA | Pre-clinical |
| CDH1 | CDH1 MUT (G278*) | Complete Match | Bicalutamide (AR inhibitor) | Responsive | BRCA | Pre-clinical |
| ESR1 | ESR1 MUT* (3-UTRSNV) | Different Alteration | ESR1 inhibitor | Resistant | BRCA | Pre-clinical |
| NOTCH2 | NOTCH2 MUT* (L1690L) | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| PTEN | PTEN MUT (F258L), PTEN MUT (F258Y) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | PTEN MUT (F258L), PTEN MUT (F258Y) | Complete Match | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | PTEN MUT (F258L), PTEN MUT (F258Y) | Complete Match | BYL719 (PIK3CA inhibitor) | Resistant | BRCA | Case report |
| PTEN | PTEN MUT (F258L), PTEN MUT (F258Y) | Complete Match | ATM inhibitor | Responsive | BRCA | Pre-clinical |
| PTEN | PTEN MUT (F258L), PTEN MUT (F258Y) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA, ED, TH, CANCER, L, G, OV | Pre-clinical |
| PTEN | PTEN MUT (F258L), PTEN MUT (F258Y) | Complete Match | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | PTEN MUT (F258L), PTEN MUT (F258Y) | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | PTEN MUT (F258L), PTEN MUT (F258Y) | Complete Match | PARP inhibitor | Responsive | ED | Case report |
| PTEN | PTEN MUT (F258L), PTEN MUT (F258Y) | Complete Match | PD1 Ab inhibitor | Resistant | CM | Early trials |
| PTEN | PTEN MUT (F258L), PTEN MUT (F258Y) | Complete Match | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | PTEN MUT (F258L), PTEN MUT (F258Y) | Complete Match | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | PTEN MUT (F258L), PTEN MUT (F258Y) | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| PTEN | PTEN MUT (F258L), PTEN MUT (F258Y) | Complete Match | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | PTEN MUT (F258L), PTEN MUT (F258Y) | Complete Match | AKT inhibitor | Responsive | PA | Case report |
| PTEN | PTEN MUT (F258L), PTEN MUT (F258Y) | Complete Match | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | PTEN MUT (F258L), PTEN MUT (F258Y) | Different Alteration | PI3K pathway inhibitor | Responsive | L, BRCA, CANCER, G, ED, TH, OV | Pre-clinical |
| PTEN | PTEN MUT (F258L), PTEN MUT (F258Y) | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | PTEN MUT (F258L), PTEN MUT (F258Y) | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | PTEN MUT (F258L), PTEN MUT (F258Y) | Different Alteration | PARP inhibitor | Responsive | ED | Case report |
| PTEN | PTEN MUT (F258L), PTEN MUT (F258Y) | Different Alteration | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | PTEN MUT (F258L), PTEN MUT (F258Y) | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | PTEN MUT (F258L), PTEN MUT (F258Y) | Different Alteration | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | PTEN MUT (F258L), PTEN MUT (F258Y) | Different Alteration | AKT inhibitor | Responsive | PA | Case report |
| PTEN | PTEN MUT (F258L), PTEN MUT (F258Y) | Different Alteration | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | PTEN MUT (F258L), PTEN MUT (F258Y) | Different Alteration | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| NF1 | NF1 MUT (R366*) | Different Mutation | Vemurafenib (BRAF inhibitor) | Resistant | CM | Pre-clinical |
| NF1 | NF1 MUT (R366*) | Different Mutation | Everolimus (MTOR inhibitor) | Responsive | HNC | Case report |
| NF1 | NF1 MUT (R366*) | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (R366*) | Complete Match | Vinblastine (Chemotherapy) | Responsive | G | Early trials |
| NF1 | NF1 MUT (R366*) | Complete Match | KIT inhibitor;MTOR inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (R366*) | Complete Match | Tamoxifen (Hormonal therapy) | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (R366*) | Complete Match | Bevacizumab (VEGFR mAb inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (R366*) | Complete Match | Retinoic Acid | Resistant | NB | Pre-clinical |
| NF1 | NF1 MUT (R366*) | Complete Match | Everolimus (MTOR inhibitor) | Responsive | NF | Late trials |
| NF1 | NF1 MUT (R366*) | Complete Match | Trametinib (MEK inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (R366*) | Complete Match | Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (R366*) | Complete Match | Nilotinib (BCR-ABL inhibitor) | Responsive | MPN, PLEN | Pre-clinical |
| NF1 | NF1 MUT (R366*) | Complete Match | MEK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (R366*) | Complete Match | Everolimus (MTOR inhibitor) | Responsive | HNC, SG | Case report |
| NF1 | NF1 MUT (R366*) | Complete Match | Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) | No Responsive | MPN | Early trials |
| NF1 | NF1 MUT (R366*) | Complete Match | PLX3397 (Pan-TK inhibitor) | Responsive | PLEN | Pre-clinical |
| NF1 | NF1 MUT (R366*) | Complete Match | MEK inhibitor | Responsive | LK, G | Pre-clinical |
| NF1 | NF1 MUT (R366*) | Complete Match | Pan-RAF inhibitor;MEK inhibitor | Responsive | CM | Pre-clinical |
| NF1 | NF1 MUT (R366*) | Complete Match | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (R366*) | Complete Match | AURK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (R366*) | Complete Match | MTOR inhibitor | Responsive | LK, G, MPN | Pre-clinical |
| NF1 | NF1 MUT (R366*) | Complete Match | Dasatinib (BCR-ABL inhibitor) | Resistant | L | Pre-clinical |
| NF1 | NF1 MUT (R366*) | Complete Match | Everolimus;Pazopanib (MTOR inhibitor;VEGFR inhibitor) | Responsive | HC | Case report |
| NF1 | NF1 MUT (R366*) | Complete Match | Everolimus (MTOR inhibitor) | No Responsive | MPN | Early trials |
| NF1 | NF1 MUT (R366*) | Complete Match | Cediranib (ALK inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (R366*) | Complete Match | PD1 Ab inhibitor | Responsive | CM | Early trials |
| NF1 | NF1 MUT (R366*) | Complete Match | Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (R366*) | Complete Match | Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (R366*) | Complete Match | Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | No Responsive | G | Case report |
| NF1 | NF1 MUT (R366*) | Complete Match | BRD4 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (R366*) | Complete Match | Tipifarnib (Farnesyltransferase inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (R366*) | Complete Match | Selumetinib (MEK inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (R366*) | Complete Match | MTOR inhibitor;HSP90 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (R366*) | Complete Match | Trametinib (MEK inhibitor) | Responsive | CM | Pre-clinical |
| NF1 | NF1 MUT (R366*) | Complete Match | Erlotinib (EGFR inhibitor) | Resistant | L | Pre-clinical |
| NF1 | NF1 MUT (R366*) | Complete Match | Trametinib (MEK inhibitor) | No Responsive | OS | Case report |
| NF1 | NF1 MUT (R366*) | Different Alteration | MTOR inhibitor | Responsive | MPN, G, LK | Pre-clinical |
| NF1 | NF1 MUT (R366*) | Different Alteration | PLX3397 (Pan-TK inhibitor) | Responsive | PLEN | Pre-clinical |
| NF1 | NF1 MUT (R366*) | Different Alteration | Erlotinib (EGFR inhibitor) | Resistant | L | Pre-clinical |
| NF1 | NF1 MUT (R366*) | Different Alteration | Trametinib (MEK inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (R366*) | Different Alteration | BRD4 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (R366*) | Different Alteration | Trametinib (MEK inhibitor) | No Responsive | OS | Case report |
| NF1 | NF1 MUT (R366*) | Different Alteration | Cediranib (ALK inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (R366*) | Different Alteration | Bevacizumab (VEGFR mAb inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (R366*) | Different Alteration | MEK inhibitor | Responsive | G, LK | Pre-clinical |
| NF1 | NF1 MUT (R366*) | Different Alteration | Vinblastine (Chemotherapy) | Responsive | G | Early trials |
| NF1 | NF1 MUT (R366*) | Different Alteration | Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (R366*) | Different Alteration | Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) | No Responsive | MPN | Early trials |
| NF1 | NF1 MUT (R366*) | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Resistant | L | Pre-clinical |
| NF1 | NF1 MUT (R366*) | Different Alteration | MTOR inhibitor;HSP90 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (R366*) | Different Alteration | Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (R366*) | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (R366*) | Different Alteration | Tamoxifen (Hormonal therapy) | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (R366*) | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | SG, HNC | Case report |
| NF1 | NF1 MUT (R366*) | Different Alteration | Pan-RAF inhibitor;MEK inhibitor | Responsive | CM | Pre-clinical |
| NF1 | NF1 MUT (R366*) | Different Alteration | Tipifarnib (Farnesyltransferase inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (R366*) | Different Alteration | Selumetinib (MEK inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (R366*) | Different Alteration | Retinoic Acid | Resistant | NB | Pre-clinical |
| NF1 | NF1 MUT (R366*) | Different Alteration | Everolimus (MTOR inhibitor) | No Responsive | MPN | Early trials |
| NF1 | NF1 MUT (R366*) | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (R366*) | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | PLEN, MPN | Pre-clinical |
| NF1 | NF1 MUT (R366*) | Different Alteration | Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (R366*) | Different Alteration | Trametinib (MEK inhibitor) | Responsive | CM | Pre-clinical |
| NF1 | NF1 MUT (R366*) | Different Alteration | AURK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (R366*) | Different Alteration | Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | No Responsive | G | Case report |
| NF1 | NF1 MUT (R366*) | Different Alteration | PD1 Ab inhibitor | Responsive | CM | Early trials |
| NF1 | NF1 MUT (R366*) | Different Alteration | MEK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (R366*) | Different Alteration | KIT inhibitor;MTOR inhibitor | Responsive | MPN | Pre-clinical |
| ROS1 | ROS1 MUT* (P194S) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | IM | Case report |
| ROS1 | ROS1 MUT* (P194S) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ROS1 | ROS1 MUT* (P194S) | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Case report |
| ROS1 | ROS1 MUT* (P194S) | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Pre-clinical |
| ROS1 | ROS1 MUT* (P194S) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Early trials |
| ARID1A | ARID1A MUT (Q479*) | Complete Match | EZH2 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | ARID1A MUT (Q479*) | Complete Match | PD1 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | ARID1A MUT (Q479*) | Complete Match | PARP inhibitor | Responsive | CANCER | Pre-clinical |
| ARID1A | ARID1A MUT (Q479*) | Complete Match | ATR inhibitor | Responsive | CANCER | Pre-clinical |
| CDH1 | CDH1 MUT (R74*) | Complete Match | Bicalutamide (AR inhibitor) | Responsive | BRCA | Pre-clinical |
| NF1 | NF1 MUT (S2601*) | Different Mutation | Vemurafenib (BRAF inhibitor) | Resistant | CM | Pre-clinical |
| NF1 | NF1 MUT (S2601*) | Different Mutation | Everolimus (MTOR inhibitor) | Responsive | HNC | Case report |
| NF1 | NF1 MUT (S2601*) | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (S2601*) | Complete Match | Vinblastine (Chemotherapy) | Responsive | G | Early trials |
| NF1 | NF1 MUT (S2601*) | Complete Match | KIT inhibitor;MTOR inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (S2601*) | Complete Match | Tamoxifen (Hormonal therapy) | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (S2601*) | Complete Match | Bevacizumab (VEGFR mAb inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (S2601*) | Complete Match | Retinoic Acid | Resistant | NB | Pre-clinical |
| NF1 | NF1 MUT (S2601*) | Complete Match | Everolimus (MTOR inhibitor) | Responsive | NF | Late trials |
| NF1 | NF1 MUT (S2601*) | Complete Match | Trametinib (MEK inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (S2601*) | Complete Match | Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (S2601*) | Complete Match | Nilotinib (BCR-ABL inhibitor) | Responsive | MPN, PLEN | Pre-clinical |
| NF1 | NF1 MUT (S2601*) | Complete Match | MEK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (S2601*) | Complete Match | Everolimus (MTOR inhibitor) | Responsive | HNC, SG | Case report |
| NF1 | NF1 MUT (S2601*) | Complete Match | Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) | No Responsive | MPN | Early trials |
| NF1 | NF1 MUT (S2601*) | Complete Match | PLX3397 (Pan-TK inhibitor) | Responsive | PLEN | Pre-clinical |
| NF1 | NF1 MUT (S2601*) | Complete Match | MEK inhibitor | Responsive | LK, G | Pre-clinical |
| NF1 | NF1 MUT (S2601*) | Complete Match | Pan-RAF inhibitor;MEK inhibitor | Responsive | CM | Pre-clinical |
| NF1 | NF1 MUT (S2601*) | Complete Match | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (S2601*) | Complete Match | AURK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (S2601*) | Complete Match | MTOR inhibitor | Responsive | LK, G, MPN | Pre-clinical |
| NF1 | NF1 MUT (S2601*) | Complete Match | Dasatinib (BCR-ABL inhibitor) | Resistant | L | Pre-clinical |
| NF1 | NF1 MUT (S2601*) | Complete Match | Everolimus;Pazopanib (MTOR inhibitor;VEGFR inhibitor) | Responsive | HC | Case report |
| NF1 | NF1 MUT (S2601*) | Complete Match | Everolimus (MTOR inhibitor) | No Responsive | MPN | Early trials |
| NF1 | NF1 MUT (S2601*) | Complete Match | Cediranib (ALK inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (S2601*) | Complete Match | PD1 Ab inhibitor | Responsive | CM | Early trials |
| NF1 | NF1 MUT (S2601*) | Complete Match | Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (S2601*) | Complete Match | Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (S2601*) | Complete Match | Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | No Responsive | G | Case report |
| NF1 | NF1 MUT (S2601*) | Complete Match | BRD4 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (S2601*) | Complete Match | Tipifarnib (Farnesyltransferase inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (S2601*) | Complete Match | Selumetinib (MEK inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (S2601*) | Complete Match | MTOR inhibitor;HSP90 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (S2601*) | Complete Match | Trametinib (MEK inhibitor) | Responsive | CM | Pre-clinical |
| NF1 | NF1 MUT (S2601*) | Complete Match | Erlotinib (EGFR inhibitor) | Resistant | L | Pre-clinical |
| NF1 | NF1 MUT (S2601*) | Complete Match | Trametinib (MEK inhibitor) | No Responsive | OS | Case report |
| NF1 | NF1 MUT (S2601*) | Different Alteration | MTOR inhibitor | Responsive | MPN, G, LK | Pre-clinical |
| NF1 | NF1 MUT (S2601*) | Different Alteration | PLX3397 (Pan-TK inhibitor) | Responsive | PLEN | Pre-clinical |
| NF1 | NF1 MUT (S2601*) | Different Alteration | Erlotinib (EGFR inhibitor) | Resistant | L | Pre-clinical |
| NF1 | NF1 MUT (S2601*) | Different Alteration | Trametinib (MEK inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (S2601*) | Different Alteration | BRD4 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (S2601*) | Different Alteration | Trametinib (MEK inhibitor) | No Responsive | OS | Case report |
| NF1 | NF1 MUT (S2601*) | Different Alteration | Cediranib (ALK inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (S2601*) | Different Alteration | Bevacizumab (VEGFR mAb inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (S2601*) | Different Alteration | MEK inhibitor | Responsive | G, LK | Pre-clinical |
| NF1 | NF1 MUT (S2601*) | Different Alteration | Vinblastine (Chemotherapy) | Responsive | G | Early trials |
| NF1 | NF1 MUT (S2601*) | Different Alteration | Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (S2601*) | Different Alteration | Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) | No Responsive | MPN | Early trials |
| NF1 | NF1 MUT (S2601*) | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Resistant | L | Pre-clinical |
| NF1 | NF1 MUT (S2601*) | Different Alteration | MTOR inhibitor;HSP90 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (S2601*) | Different Alteration | Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (S2601*) | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (S2601*) | Different Alteration | Tamoxifen (Hormonal therapy) | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (S2601*) | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | SG, HNC | Case report |
| NF1 | NF1 MUT (S2601*) | Different Alteration | Pan-RAF inhibitor;MEK inhibitor | Responsive | CM | Pre-clinical |
| NF1 | NF1 MUT (S2601*) | Different Alteration | Tipifarnib (Farnesyltransferase inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (S2601*) | Different Alteration | Selumetinib (MEK inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (S2601*) | Different Alteration | Retinoic Acid | Resistant | NB | Pre-clinical |
| NF1 | NF1 MUT (S2601*) | Different Alteration | Everolimus (MTOR inhibitor) | No Responsive | MPN | Early trials |
| NF1 | NF1 MUT (S2601*) | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (S2601*) | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | PLEN, MPN | Pre-clinical |
| NF1 | NF1 MUT (S2601*) | Different Alteration | Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (S2601*) | Different Alteration | Trametinib (MEK inhibitor) | Responsive | CM | Pre-clinical |
| NF1 | NF1 MUT (S2601*) | Different Alteration | AURK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (S2601*) | Different Alteration | Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | No Responsive | G | Case report |
| NF1 | NF1 MUT (S2601*) | Different Alteration | PD1 Ab inhibitor | Responsive | CM | Early trials |
| NF1 | NF1 MUT (S2601*) | Different Alteration | MEK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (S2601*) | Different Alteration | KIT inhibitor;MTOR inhibitor | Responsive | MPN | Pre-clinical |
| ARID1A | ARID1A MUT (Q528*) | Complete Match | EZH2 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | ARID1A MUT (Q528*) | Complete Match | PD1 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | ARID1A MUT (Q528*) | Complete Match | PARP inhibitor | Responsive | CANCER | Pre-clinical |
| ARID1A | ARID1A MUT (Q528*) | Complete Match | ATR inhibitor | Responsive | CANCER | Pre-clinical |
| TSC2 | TSC2 MUT (R1459*) | Different Mutation | Temsirolimus (MTOR inhibitor) | Responsive | ED | Case report |
| TSC2 | TSC2 MUT (R1459*) | Complete Match | Everolimus (MTOR inhibitor) | Responsive | RA, GCA | FDA guidelines |
| TSC2 | TSC2 MUT (R1459*) | Complete Match | SRC inhibitor | Responsive | LAM | Pre-clinical |
| TSC2 | TSC2 MUT (R1459*) | Complete Match | Everolimus (MTOR inhibitor) | Responsive | BLCA | Early trials |
| TSC2 | TSC2 MUT (R1459*) | Complete Match | MTOR inhibitor | Responsive | RA | Early trials |
| TSC2 | TSC2 MUT (R1459*) | Different Mutation | Everolimus (MTOR inhibitor) | Responsive | THCA | Case report |
| TSC2 | TSC2 MUT (R1459*) | Different Alteration | SRC inhibitor | Responsive | LAM | Pre-clinical |
| NOTCH1 | NOTCH1 MUT* (T887I) | Different Alteration | Gamma secretase inhibitor | Responsive | ALL | Pre-clinical |
| NOTCH1 | NOTCH1 MUT* (T887I) | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| TP53 | TP53 MUT (C135R) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (C135R) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (C135R) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (C135R) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (C135R) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (C135R) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (C135R) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (C135R) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (C135R) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (C135R) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (C135R) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (C135R) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (C135R) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (C135R) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (C135R) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| ERBB4 | ERBB4 MUT* (P920R) | Different Alteration | Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) | Responsive | LUAD | Pre-clinical |
| ERCC2 | ERCC2 MUT (splice_donor_variant) | Complete Match | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| ERCC2 | ERCC2 MUT (splice_donor_variant) | Complete Match | PD1/PDL1 inhibitor | Responsive | UTH | Early trials |
| ERCC2 | ERCC2 MUT (splice_donor_variant) | Different Alteration | PD1/PDL1 inhibitor | Responsive | UTH | Early trials |
| NTRK1 | NTRK1 MUT* (D209H) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Case report |
| NTRK1 | NTRK1 MUT* (D209H) | Different Alteration | Pan-TKR inhibitor | Responsive | CANCER | Early trials |
| NTRK1 | NTRK1 MUT* (D209H) | Different Alteration | Pan-TK inhibitor | Responsive | LUAD | Pre-clinical |
| NTRK1 | NTRK1 MUT* (D209H) | Different Alteration | Pan-TK inhibitor | Responsive | COREAD | Case report |
| U2AF1 | U2AF1 MUT (Q157R) | Complete Match | FLT3 inhibitor | Responsive | CANCER | Pre-clinical |
| RET | RET MUT* (L963V) | Different Alteration | Nintedanib (Pan-TK inhibitor) | Responsive | LUAD | Case report |
| RET | RET MUT* (L963V) | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Early trials |
| RET | RET MUT* (L963V) | Different Alteration | RET inhibitor | Responsive | LUAD | Pre-clinical |
| RET | RET MUT* (L963V) | Different Alteration | Vandetanib (Pan-TK inhibitor) | Responsive | LUAD | Early trials |
| RET | RET MUT* (L963V) | Different Alteration | Sunitinib (Pan-TK inhibitor) | Responsive | LUAD | Early trials |
| RET | RET MUT* (L963V) | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | THCA | Pre-clinical |
| RET | RET MUT* (L963V) | Different Alteration | Vandetanib (Pan-TK inhibitor) | Responsive | THCA | Pre-clinical |
| RET | RET MUT* (L963V) | Different Alteration | Sunitinib (Pan-TK inhibitor) | Responsive | THCA | Pre-clinical |
| RET | RET MUT* (L963V) | Different Alteration | RET inhibitor | Responsive | TH | Pre-clinical |
| ERBB3 | ERBB3 MUT (G284R) | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | CANCER | Pre-clinical |
| ERBB3 | ERBB3 MUT (G284R) | Complete Match | Lapatinib (ERBB2 inhibitor) | Responsive | CANCER | Pre-clinical |
| ERBB3 | ERBB3 MUT (G284R) | Complete Match | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | CANCER | Pre-clinical |
| ERBB3 | ERBB3 MUT (G284R) | Complete Match | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BLCA | Case report |
| ERBB3 | ERBB3 MUT (G284R) | Complete Match | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | CANCER | Pre-clinical |
| ERBB3 | ERBB3 MUT (G284R) | Complete Match | ERBB3 mAb inhibitor | Responsive | CANCER | Pre-clinical |
| ERBB3 | ERBB3 MUT (G284R) | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Early trials |
| ERBB2 | ERBB2 MUT (S310F) | Different Alteration | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | ERBB2 MUT (S310F) | Different Alteration | Lapatinib (ERBB2 inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | ERBB2 MUT (S310F) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | ST, BRCA, GEJA | FDA guidelines |
| ERBB2 | ERBB2 MUT (S310F) | Different Alteration | Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | ERBB2 MUT (S310F) | Different Alteration | MK2206;Trastuzumab (allosteric AKT inhibitor;ERBB2 mAb inhibitor) | Responsive | SOLID | Early trials |
| ERBB2 | ERBB2 MUT (S310F) | Different Mutation | Lapatinib (ERBB2 inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (S310F) | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (S310F) | Complete Match | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | CANCER, BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (S310F) | Complete Match | Neratinib (ERBB2 inhibitor) | Responsive | CANCER | Early trials |
| ERBB2 | ERBB2 MUT (S310F) | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | CANCER | Early trials |
| ERBB2 | ERBB2 MUT (S310F) | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Case report |
| ERBB2 | ERBB2 MUT (S310F) | Different Mutation | Lapatinib (ERBB2 inhibitor) | Responsive | BRCA, LUAD | Case report |
| ERBB2 | ERBB2 MUT (S310F) | Complete Match | Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) | Responsive | L | Early trials |
| ERBB2 | ERBB2 MUT (S310F) | Different Mutation | Neratinib (ERBB2 inhibitor) | Resistant | BRCA | Case report |
| ERBB2 | ERBB2 MUT (S310F) | Different Mutation | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (S310F) | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | LUAD | Case report |
| ERBB2 | ERBB2 MUT (S310F) | Different Mutation | Lapatinib (ERBB2 inhibitor) | Resistant | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (S310F) | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | CANCER | Pre-clinical |
| ERBB2 | ERBB2 MUT (S310F) | Complete Match | Temsirolimus (MTOR inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (S310F) | Complete Match | Dacomitinib (Pan ERBB inhibitor) | Responsive | NSCLC | Early trials |
| ERBB2 | ERBB2 MUT (S310F) | Complete Match | Neratinib (ERBB2 inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (S310F) | Different Mutation | ERBB2 inhibitor | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (S310F) | Different Mutation | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (S310F) | Different Mutation | ERBB2 mAb inhibitor | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (S310F) | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (S310F) | Different Mutation | Lapatinib (ERBB2 inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (S310F) | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (S310F) | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BRCA | Late trials |
| ERBB2 | ERBB2 MUT (S310F) | Different Alteration | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | BT | Early trials |
| ERBB2 | ERBB2 MUT (S310F) | Different Alteration | Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) | Responsive | COREAD | Late trials |
| ERBB2 | ERBB2 MUT (S310F) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | OV | Early trials |
| ERBB2 | ERBB2 MUT (S310F) | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BLCA | Case report |
| ERBB2 | ERBB2 MUT (S310F) | Different Alteration | Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) | Responsive | COREAD | Case report |
| ERBB2 | ERBB2 MUT (S310F) | Different Alteration | Rociletinib (EGFR inhibitor) | Resistant | LUAD | Case report |
| ERBB2 | ERBB2 MUT (S310F) | Different Alteration | Osimertinib (EGFR inhibitor) | Resistant | LUAD | Case report |
| ERBB2 | ERBB2 MUT (S310F) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | BT | Early trials |
| ERBB2 | ERBB2 MUT (S310F) | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Early trials |
| ERBB2 | ERBB2 MUT (S310F) | Different Alteration | Lapatinib (ERBB2 inhibitor) | Responsive | BT | Early trials |
| ERBB2 | ERBB2 MUT (S310F) | Different Alteration | Trastuzumab;HSP90 inhibitor (ERBB2 mAb inhibitor;HSP90 inhibitor) | Responsive | BRCA | Early trials |
| ERBB2 | ERBB2 MUT (S310F) | Different Alteration | HER2 inhibitor;CDK4/6 inhibitor | Responsive | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (S310F) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | ERBB2 MUT (S310F) | Different Alteration | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | ST | Early trials |
| ERBB2 | ERBB2 MUT (S310F) | Different Alteration | Trastuzumab;Everolimus;Chemotherapy (ERBB2 mAb inhibitor;MTOR inhibitor;Chemotherapy) | Responsive | BRCA | Early trials |
| ERBB2 | ERBB2 MUT (S310F) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | ST, GEJA | FDA guidelines |
| ERBB2 | ERBB2 MUT (S310F) | Different Alteration | ERBB2 inhibitor;CDK4/6 inhibitor | Responsive | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (S310F) | Different Alteration | Ado-Trastuzumab Emtansine (EGFR mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | ERBB2 MUT (S310F) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | HNC | Case report |
| ERBB2 | ERBB2 MUT (S310F) | Different Alteration | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Late trials |
| ERBB2 | ERBB2 MUT (S310F) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | No Responsive | ED | Early trials |
| ERBB2 | ERBB2 MUT (S310F) | Different Alteration | Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) | Responsive | ED | Pre-clinical |
| ERBB2 | ERBB2 MUT (S310F) | Different Alteration | Lapatinib;Chemotherapy (ERBB2 inhibitor;Chemotherapy) | Responsive | ST | Early trials |
| ERBB2 | ERBB2 MUT (S310F) | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | ST | Case report |
| ERBB2 | ERBB2 MUT (S310F) | Different Alteration | EGFR inhibitor | Resistant | LUAD | Pre-clinical |
| TP53 | TP53 MUT (C135F) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (C135F) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (C135F) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (C135F) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (C135F) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (C135F) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (C135F) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (C135F) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (C135F) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (C135F) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (C135F) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (C135F) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (C135F) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (C135F) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (C135F) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| STAG2 | STAG2 MUT (splice_acceptor_variant) | Complete Match | PARP inhibitor | Responsive | G | Pre-clinical |
| TP53 | TP53 MUT (C242G) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (C242G) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (C242G) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (C242G) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (C242G) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (C242G) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (C242G) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (C242G) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (C242G) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (C242G) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (C242G) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (C242G) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (C242G) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (C242G) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (C242G) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| PTEN | PTEN MUT (R130Q) | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | PTEN MUT (R130Q) | Different Mutation | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | PTEN MUT (R130Q) | Different Mutation | BYL719 (PIK3CA inhibitor) | Resistant | BRCA | Case report |
| PTEN | PTEN MUT (R130Q) | Complete Match | ATM inhibitor | Responsive | BRCA | Pre-clinical |
| PTEN | PTEN MUT (R130Q) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA, ED, TH, CANCER, L, G, OV | Pre-clinical |
| PTEN | PTEN MUT (R130Q) | Complete Match | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | PTEN MUT (R130Q) | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | PTEN MUT (R130Q) | Complete Match | PARP inhibitor | Responsive | ED | Case report |
| PTEN | PTEN MUT (R130Q) | Complete Match | PD1 Ab inhibitor | Resistant | CM | Early trials |
| PTEN | PTEN MUT (R130Q) | Complete Match | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | PTEN MUT (R130Q) | Complete Match | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | PTEN MUT (R130Q) | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| PTEN | PTEN MUT (R130Q) | Complete Match | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | PTEN MUT (R130Q) | Complete Match | AKT inhibitor | Responsive | PA | Case report |
| PTEN | PTEN MUT (R130Q) | Complete Match | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | PTEN MUT (R130Q) | Different Alteration | PI3K pathway inhibitor | Responsive | L, BRCA, CANCER, G, ED, TH, OV | Pre-clinical |
| PTEN | PTEN MUT (R130Q) | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | PTEN MUT (R130Q) | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | PTEN MUT (R130Q) | Different Alteration | PARP inhibitor | Responsive | ED | Case report |
| PTEN | PTEN MUT (R130Q) | Different Alteration | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | PTEN MUT (R130Q) | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | PTEN MUT (R130Q) | Different Alteration | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | PTEN MUT (R130Q) | Different Alteration | AKT inhibitor | Responsive | PA | Case report |
| PTEN | PTEN MUT (R130Q) | Different Alteration | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | PTEN MUT (R130Q) | Different Alteration | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| HRAS | HRAS MUT (G13R) | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | CER | Pre-clinical |
| HRAS | HRAS MUT (G13R) | Complete Match | MEK inhibitor +/- MTOR inhibitor | Responsive | AML | Pre-clinical |
| HRAS | HRAS MUT (G13R) | Complete Match | MTOR inhibitor | Responsive | CESC | Pre-clinical |
| HRAS | HRAS MUT (G13R) | Complete Match | Tipifarnib (Farnesyltransferase inhibitor) | Responsive | CANCER | Early trials |
| NF1 | NF1 MUT (S1420*), NF1 MUT (S1443*) | Complete Match | Vemurafenib (BRAF inhibitor) | Resistant | CM | Pre-clinical |
| NF1 | NF1 MUT (S1420*), NF1 MUT (S1443*) | Different Mutation | Everolimus (MTOR inhibitor) | Responsive | HNC | Case report |
| NF1 | NF1 MUT (S1420*), NF1 MUT (S1443*) | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (S1420*), NF1 MUT (S1443*) | Complete Match | Vinblastine (Chemotherapy) | Responsive | G | Early trials |
| NF1 | NF1 MUT (S1420*), NF1 MUT (S1443*) | Complete Match | KIT inhibitor;MTOR inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (S1420*), NF1 MUT (S1443*) | Complete Match | Tamoxifen (Hormonal therapy) | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (S1420*), NF1 MUT (S1443*) | Complete Match | Bevacizumab (VEGFR mAb inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (S1420*), NF1 MUT (S1443*) | Complete Match | Retinoic Acid | Resistant | NB | Pre-clinical |
| NF1 | NF1 MUT (S1420*), NF1 MUT (S1443*) | Complete Match | Everolimus (MTOR inhibitor) | Responsive | NF | Late trials |
| NF1 | NF1 MUT (S1420*), NF1 MUT (S1443*) | Complete Match | Trametinib (MEK inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (S1420*), NF1 MUT (S1443*) | Complete Match | Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (S1420*), NF1 MUT (S1443*) | Complete Match | Nilotinib (BCR-ABL inhibitor) | Responsive | MPN, PLEN | Pre-clinical |
| NF1 | NF1 MUT (S1420*), NF1 MUT (S1443*) | Complete Match | MEK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (S1420*), NF1 MUT (S1443*) | Complete Match | Everolimus (MTOR inhibitor) | Responsive | HNC, SG | Case report |
| NF1 | NF1 MUT (S1420*), NF1 MUT (S1443*) | Complete Match | Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) | No Responsive | MPN | Early trials |
| NF1 | NF1 MUT (S1420*), NF1 MUT (S1443*) | Complete Match | PLX3397 (Pan-TK inhibitor) | Responsive | PLEN | Pre-clinical |
| NF1 | NF1 MUT (S1420*), NF1 MUT (S1443*) | Complete Match | MEK inhibitor | Responsive | LK, G | Pre-clinical |
| NF1 | NF1 MUT (S1420*), NF1 MUT (S1443*) | Complete Match | Pan-RAF inhibitor;MEK inhibitor | Responsive | CM | Pre-clinical |
| NF1 | NF1 MUT (S1420*), NF1 MUT (S1443*) | Complete Match | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (S1420*), NF1 MUT (S1443*) | Complete Match | AURK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (S1420*), NF1 MUT (S1443*) | Complete Match | MTOR inhibitor | Responsive | LK, G, MPN | Pre-clinical |
| NF1 | NF1 MUT (S1420*), NF1 MUT (S1443*) | Complete Match | Dasatinib (BCR-ABL inhibitor) | Resistant | L | Pre-clinical |
| NF1 | NF1 MUT (S1420*), NF1 MUT (S1443*) | Complete Match | Everolimus;Pazopanib (MTOR inhibitor;VEGFR inhibitor) | Responsive | HC | Case report |
| NF1 | NF1 MUT (S1420*), NF1 MUT (S1443*) | Complete Match | Everolimus (MTOR inhibitor) | No Responsive | MPN | Early trials |
| NF1 | NF1 MUT (S1420*), NF1 MUT (S1443*) | Complete Match | Cediranib (ALK inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (S1420*), NF1 MUT (S1443*) | Complete Match | PD1 Ab inhibitor | Responsive | CM | Early trials |
| NF1 | NF1 MUT (S1420*), NF1 MUT (S1443*) | Complete Match | Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (S1420*), NF1 MUT (S1443*) | Complete Match | Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (S1420*), NF1 MUT (S1443*) | Complete Match | Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | No Responsive | G | Case report |
| NF1 | NF1 MUT (S1420*), NF1 MUT (S1443*) | Complete Match | BRD4 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (S1420*), NF1 MUT (S1443*) | Complete Match | Tipifarnib (Farnesyltransferase inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (S1420*), NF1 MUT (S1443*) | Complete Match | Selumetinib (MEK inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (S1420*), NF1 MUT (S1443*) | Complete Match | MTOR inhibitor;HSP90 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (S1420*), NF1 MUT (S1443*) | Complete Match | Trametinib (MEK inhibitor) | Responsive | CM | Pre-clinical |
| NF1 | NF1 MUT (S1420*), NF1 MUT (S1443*) | Complete Match | Erlotinib (EGFR inhibitor) | Resistant | L | Pre-clinical |
| NF1 | NF1 MUT (S1420*), NF1 MUT (S1443*) | Complete Match | Trametinib (MEK inhibitor) | No Responsive | OS | Case report |
| NF1 | NF1 MUT (S1420*), NF1 MUT (S1443*) | Different Alteration | MTOR inhibitor | Responsive | MPN, G, LK | Pre-clinical |
| NF1 | NF1 MUT (S1420*), NF1 MUT (S1443*) | Different Alteration | PLX3397 (Pan-TK inhibitor) | Responsive | PLEN | Pre-clinical |
| NF1 | NF1 MUT (S1420*), NF1 MUT (S1443*) | Different Alteration | Erlotinib (EGFR inhibitor) | Resistant | L | Pre-clinical |
| NF1 | NF1 MUT (S1420*), NF1 MUT (S1443*) | Different Alteration | Trametinib (MEK inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (S1420*), NF1 MUT (S1443*) | Different Alteration | BRD4 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (S1420*), NF1 MUT (S1443*) | Different Alteration | Trametinib (MEK inhibitor) | No Responsive | OS | Case report |
| NF1 | NF1 MUT (S1420*), NF1 MUT (S1443*) | Different Alteration | Cediranib (ALK inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (S1420*), NF1 MUT (S1443*) | Different Alteration | Bevacizumab (VEGFR mAb inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (S1420*), NF1 MUT (S1443*) | Different Alteration | MEK inhibitor | Responsive | G, LK | Pre-clinical |
| NF1 | NF1 MUT (S1420*), NF1 MUT (S1443*) | Different Alteration | Vinblastine (Chemotherapy) | Responsive | G | Early trials |
| NF1 | NF1 MUT (S1420*), NF1 MUT (S1443*) | Different Alteration | Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (S1420*), NF1 MUT (S1443*) | Different Alteration | Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) | No Responsive | MPN | Early trials |
| NF1 | NF1 MUT (S1420*), NF1 MUT (S1443*) | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Resistant | L | Pre-clinical |
| NF1 | NF1 MUT (S1420*), NF1 MUT (S1443*) | Different Alteration | MTOR inhibitor;HSP90 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (S1420*), NF1 MUT (S1443*) | Different Alteration | Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (S1420*), NF1 MUT (S1443*) | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (S1420*), NF1 MUT (S1443*) | Different Alteration | Tamoxifen (Hormonal therapy) | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (S1420*), NF1 MUT (S1443*) | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | SG, HNC | Case report |
| NF1 | NF1 MUT (S1420*), NF1 MUT (S1443*) | Different Alteration | Pan-RAF inhibitor;MEK inhibitor | Responsive | CM | Pre-clinical |
| NF1 | NF1 MUT (S1420*), NF1 MUT (S1443*) | Different Alteration | Tipifarnib (Farnesyltransferase inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (S1420*), NF1 MUT (S1443*) | Different Alteration | Selumetinib (MEK inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (S1420*), NF1 MUT (S1443*) | Different Alteration | Retinoic Acid | Resistant | NB | Pre-clinical |
| NF1 | NF1 MUT (S1420*), NF1 MUT (S1443*) | Different Alteration | Everolimus (MTOR inhibitor) | No Responsive | MPN | Early trials |
| NF1 | NF1 MUT (S1420*), NF1 MUT (S1443*) | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (S1420*), NF1 MUT (S1443*) | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | PLEN, MPN | Pre-clinical |
| NF1 | NF1 MUT (S1420*), NF1 MUT (S1443*) | Different Alteration | Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (S1420*), NF1 MUT (S1443*) | Different Alteration | Trametinib (MEK inhibitor) | Responsive | CM | Pre-clinical |
| NF1 | NF1 MUT (S1420*), NF1 MUT (S1443*) | Different Alteration | AURK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (S1420*), NF1 MUT (S1443*) | Different Alteration | Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | No Responsive | G | Case report |
| NF1 | NF1 MUT (S1420*), NF1 MUT (S1443*) | Different Alteration | PD1 Ab inhibitor | Responsive | CM | Early trials |
| NF1 | NF1 MUT (S1420*), NF1 MUT (S1443*) | Different Alteration | MEK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (S1420*), NF1 MUT (S1443*) | Different Alteration | KIT inhibitor;MTOR inhibitor | Responsive | MPN | Pre-clinical |
| PIK3CA | PIK3CA MUT (E726K), PIK3CA MUT (E542K) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (E726K), PIK3CA MUT (E542K) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (E726K), PIK3CA MUT (E542K) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (E726K), PIK3CA MUT (E542K) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (E726K), PIK3CA MUT (E542K) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (E726K), PIK3CA MUT (E542K) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (E726K), PIK3CA MUT (E542K) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (E726K), PIK3CA MUT (E542K) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (E726K), PIK3CA MUT (E542K) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (E726K), PIK3CA MUT (E542K) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (E726K), PIK3CA MUT (E542K) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (E726K), PIK3CA MUT (E542K) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (E726K), PIK3CA MUT (E542K) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (E726K), PIK3CA MUT (E542K) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| NOTCH2 | NOTCH2 MUT* (R1630G) | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| ROS1 | ROS1 MUT* (L1872V) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | IM | Case report |
| ROS1 | ROS1 MUT* (L1872V) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ROS1 | ROS1 MUT* (L1872V) | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Case report |
| ROS1 | ROS1 MUT* (L1872V) | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Pre-clinical |
| ROS1 | ROS1 MUT* (L1872V) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Early trials |
| PIK3CA | PIK3CA MUT (E453K) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (E453K) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (E453K) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (E453K) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (E453K) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (E453K) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (E453K) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (E453K) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (E453K) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (E453K) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (E453K) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (E453K) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (E453K) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (E453K) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| NTRK3 | NTRK3 MUT* (R306P) | Different Alteration | IGF1R inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK3 | NTRK3 MUT* (R306P) | Different Alteration | PI3K pathway inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK3 | NTRK3 MUT* (R306P) | Different Alteration | Midostaurin (Pan-TK inhibitor) | Responsive | BRCA | Pre-clinical |
| BRAF | BRAF MUT* (K698R) | Different Alteration | Sorafenib (Pan-TK inhibitor) | Responsive | CM, LUAD, PRAD | Pre-clinical |
| BRAF | BRAF MUT* (K698R) | Different Alteration | MEK inhibitor | Responsive | LUAD, CM, PRAD | Pre-clinical |
| BRAF | BRAF MUT* (K698R) | Different Alteration | Selumetinib (MEK inhibitor) | Responsive | OV | Case report |
| BRAF | BRAF MUT* (K698R) | Different Alteration | BRAF inhibitor;MEK inhibitor | Responsive | LUAD | Case report |
| ERBB2 | ERBB2 MUT (L755W), ERBB2 MUT (R678Q) | Different Alteration | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | ERBB2 MUT (L755W), ERBB2 MUT (R678Q) | Different Alteration | Lapatinib (ERBB2 inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | ERBB2 MUT (L755W), ERBB2 MUT (R678Q) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | ST, BRCA, GEJA | FDA guidelines |
| ERBB2 | ERBB2 MUT (L755W), ERBB2 MUT (R678Q) | Different Alteration | Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | ERBB2 MUT (L755W), ERBB2 MUT (R678Q) | Different Alteration | MK2206;Trastuzumab (allosteric AKT inhibitor;ERBB2 mAb inhibitor) | Responsive | SOLID | Early trials |
| ERBB2 | ERBB2 MUT (L755W), ERBB2 MUT (R678Q) | Different Mutation | Lapatinib (ERBB2 inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (L755W), ERBB2 MUT (R678Q) | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (L755W), ERBB2 MUT (R678Q) | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | CANCER, BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (L755W), ERBB2 MUT (R678Q) | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | CANCER | Early trials |
| ERBB2 | ERBB2 MUT (L755W) | Complete Match | Neratinib (ERBB2 inhibitor) | Responsive | CANCER | Early trials |
| ERBB2 | ERBB2 MUT (L755W), ERBB2 MUT (R678Q) | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Case report |
| ERBB2 | ERBB2 MUT (L755W), ERBB2 MUT (R678Q) | Different Mutation | Lapatinib (ERBB2 inhibitor) | Responsive | BRCA, LUAD | Case report |
| ERBB2 | ERBB2 MUT (L755W), ERBB2 MUT (R678Q) | Different Mutation | Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) | Responsive | L | Early trials |
| ERBB2 | ERBB2 MUT (L755W), ERBB2 MUT (R678Q) | Different Mutation | Neratinib (ERBB2 inhibitor) | Resistant | BRCA | Case report |
| ERBB2 | ERBB2 MUT (L755W), ERBB2 MUT (R678Q) | Different Mutation | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (L755W), ERBB2 MUT (R678Q) | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | LUAD | Case report |
| ERBB2 | ERBB2 MUT (L755W), ERBB2 MUT (R678Q) | Different Mutation | Lapatinib (ERBB2 inhibitor) | Resistant | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (L755W), ERBB2 MUT (R678Q) | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | CANCER | Pre-clinical |
| ERBB2 | ERBB2 MUT (L755W), ERBB2 MUT (R678Q) | Complete Match | Temsirolimus (MTOR inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (L755W), ERBB2 MUT (R678Q) | Complete Match | Dacomitinib (Pan ERBB inhibitor) | Responsive | NSCLC | Early trials |
| ERBB2 | ERBB2 MUT (L755W), ERBB2 MUT (R678Q) | Complete Match | Neratinib (ERBB2 inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (L755W), ERBB2 MUT (R678Q) | Different Mutation | ERBB2 inhibitor | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (L755W), ERBB2 MUT (R678Q) | Different Mutation | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (L755W), ERBB2 MUT (R678Q) | Different Mutation | ERBB2 mAb inhibitor | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (L755W), ERBB2 MUT (R678Q) | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (L755W), ERBB2 MUT (R678Q) | Different Mutation | Lapatinib (ERBB2 inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (L755W), ERBB2 MUT (R678Q) | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (L755W), ERBB2 MUT (R678Q) | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BRCA | Late trials |
| ERBB2 | ERBB2 MUT (L755W), ERBB2 MUT (R678Q) | Different Alteration | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | BT | Early trials |
| ERBB2 | ERBB2 MUT (L755W), ERBB2 MUT (R678Q) | Different Alteration | Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) | Responsive | COREAD | Late trials |
| ERBB2 | ERBB2 MUT (L755W), ERBB2 MUT (R678Q) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | OV | Early trials |
| ERBB2 | ERBB2 MUT (L755W), ERBB2 MUT (R678Q) | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BLCA | Case report |
| ERBB2 | ERBB2 MUT (L755W), ERBB2 MUT (R678Q) | Different Alteration | Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) | Responsive | COREAD | Case report |
| ERBB2 | ERBB2 MUT (L755W), ERBB2 MUT (R678Q) | Different Alteration | Rociletinib (EGFR inhibitor) | Resistant | LUAD | Case report |
| ERBB2 | ERBB2 MUT (L755W), ERBB2 MUT (R678Q) | Different Alteration | Osimertinib (EGFR inhibitor) | Resistant | LUAD | Case report |
| ERBB2 | ERBB2 MUT (L755W), ERBB2 MUT (R678Q) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | BT | Early trials |
| ERBB2 | ERBB2 MUT (L755W), ERBB2 MUT (R678Q) | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Early trials |
| ERBB2 | ERBB2 MUT (L755W), ERBB2 MUT (R678Q) | Different Alteration | Lapatinib (ERBB2 inhibitor) | Responsive | BT | Early trials |
| ERBB2 | ERBB2 MUT (L755W), ERBB2 MUT (R678Q) | Different Alteration | Trastuzumab;HSP90 inhibitor (ERBB2 mAb inhibitor;HSP90 inhibitor) | Responsive | BRCA | Early trials |
| ERBB2 | ERBB2 MUT (L755W), ERBB2 MUT (R678Q) | Different Alteration | HER2 inhibitor;CDK4/6 inhibitor | Responsive | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (L755W), ERBB2 MUT (R678Q) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | ERBB2 MUT (L755W), ERBB2 MUT (R678Q) | Different Alteration | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | ST | Early trials |
| ERBB2 | ERBB2 MUT (L755W), ERBB2 MUT (R678Q) | Different Alteration | Trastuzumab;Everolimus;Chemotherapy (ERBB2 mAb inhibitor;MTOR inhibitor;Chemotherapy) | Responsive | BRCA | Early trials |
| ERBB2 | ERBB2 MUT (L755W), ERBB2 MUT (R678Q) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | ST, GEJA | FDA guidelines |
| ERBB2 | ERBB2 MUT (L755W), ERBB2 MUT (R678Q) | Different Alteration | ERBB2 inhibitor;CDK4/6 inhibitor | Responsive | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (L755W), ERBB2 MUT (R678Q) | Different Alteration | Ado-Trastuzumab Emtansine (EGFR mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | ERBB2 MUT (L755W), ERBB2 MUT (R678Q) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | HNC | Case report |
| ERBB2 | ERBB2 MUT (L755W), ERBB2 MUT (R678Q) | Different Alteration | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Late trials |
| ERBB2 | ERBB2 MUT (L755W), ERBB2 MUT (R678Q) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | No Responsive | ED | Early trials |
| ERBB2 | ERBB2 MUT (L755W), ERBB2 MUT (R678Q) | Different Alteration | Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) | Responsive | ED | Pre-clinical |
| ERBB2 | ERBB2 MUT (L755W), ERBB2 MUT (R678Q) | Different Alteration | Lapatinib;Chemotherapy (ERBB2 inhibitor;Chemotherapy) | Responsive | ST | Early trials |
| ERBB2 | ERBB2 MUT (L755W), ERBB2 MUT (R678Q) | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | ST | Case report |
| ERBB2 | ERBB2 MUT (L755W), ERBB2 MUT (R678Q) | Different Alteration | EGFR inhibitor | Resistant | LUAD | Pre-clinical |
| TP53 | TP53 MUT (H193R) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (H193R) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (H193R) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (H193R) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (H193R) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (H193R) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (H193R) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (H193R) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (H193R) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (H193R) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (H193R) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (H193R) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (H193R) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (H193R) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (H193R) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| BCR | BCR MUT* (Q300H) | Different Alteration | Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) | Responsive | CML, ALL | FDA guidelines |
| BCR | BCR MUT* (Q300H) | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | ALL, CML | FDA guidelines |
| BCR | BCR MUT* (Q300H) | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| BCR | BCR MUT* (Q300H) | Different Alteration | Bosutinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| BCR | BCR MUT* (Q300H) | Different Alteration | Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) | Responsive | ALL | Pre-clinical |
| BCR | BCR MUT* (Q300H) | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Responsive | ALL, CML | FDA guidelines |
| PIK3CA | PIK3CA MUT (E545K), PIK3CA MUT (E453K) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (E545K), PIK3CA MUT (E453K) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (E545K), PIK3CA MUT (E453K) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (E545K), PIK3CA MUT (E453K) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (E545K), PIK3CA MUT (E453K) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (E545K), PIK3CA MUT (E453K) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (E545K), PIK3CA MUT (E453K) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (E545K), PIK3CA MUT (E453K) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (E545K), PIK3CA MUT (E453K) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (E545K), PIK3CA MUT (E453K) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (E545K), PIK3CA MUT (E453K) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (E545K), PIK3CA MUT (E453K) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (E545K), PIK3CA MUT (E453K) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (E545K), PIK3CA MUT (E453K) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (M1043I) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (M1043I) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (M1043I) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (M1043I) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (M1043I) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (M1043I) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (M1043I) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (M1043I) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (M1043I) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (M1043I) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (M1043I) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (M1043I) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (M1043I) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (M1043I) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| ROS1 | ROS1 MUT* (P1743Q) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | IM | Case report |
| ROS1 | ROS1 MUT* (P1743Q) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ROS1 | ROS1 MUT* (P1743Q) | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Case report |
| ROS1 | ROS1 MUT* (P1743Q) | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Pre-clinical |
| ROS1 | ROS1 MUT* (P1743Q) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Early trials |
| NRG1 | NRG1 MUT* (5-UTRSNV) | Different Alteration | Lapatinib (ERBB2 inhibitor) | Responsive | LUAD | Pre-clinical |
| NRG1 | NRG1 MUT* (5-UTRSNV) | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | LUAD | Case report |
| EGFR | EGFR MUT* (intron_variant) | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | L | Case report |
| EGFR | EGFR MUT* (intron_variant) | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | NSCLC | Case report |
| EGFR | EGFR MUT* (D916D) | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | L | Case report |
| EGFR | EGFR MUT* (D916D) | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | NSCLC | Case report |
| TP53 | TP53 MUT (E258*) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (E258*) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (E258*) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (E258*) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (E258*) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (E258*) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (E258*) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (E258*) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (E258*) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (E258*) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (E258*) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (E258*) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (E258*) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (E258*) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (E258*) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| MET | MET MUT* (G1288G) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | G | Case report |
| FGFR3 | FGFR3 MUT* (D318N) | Different Alteration | FGFR inhibitor | Responsive | BLCA | Case report |
| FGFR3 | FGFR3 MUT* (D318N) | Different Alteration | FGFR inhibitor | Responsive | G | Early trials |
| FGFR3 | FGFR3 MUT* (D318N) | Different Alteration | FGFR inhibitor | Responsive | NSCLC | Pre-clinical |
| PLCG2 | PLCG2 MUT (Q489*) | Different Mutation | Ibrutinib (BTK inhibitor) | Resistant | CLL | Early trials |
| CDKN2A | CDKN2A MUT (H83Y) | Complete Match | Ilorasertib (AURKA-VEGF inhibitor) | Responsive | CANCER | Early trials |
| CDKN2A | CDKN2A MUT (H83Y) | Complete Match | CDK4/6 inhibitor | Responsive | CANCER, G | Pre-clinical |
| CDKN2A | CDKN2A MUT (H83Y) | Complete Match | CDK4/6 inhibitor | Responsive | CM | Case report |
| CDKN2A | CDKN2A MUT (H83Y) | Complete Match | PD1 inhibitor | Resistant | CM | Early trials |
| CDKN2A | CDKN2A MUT (H83Y) | Different Alteration | CDK4/6 inhibitor | Responsive | CANCER, G | Pre-clinical |
| CDKN2A | CDKN2A MUT (H83Y) | Different Alteration | Ilorasertib (AURKA-VEGF inhibitor) | Responsive | CANCER | Early trials |
| CDKN2A | CDKN2A MUT (H83Y) | Different Alteration | PD1 inhibitor | Resistant | CM | Early trials |
| CDKN2A | CDKN2A MUT (H83Y) | Different Alteration | CDK4/6 inhibitor | Responsive | CM | Case report |
| BRD4 | BRD4 MUT* (intron_variant) | Different Alteration | BET inhibitor | Responsive | NMC | Case report |
| NOTCH1 | NOTCH1 MUT* (G1376S) | Different Alteration | Gamma secretase inhibitor | Responsive | ALL | Pre-clinical |
| NOTCH1 | NOTCH1 MUT* (G1376S) | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| TMPRSS2 | TMPRSS2 MUT* (A527E) | Different Alteration | DNA-PKc inhibitor | Responsive | PRAD | Pre-clinical |
| TMPRSS2 | TMPRSS2 MUT* (A527E) | Different Alteration | PARP inhibitor | Responsive | PRAD | Pre-clinical |
| TP53 | TP53 MUT (E286A) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (E286A) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (E286A) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (E286A) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (E286A) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (E286A) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (E286A) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (E286A) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (E286A) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (E286A) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (E286A) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (E286A) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (E286A) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (E286A) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (E286A) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (R213*) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (R213*) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (R213*) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (R213*) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (R213*) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (R213*) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (R213*) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R213*) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R213*) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (R213*) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (R213*) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R213*) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (R213*) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (R213*) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (R213*) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| ERCC6 | ERCC6 MUT (R612*) | Complete Match | Cisplatin (Chemotherapy) | Responsive | OV | Pre-clinical |
| PTEN | PTEN MUT (R130Q), PTEN MUT (S59*) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | PTEN MUT (R130Q), PTEN MUT (S59*) | Complete Match | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | PTEN MUT (R130Q), PTEN MUT (S59*) | Complete Match | BYL719 (PIK3CA inhibitor) | Resistant | BRCA | Case report |
| PTEN | PTEN MUT (R130Q), PTEN MUT (S59*) | Complete Match | ATM inhibitor | Responsive | BRCA | Pre-clinical |
| PTEN | PTEN MUT (R130Q), PTEN MUT (S59*) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA, ED, TH, CANCER, L, G, OV | Pre-clinical |
| PTEN | PTEN MUT (R130Q), PTEN MUT (S59*) | Complete Match | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | PTEN MUT (R130Q), PTEN MUT (S59*) | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | PTEN MUT (R130Q), PTEN MUT (S59*) | Complete Match | PARP inhibitor | Responsive | ED | Case report |
| PTEN | PTEN MUT (R130Q), PTEN MUT (S59*) | Complete Match | PD1 Ab inhibitor | Resistant | CM | Early trials |
| PTEN | PTEN MUT (R130Q), PTEN MUT (S59*) | Complete Match | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | PTEN MUT (R130Q), PTEN MUT (S59*) | Complete Match | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | PTEN MUT (R130Q), PTEN MUT (S59*) | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| PTEN | PTEN MUT (R130Q), PTEN MUT (S59*) | Complete Match | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | PTEN MUT (R130Q), PTEN MUT (S59*) | Complete Match | AKT inhibitor | Responsive | PA | Case report |
| PTEN | PTEN MUT (R130Q), PTEN MUT (S59*) | Complete Match | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | PTEN MUT (R130Q), PTEN MUT (S59*) | Different Alteration | PI3K pathway inhibitor | Responsive | L, BRCA, CANCER, G, ED, TH, OV | Pre-clinical |
| PTEN | PTEN MUT (R130Q), PTEN MUT (S59*) | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | PTEN MUT (R130Q), PTEN MUT (S59*) | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | PTEN MUT (R130Q), PTEN MUT (S59*) | Different Alteration | PARP inhibitor | Responsive | ED | Case report |
| PTEN | PTEN MUT (R130Q), PTEN MUT (S59*) | Different Alteration | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | PTEN MUT (R130Q), PTEN MUT (S59*) | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | PTEN MUT (R130Q), PTEN MUT (S59*) | Different Alteration | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | PTEN MUT (R130Q), PTEN MUT (S59*) | Different Alteration | AKT inhibitor | Responsive | PA | Case report |
| PTEN | PTEN MUT (R130Q), PTEN MUT (S59*) | Different Alteration | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | PTEN MUT (R130Q), PTEN MUT (S59*) | Different Alteration | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| FGFR2 | FGFR2 MUT* (V635A) | Different Alteration | FGFR inhibitor | Responsive | COREAD | Early trials |
| FGFR2 | FGFR2 MUT* (V635A) | Different Alteration | FGFR inhibitor | Responsive | BT | Early trials |
| KMT2A | MLL MUT* (R652*), MLL MUT* (R3744Q) | Different Alteration | EPZ-5676 (DOT1L inhibitor) | Responsive | ALL, MDS, AML | Early trials |
| KMT2A | MLL MUT* (R652*), MLL MUT* (R3744Q) | Different Alteration | BET inhibitor | Responsive | ALL | Pre-clinical |
| KMT2A | MLL MUT* (R652*), MLL MUT* (R3744Q) | Different Alteration | BET inhibitor | Responsive | AML | Pre-clinical |
| KMT2A | MLL MUT* (R652*), MLL MUT* (R3744Q) | Different Alteration | Daunorubicin (Chemotherapy) | Responsive | AML | FDA guidelines |
| KMT2A | MLL MUT* (R652*), MLL MUT* (R3744Q) | Different Alteration | Belinostat (HDAC inhibitor) | Responsive | AML | Early trials |
| KMT2A | MLL MUT* (R652*), MLL MUT* (R3744Q) | Different Alteration | DOT1L inhibitor | Responsive | AML | Early trials |
| ALK | ALK MUT* (G1121D), ALK MUT* (Y1282Y) | Different Alteration | ALK inhibitor;SRC inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (G1121D), ALK MUT* (Y1282Y) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | GB, LY | Early trials |
| ALK | ALK MUT* (G1121D), ALK MUT* (Y1282Y) | Different Alteration | Lorlatinib (ALK&ROS1 inhibitor) | Responsive | NSCLC | Early trials |
| ALK | ALK MUT* (G1121D), ALK MUT* (Y1282Y) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | THCA, IM | Case report |
| ALK | ALK MUT* (G1121D), ALK MUT* (Y1282Y) | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (G1121D), ALK MUT* (Y1282Y) | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | ALK MUT* (G1121D), ALK MUT* (Y1282Y) | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | IM, COREAD | Case report |
| ALK | ALK MUT* (G1121D), ALK MUT* (Y1282Y) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | ALK MUT* (G1121D), ALK MUT* (Y1282Y) | Different Alteration | Brigatinib (Pan-TK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | ALK MUT* (G1121D), ALK MUT* (Y1282Y) | Different Alteration | Entrictinib (Pan-TK inhibitor) | Responsive | COREAD | Case report |
| ALK | ALK MUT* (G1121D), ALK MUT* (Y1282Y) | Different Alteration | Alectinib (ALK inhibitor) | Responsive | LUAD | FDA guidelines |
| ALK | ALK MUT* (G1121D), ALK MUT* (Y1282Y) | Different Alteration | HSP90 inhibitor (HSP90 inhibitor) | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (G1121D), ALK MUT* (Y1282Y) | Different Alteration | ALK inhibitor;IGF1R inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (G1121D), ALK MUT* (Y1282Y) | Different Alteration | ALK inhibitor;MEK inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (G1121D), ALK MUT* (Y1282Y) | Different Alteration | novel ALK inhibitor | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (G1121D), ALK MUT* (Y1282Y) | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | HEMATO | Early trials |
| ALK | ALK MUT* (G1121D), ALK MUT* (Y1282Y) | Different Alteration | ALK inhibitor | Responsive | COREAD | Case report |
| ALK | ALK MUT* (G1121D), ALK MUT* (Y1282Y) | Different Alteration | Alectinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | ALK MUT* (G1121D), ALK MUT* (Y1282Y) | Different Alteration | MEK inhibitor (ALK inhibitor;MEK inhibitor) | Responsive | LUAD | Pre-clinical |
| 0 | SMARCA4 MUT (E1426*) | Complete Match | EZH2 inhibitor | Responsive | OVRT | Case report |
| 0 | SMARCA4 MUT (E1426*) | Complete Match | AURKA inhibitor | Responsive | NSCLC | Pre-clinical |
| 0 | SMARCA4 MUT (E1426*) | Complete Match | EZH2 inhibitor | Responsive | OV | Case report |
| 0 | SMARCA4 MUT (E1426*) | Different Alteration | EZH2 inhibitor | Responsive | OVRT | Case report |
| 0 | SMARCA4 MUT (E1426*) | Different Alteration | EZH2 inhibitor | Responsive | OV | Case report |
| HIF1A | HIF1A MUT (R463*) | Different Alteration | Sunitinib (Pan-TK inhibitor) | Responsive | R | Pre-clinical |
| RB1 | RB1 MUT (splice_donor_variant) | Different Alteration | Palbociclib (CDK4/6 inhibitor) | Responsive | PRAD | Pre-clinical |
| RB1 | RB1 MUT (splice_donor_variant) | Complete Match | MDM2/MDMX inhibitor | Responsive | RB | Pre-clinical |
| RB1 | RB1 MUT (splice_donor_variant) | Complete Match | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| RB1 | RB1 MUT (splice_donor_variant) | Complete Match | HDAC inhibitor | Responsive | RB | Pre-clinical |
| RB1 | RB1 MUT (splice_donor_variant) | Different Alteration | MDM2/MDMX inhibitor | Responsive | RB | Pre-clinical |
| RB1 | RB1 MUT (splice_donor_variant) | Different Alteration | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| RB1 | RB1 MUT (splice_donor_variant) | Different Alteration | HDAC inhibitor | Responsive | RB | Pre-clinical |
| NF1 | NF1 MUT (E1734*) | Different Mutation | Vemurafenib (BRAF inhibitor) | Resistant | CM | Pre-clinical |
| NF1 | NF1 MUT (E1734*) | Different Mutation | Everolimus (MTOR inhibitor) | Responsive | HNC | Case report |
| NF1 | NF1 MUT (E1734*) | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (E1734*) | Complete Match | Vinblastine (Chemotherapy) | Responsive | G | Early trials |
| NF1 | NF1 MUT (E1734*) | Complete Match | KIT inhibitor;MTOR inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (E1734*) | Complete Match | Tamoxifen (Hormonal therapy) | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (E1734*) | Complete Match | Bevacizumab (VEGFR mAb inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (E1734*) | Complete Match | Retinoic Acid | Resistant | NB | Pre-clinical |
| NF1 | NF1 MUT (E1734*) | Complete Match | Everolimus (MTOR inhibitor) | Responsive | NF | Late trials |
| NF1 | NF1 MUT (E1734*) | Complete Match | Trametinib (MEK inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (E1734*) | Complete Match | Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (E1734*) | Complete Match | Nilotinib (BCR-ABL inhibitor) | Responsive | MPN, PLEN | Pre-clinical |
| NF1 | NF1 MUT (E1734*) | Complete Match | MEK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (E1734*) | Complete Match | Everolimus (MTOR inhibitor) | Responsive | HNC, SG | Case report |
| NF1 | NF1 MUT (E1734*) | Complete Match | Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) | No Responsive | MPN | Early trials |
| NF1 | NF1 MUT (E1734*) | Complete Match | PLX3397 (Pan-TK inhibitor) | Responsive | PLEN | Pre-clinical |
| NF1 | NF1 MUT (E1734*) | Complete Match | MEK inhibitor | Responsive | LK, G | Pre-clinical |
| NF1 | NF1 MUT (E1734*) | Complete Match | Pan-RAF inhibitor;MEK inhibitor | Responsive | CM | Pre-clinical |
| NF1 | NF1 MUT (E1734*) | Complete Match | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (E1734*) | Complete Match | AURK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (E1734*) | Complete Match | MTOR inhibitor | Responsive | LK, G, MPN | Pre-clinical |
| NF1 | NF1 MUT (E1734*) | Complete Match | Dasatinib (BCR-ABL inhibitor) | Resistant | L | Pre-clinical |
| NF1 | NF1 MUT (E1734*) | Complete Match | Everolimus;Pazopanib (MTOR inhibitor;VEGFR inhibitor) | Responsive | HC | Case report |
| NF1 | NF1 MUT (E1734*) | Complete Match | Everolimus (MTOR inhibitor) | No Responsive | MPN | Early trials |
| NF1 | NF1 MUT (E1734*) | Complete Match | Cediranib (ALK inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (E1734*) | Complete Match | PD1 Ab inhibitor | Responsive | CM | Early trials |
| NF1 | NF1 MUT (E1734*) | Complete Match | Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (E1734*) | Complete Match | Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (E1734*) | Complete Match | Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | No Responsive | G | Case report |
| NF1 | NF1 MUT (E1734*) | Complete Match | BRD4 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (E1734*) | Complete Match | Tipifarnib (Farnesyltransferase inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (E1734*) | Complete Match | Selumetinib (MEK inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (E1734*) | Complete Match | MTOR inhibitor;HSP90 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (E1734*) | Complete Match | Trametinib (MEK inhibitor) | Responsive | CM | Pre-clinical |
| NF1 | NF1 MUT (E1734*) | Complete Match | Erlotinib (EGFR inhibitor) | Resistant | L | Pre-clinical |
| NF1 | NF1 MUT (E1734*) | Complete Match | Trametinib (MEK inhibitor) | No Responsive | OS | Case report |
| NF1 | NF1 MUT (E1734*) | Different Alteration | MTOR inhibitor | Responsive | MPN, G, LK | Pre-clinical |
| NF1 | NF1 MUT (E1734*) | Different Alteration | PLX3397 (Pan-TK inhibitor) | Responsive | PLEN | Pre-clinical |
| NF1 | NF1 MUT (E1734*) | Different Alteration | Erlotinib (EGFR inhibitor) | Resistant | L | Pre-clinical |
| NF1 | NF1 MUT (E1734*) | Different Alteration | Trametinib (MEK inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (E1734*) | Different Alteration | BRD4 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (E1734*) | Different Alteration | Trametinib (MEK inhibitor) | No Responsive | OS | Case report |
| NF1 | NF1 MUT (E1734*) | Different Alteration | Cediranib (ALK inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (E1734*) | Different Alteration | Bevacizumab (VEGFR mAb inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (E1734*) | Different Alteration | MEK inhibitor | Responsive | G, LK | Pre-clinical |
| NF1 | NF1 MUT (E1734*) | Different Alteration | Vinblastine (Chemotherapy) | Responsive | G | Early trials |
| NF1 | NF1 MUT (E1734*) | Different Alteration | Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (E1734*) | Different Alteration | Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) | No Responsive | MPN | Early trials |
| NF1 | NF1 MUT (E1734*) | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Resistant | L | Pre-clinical |
| NF1 | NF1 MUT (E1734*) | Different Alteration | MTOR inhibitor;HSP90 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (E1734*) | Different Alteration | Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (E1734*) | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (E1734*) | Different Alteration | Tamoxifen (Hormonal therapy) | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (E1734*) | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | SG, HNC | Case report |
| NF1 | NF1 MUT (E1734*) | Different Alteration | Pan-RAF inhibitor;MEK inhibitor | Responsive | CM | Pre-clinical |
| NF1 | NF1 MUT (E1734*) | Different Alteration | Tipifarnib (Farnesyltransferase inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (E1734*) | Different Alteration | Selumetinib (MEK inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (E1734*) | Different Alteration | Retinoic Acid | Resistant | NB | Pre-clinical |
| NF1 | NF1 MUT (E1734*) | Different Alteration | Everolimus (MTOR inhibitor) | No Responsive | MPN | Early trials |
| NF1 | NF1 MUT (E1734*) | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (E1734*) | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | PLEN, MPN | Pre-clinical |
| NF1 | NF1 MUT (E1734*) | Different Alteration | Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (E1734*) | Different Alteration | Trametinib (MEK inhibitor) | Responsive | CM | Pre-clinical |
| NF1 | NF1 MUT (E1734*) | Different Alteration | AURK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (E1734*) | Different Alteration | Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | No Responsive | G | Case report |
| NF1 | NF1 MUT (E1734*) | Different Alteration | PD1 Ab inhibitor | Responsive | CM | Early trials |
| NF1 | NF1 MUT (E1734*) | Different Alteration | MEK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (E1734*) | Different Alteration | KIT inhibitor;MTOR inhibitor | Responsive | MPN | Pre-clinical |
| BRD4 | BRD4 MUT* (P723P) | Different Alteration | BET inhibitor | Responsive | NMC | Case report |
| ESR1 | ESR1 MUT* (A593D) | Different Alteration | ESR1 inhibitor | Resistant | BRCA | Pre-clinical |
| ROS1 | ROS1 MUT* (K1661Q) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | IM | Case report |
| ROS1 | ROS1 MUT* (K1661Q) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ROS1 | ROS1 MUT* (K1661Q) | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Case report |
| ROS1 | ROS1 MUT* (K1661Q) | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Pre-clinical |
| ROS1 | ROS1 MUT* (K1661Q) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Early trials |
| MET | MET MUT* (R1166Q), MET MUT* (P1171P) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | G | Case report |
| NRG1 | NRG1 MUT* (R155I) | Different Alteration | Lapatinib (ERBB2 inhibitor) | Responsive | LUAD | Pre-clinical |
| NRG1 | NRG1 MUT* (R155I) | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | LUAD | Case report |
| ERBB4 | ERBB4 MUT* (F401L) | Different Alteration | Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) | Responsive | LUAD | Pre-clinical |
| APC | APC MUT (S2223*), APC MUT (E109*) | Complete Match | Tankyrase inhibitor | Responsive | COREAD | Pre-clinical |
| ATR | ATR MUT (R1368*) | Complete Match | Temozolomide (Chemotherapy) | Responsive | G | Pre-clinical |
| ATR | ATR MUT (R1368*) | Complete Match | Olaparib (PARP inhibitor) | Responsive | CANCER, OV | Pre-clinical |
| ATR | ATR MUT (R1368*) | Different Alteration | Olaparib (PARP inhibitor) | Responsive | OV, CANCER | Pre-clinical |
| PIK3R1 | PIK3R1 MUT (R557*), PIK3R1 MUT (R348*) | Complete Match | AKT inhibitor | Responsive | G | Pre-clinical |
| PIK3R1 | PIK3R1 MUT (R557*), PIK3R1 MUT (R348*) | Complete Match | PI3K pathway inhibitor | Responsive | ED | Case report |
| PIK3CA | PIK3CA MUT (Y1021C) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (Y1021C) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (Y1021C) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (Y1021C) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (Y1021C) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (Y1021C) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (Y1021C) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (Y1021C) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (Y1021C) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (Y1021C) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (Y1021C) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (Y1021C) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (Y1021C) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (Y1021C) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| PDGFRA | PDGFRA MUT* (I139I) | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | MDPS, MDS, ECL, HES | FDA guidelines |
| NTRK1 | NTRK1 MUT* (R342Q) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Case report |
| NTRK1 | NTRK1 MUT* (R342Q) | Different Alteration | Pan-TKR inhibitor | Responsive | CANCER | Early trials |
| NTRK1 | NTRK1 MUT* (R342Q) | Different Alteration | Pan-TK inhibitor | Responsive | LUAD | Pre-clinical |
| NTRK1 | NTRK1 MUT* (R342Q) | Different Alteration | Pan-TK inhibitor | Responsive | COREAD | Case report |
| TP53 | TP53 MUT (C124*) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (C124*) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (C124*) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (C124*) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (C124*) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (C124*) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (C124*) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (C124*) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (C124*) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (C124*) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (C124*) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (C124*) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (C124*) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (C124*) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (C124*) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| NOTCH1 | NOTCH1 MUT* (A2441T) | Different Alteration | Gamma secretase inhibitor | Responsive | ALL | Pre-clinical |
| NOTCH1 | NOTCH1 MUT* (A2441T) | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| EGFR | EGFR MUT* (R958R) | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | L | Case report |
| EGFR | EGFR MUT* (R958R) | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | NSCLC | Case report |
| PTEN | PTEN MUT (S287*) | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | PTEN MUT (S287*) | Different Mutation | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | PTEN MUT (S287*) | Different Mutation | BYL719 (PIK3CA inhibitor) | Resistant | BRCA | Case report |
| PTEN | PTEN MUT (S287*) | Complete Match | ATM inhibitor | Responsive | BRCA | Pre-clinical |
| PTEN | PTEN MUT (S287*) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA, ED, TH, CANCER, L, G, OV | Pre-clinical |
| PTEN | PTEN MUT (S287*) | Complete Match | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | PTEN MUT (S287*) | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | PTEN MUT (S287*) | Complete Match | PARP inhibitor | Responsive | ED | Case report |
| PTEN | PTEN MUT (S287*) | Complete Match | PD1 Ab inhibitor | Resistant | CM | Early trials |
| PTEN | PTEN MUT (S287*) | Complete Match | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | PTEN MUT (S287*) | Complete Match | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | PTEN MUT (S287*) | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| PTEN | PTEN MUT (S287*) | Complete Match | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | PTEN MUT (S287*) | Complete Match | AKT inhibitor | Responsive | PA | Case report |
| PTEN | PTEN MUT (S287*) | Complete Match | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | PTEN MUT (S287*) | Different Alteration | PI3K pathway inhibitor | Responsive | L, BRCA, CANCER, G, ED, TH, OV | Pre-clinical |
| PTEN | PTEN MUT (S287*) | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | PTEN MUT (S287*) | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | PTEN MUT (S287*) | Different Alteration | PARP inhibitor | Responsive | ED | Case report |
| PTEN | PTEN MUT (S287*) | Different Alteration | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | PTEN MUT (S287*) | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | PTEN MUT (S287*) | Different Alteration | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | PTEN MUT (S287*) | Different Alteration | AKT inhibitor | Responsive | PA | Case report |
| PTEN | PTEN MUT (S287*) | Different Alteration | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | PTEN MUT (S287*) | Different Alteration | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| ERCC4 | ERCC4 MUT (E359*) | Complete Match | Cisplatin (Chemotherapy) | Responsive | OV | Pre-clinical |
| TP53 | TP53 MUT (S241F) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (S241F) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (S241F) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (S241F) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (S241F) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (S241F) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (S241F) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (S241F) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (S241F) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (S241F) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (S241F) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (S241F) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (S241F) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (S241F) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (S241F) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| JAK2 | JAK2 MUT* (R138P) | Different Alteration | Ruxolitinib (JAK inhibitor) | Responsive | ALL | Pre-clinical |
| KMT2A | MLL MUT* (P1367P) | Different Alteration | EPZ-5676 (DOT1L inhibitor) | Responsive | ALL, MDS, AML | Early trials |
| KMT2A | MLL MUT* (P1367P) | Different Alteration | BET inhibitor | Responsive | ALL | Pre-clinical |
| KMT2A | MLL MUT* (P1367P) | Different Alteration | BET inhibitor | Responsive | AML | Pre-clinical |
| KMT2A | MLL MUT* (P1367P) | Different Alteration | Daunorubicin (Chemotherapy) | Responsive | AML | FDA guidelines |
| KMT2A | MLL MUT* (P1367P) | Different Alteration | Belinostat (HDAC inhibitor) | Responsive | AML | Early trials |
| KMT2A | MLL MUT* (P1367P) | Different Alteration | DOT1L inhibitor | Responsive | AML | Early trials |
| JAK2 | JAK2 MUT* (P429P) | Different Alteration | Ruxolitinib (JAK inhibitor) | Responsive | ALL | Pre-clinical |
| PIK3CA | PIK3CA MUT (H1047R), PIK3CA MUT (E726K) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (H1047R), PIK3CA MUT (E726K) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (H1047R), PIK3CA MUT (E726K) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (H1047R), PIK3CA MUT (E726K) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (H1047R), PIK3CA MUT (E726K) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (H1047R), PIK3CA MUT (E726K) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (H1047R), PIK3CA MUT (E726K) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (H1047R), PIK3CA MUT (E726K) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (H1047R), PIK3CA MUT (E726K) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (H1047R), PIK3CA MUT (E726K) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (H1047R), PIK3CA MUT (E726K) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (H1047R), PIK3CA MUT (E726K) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (H1047R), PIK3CA MUT (E726K) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (H1047R), PIK3CA MUT (E726K) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| TP53 | TP53 MUT (C238Y) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (C238Y) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (C238Y) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (C238Y) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (C238Y) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (C238Y) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (C238Y) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (C238Y) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (C238Y) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (C238Y) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (C238Y) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (C238Y) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (C238Y) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (C238Y) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (C238Y) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| ATR | ATR MUT (splice_acceptor_variant) | Complete Match | Temozolomide (Chemotherapy) | Responsive | G | Pre-clinical |
| ATR | ATR MUT (splice_acceptor_variant) | Complete Match | Olaparib (PARP inhibitor) | Responsive | CANCER, OV | Pre-clinical |
| ATR | ATR MUT (splice_acceptor_variant) | Different Alteration | Olaparib (PARP inhibitor) | Responsive | OV, CANCER | Pre-clinical |
| EGFR | EGFR MUT* (E282K) | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | L | Case report |
| EGFR | EGFR MUT* (E282K) | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | NSCLC | Case report |
| ABL1 | ABL1 MUT* (Y440H) | Different Alteration | Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) | Responsive | CML, ALL | FDA guidelines |
| ABL1 | ABL1 MUT* (Y440H) | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Responsive | ALL, CML | FDA guidelines |
| ABL1 | ABL1 MUT* (Y440H) | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| ABL1 | ABL1 MUT* (Y440H) | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | ALL, CML | FDA guidelines |
| ABL1 | ABL1 MUT* (Y440H) | Different Alteration | Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) | Responsive | ALL | Pre-clinical |
| ABL1 | ABL1 MUT* (Y440H) | Different Alteration | Bosutinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| ERBB4 | ERBB4 MUT* (P1292S) | Different Alteration | Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) | Responsive | LUAD | Pre-clinical |
| PTEN | PTEN MUT (C124G) | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | PTEN MUT (C124G) | Different Mutation | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | PTEN MUT (C124G) | Different Mutation | BYL719 (PIK3CA inhibitor) | Resistant | BRCA | Case report |
| PTEN | PTEN MUT (C124G) | Complete Match | ATM inhibitor | Responsive | BRCA | Pre-clinical |
| PTEN | PTEN MUT (C124G) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA, ED, TH, CANCER, L, G, OV | Pre-clinical |
| PTEN | PTEN MUT (C124G) | Complete Match | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | PTEN MUT (C124G) | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | PTEN MUT (C124G) | Complete Match | PARP inhibitor | Responsive | ED | Case report |
| PTEN | PTEN MUT (C124G) | Complete Match | PD1 Ab inhibitor | Resistant | CM | Early trials |
| PTEN | PTEN MUT (C124G) | Complete Match | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | PTEN MUT (C124G) | Complete Match | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | PTEN MUT (C124G) | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| PTEN | PTEN MUT (C124G) | Complete Match | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | PTEN MUT (C124G) | Complete Match | AKT inhibitor | Responsive | PA | Case report |
| PTEN | PTEN MUT (C124G) | Complete Match | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | PTEN MUT (C124G) | Different Alteration | PI3K pathway inhibitor | Responsive | L, BRCA, CANCER, G, ED, TH, OV | Pre-clinical |
| PTEN | PTEN MUT (C124G) | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | PTEN MUT (C124G) | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | PTEN MUT (C124G) | Different Alteration | PARP inhibitor | Responsive | ED | Case report |
| PTEN | PTEN MUT (C124G) | Different Alteration | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | PTEN MUT (C124G) | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | PTEN MUT (C124G) | Different Alteration | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | PTEN MUT (C124G) | Different Alteration | AKT inhibitor | Responsive | PA | Case report |
| PTEN | PTEN MUT (C124G) | Different Alteration | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | PTEN MUT (C124G) | Different Alteration | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| RET | RET MUT* (L846I) | Different Alteration | Nintedanib (Pan-TK inhibitor) | Responsive | LUAD | Case report |
| RET | RET MUT* (L846I) | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Early trials |
| RET | RET MUT* (L846I) | Different Alteration | RET inhibitor | Responsive | LUAD | Pre-clinical |
| RET | RET MUT* (L846I) | Different Alteration | Vandetanib (Pan-TK inhibitor) | Responsive | LUAD | Early trials |
| RET | RET MUT* (L846I) | Different Alteration | Sunitinib (Pan-TK inhibitor) | Responsive | LUAD | Early trials |
| RET | RET MUT* (L846I) | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | THCA | Pre-clinical |
| RET | RET MUT* (L846I) | Different Alteration | Vandetanib (Pan-TK inhibitor) | Responsive | THCA | Pre-clinical |
| RET | RET MUT* (L846I) | Different Alteration | Sunitinib (Pan-TK inhibitor) | Responsive | THCA | Pre-clinical |
| RET | RET MUT* (L846I) | Different Alteration | RET inhibitor | Responsive | TH | Pre-clinical |
| NTRK1 | NTRK1 MUT* (R583H) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Case report |
| NTRK1 | NTRK1 MUT* (R583H) | Different Alteration | Pan-TKR inhibitor | Responsive | CANCER | Early trials |
| NTRK1 | NTRK1 MUT* (R583H) | Different Alteration | Pan-TK inhibitor | Responsive | LUAD | Pre-clinical |
| NTRK1 | NTRK1 MUT* (R583H) | Different Alteration | Pan-TK inhibitor | Responsive | COREAD | Case report |
| NOTCH2 | NOTCH2 MUT* (E1780K) | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| ESR1 | ESR1 MUT* (G274G) | Different Alteration | ESR1 inhibitor | Resistant | BRCA | Pre-clinical |
| ERBB4 | ERBB4 MUT* (E317E) | Different Alteration | Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) | Responsive | LUAD | Pre-clinical |
| BCR | BCR MUT* (intron_variant) | Different Alteration | Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) | Responsive | CML, ALL | FDA guidelines |
| BCR | BCR MUT* (intron_variant) | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | ALL, CML | FDA guidelines |
| BCR | BCR MUT* (intron_variant) | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| BCR | BCR MUT* (intron_variant) | Different Alteration | Bosutinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| BCR | BCR MUT* (intron_variant) | Different Alteration | Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) | Responsive | ALL | Pre-clinical |
| BCR | BCR MUT* (intron_variant) | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Responsive | ALL, CML | FDA guidelines |
| BRCA1 | BRCA1 MUT (Q934*) | Complete Match | Chemotherapy (PARP inhibitor;Chemotherapy) | Responsive | OV | Early trials |
| BRCA1 | BRCA1 MUT (Q934*) | Complete Match | PARP inhibitor | Responsive | BRCA | Early trials |
| BRCA1 | BRCA1 MUT (Q934*) | Complete Match | PARP inhibitor;Chemotherapy | Responsive | OV | Early trials |
| BRCA1 | BRCA1 MUT (Q934*) | Complete Match | Rucaparib (PARP inhibitor) | Responsive | OV | FDA guidelines |
| BRCA1 | BRCA1 MUT (Q934*) | Complete Match | Platinum Agent (Chemotherapy) | Responsive | BRCA | Early trials |
| BRCA1 | BRCA1 MUT (Q934*) | Complete Match | WEE1 inhibitor | Responsive | CANCER | Case report |
| BRCA1 | BRCA1 MUT (Q934*) | Complete Match | Platinum Agent (Chemotherapy) | Responsive | OV | Late trials |
| BRCA1 | BRCA1 MUT (Q934*) | Complete Match | Olaparib (PARP inhibitor) | Responsive | PRAD | Early trials |
| BRCA1 | BRCA1 MUT (Q934*) | Complete Match | Veliparib;Cisplatin (PARP inhibitor;Chemotherapy) | Responsive | BRCA | Early trials |
| BRCA1 | BRCA1 MUT (Q934*) | Complete Match | PARP inhibitor | Responsive | PA | Case report |
| BRCA1 | BRCA1 MUT (Q934*) | Complete Match | Olaparib (PARP inhibitor) | Responsive | OV | FDA guidelines |
| BRCA1 | BRCA1 MUT (Q934*) | Different Alteration | PARP inhibitor | Responsive | OV | Pre-clinical |
| RET | RET MUT* (V778I) | Different Alteration | Nintedanib (Pan-TK inhibitor) | Responsive | LUAD | Case report |
| RET | RET MUT* (V778I) | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Early trials |
| RET | RET MUT* (V778I) | Different Alteration | RET inhibitor | Responsive | LUAD | Pre-clinical |
| RET | RET MUT* (V778I) | Different Alteration | Vandetanib (Pan-TK inhibitor) | Responsive | LUAD | Early trials |
| RET | RET MUT* (V778I) | Different Alteration | Sunitinib (Pan-TK inhibitor) | Responsive | LUAD | Early trials |
| RET | RET MUT* (V778I) | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | THCA | Pre-clinical |
| RET | RET MUT* (V778I) | Different Alteration | Vandetanib (Pan-TK inhibitor) | Responsive | THCA | Pre-clinical |
| RET | RET MUT* (V778I) | Different Alteration | Sunitinib (Pan-TK inhibitor) | Responsive | THCA | Pre-clinical |
| RET | RET MUT* (V778I) | Different Alteration | RET inhibitor | Responsive | TH | Pre-clinical |
| PIK3CA | PIK3CA MUT (R108H) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (R108H) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (R108H) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (R108H) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (R108H) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (R108H) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (R108H) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (R108H) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (R108H) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (R108H) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (R108H) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (R108H) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (R108H) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (R108H) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| ROS1 | ROS1 MUT* (W1694*) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | IM | Case report |
| ROS1 | ROS1 MUT* (W1694*) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ROS1 | ROS1 MUT* (W1694*) | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Case report |
| ROS1 | ROS1 MUT* (W1694*) | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Pre-clinical |
| ROS1 | ROS1 MUT* (W1694*) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Early trials |
| TP53 | TP53 MUT (L289F) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (L289F) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (L289F) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (L289F) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (L289F) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (L289F) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (L289F) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (L289F) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (L289F) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (L289F) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (L289F) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (L289F) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (L289F) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (L289F) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (L289F) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| ABL1 | ABL1 MUT* (I347I) | Different Alteration | Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) | Responsive | CML, ALL | FDA guidelines |
| ABL1 | ABL1 MUT* (I347I) | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Responsive | ALL, CML | FDA guidelines |
| ABL1 | ABL1 MUT* (I347I) | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| ABL1 | ABL1 MUT* (I347I) | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | ALL, CML | FDA guidelines |
| ABL1 | ABL1 MUT* (I347I) | Different Alteration | Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) | Responsive | ALL | Pre-clinical |
| ABL1 | ABL1 MUT* (I347I) | Different Alteration | Bosutinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| PIK3CA | PIK3CA MUT (E726K) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (E726K) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (E726K) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (E726K) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (E726K) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (E726K) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (E726K) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (E726K) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (E726K) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (E726K) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (E726K) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (E726K) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (E726K) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (E726K) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| TP53 | TP53 MUT (L194P) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (L194P) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (L194P) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (L194P) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (L194P) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (L194P) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (L194P) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (L194P) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (L194P) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (L194P) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (L194P) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (L194P) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (L194P) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (L194P) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (L194P) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| RB1 | RB1 MUT (E864*) | Different Alteration | Palbociclib (CDK4/6 inhibitor) | Responsive | PRAD | Pre-clinical |
| RB1 | RB1 MUT (E864*) | Complete Match | MDM2/MDMX inhibitor | Responsive | RB | Pre-clinical |
| RB1 | RB1 MUT (E864*) | Complete Match | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| RB1 | RB1 MUT (E864*) | Complete Match | HDAC inhibitor | Responsive | RB | Pre-clinical |
| RB1 | RB1 MUT (E864*) | Different Alteration | MDM2/MDMX inhibitor | Responsive | RB | Pre-clinical |
| RB1 | RB1 MUT (E864*) | Different Alteration | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| RB1 | RB1 MUT (E864*) | Different Alteration | HDAC inhibitor | Responsive | RB | Pre-clinical |
| SETD2 | SETD2 MUT (S470*) | Complete Match | WEE1 inhibitor | Responsive | CANCER | Pre-clinical |
| SETD2 | SETD2 MUT (S470*) | Different Alteration | WEE1 inhibitor | Responsive | CANCER | Pre-clinical |
| PIK3CA | PIK3CA MUT (H1047L), PIK3CA MUT (E726K) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (H1047L), PIK3CA MUT (E726K) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (H1047L), PIK3CA MUT (E726K) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (H1047L), PIK3CA MUT (E726K) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (H1047L), PIK3CA MUT (E726K) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (H1047L), PIK3CA MUT (E726K) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (H1047L), PIK3CA MUT (E726K) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (H1047L), PIK3CA MUT (E726K) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (H1047L), PIK3CA MUT (E726K) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (H1047L), PIK3CA MUT (E726K) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (H1047L), PIK3CA MUT (E726K) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (H1047L), PIK3CA MUT (E726K) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (H1047L), PIK3CA MUT (E726K) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (H1047L), PIK3CA MUT (E726K) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| ROS1 | ROS1 MUT* (E596K) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | IM | Case report |
| ROS1 | ROS1 MUT* (E596K) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ROS1 | ROS1 MUT* (E596K) | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Case report |
| ROS1 | ROS1 MUT* (E596K) | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Pre-clinical |
| ROS1 | ROS1 MUT* (E596K) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (L755S) | Different Alteration | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | ERBB2 MUT (L755S) | Different Alteration | Lapatinib (ERBB2 inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | ERBB2 MUT (L755S) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | ST, BRCA, GEJA | FDA guidelines |
| ERBB2 | ERBB2 MUT (L755S) | Different Alteration | Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | ERBB2 MUT (L755S) | Different Alteration | MK2206;Trastuzumab (allosteric AKT inhibitor;ERBB2 mAb inhibitor) | Responsive | SOLID | Early trials |
| ERBB2 | ERBB2 MUT (L755S) | Different Mutation | Lapatinib (ERBB2 inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (L755S) | Complete Match | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (L755S) | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | CANCER, BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (L755S) | Complete Match | Neratinib (ERBB2 inhibitor) | Responsive | CANCER | Early trials |
| ERBB2 | ERBB2 MUT (L755S) | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | CANCER | Early trials |
| ERBB2 | ERBB2 MUT (L755S) | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Case report |
| ERBB2 | ERBB2 MUT (L755S) | Different Mutation | Lapatinib (ERBB2 inhibitor) | Responsive | BRCA, LUAD | Case report |
| ERBB2 | ERBB2 MUT (L755S) | Different Mutation | Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) | Responsive | L | Early trials |
| ERBB2 | ERBB2 MUT (L755S) | Different Mutation | Neratinib (ERBB2 inhibitor) | Resistant | BRCA | Case report |
| ERBB2 | ERBB2 MUT (L755S) | Different Mutation | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (L755S) | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | LUAD | Case report |
| ERBB2 | ERBB2 MUT (L755S) | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (L755S) | Different Mutation | Lapatinib (ERBB2 inhibitor) | Resistant | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (L755S) | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | CANCER | Pre-clinical |
| ERBB2 | ERBB2 MUT (L755S) | Complete Match | Temsirolimus (MTOR inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (L755S) | Complete Match | Dacomitinib (Pan ERBB inhibitor) | Responsive | NSCLC | Early trials |
| ERBB2 | ERBB2 MUT (L755S) | Complete Match | Neratinib (ERBB2 inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (L755S) | Different Mutation | ERBB2 inhibitor | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (L755S) | Different Mutation | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (L755S) | Different Mutation | ERBB2 mAb inhibitor | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (L755S) | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (L755S) | Different Mutation | Lapatinib (ERBB2 inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (L755S) | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (L755S) | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BRCA | Late trials |
| ERBB2 | ERBB2 MUT (L755S) | Different Alteration | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | BT | Early trials |
| ERBB2 | ERBB2 MUT (L755S) | Different Alteration | Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) | Responsive | COREAD | Late trials |
| ERBB2 | ERBB2 MUT (L755S) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | OV | Early trials |
| ERBB2 | ERBB2 MUT (L755S) | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BLCA | Case report |
| ERBB2 | ERBB2 MUT (L755S) | Different Alteration | Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) | Responsive | COREAD | Case report |
| ERBB2 | ERBB2 MUT (L755S) | Different Alteration | Rociletinib (EGFR inhibitor) | Resistant | LUAD | Case report |
| ERBB2 | ERBB2 MUT (L755S) | Different Alteration | Osimertinib (EGFR inhibitor) | Resistant | LUAD | Case report |
| ERBB2 | ERBB2 MUT (L755S) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | BT | Early trials |
| ERBB2 | ERBB2 MUT (L755S) | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Early trials |
| ERBB2 | ERBB2 MUT (L755S) | Different Alteration | Lapatinib (ERBB2 inhibitor) | Responsive | BT | Early trials |
| ERBB2 | ERBB2 MUT (L755S) | Different Alteration | Trastuzumab;HSP90 inhibitor (ERBB2 mAb inhibitor;HSP90 inhibitor) | Responsive | BRCA | Early trials |
| ERBB2 | ERBB2 MUT (L755S) | Different Alteration | HER2 inhibitor;CDK4/6 inhibitor | Responsive | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (L755S) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | ERBB2 MUT (L755S) | Different Alteration | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | ST | Early trials |
| ERBB2 | ERBB2 MUT (L755S) | Different Alteration | Trastuzumab;Everolimus;Chemotherapy (ERBB2 mAb inhibitor;MTOR inhibitor;Chemotherapy) | Responsive | BRCA | Early trials |
| ERBB2 | ERBB2 MUT (L755S) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | ST, GEJA | FDA guidelines |
| ERBB2 | ERBB2 MUT (L755S) | Different Alteration | ERBB2 inhibitor;CDK4/6 inhibitor | Responsive | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (L755S) | Different Alteration | Ado-Trastuzumab Emtansine (EGFR mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | ERBB2 MUT (L755S) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | HNC | Case report |
| ERBB2 | ERBB2 MUT (L755S) | Different Alteration | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Late trials |
| ERBB2 | ERBB2 MUT (L755S) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | No Responsive | ED | Early trials |
| ERBB2 | ERBB2 MUT (L755S) | Different Alteration | Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) | Responsive | ED | Pre-clinical |
| ERBB2 | ERBB2 MUT (L755S) | Different Alteration | Lapatinib;Chemotherapy (ERBB2 inhibitor;Chemotherapy) | Responsive | ST | Early trials |
| ERBB2 | ERBB2 MUT (L755S) | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | ST | Case report |
| ERBB2 | ERBB2 MUT (L755S) | Different Alteration | EGFR inhibitor | Resistant | LUAD | Pre-clinical |
| EPHA3 | EPHA3 MUT (splice_donor_variant) | Different Alteration | EPHA3 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (H193Y) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (H193Y) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (H193Y) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (H193Y) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (H193Y) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (H193Y) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (H193Y) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (H193Y) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (H193Y) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (H193Y) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (H193Y) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (H193Y) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (H193Y) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (H193Y) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (H193Y) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| FAT1 | FAT1 MUT (Q3825*) | Complete Match | BET inhibitor | Responsive | HNSC | Pre-clinical |
| TP53 | TP53 MUT (S215I) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (S215I) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (S215I) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (S215I) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (S215I) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (S215I) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (S215I) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (S215I) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (S215I) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (S215I) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (S215I) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (S215I) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (S215I) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (S215I) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (S215I) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| ALK | ALK MUT* (M301I) | Different Alteration | ALK inhibitor;SRC inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (M301I) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | GB, LY | Early trials |
| ALK | ALK MUT* (M301I) | Different Alteration | Lorlatinib (ALK&ROS1 inhibitor) | Responsive | NSCLC | Early trials |
| ALK | ALK MUT* (M301I) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | THCA, IM | Case report |
| ALK | ALK MUT* (M301I) | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (M301I) | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | ALK MUT* (M301I) | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | IM, COREAD | Case report |
| ALK | ALK MUT* (M301I) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | ALK MUT* (M301I) | Different Alteration | Brigatinib (Pan-TK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | ALK MUT* (M301I) | Different Alteration | Entrictinib (Pan-TK inhibitor) | Responsive | COREAD | Case report |
| ALK | ALK MUT* (M301I) | Different Alteration | Alectinib (ALK inhibitor) | Responsive | LUAD | FDA guidelines |
| ALK | ALK MUT* (M301I) | Different Alteration | HSP90 inhibitor (HSP90 inhibitor) | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (M301I) | Different Alteration | ALK inhibitor;IGF1R inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (M301I) | Different Alteration | ALK inhibitor;MEK inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (M301I) | Different Alteration | novel ALK inhibitor | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (M301I) | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | HEMATO | Early trials |
| ALK | ALK MUT* (M301I) | Different Alteration | ALK inhibitor | Responsive | COREAD | Case report |
| ALK | ALK MUT* (M301I) | Different Alteration | Alectinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | ALK MUT* (M301I) | Different Alteration | MEK inhibitor (ALK inhibitor;MEK inhibitor) | Responsive | LUAD | Pre-clinical |
| FGFR2 | FGFR2 MUT* (S588C) | Different Alteration | FGFR inhibitor | Responsive | COREAD | Early trials |
| FGFR2 | FGFR2 MUT* (S588C) | Different Alteration | FGFR inhibitor | Responsive | BT | Early trials |
| TP53 | TP53 MUT (M246I) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (M246I) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (M246I) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (M246I) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (M246I) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (M246I) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (M246I) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (M246I) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (M246I) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (M246I) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (M246I) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (M246I) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (M246I) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (M246I) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (M246I) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| EGFR | EGFR MUT (S768I) | Different Alteration | Cetuximab (EGFR mAb inhibitor) | Responsive | COREAD | FDA guidelines |
| EGFR | EGFR MUT (S768I) | Different Alteration | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | FDA guidelines |
| EGFR | EGFR MUT (S768I) | Different Mutation | Rindopepimut (Vaccine) | Responsive | GB | Late trials |
| EGFR | EGFR MUT (S768I) | Complete Match | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | NSCLC | FDA guidelines |
| EGFR | EGFR MUT (S768I) | Complete Match | Gefitinib (EGFR inhibitor) | Responsive | NSCLC | FDA guidelines |
| EGFR | EGFR MUT (S768I) | Complete Match | HSP90 inhibitor | Responsive | L | Early trials |
| EGFR | EGFR MUT (S768I) | Complete Match | Afatinib;Cetuximab (ERBB2 & EGFR inhibitor;EGFR mAb inhibitor) | Responsive | L | Early trials |
| EGFR | EGFR MUT (S768I) | Complete Match | MEK inhibitor | Responsive | L | Pre-clinical |
| EGFR | EGFR MUT (S768I) | Complete Match | EGFR TK inhibitor | Responsive | L | Late trials |
| EGFR | EGFR MUT (S768I) | Complete Match | Erlotinib (EGFR inhibitor) | Responsive | NSCLC | NCCN guidelines |
| EGFR | EGFR MUT (S768I) | Different Mutation | Osimertinib (EGFR inhibitor) | Resistant | L | Early trials |
| EGFR | EGFR MUT (S768I) | Different Mutation | EGFR-TKI's (EGFR inhibitor) | Resistant | L | Late trials |
| EGFR | EGFR MUT (S768I) | Different Mutation | HSP90 inhibitor | Responsive | L | Case report |
| EGFR | EGFR MUT (S768I) | Different Mutation | EGFR inhibitor | Resistant | L | Late trials |
| EGFR | EGFR MUT (S768I) | Different Mutation | Poziotinib (EGFR inhibitor) | Responsive | L | Early trials |
| EGFR | EGFR MUT (S768I) | Different Mutation | Osimertinib (EGFR inhibitor) | Responsive | L | Pre-clinical |
| EGFR | EGFR MUT (S768I) | Different Mutation | HSP90 inhibitor (HSP90 inhibitor) | Responsive | L | Early trials |
| EGFR | EGFR MUT (S768I) | Different Mutation | Erlotinib (EGFR inhibitor) | Responsive | G | Pre-clinical |
| EGFR | EGFR MUT (S768I) | Different Mutation | Erlotinib (EGFR inhibitor) | Responsive | NSCLC | FDA guidelines |
| EGFR | EGFR MUT (S768I) | Different Mutation | Osimertinib (EGFR inhibitor) | Responsive | L | Early trials |
| EGFR | EGFR MUT (S768I) | Different Mutation | Rociletinib (EGFR inhibitor) | Resistant | LUAD | Case report |
| EGFR | EGFR MUT (S768I) | Different Mutation | Panitumumab (EGFR mAb inhibitor) | Responsive | COREAD | Case report |
| EGFR | EGFR MUT (S768I) | Different Mutation | novel EGFR mAb inhibitor | Responsive | COREAD | Early trials |
| EGFR | EGFR MUT (S768I) | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| EGFR | EGFR MUT (S768I) | Different Mutation | Cetuximab;Sirolimus (EGFR mAb inhibitor;MTOR inhibitor) | Responsive | HNC | Case report |
| EGFR | EGFR MUT (S768I) | Different Mutation | Erlotinib (EGFR inhibitor) | Responsive | L | Case report |
| EGFR | EGFR MUT (S768I) | Different Mutation | Gefitinib (EGFR inhibitor) | No Responsive | HNC | Case report |
| EGFR | EGFR MUT (S768I) | Different Mutation | EGFR inhibitor | Responsive | L | Early trials |
| EGFR | EGFR MUT (S768I) | Different Mutation | Afatinib;Cetuximab (ERBB2 & EGFR inhibitor;EGFR mAb inhibitor) | Responsive | L | Early trials |
| EGFR | EGFR MUT (S768I) | Different Mutation | Erlotinib (EGFR inhibitor) | Resistant | L | NCCN/CAP guidelines |
| EGFR | EGFR MUT (S768I) | Different Mutation | Osimertinib (EGFR inhibitor) | Responsive | NSCLC | FDA guidelines |
| EGFR | EGFR MUT (S768I) | Different Mutation | EGFR inhibitor | Responsive | NSCLC | Late trials |
| EGFR | EGFR MUT (S768I) | Different Mutation | Afatinib;Nimotuzumab (ERBB2 & EGFR inhibitor;EGFR mAb inhibitor) | Responsive | L | Early trials |
| EGFR | EGFR MUT (S768I) | Different Mutation | Afatinib (ERBB2 & EGFR inhibitor) | Resistant | L | NCCN/CAP guidelines |
| EGFR | EGFR MUT (S768I) | Different Mutation | Erlotinib (EGFR inhibitor) | Responsive | L | Early trials |
| EGFR | EGFR MUT (S768I) | Different Mutation | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | L | Late trials |
| EGFR | EGFR MUT (S768I) | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Pre-clinical |
| EGFR | EGFR MUT (S768I) | Different Mutation | Erlotinib (EGFR inhibitor) | No Responsive | L | Case report |
| EGFR | EGFR MUT (S768I) | Different Mutation | Lapatinib (ERBB2 inhibitor) | Responsive | ED | Case report |
| EGFR | EGFR MUT (S768I) | Different Mutation | EGFR inhibitor | No Responsive | G | Early trials |
| EGFR | EGFR MUT (S768I) | Different Mutation | EGFR inhibitor | Resistant | NSCLC | Case report |
| EGFR | EGFR MUT (S768I) | Different Mutation | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| EGFR | EGFR MUT (S768I) | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant;Resistant | COREAD | Pre-clinical;Case report |
| EGFR | EGFR MUT (S768I) | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Responsive | HNC | Case report |
| EGFR | EGFR MUT (S768I) | Different Alteration | Gefitinib (EGFR inhibitor) | Responsive | ED | Late trials |
| EGFR | EGFR MUT (S768I) | Different Alteration | Gefitinib (EGFR inhibitor) | No Responsive | HNC | Early trials |
| EGFR | EGFR MUT (S768I) | Different Alteration | EGFR inhibitor | Responsive | HNSC | Case report |
| EGFR | EGFR MUT (S768I) | Different Alteration | EGFR inhibitor | No Responsive | G | Early trials |
| EGFR | EGFR MUT (S768I) | Different Alteration | Erlotinib (EGFR inhibitor) | No Responsive | L | Early trials |
| EGFR | EGFR MUT (S768I) | Different Alteration | EGFR mAb inhibitor | Responsive | COREAD | Late trials |
| EGFR | EGFR MUT (S768I) | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | L | Case report |
| EGFR | EGFR MUT (S768I) | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | NSCLC | Case report |
| CDKN1B | CDKN1B MUT (E105*) | Complete Match | CDK2/4 inhibitor | Responsive | CANCER | Pre-clinical |
| CDKN1B | CDKN1B MUT (E105*) | Different Alteration | CDK2/4 inhibitor | Responsive | CANCER | Pre-clinical |
| PIK3CA | PIK3CA MUT (E453K), PIK3CA MUT (E81K) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (E453K), PIK3CA MUT (E81K) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (E453K), PIK3CA MUT (E81K) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (E453K), PIK3CA MUT (E81K) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (E453K), PIK3CA MUT (E81K) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (E453K), PIK3CA MUT (E81K) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (E453K), PIK3CA MUT (E81K) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (E453K), PIK3CA MUT (E81K) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (E453K), PIK3CA MUT (E81K) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (E453K), PIK3CA MUT (E81K) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (E453K), PIK3CA MUT (E81K) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (E453K), PIK3CA MUT (E81K) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (E453K), PIK3CA MUT (E81K) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (E453K), PIK3CA MUT (E81K) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| NRG1 | NRG1 MUT* (E579E) | Different Alteration | Lapatinib (ERBB2 inhibitor) | Responsive | LUAD | Pre-clinical |
| NRG1 | NRG1 MUT* (E579E) | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | LUAD | Case report |
| TP53 | TP53 MUT (R280*) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (R280*) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (R280*) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (R280*) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (R280*) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (R280*) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (R280*) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R280*) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R280*) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (R280*) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (R280*) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R280*) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (R280*) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (R280*) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (R280*) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| ABL1 | ABL1 MUT* (D482E) | Different Alteration | Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) | Responsive | CML, ALL | FDA guidelines |
| ABL1 | ABL1 MUT* (D482E) | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Responsive | ALL, CML | FDA guidelines |
| ABL1 | ABL1 MUT* (D482E) | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| ABL1 | ABL1 MUT* (D482E) | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | ALL, CML | FDA guidelines |
| ABL1 | ABL1 MUT* (D482E) | Different Alteration | Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) | Responsive | ALL | Pre-clinical |
| ABL1 | ABL1 MUT* (D482E) | Different Alteration | Bosutinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| PIK3CA | PIK3CA MUT (H1047R), PIK3CA MUT (R88Q) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (H1047R), PIK3CA MUT (R88Q) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (H1047R), PIK3CA MUT (R88Q) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (H1047R), PIK3CA MUT (R88Q) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (H1047R), PIK3CA MUT (R88Q) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (H1047R), PIK3CA MUT (R88Q) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (H1047R), PIK3CA MUT (R88Q) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (H1047R), PIK3CA MUT (R88Q) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (H1047R), PIK3CA MUT (R88Q) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (H1047R), PIK3CA MUT (R88Q) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (H1047R), PIK3CA MUT (R88Q) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (H1047R), PIK3CA MUT (R88Q) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (H1047R), PIK3CA MUT (R88Q) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (H1047R), PIK3CA MUT (R88Q) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| TP53 | TP53 MUT (Q331*) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (Q331*) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (Q331*) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (Q331*) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (Q331*) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (Q331*) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (Q331*) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Q331*) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Q331*) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (Q331*) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (Q331*) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Q331*) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (Q331*) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (Q331*) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (Q331*) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (W91*) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (W91*) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (W91*) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (W91*) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (W91*) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (W91*) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (W91*) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (W91*) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (W91*) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (W91*) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (W91*) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (W91*) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (W91*) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (W91*) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (W91*) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| NOTCH2 | NOTCH2 MUT* (V1666F) | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (E542K), PIK3CA MUT (E545G) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (E542K), PIK3CA MUT (E545G) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (E542K), PIK3CA MUT (E545G) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (E542K), PIK3CA MUT (E545G) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (E542K), PIK3CA MUT (E545G) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (E542K), PIK3CA MUT (E545G) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (E542K), PIK3CA MUT (E545G) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (E542K), PIK3CA MUT (E545G) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (E542K), PIK3CA MUT (E545G) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (E542K), PIK3CA MUT (E545G) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (E542K), PIK3CA MUT (E545G) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (E542K), PIK3CA MUT (E545G) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (E542K), PIK3CA MUT (E545G) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (E542K), PIK3CA MUT (E545G) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| KMT2A | MLL MUT* (splice_acceptor_variant) | Different Alteration | EPZ-5676 (DOT1L inhibitor) | Responsive | ALL, MDS, AML | Early trials |
| KMT2A | MLL MUT* (splice_acceptor_variant) | Different Alteration | BET inhibitor | Responsive | ALL | Pre-clinical |
| KMT2A | MLL MUT* (splice_acceptor_variant) | Different Alteration | BET inhibitor | Responsive | AML | Pre-clinical |
| KMT2A | MLL MUT* (splice_acceptor_variant) | Different Alteration | Daunorubicin (Chemotherapy) | Responsive | AML | FDA guidelines |
| KMT2A | MLL MUT* (splice_acceptor_variant) | Different Alteration | Belinostat (HDAC inhibitor) | Responsive | AML | Early trials |
| KMT2A | MLL MUT* (splice_acceptor_variant) | Different Alteration | DOT1L inhibitor | Responsive | AML | Early trials |
| PTPRD | PTPRD MUT (E661*) | Complete Match | IGF1R inhibitor | Responsive | S | Case report |
| ROS1 | ROS1 MUT* (T2266R) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | IM | Case report |
| ROS1 | ROS1 MUT* (T2266R) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ROS1 | ROS1 MUT* (T2266R) | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Case report |
| ROS1 | ROS1 MUT* (T2266R) | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Pre-clinical |
| ROS1 | ROS1 MUT* (T2266R) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Early trials |
| TP53 | TP53 MUT (R273P) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (R273P) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (R273P) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (R273P) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (R273P) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (R273P) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (R273P) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R273P) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R273P) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (R273P) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (R273P) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R273P) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (R273P) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (R273P) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (R273P) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (S127P) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (S127P) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (S127P) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (S127P) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (S127P) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (S127P) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (S127P) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (S127P) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (S127P) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (S127P) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (S127P) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (S127P) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (S127P) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (S127P) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (S127P) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TMPRSS2 | TMPRSS2 MUT* (P83P) | Different Alteration | DNA-PKc inhibitor | Responsive | PRAD | Pre-clinical |
| TMPRSS2 | TMPRSS2 MUT* (P83P) | Different Alteration | PARP inhibitor | Responsive | PRAD | Pre-clinical |
| NOTCH1 | NOTCH1 MUT* (A2036V) | Different Alteration | Gamma secretase inhibitor | Responsive | ALL | Pre-clinical |
| NOTCH1 | NOTCH1 MUT* (A2036V) | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| MSH2 | MSH2 MUT (R621*) | Complete Match | PD1/PDL1 inhibitor | Responsive | UTH | Early trials |
| MSH2 | MSH2 MUT (R621*) | Different Alteration | PD1/PDL1 inhibitor | Responsive | UTH | Early trials |
| TP53 | TP53 MUT (E221*) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (E221*) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (E221*) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (E221*) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (E221*) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (E221*) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (E221*) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (E221*) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (E221*) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (E221*) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (E221*) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (E221*) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (E221*) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (E221*) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (E221*) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| NOTCH1 | NOTCH1 MUT* (E1901K) | Different Alteration | Gamma secretase inhibitor | Responsive | ALL | Pre-clinical |
| NOTCH1 | NOTCH1 MUT* (E1901K) | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| ALK | ALK MUT* (R1275*) | Different Alteration | ALK inhibitor;SRC inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (R1275*) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | GB, LY | Early trials |
| ALK | ALK MUT* (R1275*) | Different Alteration | Lorlatinib (ALK&ROS1 inhibitor) | Responsive | NSCLC | Early trials |
| ALK | ALK MUT* (R1275*) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | THCA, IM | Case report |
| ALK | ALK MUT* (R1275*) | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (R1275*) | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | ALK MUT* (R1275*) | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | IM, COREAD | Case report |
| ALK | ALK MUT* (R1275*) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | ALK MUT* (R1275*) | Different Alteration | Brigatinib (Pan-TK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | ALK MUT* (R1275*) | Different Alteration | Entrictinib (Pan-TK inhibitor) | Responsive | COREAD | Case report |
| ALK | ALK MUT* (R1275*) | Different Alteration | Alectinib (ALK inhibitor) | Responsive | LUAD | FDA guidelines |
| ALK | ALK MUT* (R1275*) | Different Alteration | HSP90 inhibitor (HSP90 inhibitor) | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (R1275*) | Different Alteration | ALK inhibitor;IGF1R inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (R1275*) | Different Alteration | ALK inhibitor;MEK inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (R1275*) | Different Alteration | novel ALK inhibitor | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (R1275*) | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | HEMATO | Early trials |
| ALK | ALK MUT* (R1275*) | Different Alteration | ALK inhibitor | Responsive | COREAD | Case report |
| ALK | ALK MUT* (R1275*) | Different Alteration | Alectinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | ALK MUT* (R1275*) | Different Alteration | MEK inhibitor (ALK inhibitor;MEK inhibitor) | Responsive | LUAD | Pre-clinical |
| TP53 | TP53 MUT (I255N) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (I255N) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (I255N) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (I255N) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (I255N) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (I255N) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (I255N) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (I255N) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (I255N) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (I255N) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (I255N) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (I255N) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (I255N) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (I255N) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (I255N) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| PIK3CA | PIK3CA MUT (E1037K) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (E1037K) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (E1037K) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (E1037K) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (E1037K) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (E1037K) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (E1037K) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (E1037K) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (E1037K) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (E1037K) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (E1037K) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (E1037K) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (E1037K) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (E1037K) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| NTRK1 | NTRK1 MUT* (R347L) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Case report |
| NTRK1 | NTRK1 MUT* (R347L) | Different Alteration | Pan-TKR inhibitor | Responsive | CANCER | Early trials |
| NTRK1 | NTRK1 MUT* (R347L) | Different Alteration | Pan-TK inhibitor | Responsive | LUAD | Pre-clinical |
| NTRK1 | NTRK1 MUT* (R347L) | Different Alteration | Pan-TK inhibitor | Responsive | COREAD | Case report |
| CDH1 | CDH1 MUT (Q511*) | Complete Match | Bicalutamide (AR inhibitor) | Responsive | BRCA | Pre-clinical |
| TP53 | TP53 MUT (C238F) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (C238F) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (C238F) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (C238F) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (C238F) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (C238F) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (C238F) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (C238F) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (C238F) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (C238F) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (C238F) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (C238F) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (C238F) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (C238F) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (C238F) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| KMT2A | MLL MUT* (P3959P) | Different Alteration | EPZ-5676 (DOT1L inhibitor) | Responsive | ALL, MDS, AML | Early trials |
| KMT2A | MLL MUT* (P3959P) | Different Alteration | BET inhibitor | Responsive | ALL | Pre-clinical |
| KMT2A | MLL MUT* (P3959P) | Different Alteration | BET inhibitor | Responsive | AML | Pre-clinical |
| KMT2A | MLL MUT* (P3959P) | Different Alteration | Daunorubicin (Chemotherapy) | Responsive | AML | FDA guidelines |
| KMT2A | MLL MUT* (P3959P) | Different Alteration | Belinostat (HDAC inhibitor) | Responsive | AML | Early trials |
| KMT2A | MLL MUT* (P3959P) | Different Alteration | DOT1L inhibitor | Responsive | AML | Early trials |
| KMT2A | MLL MUT* (S2872L) | Different Alteration | EPZ-5676 (DOT1L inhibitor) | Responsive | ALL, MDS, AML | Early trials |
| KMT2A | MLL MUT* (S2872L) | Different Alteration | BET inhibitor | Responsive | ALL | Pre-clinical |
| KMT2A | MLL MUT* (S2872L) | Different Alteration | BET inhibitor | Responsive | AML | Pre-clinical |
| KMT2A | MLL MUT* (S2872L) | Different Alteration | Daunorubicin (Chemotherapy) | Responsive | AML | FDA guidelines |
| KMT2A | MLL MUT* (S2872L) | Different Alteration | Belinostat (HDAC inhibitor) | Responsive | AML | Early trials |
| KMT2A | MLL MUT* (S2872L) | Different Alteration | DOT1L inhibitor | Responsive | AML | Early trials |
| PDGFB | PDGFB MUT* (E126D) | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | DFS | FDA guidelines |
| PML | PML MUT* (S341L) | Different Alteration | Volasertib (PLK1 inhibitor) | Responsive | AML | Early trials |
| PML | PML MUT* (S341L) | Different Alteration | Tretinoin (Retinoid) | Responsive | APML | FDA guidelines |
| PML | PML MUT* (S341L) | Different Alteration | Tretinoin;Arsenic Trioxide (Retinoid;Chemotherapy) | Responsive | AML | FDA guidelines |
| TP53 | TP53 MUT (Y234C) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (Y234C) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (Y234C) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (Y234C) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (Y234C) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (Y234C) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (Y234C) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Y234C) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Y234C) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (Y234C) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (Y234C) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Y234C) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (Y234C) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (Y234C) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (Y234C) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| EGFR | EGFR MUT (E114K) | Different Alteration | Cetuximab (EGFR mAb inhibitor) | Responsive | COREAD | FDA guidelines |
| EGFR | EGFR MUT (E114K) | Different Alteration | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | FDA guidelines |
| EGFR | EGFR MUT (E114K) | Different Mutation | Rindopepimut (Vaccine) | Responsive | GB | Late trials |
| EGFR | EGFR MUT (E114K) | Different Mutation | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | NSCLC | FDA guidelines |
| EGFR | EGFR MUT (E114K) | Different Mutation | Gefitinib (EGFR inhibitor) | Responsive | NSCLC | FDA guidelines |
| EGFR | EGFR MUT (E114K) | Different Mutation | HSP90 inhibitor | Responsive | L | Early trials |
| EGFR | EGFR MUT (E114K) | Different Mutation | Afatinib;Cetuximab (ERBB2 & EGFR inhibitor;EGFR mAb inhibitor) | Responsive | L | Early trials |
| EGFR | EGFR MUT (E114K) | Different Mutation | MEK inhibitor | Responsive | L | Pre-clinical |
| EGFR | EGFR MUT (E114K) | Different Mutation | EGFR TK inhibitor | Responsive | L | Late trials |
| EGFR | EGFR MUT (E114K) | Different Mutation | Erlotinib (EGFR inhibitor) | Responsive | NSCLC | NCCN guidelines |
| EGFR | EGFR MUT (E114K) | Different Mutation | Osimertinib (EGFR inhibitor) | Resistant | L | Early trials |
| EGFR | EGFR MUT (E114K) | Different Mutation | EGFR-TKI's (EGFR inhibitor) | Resistant | L | Late trials |
| EGFR | EGFR MUT (E114K) | Different Mutation | HSP90 inhibitor | Responsive | L | Case report |
| EGFR | EGFR MUT (E114K) | Different Mutation | EGFR inhibitor | Resistant | L | Late trials |
| EGFR | EGFR MUT (E114K) | Different Mutation | Poziotinib (EGFR inhibitor) | Responsive | L | Early trials |
| EGFR | EGFR MUT (E114K) | Different Mutation | Osimertinib (EGFR inhibitor) | Responsive | L | Pre-clinical |
| EGFR | EGFR MUT (E114K) | Different Mutation | HSP90 inhibitor (HSP90 inhibitor) | Responsive | L | Early trials |
| EGFR | EGFR MUT (E114K) | Different Mutation | Erlotinib (EGFR inhibitor) | Responsive | G | Pre-clinical |
| EGFR | EGFR MUT (E114K) | Different Mutation | Erlotinib (EGFR inhibitor) | Responsive | NSCLC | FDA guidelines |
| EGFR | EGFR MUT (E114K) | Different Mutation | Osimertinib (EGFR inhibitor) | Responsive | L | Early trials |
| EGFR | EGFR MUT (E114K) | Different Mutation | Rociletinib (EGFR inhibitor) | Resistant | LUAD | Case report |
| EGFR | EGFR MUT (E114K) | Different Mutation | Panitumumab (EGFR mAb inhibitor) | Responsive | COREAD | Case report |
| EGFR | EGFR MUT (E114K) | Different Mutation | novel EGFR mAb inhibitor | Responsive | COREAD | Early trials |
| EGFR | EGFR MUT (E114K) | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| EGFR | EGFR MUT (E114K) | Different Mutation | Cetuximab;Sirolimus (EGFR mAb inhibitor;MTOR inhibitor) | Responsive | HNC | Case report |
| EGFR | EGFR MUT (E114K) | Different Mutation | Erlotinib (EGFR inhibitor) | Responsive | L | Case report |
| EGFR | EGFR MUT (E114K) | Different Mutation | Gefitinib (EGFR inhibitor) | No Responsive | HNC | Case report |
| EGFR | EGFR MUT (E114K) | Different Mutation | EGFR inhibitor | Responsive | L | Early trials |
| EGFR | EGFR MUT (E114K) | Different Mutation | Erlotinib (EGFR inhibitor) | Resistant | L | NCCN/CAP guidelines |
| EGFR | EGFR MUT (E114K) | Different Mutation | Osimertinib (EGFR inhibitor) | Responsive | NSCLC | FDA guidelines |
| EGFR | EGFR MUT (E114K) | Different Mutation | EGFR inhibitor | Responsive | NSCLC | Late trials |
| EGFR | EGFR MUT (E114K) | Different Mutation | Afatinib;Nimotuzumab (ERBB2 & EGFR inhibitor;EGFR mAb inhibitor) | Responsive | L | Early trials |
| EGFR | EGFR MUT (E114K) | Different Mutation | Afatinib (ERBB2 & EGFR inhibitor) | Resistant | L | NCCN/CAP guidelines |
| EGFR | EGFR MUT (E114K) | Different Mutation | Erlotinib (EGFR inhibitor) | Responsive | L | Early trials |
| EGFR | EGFR MUT (E114K) | Different Mutation | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | L | Late trials |
| EGFR | EGFR MUT (E114K) | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Pre-clinical |
| EGFR | EGFR MUT (E114K) | Different Mutation | Erlotinib (EGFR inhibitor) | No Responsive | L | Case report |
| EGFR | EGFR MUT (E114K) | Different Mutation | Lapatinib (ERBB2 inhibitor) | Responsive | ED | Case report |
| EGFR | EGFR MUT (E114K) | Different Mutation | EGFR inhibitor | No Responsive | G | Early trials |
| EGFR | EGFR MUT (E114K) | Different Mutation | EGFR inhibitor | Resistant | NSCLC | Case report |
| EGFR | EGFR MUT (E114K) | Different Mutation | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| EGFR | EGFR MUT (E114K) | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant;Resistant | COREAD | Pre-clinical;Case report |
| EGFR | EGFR MUT (E114K) | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Responsive | HNC | Case report |
| EGFR | EGFR MUT (E114K) | Different Alteration | Gefitinib (EGFR inhibitor) | Responsive | ED | Late trials |
| EGFR | EGFR MUT (E114K) | Different Alteration | Gefitinib (EGFR inhibitor) | No Responsive | HNC | Early trials |
| EGFR | EGFR MUT (E114K) | Different Alteration | EGFR inhibitor | Responsive | HNSC | Case report |
| EGFR | EGFR MUT (E114K) | Different Alteration | EGFR inhibitor | No Responsive | G | Early trials |
| EGFR | EGFR MUT (E114K) | Different Alteration | Erlotinib (EGFR inhibitor) | No Responsive | L | Early trials |
| EGFR | EGFR MUT (E114K) | Different Alteration | EGFR mAb inhibitor | Responsive | COREAD | Late trials |
| EGFR | EGFR MUT (E114K) | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | L | Case report |
| EGFR | EGFR MUT (E114K) | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | NSCLC | Case report |
| NOTCH1 | NOTCH1 MUT* (S2523L) | Different Alteration | Gamma secretase inhibitor | Responsive | ALL | Pre-clinical |
| NOTCH1 | NOTCH1 MUT* (S2523L) | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| GATA3 | GATA3 MUT (splice_acceptor_variant) | Complete Match | Aromatase ihibitor | Responsive | BRCA | Pre-clinical |
| TP53 | TP53 MUT (Y163C) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (Y163C) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (Y163C) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (Y163C) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (Y163C) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (Y163C) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (Y163C) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Y163C) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Y163C) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (Y163C) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (Y163C) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Y163C) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (Y163C) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (Y163C) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (Y163C) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| CDK12 | CDK12 MUT (E488*) | Complete Match | PARP inhibitor | Responsive | OV | Pre-clinical |
| CDK12 | CDK12 MUT (E488*) | Different Alteration | PARP inhibitor | Responsive | OV | Pre-clinical |
| NTRK1 | NTRK1 MUT* (S287I) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Case report |
| NTRK1 | NTRK1 MUT* (S287I) | Different Alteration | Pan-TKR inhibitor | Responsive | CANCER | Early trials |
| NTRK1 | NTRK1 MUT* (S287I) | Different Alteration | Pan-TK inhibitor | Responsive | LUAD | Pre-clinical |
| NTRK1 | NTRK1 MUT* (S287I) | Different Alteration | Pan-TK inhibitor | Responsive | COREAD | Case report |
| TP53 | TP53 MUT (T125T) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (T125T) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (T125T) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (T125T) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (T125T) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (T125T) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (T125T) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (T125T) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (T125T) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (T125T) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (T125T) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (T125T) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (T125T) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (T125T) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (T125T) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| AKT3 | AKT3 MUT* (A373G) | Different Alteration | ATP competitive AKT inhibitor | Responsive | BRCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (D350N) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (D350N) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (D350N) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (D350N) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (D350N) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (D350N) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (D350N) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (D350N) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (D350N) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (D350N) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (D350N) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (D350N) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (D350N) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (D350N) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| NOTCH2 | NOTCH2 MUT* (S2153A) | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| AKT3 | AKT3 MUT* (L274L) | Different Alteration | ATP competitive AKT inhibitor | Responsive | BRCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (G1049R) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (G1049R) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (G1049R) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (G1049R) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (G1049R) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (G1049R) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (G1049R) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (G1049R) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (G1049R) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (G1049R) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (G1049R) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (G1049R) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (G1049R) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (G1049R) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| STAG2 | STAG2 MUT (R216*) | Complete Match | PARP inhibitor | Responsive | G | Pre-clinical |
| TP53 | TP53 MUT (L265P) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (L265P) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (L265P) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (L265P) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (L265P) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (L265P) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (L265P) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (L265P) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (L265P) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (L265P) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (L265P) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (L265P) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (L265P) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (L265P) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (L265P) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (P278A) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (P278A) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (P278A) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (P278A) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (P278A) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (P278A) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (P278A) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (P278A) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (P278A) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (P278A) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (P278A) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (P278A) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (P278A) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (P278A) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (P278A) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (R342*) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (R342*) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (R342*) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (R342*) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (R342*) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (R342*) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (R342*) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R342*) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R342*) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (R342*) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (R342*) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R342*) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (R342*) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (R342*) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (R342*) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| AKT3 | AKT3 MUT* (S375*) | Different Alteration | ATP competitive AKT inhibitor | Responsive | BRCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (R88Q) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (R88Q) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (R88Q) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (R88Q) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (R88Q) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (R88Q) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (R88Q) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (R88Q) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (R88Q) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (R88Q) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (R88Q) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (R88Q) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (R88Q) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (R88Q) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| TP53 | TP53 MUT (Q144*) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (Q144*) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (Q144*) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (Q144*) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (Q144*) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (Q144*) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (Q144*) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Q144*) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Q144*) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (Q144*) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (Q144*) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Q144*) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (Q144*) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (Q144*) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (Q144*) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| CDH1 | CDH1 MUT (Q641*) | Complete Match | Bicalutamide (AR inhibitor) | Responsive | BRCA | Pre-clinical |
| RB1 | RB1 MUT (C853*) | Different Alteration | Palbociclib (CDK4/6 inhibitor) | Responsive | PRAD | Pre-clinical |
| RB1 | RB1 MUT (C853*) | Complete Match | MDM2/MDMX inhibitor | Responsive | RB | Pre-clinical |
| RB1 | RB1 MUT (C853*) | Complete Match | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| RB1 | RB1 MUT (C853*) | Complete Match | HDAC inhibitor | Responsive | RB | Pre-clinical |
| RB1 | RB1 MUT (C853*) | Different Alteration | MDM2/MDMX inhibitor | Responsive | RB | Pre-clinical |
| RB1 | RB1 MUT (C853*) | Different Alteration | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| RB1 | RB1 MUT (C853*) | Different Alteration | HDAC inhibitor | Responsive | RB | Pre-clinical |
| ARID1A | ARID1A MUT (Q2037*) | Complete Match | EZH2 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | ARID1A MUT (Q2037*) | Complete Match | PD1 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | ARID1A MUT (Q2037*) | Complete Match | PARP inhibitor | Responsive | CANCER | Pre-clinical |
| ARID1A | ARID1A MUT (Q2037*) | Complete Match | ATR inhibitor | Responsive | CANCER | Pre-clinical |
| ERBB4 | ERBB4 MUT* (T703K) | Different Alteration | Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) | Responsive | LUAD | Pre-clinical |
| ATM | ATM MUT (R2993*) | Different Mutation | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| ATM | ATM MUT (R2993*) | Complete Match | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| ATM | ATM MUT (R2993*) | Complete Match | Olaparib (PARP inhibitor) | Responsive | ST, PRAD | Early trials |
| ATM | ATM MUT (R2993*) | Complete Match | PARP inhibitor | Responsive | ST | Early trials |
| ATM | ATM MUT (R2993*) | Complete Match | ATR inhibitor | Responsive | COREAD | Case report |
| ATM | ATM MUT (R2993*) | Complete Match | DNA-PKc inhibitor | Responsive | LY | Pre-clinical |
| ATM | ATM MUT (R2993*) | Complete Match | Temozolomide (Chemotherapy) | Responsive | G | Pre-clinical |
| ATM | ATM MUT (R2993*) | Complete Match | PD1/PDL1 inhibitor | Responsive | UTH | Early trials |
| ATM | ATM MUT (R2993*) | Different Alteration | PD1/PDL1 inhibitor | Responsive | UTH | Early trials |
| ATM | ATM MUT (R2993*) | Different Alteration | DNA-PKc inhibitor | Responsive | LY | Pre-clinical |
| ATM | ATM MUT (R2993*) | Different Alteration | PARP inhibitor | Responsive | ST | Early trials |
| ATM | ATM MUT (R2993*) | Different Alteration | ATR inhibitor | Responsive | COREAD | Case report |
| ATM | ATM MUT (R2993*) | Different Alteration | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| NOTCH1 | NOTCH1 MUT* (T1997T) | Different Alteration | Gamma secretase inhibitor | Responsive | ALL | Pre-clinical |
| NOTCH1 | NOTCH1 MUT* (T1997T) | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| TP53 | TP53 MUT (G279E) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (G279E) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (G279E) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (G279E) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (G279E) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (G279E) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (G279E) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (G279E) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (G279E) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (G279E) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (G279E) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (G279E) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (G279E) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (G279E) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (G279E) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| JAK2 | JAK2 MUT* (A140V) | Different Alteration | Ruxolitinib (JAK inhibitor) | Responsive | ALL | Pre-clinical |
| ROS1 | ROS1 MUT* (I855M) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | IM | Case report |
| ROS1 | ROS1 MUT* (I855M) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ROS1 | ROS1 MUT* (I855M) | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Case report |
| ROS1 | ROS1 MUT* (I855M) | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Pre-clinical |
| ROS1 | ROS1 MUT* (I855M) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Early trials |
| FAT1 | FAT1 MUT (Q2852*) | Complete Match | BET inhibitor | Responsive | HNSC | Pre-clinical |
| TP53 | TP53 MUT (E204*) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (E204*) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (E204*) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (E204*) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (E204*) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (E204*) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (E204*) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (E204*) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (E204*) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (E204*) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (E204*) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (E204*) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (E204*) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (E204*) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (E204*) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| CDH1 | CDH1 MUT (K668*) | Complete Match | Bicalutamide (AR inhibitor) | Responsive | BRCA | Pre-clinical |
| KMT2A | MLL MUT* (S3380L) | Different Alteration | EPZ-5676 (DOT1L inhibitor) | Responsive | ALL, MDS, AML | Early trials |
| KMT2A | MLL MUT* (S3380L) | Different Alteration | BET inhibitor | Responsive | ALL | Pre-clinical |
| KMT2A | MLL MUT* (S3380L) | Different Alteration | BET inhibitor | Responsive | AML | Pre-clinical |
| KMT2A | MLL MUT* (S3380L) | Different Alteration | Daunorubicin (Chemotherapy) | Responsive | AML | FDA guidelines |
| KMT2A | MLL MUT* (S3380L) | Different Alteration | Belinostat (HDAC inhibitor) | Responsive | AML | Early trials |
| KMT2A | MLL MUT* (S3380L) | Different Alteration | DOT1L inhibitor | Responsive | AML | Early trials |
| NTRK1 | NTRK1 MUT* (S371F) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Case report |
| NTRK1 | NTRK1 MUT* (S371F) | Different Alteration | Pan-TKR inhibitor | Responsive | CANCER | Early trials |
| NTRK1 | NTRK1 MUT* (S371F) | Different Alteration | Pan-TK inhibitor | Responsive | LUAD | Pre-clinical |
| NTRK1 | NTRK1 MUT* (S371F) | Different Alteration | Pan-TK inhibitor | Responsive | COREAD | Case report |
| NOTCH2 | NOTCH2 MUT* (A2331S) | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| ESR1 | ESR1 MUT* (L448L) | Different Alteration | ESR1 inhibitor | Resistant | BRCA | Pre-clinical |
| EGFR | EGFR MUT* (D1051N), EGFR MUT* (intron_variant) | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | L | Case report |
| EGFR | EGFR MUT* (D1051N), EGFR MUT* (intron_variant) | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | NSCLC | Case report |
| ABL1 | ABL1 MUT* (E588Q) | Different Alteration | Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) | Responsive | CML, ALL | FDA guidelines |
| ABL1 | ABL1 MUT* (E588Q) | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Responsive | ALL, CML | FDA guidelines |
| ABL1 | ABL1 MUT* (E588Q) | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| ABL1 | ABL1 MUT* (E588Q) | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | ALL, CML | FDA guidelines |
| ABL1 | ABL1 MUT* (E588Q) | Different Alteration | Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) | Responsive | ALL | Pre-clinical |
| ABL1 | ABL1 MUT* (E588Q) | Different Alteration | Bosutinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| STAG2 | STAG2 MUT (Q167*) | Complete Match | PARP inhibitor | Responsive | G | Pre-clinical |
| ROS1 | ROS1 MUT* (H189Y), ROS1 MUT* (3-UTRSNV) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | IM | Case report |
| ROS1 | ROS1 MUT* (H189Y), ROS1 MUT* (3-UTRSNV) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ROS1 | ROS1 MUT* (H189Y), ROS1 MUT* (3-UTRSNV) | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Case report |
| ROS1 | ROS1 MUT* (H189Y), ROS1 MUT* (3-UTRSNV) | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Pre-clinical |
| ROS1 | ROS1 MUT* (H189Y), ROS1 MUT* (3-UTRSNV) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Early trials |
| MET | MET MUT* (L581L), MET MUT* (R992T) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | G | Case report |
| NOTCH1 | NOTCH1 MUT* (F1259F) | Different Alteration | Gamma secretase inhibitor | Responsive | ALL | Pre-clinical |
| NOTCH1 | NOTCH1 MUT* (F1259F) | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| BRAF | BRAF MUT* (D449N) | Different Alteration | Sorafenib (Pan-TK inhibitor) | Responsive | CM, LUAD, PRAD | Pre-clinical |
| BRAF | BRAF MUT* (D449N) | Different Alteration | MEK inhibitor | Responsive | LUAD, CM, PRAD | Pre-clinical |
| BRAF | BRAF MUT* (D449N) | Different Alteration | Selumetinib (MEK inhibitor) | Responsive | OV | Case report |
| BRAF | BRAF MUT* (D449N) | Different Alteration | BRAF inhibitor;MEK inhibitor | Responsive | LUAD | Case report |
| ERBB4 | ERBB4 MUT* (E1144Q), ERBB4 MUT* (S184L), ERBB4 MUT* (3-UTRSNV) | Different Alteration | Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (R1209P) | Different Alteration | ALK inhibitor;SRC inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (R1209P) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | GB, LY | Early trials |
| ALK | ALK MUT* (R1209P) | Different Alteration | Lorlatinib (ALK&ROS1 inhibitor) | Responsive | NSCLC | Early trials |
| ALK | ALK MUT* (R1209P) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | THCA, IM | Case report |
| ALK | ALK MUT* (R1209P) | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (R1209P) | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | ALK MUT* (R1209P) | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | IM, COREAD | Case report |
| ALK | ALK MUT* (R1209P) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | ALK MUT* (R1209P) | Different Alteration | Brigatinib (Pan-TK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | ALK MUT* (R1209P) | Different Alteration | Entrictinib (Pan-TK inhibitor) | Responsive | COREAD | Case report |
| ALK | ALK MUT* (R1209P) | Different Alteration | Alectinib (ALK inhibitor) | Responsive | LUAD | FDA guidelines |
| ALK | ALK MUT* (R1209P) | Different Alteration | HSP90 inhibitor (HSP90 inhibitor) | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (R1209P) | Different Alteration | ALK inhibitor;IGF1R inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (R1209P) | Different Alteration | ALK inhibitor;MEK inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (R1209P) | Different Alteration | novel ALK inhibitor | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (R1209P) | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | HEMATO | Early trials |
| ALK | ALK MUT* (R1209P) | Different Alteration | ALK inhibitor | Responsive | COREAD | Case report |
| ALK | ALK MUT* (R1209P) | Different Alteration | Alectinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | ALK MUT* (R1209P) | Different Alteration | MEK inhibitor (ALK inhibitor;MEK inhibitor) | Responsive | LUAD | Pre-clinical |
| SETD2 | SETD2 MUT (S791*) | Complete Match | WEE1 inhibitor | Responsive | CANCER | Pre-clinical |
| SETD2 | SETD2 MUT (S791*) | Different Alteration | WEE1 inhibitor | Responsive | CANCER | Pre-clinical |
| PDGFRA | PDGFRA MUT* (D985N) | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | MDPS, MDS, ECL, HES | FDA guidelines |
| PBRM1 | PBRM1 MUT (splice_acceptor_variant) | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | R | Pre-clinical |
| PBRM1 | PBRM1 MUT (splice_acceptor_variant) | Complete Match | anti-PD1 inhibitor | Responsive | RCCC | Early trials |
| PBRM1 | PBRM1 MUT (splice_acceptor_variant) | Complete Match | Everolimus (MTOR inhibitor) | Responsive | RCC | Early trials |
| PBRM1 | PBRM1 MUT (splice_acceptor_variant) | Complete Match | EZH2 inhibitor | Responsive | CANCER | Pre-clinical |
| PBRM1 | PBRM1 MUT (splice_acceptor_variant) | Different Alteration | EZH2 inhibitor | Responsive | CANCER | Pre-clinical |
| PIK3CA | PIK3CA MUT (E726K), PIK3CA MUT (E726G) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (E726K), PIK3CA MUT (E726G) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (E726K), PIK3CA MUT (E726G) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (E726K), PIK3CA MUT (E726G) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (E726K), PIK3CA MUT (E726G) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (E726K), PIK3CA MUT (E726G) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (E726K), PIK3CA MUT (E726G) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (E726K), PIK3CA MUT (E726G) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (E726K), PIK3CA MUT (E726G) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (E726K), PIK3CA MUT (E726G) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (E726K), PIK3CA MUT (E726G) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (E726K), PIK3CA MUT (E726G) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (E726K), PIK3CA MUT (E726G) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (E726K), PIK3CA MUT (E726G) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| TP53 | TP53 MUT (V157F) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (V157F) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (V157F) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (V157F) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (V157F) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (V157F) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (V157F) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (V157F) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (V157F) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (V157F) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (V157F) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (V157F) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (V157F) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (V157F) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (V157F) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| PDGFRA | PDGFRA MUT* (P345S) | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | MDPS, MDS, ECL, HES | FDA guidelines |
| PIK3CA | PIK3CA MUT (Q546K) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (Q546K) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (Q546K) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (Q546K) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (Q546K) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (Q546K) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (Q546K) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (Q546K) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (Q546K) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (Q546K) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (Q546K) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (Q546K) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (Q546K) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (Q546K) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (D769H) | Different Alteration | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | ERBB2 MUT (D769H) | Different Alteration | Lapatinib (ERBB2 inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | ERBB2 MUT (D769H) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | ST, BRCA, GEJA | FDA guidelines |
| ERBB2 | ERBB2 MUT (D769H) | Different Alteration | Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | ERBB2 MUT (D769H) | Different Alteration | MK2206;Trastuzumab (allosteric AKT inhibitor;ERBB2 mAb inhibitor) | Responsive | SOLID | Early trials |
| ERBB2 | ERBB2 MUT (D769H) | Complete Match | Lapatinib (ERBB2 inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (D769H) | Complete Match | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (D769H) | Complete Match | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | CANCER, BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (D769H) | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | CANCER | Early trials |
| ERBB2 | ERBB2 MUT (D769H) | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Case report |
| ERBB2 | ERBB2 MUT (D769H) | Different Mutation | Lapatinib (ERBB2 inhibitor) | Responsive | BRCA, LUAD | Case report |
| ERBB2 | ERBB2 MUT (D769H) | Different Mutation | Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) | Responsive | L | Early trials |
| ERBB2 | ERBB2 MUT (D769H) | Different Mutation | Neratinib (ERBB2 inhibitor) | Resistant | BRCA | Case report |
| ERBB2 | ERBB2 MUT (D769H) | Different Mutation | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (D769H) | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | LUAD | Case report |
| ERBB2 | ERBB2 MUT (D769H) | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (D769H) | Different Mutation | Lapatinib (ERBB2 inhibitor) | Resistant | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (D769H) | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | CANCER | Pre-clinical |
| ERBB2 | ERBB2 MUT (D769H) | Complete Match | Temsirolimus (MTOR inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (D769H) | Complete Match | Dacomitinib (Pan ERBB inhibitor) | Responsive | NSCLC | Early trials |
| ERBB2 | ERBB2 MUT (D769H) | Complete Match | Neratinib (ERBB2 inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (D769H) | Different Mutation | ERBB2 inhibitor | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (D769H) | Different Mutation | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (D769H) | Different Mutation | ERBB2 mAb inhibitor | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (D769H) | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (D769H) | Different Mutation | Lapatinib (ERBB2 inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (D769H) | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (D769H) | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BRCA | Late trials |
| ERBB2 | ERBB2 MUT (D769H) | Different Alteration | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | BT | Early trials |
| ERBB2 | ERBB2 MUT (D769H) | Different Alteration | Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) | Responsive | COREAD | Late trials |
| ERBB2 | ERBB2 MUT (D769H) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | OV | Early trials |
| ERBB2 | ERBB2 MUT (D769H) | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BLCA | Case report |
| ERBB2 | ERBB2 MUT (D769H) | Different Alteration | Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) | Responsive | COREAD | Case report |
| ERBB2 | ERBB2 MUT (D769H) | Different Alteration | Rociletinib (EGFR inhibitor) | Resistant | LUAD | Case report |
| ERBB2 | ERBB2 MUT (D769H) | Different Alteration | Osimertinib (EGFR inhibitor) | Resistant | LUAD | Case report |
| ERBB2 | ERBB2 MUT (D769H) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | BT | Early trials |
| ERBB2 | ERBB2 MUT (D769H) | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Early trials |
| ERBB2 | ERBB2 MUT (D769H) | Different Alteration | Lapatinib (ERBB2 inhibitor) | Responsive | BT | Early trials |
| ERBB2 | ERBB2 MUT (D769H) | Different Alteration | Trastuzumab;HSP90 inhibitor (ERBB2 mAb inhibitor;HSP90 inhibitor) | Responsive | BRCA | Early trials |
| ERBB2 | ERBB2 MUT (D769H) | Different Alteration | HER2 inhibitor;CDK4/6 inhibitor | Responsive | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (D769H) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | ERBB2 MUT (D769H) | Different Alteration | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | ST | Early trials |
| ERBB2 | ERBB2 MUT (D769H) | Different Alteration | Trastuzumab;Everolimus;Chemotherapy (ERBB2 mAb inhibitor;MTOR inhibitor;Chemotherapy) | Responsive | BRCA | Early trials |
| ERBB2 | ERBB2 MUT (D769H) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | ST, GEJA | FDA guidelines |
| ERBB2 | ERBB2 MUT (D769H) | Different Alteration | ERBB2 inhibitor;CDK4/6 inhibitor | Responsive | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (D769H) | Different Alteration | Ado-Trastuzumab Emtansine (EGFR mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | ERBB2 MUT (D769H) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | HNC | Case report |
| ERBB2 | ERBB2 MUT (D769H) | Different Alteration | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Late trials |
| ERBB2 | ERBB2 MUT (D769H) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | No Responsive | ED | Early trials |
| ERBB2 | ERBB2 MUT (D769H) | Different Alteration | Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) | Responsive | ED | Pre-clinical |
| ERBB2 | ERBB2 MUT (D769H) | Different Alteration | Lapatinib;Chemotherapy (ERBB2 inhibitor;Chemotherapy) | Responsive | ST | Early trials |
| ERBB2 | ERBB2 MUT (D769H) | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | ST | Case report |
| ERBB2 | ERBB2 MUT (D769H) | Different Alteration | EGFR inhibitor | Resistant | LUAD | Pre-clinical |
| ALK | ALK MUT* (L1048L) | Different Alteration | ALK inhibitor;SRC inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (L1048L) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | GB, LY | Early trials |
| ALK | ALK MUT* (L1048L) | Different Alteration | Lorlatinib (ALK&ROS1 inhibitor) | Responsive | NSCLC | Early trials |
| ALK | ALK MUT* (L1048L) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | THCA, IM | Case report |
| ALK | ALK MUT* (L1048L) | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (L1048L) | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | ALK MUT* (L1048L) | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | IM, COREAD | Case report |
| ALK | ALK MUT* (L1048L) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | ALK MUT* (L1048L) | Different Alteration | Brigatinib (Pan-TK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | ALK MUT* (L1048L) | Different Alteration | Entrictinib (Pan-TK inhibitor) | Responsive | COREAD | Case report |
| ALK | ALK MUT* (L1048L) | Different Alteration | Alectinib (ALK inhibitor) | Responsive | LUAD | FDA guidelines |
| ALK | ALK MUT* (L1048L) | Different Alteration | HSP90 inhibitor (HSP90 inhibitor) | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (L1048L) | Different Alteration | ALK inhibitor;IGF1R inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (L1048L) | Different Alteration | ALK inhibitor;MEK inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (L1048L) | Different Alteration | novel ALK inhibitor | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (L1048L) | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | HEMATO | Early trials |
| ALK | ALK MUT* (L1048L) | Different Alteration | ALK inhibitor | Responsive | COREAD | Case report |
| ALK | ALK MUT* (L1048L) | Different Alteration | Alectinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | ALK MUT* (L1048L) | Different Alteration | MEK inhibitor (ALK inhibitor;MEK inhibitor) | Responsive | LUAD | Pre-clinical |
| TP53 | TP53 MUT (E286Q) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (E286Q) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (E286Q) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (E286Q) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (E286Q) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (E286Q) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (E286Q) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (E286Q) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (E286Q) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (E286Q) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (E286Q) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (E286Q) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (E286Q) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (E286Q) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (E286Q) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| STK11 | STK11 MUT (Q123*) | Different Mutation | Everolimus (MTOR inhibitor) | Responsive | PA | Case report |
| STK11 | STK11 MUT (Q123*) | Complete Match | Phenformin (Anti-diabetic) | Responsive | LUAD | Pre-clinical |
| STK11 | STK11 MUT (Q123*) | Complete Match | MTOR inhibitor | Responsive | CANCER | Pre-clinical |
| STK11 | STK11 MUT (Q123*) | Complete Match | BET inhibitor | Resistant | L | Pre-clinical |
| STK11 | STK11 MUT (Q123*) | Complete Match | PD1 inhibitor | Resistant | CANCER | Early trials |
| STK11 | STK11 MUT (Q123*) | Complete Match | SRC inhibitor;PI3K/MEK inhibitor | Responsive | LUAD | Pre-clinical |
| STK11 | STK11 MUT (Q123*) | Complete Match | MEK inhibitor | Responsive | LUAD | Pre-clinical |
| STK11 | STK11 MUT (Q123*) | Different Alteration | MTOR inhibitor | Responsive | CANCER | Pre-clinical |
| STK11 | STK11 MUT (Q123*) | Different Alteration | PD1 inhibitor | Resistant | CANCER | Early trials |
| STK11 | STK11 MUT (Q123*) | Different Alteration | Phenformin (Anti-diabetic) | Responsive | LUAD | Pre-clinical |
| STK11 | STK11 MUT (Q123*) | Different Alteration | MEK inhibitor | Responsive | LUAD | Pre-clinical |
| STK11 | STK11 MUT (Q123*) | Different Alteration | SRC inhibitor;PI3K/MEK inhibitor | Responsive | LUAD | Pre-clinical |
| CDH1 | CDH1 MUT (Q503*) | Complete Match | Bicalutamide (AR inhibitor) | Responsive | BRCA | Pre-clinical |
| TP53 | TP53 MUT (M237I) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (M237I) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (M237I) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (M237I) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (M237I) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (M237I) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (M237I) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (M237I) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (M237I) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (M237I) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (M237I) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (M237I) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (M237I) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (M237I) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (M237I) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| NTRK1 | NTRK1 MUT* (L96V) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Case report |
| NTRK1 | NTRK1 MUT* (L96V) | Different Alteration | Pan-TKR inhibitor | Responsive | CANCER | Early trials |
| NTRK1 | NTRK1 MUT* (L96V) | Different Alteration | Pan-TK inhibitor | Responsive | LUAD | Pre-clinical |
| NTRK1 | NTRK1 MUT* (L96V) | Different Alteration | Pan-TK inhibitor | Responsive | COREAD | Case report |
| TP53 | TP53 MUT (G245S) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (G245S) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (G245S) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (G245S) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (G245S) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (G245S) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (G245S) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (G245S) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (G245S) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (G245S) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (G245S) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (G245S) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (G245S) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (G245S) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (G245S) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| BRD4 | BRD4 MUT* (M1073I) | Different Alteration | BET inhibitor | Responsive | NMC | Case report |
| ARID1A | ARID1A MUT (R1989*) | Complete Match | EZH2 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | ARID1A MUT (R1989*) | Complete Match | PD1 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | ARID1A MUT (R1989*) | Complete Match | PARP inhibitor | Responsive | CANCER | Pre-clinical |
| ARID1A | ARID1A MUT (R1989*) | Complete Match | ATR inhibitor | Responsive | CANCER | Pre-clinical |
| PIK3R1 | PIK3R1 MUT (I559T) | Complete Match | AKT inhibitor | Responsive | G | Pre-clinical |
| PIK3R1 | PIK3R1 MUT (I559T) | Complete Match | PI3K pathway inhibitor | Responsive | ED | Case report |
| TP53 | TP53 MUT (V173L) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (V173L) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (V173L) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (V173L) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (V173L) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (V173L) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (V173L) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (V173L) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (V173L) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (V173L) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (V173L) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (V173L) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (V173L) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (V173L) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (V173L) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| RAF1 | RAF1 MUT* (E607Q) | Different Alteration | Sorafenib (Pan-TK inhibitor) | Responsive | PRAD | Pre-clinical |
| RAF1 | RAF1 MUT* (E607Q) | Different Alteration | Pan-RAF inhibitor | Responsive | PRAD | Pre-clinical |
| RAF1 | RAF1 MUT* (E607Q) | Different Alteration | U0126 (MEK inhibitor) | Responsive | PRAD | Pre-clinical |
| GNAS | GNAS MUT (R201H) | Complete Match | JAK inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (F270I) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (F270I) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (F270I) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (F270I) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (F270I) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (F270I) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (F270I) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (F270I) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (F270I) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (F270I) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (F270I) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (F270I) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (F270I) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (F270I) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (F270I) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (L130V) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (L130V) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (L130V) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (L130V) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (L130V) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (L130V) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (L130V) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (L130V) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (L130V) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (L130V) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (L130V) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (L130V) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (L130V) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (L130V) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (L130V) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| BRCA1 | BRCA1 MUT (splice_donor_variant) | Complete Match | Chemotherapy (PARP inhibitor;Chemotherapy) | Responsive | OV | Early trials |
| BRCA1 | BRCA1 MUT (splice_donor_variant) | Complete Match | PARP inhibitor | Responsive | BRCA | Early trials |
| BRCA1 | BRCA1 MUT (splice_donor_variant) | Complete Match | PARP inhibitor;Chemotherapy | Responsive | OV | Early trials |
| BRCA1 | BRCA1 MUT (splice_donor_variant) | Complete Match | Rucaparib (PARP inhibitor) | Responsive | OV | FDA guidelines |
| BRCA1 | BRCA1 MUT (splice_donor_variant) | Complete Match | Platinum Agent (Chemotherapy) | Responsive | BRCA | Early trials |
| BRCA1 | BRCA1 MUT (splice_donor_variant) | Complete Match | WEE1 inhibitor | Responsive | CANCER | Case report |
| BRCA1 | BRCA1 MUT (splice_donor_variant) | Complete Match | Platinum Agent (Chemotherapy) | Responsive | OV | Late trials |
| BRCA1 | BRCA1 MUT (splice_donor_variant) | Complete Match | Olaparib (PARP inhibitor) | Responsive | PRAD | Early trials |
| BRCA1 | BRCA1 MUT (splice_donor_variant) | Complete Match | Veliparib;Cisplatin (PARP inhibitor;Chemotherapy) | Responsive | BRCA | Early trials |
| BRCA1 | BRCA1 MUT (splice_donor_variant) | Complete Match | PARP inhibitor | Responsive | PA | Case report |
| BRCA1 | BRCA1 MUT (splice_donor_variant) | Complete Match | Olaparib (PARP inhibitor) | Responsive | OV | FDA guidelines |
| BRCA1 | BRCA1 MUT (splice_donor_variant) | Different Alteration | PARP inhibitor | Responsive | OV | Pre-clinical |
| EGFR | EGFR MUT* (R334R) | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | L | Case report |
| EGFR | EGFR MUT* (R334R) | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | NSCLC | Case report |
| CDKN1B | CDKN1B MUT (S27*) | Complete Match | CDK2/4 inhibitor | Responsive | CANCER | Pre-clinical |
| CDKN1B | CDKN1B MUT (S27*) | Different Alteration | CDK2/4 inhibitor | Responsive | CANCER | Pre-clinical |
| KMT2D | MLL2 MUT (L2255*) | Complete Match | Bicalutamide (AR inhibitor) | Responsive | LUSC | Pre-clinical |
| TP53 | TP53 MUT (D281Y) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (D281Y) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (D281Y) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (D281Y) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (D281Y) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (D281Y) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (D281Y) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (D281Y) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (D281Y) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (D281Y) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (D281Y) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (D281Y) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (D281Y) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (D281Y) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (D281Y) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| ERBB4 | ERBB4 MUT* (D73V) | Different Alteration | Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) | Responsive | LUAD | Pre-clinical |
| PDGFRA | PDGFRA MUT* (E571K) | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | MDPS, MDS, ECL, HES | FDA guidelines |
| KRAS | KRAS MUT (G12D) | Complete Match | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | FDA guidelines |
| KRAS | KRAS MUT (G12D) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | FDA guidelines |
| KRAS | KRAS MUT (G12D) | Different Mutation | Cetuximab (EGFR mAb inhibitor) | No Responsive | COREAD | Late trials |
| KRAS | KRAS MUT (G12D) | Complete Match | MEK inhibitor | Responsive | ALL | Pre-clinical |
| KRAS | KRAS MUT (G12D) | Complete Match | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Resistant | GIST | Case report |
| KRAS | KRAS MUT (G12D) | Complete Match | MEK inhibitor | Responsive | OV, CER, AML | Pre-clinical |
| KRAS | KRAS MUT (G12D) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Responsive | L | Early trials |
| KRAS | KRAS MUT (G12D) | Complete Match | MEK inhibitor;PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | KRAS MUT (G12D) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | NCCN guidelines |
| KRAS | KRAS MUT (G12D) | Complete Match | Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) | Responsive | HC | Early trials |
| KRAS | KRAS MUT (G12D) | Complete Match | EGFR inhibitor | Resistant | L | NCCN guidelines |
| KRAS | KRAS MUT (G12D) | Complete Match | CDK4 inhibitor | Responsive | L | Pre-clinical |
| KRAS | KRAS MUT (G12D) | Complete Match | Selumetinib (MEK inhibitor) | Responsive | NSCLC | Early trials |
| KRAS | KRAS MUT (G12D) | Complete Match | BET inhibitor | Responsive | L | Pre-clinical |
| KRAS | KRAS MUT (G12D) | Complete Match | Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) | Responsive | OV | Pre-clinical |
| KRAS | KRAS MUT (G12D) | Complete Match | FAK inhibitor | Responsive | L | Pre-clinical |
| KRAS | KRAS MUT (G12D) | Complete Match | EGFR inhibitor | Resistant | NSCLC | Pre-clinical |
| KRAS | KRAS MUT (G12D) | Complete Match | EZH2 inhibitor | Resistant | CANCER | Pre-clinical |
| KRAS | KRAS MUT (G12D) | Complete Match | MEK inhibitor | Responsive | BT, L | Early trials |
| KRAS | KRAS MUT (G12D) | Complete Match | MEK inhibitor;IGF1R inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | KRAS MUT (G12D) | Complete Match | MTOR inhibitor;BH3 mimetics | Responsive | COREAD | Pre-clinical |
| KRAS | KRAS MUT (G12D) | Complete Match | EGFR mAb inhibitor;MEK inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | KRAS MUT (G12D) | Complete Match | pan-RAF inhibitor | Responsive | ED | Case report |
| KRAS | KRAS MUT (G12D) | Complete Match | EGFR mAb inhibitor | Resistant | ST | Pre-clinical |
| KRAS | KRAS MUT (G12D) | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | L | Early trials |
| KRAS | KRAS MUT (G12D) | Complete Match | Selumetinib (MEK inhibitor) | No Responsive | L | Early trials |
| KRAS | KRAS MUT (G12D) | Complete Match | CDK4/6 inhibitor;MEK inhibitor | Responsive | L | Early trials |
| KRAS | KRAS MUT (G12D) | Complete Match | Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) | Responsive | LUAD | Pre-clinical |
| KRAS | KRAS MUT (G12D) | Complete Match | Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) | Resistant | COREAD | Late trials |
| KRAS | KRAS MUT (G12D) | Complete Match | pan-RAF inhibitor | Responsive | L | Early trials |
| KRAS | KRAS MUT (G12D) | Complete Match | JAK/TBK1/IKKε inhibitor | Responsive | L | Pre-clinical |
| KRAS | KRAS MUT (G12D) | Complete Match | FAS inhibitor | Responsive | L | Case report |
| KRAS | KRAS MUT (G12D) | Complete Match | HSP90 inhibitor | Responsive | L | Pre-clinical |
| KRAS | KRAS MUT (G12D) | Complete Match | ERK inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | KRAS MUT (G12D) | Complete Match | PI3K pathway inhibitor;MEK inhibitor | No Responsive | PA | Early trials |
| KRAS | KRAS MUT (G12D) | Complete Match | MEK inhibitor;BCL-XL inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | KRAS MUT (G12D) | Complete Match | Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) | Responsive | PA | Early trials |
| KRAS | KRAS MUT (G12D) | Complete Match | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | NCCN guidelines |
| KRAS | KRAS MUT (G12D) | Complete Match | PI3K pathway inhibitor | Resistant | ED | Pre-clinical |
| KRAS | KRAS MUT (G12D) | Complete Match | CDK4/6 inhibitor;MEK inhibitor | Responsive | CESC | Pre-clinical |
| KRAS | KRAS MUT (G12D) | Different Alteration | BRAF inhibitor;MEK inhibitor | Resistant | COREAD | Case report |
| KRAS | KRAS MUT (G12D) | Different Alteration | BRAF inhibitor;EGFR mAb inhibitor | Resistant | COREAD | Case report |
| KMT2A | MLL MUT* (T1842A) | Different Alteration | EPZ-5676 (DOT1L inhibitor) | Responsive | ALL, MDS, AML | Early trials |
| KMT2A | MLL MUT* (T1842A) | Different Alteration | BET inhibitor | Responsive | ALL | Pre-clinical |
| KMT2A | MLL MUT* (T1842A) | Different Alteration | BET inhibitor | Responsive | AML | Pre-clinical |
| KMT2A | MLL MUT* (T1842A) | Different Alteration | Daunorubicin (Chemotherapy) | Responsive | AML | FDA guidelines |
| KMT2A | MLL MUT* (T1842A) | Different Alteration | Belinostat (HDAC inhibitor) | Responsive | AML | Early trials |
| KMT2A | MLL MUT* (T1842A) | Different Alteration | DOT1L inhibitor | Responsive | AML | Early trials |
| NF1 | NF1 MUT (splice_donor_variant) | Different Mutation | Vemurafenib (BRAF inhibitor) | Resistant | CM | Pre-clinical |
| NF1 | NF1 MUT (splice_donor_variant) | Different Mutation | Everolimus (MTOR inhibitor) | Responsive | HNC | Case report |
| NF1 | NF1 MUT (splice_donor_variant) | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (splice_donor_variant) | Complete Match | Vinblastine (Chemotherapy) | Responsive | G | Early trials |
| NF1 | NF1 MUT (splice_donor_variant) | Complete Match | KIT inhibitor;MTOR inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (splice_donor_variant) | Complete Match | Tamoxifen (Hormonal therapy) | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (splice_donor_variant) | Complete Match | Bevacizumab (VEGFR mAb inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (splice_donor_variant) | Complete Match | Retinoic Acid | Resistant | NB | Pre-clinical |
| NF1 | NF1 MUT (splice_donor_variant) | Complete Match | Everolimus (MTOR inhibitor) | Responsive | NF | Late trials |
| NF1 | NF1 MUT (splice_donor_variant) | Complete Match | Trametinib (MEK inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (splice_donor_variant) | Complete Match | Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (splice_donor_variant) | Complete Match | Nilotinib (BCR-ABL inhibitor) | Responsive | MPN, PLEN | Pre-clinical |
| NF1 | NF1 MUT (splice_donor_variant) | Complete Match | MEK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (splice_donor_variant) | Complete Match | Everolimus (MTOR inhibitor) | Responsive | HNC, SG | Case report |
| NF1 | NF1 MUT (splice_donor_variant) | Complete Match | Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) | No Responsive | MPN | Early trials |
| NF1 | NF1 MUT (splice_donor_variant) | Complete Match | PLX3397 (Pan-TK inhibitor) | Responsive | PLEN | Pre-clinical |
| NF1 | NF1 MUT (splice_donor_variant) | Complete Match | MEK inhibitor | Responsive | LK, G | Pre-clinical |
| NF1 | NF1 MUT (splice_donor_variant) | Complete Match | Pan-RAF inhibitor;MEK inhibitor | Responsive | CM | Pre-clinical |
| NF1 | NF1 MUT (splice_donor_variant) | Complete Match | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (splice_donor_variant) | Complete Match | AURK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (splice_donor_variant) | Complete Match | MTOR inhibitor | Responsive | LK, G, MPN | Pre-clinical |
| NF1 | NF1 MUT (splice_donor_variant) | Complete Match | Dasatinib (BCR-ABL inhibitor) | Resistant | L | Pre-clinical |
| NF1 | NF1 MUT (splice_donor_variant) | Complete Match | Everolimus;Pazopanib (MTOR inhibitor;VEGFR inhibitor) | Responsive | HC | Case report |
| NF1 | NF1 MUT (splice_donor_variant) | Complete Match | Everolimus (MTOR inhibitor) | No Responsive | MPN | Early trials |
| NF1 | NF1 MUT (splice_donor_variant) | Complete Match | Cediranib (ALK inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (splice_donor_variant) | Complete Match | PD1 Ab inhibitor | Responsive | CM | Early trials |
| NF1 | NF1 MUT (splice_donor_variant) | Complete Match | Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (splice_donor_variant) | Complete Match | Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (splice_donor_variant) | Complete Match | Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | No Responsive | G | Case report |
| NF1 | NF1 MUT (splice_donor_variant) | Complete Match | BRD4 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (splice_donor_variant) | Complete Match | Tipifarnib (Farnesyltransferase inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (splice_donor_variant) | Complete Match | Selumetinib (MEK inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (splice_donor_variant) | Complete Match | MTOR inhibitor;HSP90 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (splice_donor_variant) | Complete Match | Trametinib (MEK inhibitor) | Responsive | CM | Pre-clinical |
| NF1 | NF1 MUT (splice_donor_variant) | Complete Match | Erlotinib (EGFR inhibitor) | Resistant | L | Pre-clinical |
| NF1 | NF1 MUT (splice_donor_variant) | Complete Match | Trametinib (MEK inhibitor) | No Responsive | OS | Case report |
| NF1 | NF1 MUT (splice_donor_variant) | Different Alteration | MTOR inhibitor | Responsive | MPN, G, LK | Pre-clinical |
| NF1 | NF1 MUT (splice_donor_variant) | Different Alteration | PLX3397 (Pan-TK inhibitor) | Responsive | PLEN | Pre-clinical |
| NF1 | NF1 MUT (splice_donor_variant) | Different Alteration | Erlotinib (EGFR inhibitor) | Resistant | L | Pre-clinical |
| NF1 | NF1 MUT (splice_donor_variant) | Different Alteration | Trametinib (MEK inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (splice_donor_variant) | Different Alteration | BRD4 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (splice_donor_variant) | Different Alteration | Trametinib (MEK inhibitor) | No Responsive | OS | Case report |
| NF1 | NF1 MUT (splice_donor_variant) | Different Alteration | Cediranib (ALK inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (splice_donor_variant) | Different Alteration | Bevacizumab (VEGFR mAb inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (splice_donor_variant) | Different Alteration | MEK inhibitor | Responsive | G, LK | Pre-clinical |
| NF1 | NF1 MUT (splice_donor_variant) | Different Alteration | Vinblastine (Chemotherapy) | Responsive | G | Early trials |
| NF1 | NF1 MUT (splice_donor_variant) | Different Alteration | Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (splice_donor_variant) | Different Alteration | Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) | No Responsive | MPN | Early trials |
| NF1 | NF1 MUT (splice_donor_variant) | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Resistant | L | Pre-clinical |
| NF1 | NF1 MUT (splice_donor_variant) | Different Alteration | MTOR inhibitor;HSP90 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (splice_donor_variant) | Different Alteration | Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (splice_donor_variant) | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (splice_donor_variant) | Different Alteration | Tamoxifen (Hormonal therapy) | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (splice_donor_variant) | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | SG, HNC | Case report |
| NF1 | NF1 MUT (splice_donor_variant) | Different Alteration | Pan-RAF inhibitor;MEK inhibitor | Responsive | CM | Pre-clinical |
| NF1 | NF1 MUT (splice_donor_variant) | Different Alteration | Tipifarnib (Farnesyltransferase inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (splice_donor_variant) | Different Alteration | Selumetinib (MEK inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (splice_donor_variant) | Different Alteration | Retinoic Acid | Resistant | NB | Pre-clinical |
| NF1 | NF1 MUT (splice_donor_variant) | Different Alteration | Everolimus (MTOR inhibitor) | No Responsive | MPN | Early trials |
| NF1 | NF1 MUT (splice_donor_variant) | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (splice_donor_variant) | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | PLEN, MPN | Pre-clinical |
| NF1 | NF1 MUT (splice_donor_variant) | Different Alteration | Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (splice_donor_variant) | Different Alteration | Trametinib (MEK inhibitor) | Responsive | CM | Pre-clinical |
| NF1 | NF1 MUT (splice_donor_variant) | Different Alteration | AURK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (splice_donor_variant) | Different Alteration | Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | No Responsive | G | Case report |
| NF1 | NF1 MUT (splice_donor_variant) | Different Alteration | PD1 Ab inhibitor | Responsive | CM | Early trials |
| NF1 | NF1 MUT (splice_donor_variant) | Different Alteration | MEK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (splice_donor_variant) | Different Alteration | KIT inhibitor;MTOR inhibitor | Responsive | MPN | Pre-clinical |
| EGFR | EGFR MUT* (3-UTRSNV) | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | L | Case report |
| EGFR | EGFR MUT* (3-UTRSNV) | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | NSCLC | Case report |
| JAK2 | JAK2 MUT* (splice_acceptor_variant) | Different Alteration | Ruxolitinib (JAK inhibitor) | Responsive | ALL | Pre-clinical |
| ROS1 | ROS1 MUT* (S932T) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | IM | Case report |
| ROS1 | ROS1 MUT* (S932T) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ROS1 | ROS1 MUT* (S932T) | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Case report |
| ROS1 | ROS1 MUT* (S932T) | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Pre-clinical |
| ROS1 | ROS1 MUT* (S932T) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Early trials |
| ERBB4 | ERBB4 MUT* (Y1022C) | Different Alteration | Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) | Responsive | LUAD | Pre-clinical |
| TP53 | TP53 MUT (E56*) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (E56*) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (E56*) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (E56*) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (E56*) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (E56*) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (E56*) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (E56*) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (E56*) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (E56*) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (E56*) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (E56*) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (E56*) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (E56*) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (E56*) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| NOTCH1 | NOTCH1 MUT* (Q2487L) | Different Alteration | Gamma secretase inhibitor | Responsive | ALL | Pre-clinical |
| NOTCH1 | NOTCH1 MUT* (Q2487L) | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| AKT1 | AKT1 MUT (L52R) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| AKT1 | AKT1 MUT (L52R) | Different Mutation | allosteric AKT inhibitor | Responsive | CANCER | Early trials |
| AKT1 | AKT1 MUT (L52R) | Different Mutation | non-allosteric AKT inhibitor | Responsive | CANCER | Early trials |
| AKT1 | AKT1 MUT (L52R) | Different Mutation | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| AKT1 | AKT1 MUT (L52R) | Different Mutation | Temsirolimus (MTOR inhibitor) | Responsive | ED | Early trials |
| AKT1 | AKT1 MUT (L52R) | Different Mutation | AKT inhibitor | Responsive | CANCER | Pre-clinical |
| AKT1 | AKT1 MUT (L52R) | Different Mutation | Everolimus (MTOR inhibitor) | Responsive | FH | Case report |
| TP53 | TP53 MUT (E285K) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (E285K) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (E285K) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (E285K) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (E285K) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (E285K) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (E285K) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (E285K) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (E285K) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (E285K) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (E285K) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (E285K) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (E285K) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (E285K) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (E285K) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| RET | RET MUT* (D547D) | Different Alteration | Nintedanib (Pan-TK inhibitor) | Responsive | LUAD | Case report |
| RET | RET MUT* (D547D) | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Early trials |
| RET | RET MUT* (D547D) | Different Alteration | RET inhibitor | Responsive | LUAD | Pre-clinical |
| RET | RET MUT* (D547D) | Different Alteration | Vandetanib (Pan-TK inhibitor) | Responsive | LUAD | Early trials |
| RET | RET MUT* (D547D) | Different Alteration | Sunitinib (Pan-TK inhibitor) | Responsive | LUAD | Early trials |
| RET | RET MUT* (D547D) | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | THCA | Pre-clinical |
| RET | RET MUT* (D547D) | Different Alteration | Vandetanib (Pan-TK inhibitor) | Responsive | THCA | Pre-clinical |
| RET | RET MUT* (D547D) | Different Alteration | Sunitinib (Pan-TK inhibitor) | Responsive | THCA | Pre-clinical |
| RET | RET MUT* (D547D) | Different Alteration | RET inhibitor | Responsive | TH | Pre-clinical |
| FAT1 | FAT1 MUT (S3029*) | Complete Match | BET inhibitor | Responsive | HNSC | Pre-clinical |
| FBXW7 | FBXW7 MUT (G391D) | Complete Match | Steroid | Responsive | ALL | Late trials |
| FBXW7 | FBXW7 MUT (G391D) | Complete Match | Tubulin inhibitor | Resistant | CANCER | Pre-clinical |
| FBXW7 | FBXW7 MUT (G391D) | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | COREAD | Pre-clinical |
| FBXW7 | FBXW7 MUT (G391D) | Different Alteration | Tubulin inhibitor | Resistant | CANCER | Pre-clinical |
| ROS1 | ROS1 MUT* (R1910*) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | IM | Case report |
| ROS1 | ROS1 MUT* (R1910*) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ROS1 | ROS1 MUT* (R1910*) | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Case report |
| ROS1 | ROS1 MUT* (R1910*) | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Pre-clinical |
| ROS1 | ROS1 MUT* (R1910*) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Early trials |
| RB1 | RB1 MUT (R552*) | Different Alteration | Palbociclib (CDK4/6 inhibitor) | Responsive | PRAD | Pre-clinical |
| RB1 | RB1 MUT (R552*) | Complete Match | MDM2/MDMX inhibitor | Responsive | RB | Pre-clinical |
| RB1 | RB1 MUT (R552*) | Complete Match | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| RB1 | RB1 MUT (R552*) | Complete Match | HDAC inhibitor | Responsive | RB | Pre-clinical |
| RB1 | RB1 MUT (R552*) | Different Alteration | MDM2/MDMX inhibitor | Responsive | RB | Pre-clinical |
| RB1 | RB1 MUT (R552*) | Different Alteration | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| RB1 | RB1 MUT (R552*) | Different Alteration | HDAC inhibitor | Responsive | RB | Pre-clinical |
| TP53 | TP53 MUT (V173M) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (V173M) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (V173M) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (V173M) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (V173M) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (V173M) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (V173M) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (V173M) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (V173M) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (V173M) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (V173M) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (V173M) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (V173M) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (V173M) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (V173M) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (E286K) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (E286K) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (E286K) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (E286K) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (E286K) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (E286K) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (E286K) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (E286K) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (E286K) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (E286K) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (E286K) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (E286K) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (E286K) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (E286K) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (E286K) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| EGFR | EGFR MUT* (T273A) | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | L | Case report |
| EGFR | EGFR MUT* (T273A) | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | NSCLC | Case report |
| ERBB4 | ERBB4 MUT* (L913L) | Different Alteration | Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) | Responsive | LUAD | Pre-clinical |
| TP53 | TP53 MUT (Y220S) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (Y220S) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (Y220S) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (Y220S) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (Y220S) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (Y220S) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (Y220S) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Y220S) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Y220S) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (Y220S) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (Y220S) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Y220S) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (Y220S) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (Y220S) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (Y220S) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| ERBB4 | ERBB4 MUT* (N482D) | Different Alteration | Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) | Responsive | LUAD | Pre-clinical |
| NOTCH2 | NOTCH2 MUT* (L1717I) | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| NOTCH2 | NOTCH2 MUT* (G2381G) | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| NRG1 | NRG1 MUT* (R282H) | Different Alteration | Lapatinib (ERBB2 inhibitor) | Responsive | LUAD | Pre-clinical |
| NRG1 | NRG1 MUT* (R282H) | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | LUAD | Case report |
| HIF1A | HIF1A MUT (Q730*) | Different Alteration | Sunitinib (Pan-TK inhibitor) | Responsive | R | Pre-clinical |
| NOTCH2 | NOTCH2 MUT* (V2469I) | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK1 | NTRK1 MUT* (Q626K) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Case report |
| NTRK1 | NTRK1 MUT* (Q626K) | Different Alteration | Pan-TKR inhibitor | Responsive | CANCER | Early trials |
| NTRK1 | NTRK1 MUT* (Q626K) | Different Alteration | Pan-TK inhibitor | Responsive | LUAD | Pre-clinical |
| NTRK1 | NTRK1 MUT* (Q626K) | Different Alteration | Pan-TK inhibitor | Responsive | COREAD | Case report |
| RB1 | RB1 MUT (R455*) | Different Alteration | Palbociclib (CDK4/6 inhibitor) | Responsive | PRAD | Pre-clinical |
| RB1 | RB1 MUT (R455*) | Complete Match | MDM2/MDMX inhibitor | Responsive | RB | Pre-clinical |
| RB1 | RB1 MUT (R455*) | Complete Match | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| RB1 | RB1 MUT (R455*) | Complete Match | HDAC inhibitor | Responsive | RB | Pre-clinical |
| RB1 | RB1 MUT (R455*) | Different Alteration | MDM2/MDMX inhibitor | Responsive | RB | Pre-clinical |
| RB1 | RB1 MUT (R455*) | Different Alteration | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| RB1 | RB1 MUT (R455*) | Different Alteration | HDAC inhibitor | Responsive | RB | Pre-clinical |
| MTOR | MTOR MUT (I1973F) | Different Mutation | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Pre-clinical |
| MTOR | MTOR MUT (I1973F) | Different Mutation | Everolimus (MTOR inhibitor) | Responsive | R | Case report |
| MTOR | MTOR MUT (I1973F) | Complete Match | Everolimus (MTOR inhibitor) | Responsive | AS, R, ST, AG | Case report |
| MTOR | MTOR MUT (I1973F) | Different Mutation | Everolimus (MTOR inhibitor) | Responsive | BLCA | Case report |
| MTOR | MTOR MUT (I1973F) | Different Mutation | Everolimus (MTOR inhibitor) | Responsive | ST | Case report |
| MTOR | MTOR MUT (I1973F) | Different Mutation | Everolimus (MTOR inhibitor) | Resistant | THCA | Case report |
| MTOR | MTOR MUT (I1973F) | Different Mutation | MTOR kinase inhibitor | Responsive | CANCER | Pre-clinical |
| KMT2A | MLL MUT* (K1185K) | Different Alteration | EPZ-5676 (DOT1L inhibitor) | Responsive | ALL, MDS, AML | Early trials |
| KMT2A | MLL MUT* (K1185K) | Different Alteration | BET inhibitor | Responsive | ALL | Pre-clinical |
| KMT2A | MLL MUT* (K1185K) | Different Alteration | BET inhibitor | Responsive | AML | Pre-clinical |
| KMT2A | MLL MUT* (K1185K) | Different Alteration | Daunorubicin (Chemotherapy) | Responsive | AML | FDA guidelines |
| KMT2A | MLL MUT* (K1185K) | Different Alteration | Belinostat (HDAC inhibitor) | Responsive | AML | Early trials |
| KMT2A | MLL MUT* (K1185K) | Different Alteration | DOT1L inhibitor | Responsive | AML | Early trials |
| PIK3CA | PIK3CA MUT (G1007R) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (G1007R) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (G1007R) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (G1007R) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (G1007R) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (G1007R) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (G1007R) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (G1007R) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (G1007R) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (G1007R) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (G1007R) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (G1007R) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (G1007R) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (G1007R) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (K111E) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (K111E) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (K111E) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (K111E) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (K111E) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (K111E) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (K111E) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (K111E) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (K111E) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (K111E) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (K111E) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (K111E) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (K111E) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (K111E) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| TP53 | TP53 MUT (N247I) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (N247I) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (N247I) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (N247I) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (N247I) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (N247I) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (N247I) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (N247I) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (N247I) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (N247I) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (N247I) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (N247I) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (N247I) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (N247I) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (N247I) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| SMARCA1 | SMARCA1 MUT (K773*) | Complete Match | EZH2 inhibitor | Responsive | CANCER | Pre-clinical |
| ERBB4 | ERBB4 MUT* (5-UTRSNV) | Different Alteration | Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) | Responsive | LUAD | Pre-clinical |
| 0 | SMARCA4 MUT (splice_acceptor_variant) | Complete Match | EZH2 inhibitor | Responsive | OVRT | Case report |
| 0 | SMARCA4 MUT (splice_acceptor_variant) | Complete Match | AURKA inhibitor | Responsive | NSCLC | Pre-clinical |
| 0 | SMARCA4 MUT (splice_acceptor_variant) | Complete Match | EZH2 inhibitor | Responsive | OV | Case report |
| 0 | SMARCA4 MUT (splice_acceptor_variant) | Different Alteration | EZH2 inhibitor | Responsive | OVRT | Case report |
| 0 | SMARCA4 MUT (splice_acceptor_variant) | Different Alteration | EZH2 inhibitor | Responsive | OV | Case report |
| PIK3CA | PIK3CA MUT (E453K), PIK3CA MUT (H1047R) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (E453K), PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (E453K), PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (E453K), PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (E453K), PIK3CA MUT (H1047R) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (E453K), PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (E453K), PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (E453K), PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (E453K), PIK3CA MUT (H1047R) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (E453K), PIK3CA MUT (H1047R) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (E453K), PIK3CA MUT (H1047R) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (E453K), PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (E453K), PIK3CA MUT (H1047R) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (E453K), PIK3CA MUT (H1047R) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| BCR | BCR MUT* (D904N) | Different Alteration | Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) | Responsive | CML, ALL | FDA guidelines |
| BCR | BCR MUT* (D904N) | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | ALL, CML | FDA guidelines |
| BCR | BCR MUT* (D904N) | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| BCR | BCR MUT* (D904N) | Different Alteration | Bosutinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| BCR | BCR MUT* (D904N) | Different Alteration | Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) | Responsive | ALL | Pre-clinical |
| BCR | BCR MUT* (D904N) | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Responsive | ALL, CML | FDA guidelines |
| TP53 | TP53 MUT (W91*), TP53 MUT (Y220S) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (W91*), TP53 MUT (Y220S) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (W91*), TP53 MUT (Y220S) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (W91*), TP53 MUT (Y220S) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (W91*), TP53 MUT (Y220S) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (W91*), TP53 MUT (Y220S) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (W91*), TP53 MUT (Y220S) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (W91*), TP53 MUT (Y220S) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (W91*), TP53 MUT (Y220S) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (W91*), TP53 MUT (Y220S) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (W91*), TP53 MUT (Y220S) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (W91*), TP53 MUT (Y220S) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (W91*), TP53 MUT (Y220S) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (W91*), TP53 MUT (Y220S) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (W91*), TP53 MUT (Y220S) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| EGFR | EGFR MUT* (C526S) | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | L | Case report |
| EGFR | EGFR MUT* (C526S) | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | NSCLC | Case report |
| FGFR2 | FGFR2 MUT* (intron_variant) | Different Alteration | FGFR inhibitor | Responsive | COREAD | Early trials |
| FGFR2 | FGFR2 MUT* (intron_variant) | Different Alteration | FGFR inhibitor | Responsive | BT | Early trials |
| KMT2A | MLL MUT* (D1674H) | Different Alteration | EPZ-5676 (DOT1L inhibitor) | Responsive | ALL, MDS, AML | Early trials |
| KMT2A | MLL MUT* (D1674H) | Different Alteration | BET inhibitor | Responsive | ALL | Pre-clinical |
| KMT2A | MLL MUT* (D1674H) | Different Alteration | BET inhibitor | Responsive | AML | Pre-clinical |
| KMT2A | MLL MUT* (D1674H) | Different Alteration | Daunorubicin (Chemotherapy) | Responsive | AML | FDA guidelines |
| KMT2A | MLL MUT* (D1674H) | Different Alteration | Belinostat (HDAC inhibitor) | Responsive | AML | Early trials |
| KMT2A | MLL MUT* (D1674H) | Different Alteration | DOT1L inhibitor | Responsive | AML | Early trials |
| BCR | BCR MUT* (L1128L) | Different Alteration | Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) | Responsive | CML, ALL | FDA guidelines |
| BCR | BCR MUT* (L1128L) | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | ALL, CML | FDA guidelines |
| BCR | BCR MUT* (L1128L) | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| BCR | BCR MUT* (L1128L) | Different Alteration | Bosutinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| BCR | BCR MUT* (L1128L) | Different Alteration | Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) | Responsive | ALL | Pre-clinical |
| BCR | BCR MUT* (L1128L) | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Responsive | ALL, CML | FDA guidelines |
| ESR1 | ESR1 MUT* (E523Q) | Different Alteration | ESR1 inhibitor | Resistant | BRCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (N1044Y) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (N1044Y) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (N1044Y) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (N1044Y) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (N1044Y) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (N1044Y) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (N1044Y) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (N1044Y) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (N1044Y) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (N1044Y) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (N1044Y) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (N1044Y) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (N1044Y) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (N1044Y) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| TP53 | TP53 MUT (L265R) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (L265R) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (L265R) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (L265R) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (L265R) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (L265R) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (L265R) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (L265R) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (L265R) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (L265R) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (L265R) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (L265R) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (L265R) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (L265R) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (L265R) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| PTEN | PTEN MUT (H123D) | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | PTEN MUT (H123D) | Different Mutation | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | PTEN MUT (H123D) | Different Mutation | BYL719 (PIK3CA inhibitor) | Resistant | BRCA | Case report |
| PTEN | PTEN MUT (H123D) | Complete Match | ATM inhibitor | Responsive | BRCA | Pre-clinical |
| PTEN | PTEN MUT (H123D) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA, ED, TH, CANCER, L, G, OV | Pre-clinical |
| PTEN | PTEN MUT (H123D) | Complete Match | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | PTEN MUT (H123D) | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | PTEN MUT (H123D) | Complete Match | PARP inhibitor | Responsive | ED | Case report |
| PTEN | PTEN MUT (H123D) | Complete Match | PD1 Ab inhibitor | Resistant | CM | Early trials |
| PTEN | PTEN MUT (H123D) | Complete Match | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | PTEN MUT (H123D) | Complete Match | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | PTEN MUT (H123D) | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| PTEN | PTEN MUT (H123D) | Complete Match | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | PTEN MUT (H123D) | Complete Match | AKT inhibitor | Responsive | PA | Case report |
| PTEN | PTEN MUT (H123D) | Complete Match | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | PTEN MUT (H123D) | Different Alteration | PI3K pathway inhibitor | Responsive | L, BRCA, CANCER, G, ED, TH, OV | Pre-clinical |
| PTEN | PTEN MUT (H123D) | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | PTEN MUT (H123D) | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | PTEN MUT (H123D) | Different Alteration | PARP inhibitor | Responsive | ED | Case report |
| PTEN | PTEN MUT (H123D) | Different Alteration | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | PTEN MUT (H123D) | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | PTEN MUT (H123D) | Different Alteration | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | PTEN MUT (H123D) | Different Alteration | AKT inhibitor | Responsive | PA | Case report |
| PTEN | PTEN MUT (H123D) | Different Alteration | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | PTEN MUT (H123D) | Different Alteration | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| NOTCH2 | NOTCH2 MUT* (L566F) | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| CRLF2 | CRLF2 MUT* (intron_variant) | Different Alteration | MTOR inhibitor | Responsive | ALL | Pre-clinical |
| CRLF2 | CRLF2 MUT* (intron_variant) | Different Alteration | BET inhibitor | Responsive | ALL | Pre-clinical |
| PIK3CA | PIK3CA MUT (P104L) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (P104L) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (P104L) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (P104L) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (P104L) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (P104L) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (P104L) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (P104L) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (P104L) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (P104L) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (P104L) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (P104L) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (P104L) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (P104L) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| TP53 | TP53 MUT (V157G) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (V157G) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (V157G) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (V157G) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (V157G) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (V157G) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (V157G) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (V157G) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (V157G) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (V157G) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (V157G) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (V157G) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (V157G) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (V157G) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (V157G) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| ABL1 | ABL1 MUT* (D71N) | Different Alteration | Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) | Responsive | CML, ALL | FDA guidelines |
| ABL1 | ABL1 MUT* (D71N) | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Responsive | ALL, CML | FDA guidelines |
| ABL1 | ABL1 MUT* (D71N) | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| ABL1 | ABL1 MUT* (D71N) | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | ALL, CML | FDA guidelines |
| ABL1 | ABL1 MUT* (D71N) | Different Alteration | Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) | Responsive | ALL | Pre-clinical |
| ABL1 | ABL1 MUT* (D71N) | Different Alteration | Bosutinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| TP53 | TP53 MUT (Y126N) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (Y126N) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (Y126N) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (Y126N) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (Y126N) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (Y126N) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (Y126N) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Y126N) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Y126N) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (Y126N) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (Y126N) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Y126N) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (Y126N) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (Y126N) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (Y126N) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| NTRK3 | NTRK3 MUT* (R582W) | Different Alteration | IGF1R inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK3 | NTRK3 MUT* (R582W) | Different Alteration | PI3K pathway inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK3 | NTRK3 MUT* (R582W) | Different Alteration | Midostaurin (Pan-TK inhibitor) | Responsive | BRCA | Pre-clinical |
| AKT3 | AKT3 MUT* (S474F) | Different Alteration | ATP competitive AKT inhibitor | Responsive | BRCA | Pre-clinical |
| DNMT3A | DNMT3A MUT (G890D) | Complete Match | Daunorubicin (Chemotherapy) | Responsive | AML | FDA guidelines |
| NRG1 | NRG1 MUT* (intron_variant) | Different Alteration | Lapatinib (ERBB2 inhibitor) | Responsive | LUAD | Pre-clinical |
| NRG1 | NRG1 MUT* (intron_variant) | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | LUAD | Case report |
| ATR | ATR MUT (E1922*) | Complete Match | Temozolomide (Chemotherapy) | Responsive | G | Pre-clinical |
| ATR | ATR MUT (E1922*) | Complete Match | Olaparib (PARP inhibitor) | Responsive | CANCER, OV | Pre-clinical |
| ATR | ATR MUT (E1922*) | Different Alteration | Olaparib (PARP inhibitor) | Responsive | OV, CANCER | Pre-clinical |
| TP53 | TP53 MUT (K132E) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (K132E) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (K132E) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (K132E) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (K132E) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (K132E) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (K132E) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (K132E) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (K132E) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (K132E) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (K132E) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (K132E) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (K132E) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (K132E) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (K132E) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| ERBB3 | ERBB3 MUT (V104L) | Different Mutation | PI3K pathway inhibitor;MEK inhibitor | Responsive | CANCER | Pre-clinical |
| ERBB3 | ERBB3 MUT (V104L) | Different Mutation | Lapatinib (ERBB2 inhibitor) | Responsive | CANCER | Pre-clinical |
| ERBB3 | ERBB3 MUT (V104L) | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | CANCER | Pre-clinical |
| ERBB3 | ERBB3 MUT (V104L) | Different Mutation | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BLCA | Case report |
| ERBB3 | ERBB3 MUT (V104L) | Different Mutation | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | CANCER | Pre-clinical |
| ERBB3 | ERBB3 MUT (V104L) | Different Mutation | ERBB3 mAb inhibitor | Responsive | CANCER | Pre-clinical |
| ERBB3 | ERBB3 MUT (V104L) | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Early trials |
| BRCA2 | BRCA2 MUT (splice_donor_variant) | Complete Match | PD1 Ab inhibitor | Responsive | CM | Case report |
| BRCA2 | BRCA2 MUT (splice_donor_variant) | Complete Match | Olaparib (PARP inhibitor) | Responsive | OV | FDA guidelines |
| BRCA2 | BRCA2 MUT (splice_donor_variant) | Complete Match | Platinum Agent (Chemotherapy) | Responsive | OV | Late trials |
| BRCA2 | BRCA2 MUT (splice_donor_variant) | Complete Match | Chemotherapy (PARP inhibitor;Chemotherapy) | Responsive | OV | Early trials |
| BRCA2 | BRCA2 MUT (splice_donor_variant) | Complete Match | PARP inhibitor;Chemotherapy | Responsive | OV | Early trials |
| BRCA2 | BRCA2 MUT (splice_donor_variant) | Complete Match | Platinum Agent (Chemotherapy) | Responsive | PA | Case report |
| BRCA2 | BRCA2 MUT (splice_donor_variant) | Complete Match | Olaparib (PARP inhibitor) | Responsive | PRAD | Early trials |
| BRCA2 | BRCA2 MUT (splice_donor_variant) | Complete Match | Rucaparib (PARP inhibitor) | Responsive | OV | FDA guidelines |
| BRCA2 | BRCA2 MUT (splice_donor_variant) | Complete Match | PD1/PDL1 inhibitor | Responsive | UTH | Early trials |
| BRCA2 | BRCA2 MUT (splice_donor_variant) | Complete Match | Veliparib;Cisplatin (PARP inhibitor;Chemotherapy) | Responsive | BRCA | Early trials |
| BRCA2 | BRCA2 MUT (splice_donor_variant) | Complete Match | Platinum Agent (Chemotherapy) | Responsive | BRCA | Early trials |
| BRCA2 | BRCA2 MUT (splice_donor_variant) | Complete Match | PARP inhibitor | Responsive | BRCA | Early trials |
| BRCA2 | BRCA2 MUT (splice_donor_variant) | Different Alteration | PD1/PDL1 inhibitor | Responsive | UTH | Early trials |
| BRCA2 | BRCA2 MUT (splice_donor_variant) | Different Alteration | PARP inhibitor | Responsive | OV | Pre-clinical |
| BCR | BCR MUT* (K815N) | Different Alteration | Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) | Responsive | CML, ALL | FDA guidelines |
| BCR | BCR MUT* (K815N) | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | ALL, CML | FDA guidelines |
| BCR | BCR MUT* (K815N) | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| BCR | BCR MUT* (K815N) | Different Alteration | Bosutinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| BCR | BCR MUT* (K815N) | Different Alteration | Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) | Responsive | ALL | Pre-clinical |
| BCR | BCR MUT* (K815N) | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Responsive | ALL, CML | FDA guidelines |
| JAK2 | JAK2 MUT* (Y132*) | Different Alteration | Ruxolitinib (JAK inhibitor) | Responsive | ALL | Pre-clinical |
| TP53 | TP53 MUT (Y205N) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (Y205N) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (Y205N) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (Y205N) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (Y205N) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (Y205N) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (Y205N) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Y205N) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Y205N) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (Y205N) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (Y205N) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Y205N) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (Y205N) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (Y205N) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (Y205N) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| PTEN | PTEN MUT (H93D) | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | PTEN MUT (H93D) | Different Mutation | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | PTEN MUT (H93D) | Different Mutation | BYL719 (PIK3CA inhibitor) | Resistant | BRCA | Case report |
| PTEN | PTEN MUT (H93D) | Complete Match | ATM inhibitor | Responsive | BRCA | Pre-clinical |
| PTEN | PTEN MUT (H93D) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA, ED, TH, CANCER, L, G, OV | Pre-clinical |
| PTEN | PTEN MUT (H93D) | Complete Match | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | PTEN MUT (H93D) | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | PTEN MUT (H93D) | Complete Match | PARP inhibitor | Responsive | ED | Case report |
| PTEN | PTEN MUT (H93D) | Complete Match | PD1 Ab inhibitor | Resistant | CM | Early trials |
| PTEN | PTEN MUT (H93D) | Complete Match | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | PTEN MUT (H93D) | Complete Match | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | PTEN MUT (H93D) | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| PTEN | PTEN MUT (H93D) | Complete Match | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | PTEN MUT (H93D) | Complete Match | AKT inhibitor | Responsive | PA | Case report |
| PTEN | PTEN MUT (H93D) | Complete Match | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | PTEN MUT (H93D) | Different Alteration | PI3K pathway inhibitor | Responsive | L, BRCA, CANCER, G, ED, TH, OV | Pre-clinical |
| PTEN | PTEN MUT (H93D) | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | PTEN MUT (H93D) | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | PTEN MUT (H93D) | Different Alteration | PARP inhibitor | Responsive | ED | Case report |
| PTEN | PTEN MUT (H93D) | Different Alteration | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | PTEN MUT (H93D) | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | PTEN MUT (H93D) | Different Alteration | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | PTEN MUT (H93D) | Different Alteration | AKT inhibitor | Responsive | PA | Case report |
| PTEN | PTEN MUT (H93D) | Different Alteration | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | PTEN MUT (H93D) | Different Alteration | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| RB1 | RB1 MUT (L206*) | Different Alteration | Palbociclib (CDK4/6 inhibitor) | Responsive | PRAD | Pre-clinical |
| RB1 | RB1 MUT (L206*) | Complete Match | MDM2/MDMX inhibitor | Responsive | RB | Pre-clinical |
| RB1 | RB1 MUT (L206*) | Complete Match | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| RB1 | RB1 MUT (L206*) | Complete Match | HDAC inhibitor | Responsive | RB | Pre-clinical |
| RB1 | RB1 MUT (L206*) | Different Alteration | MDM2/MDMX inhibitor | Responsive | RB | Pre-clinical |
| RB1 | RB1 MUT (L206*) | Different Alteration | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| RB1 | RB1 MUT (L206*) | Different Alteration | HDAC inhibitor | Responsive | RB | Pre-clinical |
| RET | RET MUT* (P117T) | Different Alteration | Nintedanib (Pan-TK inhibitor) | Responsive | LUAD | Case report |
| RET | RET MUT* (P117T) | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Early trials |
| RET | RET MUT* (P117T) | Different Alteration | RET inhibitor | Responsive | LUAD | Pre-clinical |
| RET | RET MUT* (P117T) | Different Alteration | Vandetanib (Pan-TK inhibitor) | Responsive | LUAD | Early trials |
| RET | RET MUT* (P117T) | Different Alteration | Sunitinib (Pan-TK inhibitor) | Responsive | LUAD | Early trials |
| RET | RET MUT* (P117T) | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | THCA | Pre-clinical |
| RET | RET MUT* (P117T) | Different Alteration | Vandetanib (Pan-TK inhibitor) | Responsive | THCA | Pre-clinical |
| RET | RET MUT* (P117T) | Different Alteration | Sunitinib (Pan-TK inhibitor) | Responsive | THCA | Pre-clinical |
| RET | RET MUT* (P117T) | Different Alteration | RET inhibitor | Responsive | TH | Pre-clinical |
| TP53 | TP53 MUT (A161T) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (A161T) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (A161T) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (A161T) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (A161T) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (A161T) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (A161T) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (A161T) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (A161T) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (A161T) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (A161T) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (A161T) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (A161T) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (A161T) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (A161T) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| NOTCH2 | NOTCH2 MUT* (S965C) | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| AKT3 | AKT3 MUT* (E84K) | Different Alteration | ATP competitive AKT inhibitor | Responsive | BRCA | Pre-clinical |
| SF3B1 | SF3B1 MUT (E622Q) | Different Mutation | Spliceosome inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (H168P) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (H168P) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (H168P) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (H168P) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (H168P) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (H168P) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (H168P) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (H168P) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (H168P) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (H168P) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (H168P) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (H168P) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (H168P) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (H168P) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (H168P) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| PIK3CA | PIK3CA MUT (M1040V) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (M1040V) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (M1040V) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (M1040V) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (M1040V) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (M1040V) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (M1040V) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (M1040V) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (M1040V) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (M1040V) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (M1040V) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (M1040V) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (M1040V) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (M1040V) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| NOTCH2 | NOTCH2 MUT* (R268S) | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| ARID1A | ARID1A MUT (splice_donor_variant) | Complete Match | EZH2 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | ARID1A MUT (splice_donor_variant) | Complete Match | PD1 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | ARID1A MUT (splice_donor_variant) | Complete Match | PARP inhibitor | Responsive | CANCER | Pre-clinical |
| ARID1A | ARID1A MUT (splice_donor_variant) | Complete Match | ATR inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (C135Y) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (C135Y) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (C135Y) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (C135Y) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (C135Y) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (C135Y) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (C135Y) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (C135Y) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (C135Y) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (C135Y) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (C135Y) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (C135Y) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (C135Y) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (C135Y) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (C135Y) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| BRD4 | BRD4 MUT* (P15L) | Different Alteration | BET inhibitor | Responsive | NMC | Case report |
| ROS1 | ROS1 MUT* (N2234K) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | IM | Case report |
| ROS1 | ROS1 MUT* (N2234K) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ROS1 | ROS1 MUT* (N2234K) | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Case report |
| ROS1 | ROS1 MUT* (N2234K) | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Pre-clinical |
| ROS1 | ROS1 MUT* (N2234K) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Early trials |
| ERBB4 | ERBB4 MUT* (F1004S) | Different Alteration | Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) | Responsive | LUAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (K111N) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (K111N) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (K111N) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (K111N) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (K111N) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (K111N) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (K111N) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (K111N) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (K111N) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (K111N) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (K111N) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (K111N) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (K111N) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (K111N) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| EPHA2 | EPHA2 MUT (CdsStopSNV) | Different Mutation | MTOR inhibitor | Responsive | LUSC | Pre-clinical |
| EPHA2 | EPHA2 MUT (CdsStopSNV) | Different Mutation | Dasatinib (BCR-ABL inhibitor) | Responsive | LUSC | Pre-clinical |
| EPHA2 | EPHA2 MUT (CdsStopSNV) | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Responsive | CANCER | Pre-clinical |
| NOTCH1 | NOTCH1 MUT* (P2399S) | Different Alteration | Gamma secretase inhibitor | Responsive | ALL | Pre-clinical |
| NOTCH1 | NOTCH1 MUT* (P2399S) | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| KMT2A | MLL MUT* (Q1195*) | Different Alteration | EPZ-5676 (DOT1L inhibitor) | Responsive | ALL, MDS, AML | Early trials |
| KMT2A | MLL MUT* (Q1195*) | Different Alteration | BET inhibitor | Responsive | ALL | Pre-clinical |
| KMT2A | MLL MUT* (Q1195*) | Different Alteration | BET inhibitor | Responsive | AML | Pre-clinical |
| KMT2A | MLL MUT* (Q1195*) | Different Alteration | Daunorubicin (Chemotherapy) | Responsive | AML | FDA guidelines |
| KMT2A | MLL MUT* (Q1195*) | Different Alteration | Belinostat (HDAC inhibitor) | Responsive | AML | Early trials |
| KMT2A | MLL MUT* (Q1195*) | Different Alteration | DOT1L inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (K132N) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (K132N) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (K132N) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (K132N) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (K132N) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (K132N) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (K132N) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (K132N) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (K132N) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (K132N) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (K132N) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (K132N) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (K132N) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (K132N) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (K132N) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| ALK | ALK MUT* (G843R) | Different Alteration | ALK inhibitor;SRC inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (G843R) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | GB, LY | Early trials |
| ALK | ALK MUT* (G843R) | Different Alteration | Lorlatinib (ALK&ROS1 inhibitor) | Responsive | NSCLC | Early trials |
| ALK | ALK MUT* (G843R) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | THCA, IM | Case report |
| ALK | ALK MUT* (G843R) | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (G843R) | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | ALK MUT* (G843R) | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | IM, COREAD | Case report |
| ALK | ALK MUT* (G843R) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | ALK MUT* (G843R) | Different Alteration | Brigatinib (Pan-TK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | ALK MUT* (G843R) | Different Alteration | Entrictinib (Pan-TK inhibitor) | Responsive | COREAD | Case report |
| ALK | ALK MUT* (G843R) | Different Alteration | Alectinib (ALK inhibitor) | Responsive | LUAD | FDA guidelines |
| ALK | ALK MUT* (G843R) | Different Alteration | HSP90 inhibitor (HSP90 inhibitor) | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (G843R) | Different Alteration | ALK inhibitor;IGF1R inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (G843R) | Different Alteration | ALK inhibitor;MEK inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (G843R) | Different Alteration | novel ALK inhibitor | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (G843R) | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | HEMATO | Early trials |
| ALK | ALK MUT* (G843R) | Different Alteration | ALK inhibitor | Responsive | COREAD | Case report |
| ALK | ALK MUT* (G843R) | Different Alteration | Alectinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | ALK MUT* (G843R) | Different Alteration | MEK inhibitor (ALK inhibitor;MEK inhibitor) | Responsive | LUAD | Pre-clinical |
| TP53 | TP53 MUT (C135W) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (C135W) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (C135W) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (C135W) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (C135W) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (C135W) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (C135W) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (C135W) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (C135W) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (C135W) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (C135W) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (C135W) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (C135W) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (C135W) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (C135W) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| BRAF | BRAF MUT* (R347L) | Different Alteration | Sorafenib (Pan-TK inhibitor) | Responsive | CM, LUAD, PRAD | Pre-clinical |
| BRAF | BRAF MUT* (R347L) | Different Alteration | MEK inhibitor | Responsive | LUAD, CM, PRAD | Pre-clinical |
| BRAF | BRAF MUT* (R347L) | Different Alteration | Selumetinib (MEK inhibitor) | Responsive | OV | Case report |
| BRAF | BRAF MUT* (R347L) | Different Alteration | BRAF inhibitor;MEK inhibitor | Responsive | LUAD | Case report |
| LRP1B | LRP1B MUT (Q400*) | Complete Match | Liposomal Doxorubicin (Chemotherapy) | Resistant | OV | Early trials |
| LRP1B | LRP1B MUT (Q400*) | Different Alteration | Liposomal Doxorubicin (Chemotherapy) | Resistant | OV | Early trials |
| PIK3CA | PIK3CA MUT (H1047R), PIK3CA MUT (V344M) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (H1047R), PIK3CA MUT (V344M) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (H1047R), PIK3CA MUT (V344M) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (H1047R), PIK3CA MUT (V344M) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (H1047R), PIK3CA MUT (V344M) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (H1047R), PIK3CA MUT (V344M) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (H1047R), PIK3CA MUT (V344M) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (H1047R), PIK3CA MUT (V344M) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (H1047R), PIK3CA MUT (V344M) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (H1047R), PIK3CA MUT (V344M) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (H1047R), PIK3CA MUT (V344M) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (H1047R), PIK3CA MUT (V344M) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (H1047R), PIK3CA MUT (V344M) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (H1047R), PIK3CA MUT (V344M) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| TP53 | TP53 MUT (A276P) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (A276P) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (A276P) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (A276P) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (A276P) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (A276P) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (A276P) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (A276P) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (A276P) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (A276P) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (A276P) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (A276P) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (A276P) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (A276P) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (A276P) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| FGFR2 | FGFR2 MUT* (V113A) | Different Alteration | FGFR inhibitor | Responsive | COREAD | Early trials |
| FGFR2 | FGFR2 MUT* (V113A) | Different Alteration | FGFR inhibitor | Responsive | BT | Early trials |
| CDH1 | CDH1 MUT (T379T) | Complete Match | Bicalutamide (AR inhibitor) | Responsive | BRCA | Pre-clinical |
| KMT2A | MLL MUT* (S1002C) | Different Alteration | EPZ-5676 (DOT1L inhibitor) | Responsive | ALL, MDS, AML | Early trials |
| KMT2A | MLL MUT* (S1002C) | Different Alteration | BET inhibitor | Responsive | ALL | Pre-clinical |
| KMT2A | MLL MUT* (S1002C) | Different Alteration | BET inhibitor | Responsive | AML | Pre-clinical |
| KMT2A | MLL MUT* (S1002C) | Different Alteration | Daunorubicin (Chemotherapy) | Responsive | AML | FDA guidelines |
| KMT2A | MLL MUT* (S1002C) | Different Alteration | Belinostat (HDAC inhibitor) | Responsive | AML | Early trials |
| KMT2A | MLL MUT* (S1002C) | Different Alteration | DOT1L inhibitor | Responsive | AML | Early trials |
| PML | PML MUT* (L726L) | Different Alteration | Volasertib (PLK1 inhibitor) | Responsive | AML | Early trials |
| PML | PML MUT* (L726L) | Different Alteration | Tretinoin (Retinoid) | Responsive | APML | FDA guidelines |
| PML | PML MUT* (L726L) | Different Alteration | Tretinoin;Arsenic Trioxide (Retinoid;Chemotherapy) | Responsive | AML | FDA guidelines |
| TP53 | TP53 MUT (V197G) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (V197G) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (V197G) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (V197G) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (V197G) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (V197G) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (V197G) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (V197G) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (V197G) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (V197G) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (V197G) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (V197G) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (V197G) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (V197G) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (V197G) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| FGFR2 | FGFR2 MUT* (H545Q) | Different Alteration | FGFR inhibitor | Responsive | COREAD | Early trials |
| FGFR2 | FGFR2 MUT* (H545Q) | Different Alteration | FGFR inhibitor | Responsive | BT | Early trials |
| ROS1 | ROS1 MUT* (V2068V) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | IM | Case report |
| ROS1 | ROS1 MUT* (V2068V) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ROS1 | ROS1 MUT* (V2068V) | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Case report |
| ROS1 | ROS1 MUT* (V2068V) | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Pre-clinical |
| ROS1 | ROS1 MUT* (V2068V) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Early trials |
| PTEN | PTEN MUT (Y46*) | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | PTEN MUT (Y46*) | Different Mutation | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | PTEN MUT (Y46*) | Different Mutation | BYL719 (PIK3CA inhibitor) | Resistant | BRCA | Case report |
| PTEN | PTEN MUT (Y46*) | Complete Match | ATM inhibitor | Responsive | BRCA | Pre-clinical |
| PTEN | PTEN MUT (Y46*) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA, ED, TH, CANCER, L, G, OV | Pre-clinical |
| PTEN | PTEN MUT (Y46*) | Complete Match | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | PTEN MUT (Y46*) | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | PTEN MUT (Y46*) | Complete Match | PARP inhibitor | Responsive | ED | Case report |
| PTEN | PTEN MUT (Y46*) | Complete Match | PD1 Ab inhibitor | Resistant | CM | Early trials |
| PTEN | PTEN MUT (Y46*) | Complete Match | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | PTEN MUT (Y46*) | Complete Match | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | PTEN MUT (Y46*) | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| PTEN | PTEN MUT (Y46*) | Complete Match | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | PTEN MUT (Y46*) | Complete Match | AKT inhibitor | Responsive | PA | Case report |
| PTEN | PTEN MUT (Y46*) | Complete Match | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | PTEN MUT (Y46*) | Different Alteration | PI3K pathway inhibitor | Responsive | L, BRCA, CANCER, G, ED, TH, OV | Pre-clinical |
| PTEN | PTEN MUT (Y46*) | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | PTEN MUT (Y46*) | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | PTEN MUT (Y46*) | Different Alteration | PARP inhibitor | Responsive | ED | Case report |
| PTEN | PTEN MUT (Y46*) | Different Alteration | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | PTEN MUT (Y46*) | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | PTEN MUT (Y46*) | Different Alteration | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | PTEN MUT (Y46*) | Different Alteration | AKT inhibitor | Responsive | PA | Case report |
| PTEN | PTEN MUT (Y46*) | Different Alteration | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | PTEN MUT (Y46*) | Different Alteration | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| PIK3CA | PIK3CA MUT (E365V), PIK3CA MUT (H1047R) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (E365V), PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (E365V), PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (E365V), PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (E365V), PIK3CA MUT (H1047R) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (E365V), PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (E365V), PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (E365V), PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (E365V), PIK3CA MUT (H1047R) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (E365V), PIK3CA MUT (H1047R) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (E365V), PIK3CA MUT (H1047R) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (E365V), PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (E365V), PIK3CA MUT (H1047R) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (E365V), PIK3CA MUT (H1047R) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| PDGFRA | PDGFRA MUT (R822H) | Different Alteration | Sunitinib (Pan-TK inhibitor) | Responsive | R | Pre-clinical |
| PDGFRA | PDGFRA MUT (R822H) | Complete Match | Sunitinib (Pan-TK inhibitor) | Responsive | GIST | NCCN guidelines |
| PDGFRA | PDGFRA MUT (R822H) | Complete Match | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | GIST | NCCN guidelines |
| PDGFRA | PDGFRA MUT (R822H) | Complete Match | Regorafenib (Pan-kinase inhibitor) | Responsive | GIST | NCCN guidelines |
| PDGFRA | PDGFRA MUT (R822H) | Different Mutation | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | CM | Pre-clinical |
| PDGFRA | PDGFRA MUT (R822H) | Different Mutation | Crenolanib (FLT3 inhibitor) | Responsive | CM | Pre-clinical |
| PDGFRA | PDGFRA MUT (R822H) | Different Mutation | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Resistant | HES | Case report |
| PDGFRA | PDGFRA MUT (R822H) | Different Mutation | Crenolanib (FLT3 inhibitor) | Responsive | GIST | Early trials |
| PDGFRA | PDGFRA MUT (R822H) | Different Mutation | HSP90 inhibitor | Responsive | GIST | Pre-clinical |
| PDGFRA | PDGFRA MUT (R822H) | Different Mutation | HSP90 inhibitor (HSP90 inhibitor) | Responsive | GIST | Pre-clinical |
| PDGFRA | PDGFRA MUT (R822H) | Different Mutation | Dasatinib (BCR-ABL inhibitor) | Responsive | GIST | Pre-clinical |
| PDGFRA | PDGFRA MUT (R822H) | Different Mutation | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Resistant | GIST | Late trials |
| PDGFRA | PDGFRA MUT (R822H) | Different Mutation | PDGFR inhibitor | Responsive | GIST | Early trials |
| PDGFRA | PDGFRA MUT (R822H) | Different Mutation | Sunitinib (Pan-TK inhibitor) | Resistant | GIST | Late trials |
| PDGFRA | PDGFRA MUT (R822H) | Different Mutation | Sorafenib (Pan-TK inhibitor) | Responsive | GIST | Early trials |
| PDGFRA | PDGFRA MUT (R822H) | Different Mutation | Sunitinib (Pan-TK inhibitor) | Responsive | GIST | Late trials |
| PDGFRA | PDGFRA MUT (R822H) | Different Alteration | PDGFR inhibitor | No Responsive | G | Pre-clinical |
| PDGFRA | PDGFRA MUT (R822H) | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | MDPS, MDS, ECL, HES | FDA guidelines |
| PIK3CA | PIK3CA MUT (Q546R), PIK3CA MUT (G1007R) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (Q546R), PIK3CA MUT (G1007R) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (Q546R), PIK3CA MUT (G1007R) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (Q546R), PIK3CA MUT (G1007R) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (Q546R), PIK3CA MUT (G1007R) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (Q546R), PIK3CA MUT (G1007R) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (Q546R), PIK3CA MUT (G1007R) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (Q546R), PIK3CA MUT (G1007R) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (Q546R), PIK3CA MUT (G1007R) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (Q546R), PIK3CA MUT (G1007R) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (Q546R), PIK3CA MUT (G1007R) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (Q546R), PIK3CA MUT (G1007R) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (Q546R), PIK3CA MUT (G1007R) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (Q546R), PIK3CA MUT (G1007R) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| TP53 | TP53 MUT (G187S) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (G187S) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (G187S) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (G187S) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (G187S) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (G187S) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (G187S) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (G187S) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (G187S) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (G187S) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (G187S) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (G187S) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (G187S) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (G187S) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (G187S) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| ATM | ATM MUT (R3047*) | Different Mutation | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| ATM | ATM MUT (R3047*) | Complete Match | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| ATM | ATM MUT (R3047*) | Complete Match | Olaparib (PARP inhibitor) | Responsive | ST, PRAD | Early trials |
| ATM | ATM MUT (R3047*) | Complete Match | PARP inhibitor | Responsive | ST | Early trials |
| ATM | ATM MUT (R3047*) | Complete Match | ATR inhibitor | Responsive | COREAD | Case report |
| ATM | ATM MUT (R3047*) | Complete Match | DNA-PKc inhibitor | Responsive | LY | Pre-clinical |
| ATM | ATM MUT (R3047*) | Complete Match | Temozolomide (Chemotherapy) | Responsive | G | Pre-clinical |
| ATM | ATM MUT (R3047*) | Complete Match | PD1/PDL1 inhibitor | Responsive | UTH | Early trials |
| ATM | ATM MUT (R3047*) | Different Alteration | PD1/PDL1 inhibitor | Responsive | UTH | Early trials |
| ATM | ATM MUT (R3047*) | Different Alteration | DNA-PKc inhibitor | Responsive | LY | Pre-clinical |
| ATM | ATM MUT (R3047*) | Different Alteration | PARP inhibitor | Responsive | ST | Early trials |
| ATM | ATM MUT (R3047*) | Different Alteration | ATR inhibitor | Responsive | COREAD | Case report |
| ATM | ATM MUT (R3047*) | Different Alteration | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| PIK3CA | PIK3CA MUT (M1043I), PIK3CA MUT (E542K) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (M1043I), PIK3CA MUT (E542K) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (M1043I), PIK3CA MUT (E542K) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (M1043I), PIK3CA MUT (E542K) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (M1043I), PIK3CA MUT (E542K) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (M1043I), PIK3CA MUT (E542K) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (M1043I), PIK3CA MUT (E542K) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (M1043I), PIK3CA MUT (E542K) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (M1043I), PIK3CA MUT (E542K) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (M1043I), PIK3CA MUT (E542K) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (M1043I), PIK3CA MUT (E542K) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (M1043I), PIK3CA MUT (E542K) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (M1043I), PIK3CA MUT (E542K) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (M1043I), PIK3CA MUT (E542K) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (M1004I), PIK3CA MUT (H1047R) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (M1004I), PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (M1004I), PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (M1004I), PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (M1004I), PIK3CA MUT (H1047R) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (M1004I), PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (M1004I), PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (M1004I), PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (M1004I), PIK3CA MUT (H1047R) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (M1004I), PIK3CA MUT (H1047R) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (M1004I), PIK3CA MUT (H1047R) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (M1004I), PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (M1004I), PIK3CA MUT (H1047R) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (M1004I), PIK3CA MUT (H1047R) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (E542G) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (E542G) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (E542G) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (E542G) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (E542G) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (E542G) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (E542G) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (E542G) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (E542G) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (E542G) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (E542G) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (E542G) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (E542G) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (E542G) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| EGFR | EGFR MUT* (A1201V) | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | L | Case report |
| EGFR | EGFR MUT* (A1201V) | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | NSCLC | Case report |
| TP53 | TP53 MUT (P151H) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (P151H) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (P151H) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (P151H) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (P151H) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (P151H) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (P151H) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (P151H) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (P151H) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (P151H) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (P151H) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (P151H) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (P151H) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (P151H) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (P151H) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| BCR | BCR MUT* (E771Q) | Different Alteration | Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) | Responsive | CML, ALL | FDA guidelines |
| BCR | BCR MUT* (E771Q) | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | ALL, CML | FDA guidelines |
| BCR | BCR MUT* (E771Q) | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| BCR | BCR MUT* (E771Q) | Different Alteration | Bosutinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| BCR | BCR MUT* (E771Q) | Different Alteration | Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) | Responsive | ALL | Pre-clinical |
| BCR | BCR MUT* (E771Q) | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Responsive | ALL, CML | FDA guidelines |
| FLCN | FLCN MUT (S333*) | Complete Match | Everolimus (MTOR inhibitor) | Responsive | R | Case report |
| FLCN | FLCN MUT (S333*) | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | TH | Case report |
| TP53 | TP53 MUT (I232S) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (I232S) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (I232S) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (I232S) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (I232S) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (I232S) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (I232S) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (I232S) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (I232S) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (I232S) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (I232S) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (I232S) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (I232S) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (I232S) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (I232S) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| FGFR2 | FGFR2 MUT* (D472Y), FGFR2 MUT* (E471D) | Different Alteration | FGFR inhibitor | Responsive | COREAD | Early trials |
| FGFR2 | FGFR2 MUT* (D472Y), FGFR2 MUT* (E471D) | Different Alteration | FGFR inhibitor | Responsive | BT | Early trials |
| TP53 | TP53 MUT (E198*) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (E198*) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (E198*) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (E198*) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (E198*) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (E198*) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (E198*) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (E198*) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (E198*) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (E198*) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (E198*) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (E198*) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (E198*) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (E198*) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (E198*) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| NF1 | NF1 MUT (Q347*) | Different Mutation | Vemurafenib (BRAF inhibitor) | Resistant | CM | Pre-clinical |
| NF1 | NF1 MUT (Q347*) | Different Mutation | Everolimus (MTOR inhibitor) | Responsive | HNC | Case report |
| NF1 | NF1 MUT (Q347*) | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (Q347*) | Complete Match | Vinblastine (Chemotherapy) | Responsive | G | Early trials |
| NF1 | NF1 MUT (Q347*) | Complete Match | KIT inhibitor;MTOR inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (Q347*) | Complete Match | Tamoxifen (Hormonal therapy) | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (Q347*) | Complete Match | Bevacizumab (VEGFR mAb inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (Q347*) | Complete Match | Retinoic Acid | Resistant | NB | Pre-clinical |
| NF1 | NF1 MUT (Q347*) | Complete Match | Everolimus (MTOR inhibitor) | Responsive | NF | Late trials |
| NF1 | NF1 MUT (Q347*) | Complete Match | Trametinib (MEK inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (Q347*) | Complete Match | Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (Q347*) | Complete Match | Nilotinib (BCR-ABL inhibitor) | Responsive | MPN, PLEN | Pre-clinical |
| NF1 | NF1 MUT (Q347*) | Complete Match | MEK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (Q347*) | Complete Match | Everolimus (MTOR inhibitor) | Responsive | HNC, SG | Case report |
| NF1 | NF1 MUT (Q347*) | Complete Match | Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) | No Responsive | MPN | Early trials |
| NF1 | NF1 MUT (Q347*) | Complete Match | PLX3397 (Pan-TK inhibitor) | Responsive | PLEN | Pre-clinical |
| NF1 | NF1 MUT (Q347*) | Complete Match | MEK inhibitor | Responsive | LK, G | Pre-clinical |
| NF1 | NF1 MUT (Q347*) | Complete Match | Pan-RAF inhibitor;MEK inhibitor | Responsive | CM | Pre-clinical |
| NF1 | NF1 MUT (Q347*) | Complete Match | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (Q347*) | Complete Match | AURK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (Q347*) | Complete Match | MTOR inhibitor | Responsive | LK, G, MPN | Pre-clinical |
| NF1 | NF1 MUT (Q347*) | Complete Match | Dasatinib (BCR-ABL inhibitor) | Resistant | L | Pre-clinical |
| NF1 | NF1 MUT (Q347*) | Complete Match | Everolimus;Pazopanib (MTOR inhibitor;VEGFR inhibitor) | Responsive | HC | Case report |
| NF1 | NF1 MUT (Q347*) | Complete Match | Everolimus (MTOR inhibitor) | No Responsive | MPN | Early trials |
| NF1 | NF1 MUT (Q347*) | Complete Match | Cediranib (ALK inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (Q347*) | Complete Match | PD1 Ab inhibitor | Responsive | CM | Early trials |
| NF1 | NF1 MUT (Q347*) | Complete Match | Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (Q347*) | Complete Match | Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (Q347*) | Complete Match | Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | No Responsive | G | Case report |
| NF1 | NF1 MUT (Q347*) | Complete Match | BRD4 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (Q347*) | Complete Match | Tipifarnib (Farnesyltransferase inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (Q347*) | Complete Match | Selumetinib (MEK inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (Q347*) | Complete Match | MTOR inhibitor;HSP90 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (Q347*) | Complete Match | Trametinib (MEK inhibitor) | Responsive | CM | Pre-clinical |
| NF1 | NF1 MUT (Q347*) | Complete Match | Erlotinib (EGFR inhibitor) | Resistant | L | Pre-clinical |
| NF1 | NF1 MUT (Q347*) | Complete Match | Trametinib (MEK inhibitor) | No Responsive | OS | Case report |
| NF1 | NF1 MUT (Q347*) | Different Alteration | MTOR inhibitor | Responsive | MPN, G, LK | Pre-clinical |
| NF1 | NF1 MUT (Q347*) | Different Alteration | PLX3397 (Pan-TK inhibitor) | Responsive | PLEN | Pre-clinical |
| NF1 | NF1 MUT (Q347*) | Different Alteration | Erlotinib (EGFR inhibitor) | Resistant | L | Pre-clinical |
| NF1 | NF1 MUT (Q347*) | Different Alteration | Trametinib (MEK inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (Q347*) | Different Alteration | BRD4 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (Q347*) | Different Alteration | Trametinib (MEK inhibitor) | No Responsive | OS | Case report |
| NF1 | NF1 MUT (Q347*) | Different Alteration | Cediranib (ALK inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (Q347*) | Different Alteration | Bevacizumab (VEGFR mAb inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (Q347*) | Different Alteration | MEK inhibitor | Responsive | G, LK | Pre-clinical |
| NF1 | NF1 MUT (Q347*) | Different Alteration | Vinblastine (Chemotherapy) | Responsive | G | Early trials |
| NF1 | NF1 MUT (Q347*) | Different Alteration | Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (Q347*) | Different Alteration | Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) | No Responsive | MPN | Early trials |
| NF1 | NF1 MUT (Q347*) | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Resistant | L | Pre-clinical |
| NF1 | NF1 MUT (Q347*) | Different Alteration | MTOR inhibitor;HSP90 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (Q347*) | Different Alteration | Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (Q347*) | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (Q347*) | Different Alteration | Tamoxifen (Hormonal therapy) | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (Q347*) | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | SG, HNC | Case report |
| NF1 | NF1 MUT (Q347*) | Different Alteration | Pan-RAF inhibitor;MEK inhibitor | Responsive | CM | Pre-clinical |
| NF1 | NF1 MUT (Q347*) | Different Alteration | Tipifarnib (Farnesyltransferase inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (Q347*) | Different Alteration | Selumetinib (MEK inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (Q347*) | Different Alteration | Retinoic Acid | Resistant | NB | Pre-clinical |
| NF1 | NF1 MUT (Q347*) | Different Alteration | Everolimus (MTOR inhibitor) | No Responsive | MPN | Early trials |
| NF1 | NF1 MUT (Q347*) | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (Q347*) | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | PLEN, MPN | Pre-clinical |
| NF1 | NF1 MUT (Q347*) | Different Alteration | Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (Q347*) | Different Alteration | Trametinib (MEK inhibitor) | Responsive | CM | Pre-clinical |
| NF1 | NF1 MUT (Q347*) | Different Alteration | AURK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (Q347*) | Different Alteration | Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | No Responsive | G | Case report |
| NF1 | NF1 MUT (Q347*) | Different Alteration | PD1 Ab inhibitor | Responsive | CM | Early trials |
| NF1 | NF1 MUT (Q347*) | Different Alteration | MEK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (Q347*) | Different Alteration | KIT inhibitor;MTOR inhibitor | Responsive | MPN | Pre-clinical |
| TP53 | TP53 MUT (R158G) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (R158G) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (R158G) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (R158G) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (R158G) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (R158G) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (R158G) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R158G) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R158G) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (R158G) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (R158G) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R158G) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (R158G) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (R158G) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (R158G) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| FGFR2 | FGFR2 MUT* (G818G) | Different Alteration | FGFR inhibitor | Responsive | COREAD | Early trials |
| FGFR2 | FGFR2 MUT* (G818G) | Different Alteration | FGFR inhibitor | Responsive | BT | Early trials |
| PIK3CA | PIK3CA MUT (P366R) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (P366R) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (P366R) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (P366R) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (P366R) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (P366R) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (P366R) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (P366R) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (P366R) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (P366R) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (P366R) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (P366R) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (P366R) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (P366R) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| TP53 | TP53 MUT (R282G) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (R282G) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (R282G) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (R282G) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (R282G) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (R282G) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (R282G) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R282G) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R282G) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (R282G) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (R282G) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R282G) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (R282G) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (R282G) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (R282G) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| KRAS | KRAS MUT (G12C) | Complete Match | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | FDA guidelines |
| KRAS | KRAS MUT (G12C) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | FDA guidelines |
| KRAS | KRAS MUT (G12C) | Different Mutation | Cetuximab (EGFR mAb inhibitor) | No Responsive | COREAD | Late trials |
| KRAS | KRAS MUT (G12C) | Complete Match | MEK inhibitor | Responsive | ALL | Pre-clinical |
| KRAS | KRAS MUT (G12C) | Complete Match | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Resistant | GIST | Case report |
| KRAS | KRAS MUT (G12C) | Complete Match | MEK inhibitor | Responsive | OV, CER, AML | Pre-clinical |
| KRAS | KRAS MUT (G12C) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Responsive | L | Early trials |
| KRAS | KRAS MUT (G12C) | Complete Match | MEK inhibitor;PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | KRAS MUT (G12C) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | NCCN guidelines |
| KRAS | KRAS MUT (G12C) | Complete Match | Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) | Responsive | HC | Early trials |
| KRAS | KRAS MUT (G12C) | Complete Match | EGFR inhibitor | Resistant | L | NCCN guidelines |
| KRAS | KRAS MUT (G12C) | Complete Match | CDK4 inhibitor | Responsive | L | Pre-clinical |
| KRAS | KRAS MUT (G12C) | Complete Match | Selumetinib (MEK inhibitor) | Responsive | NSCLC | Early trials |
| KRAS | KRAS MUT (G12C) | Complete Match | BET inhibitor | Responsive | L | Pre-clinical |
| KRAS | KRAS MUT (G12C) | Complete Match | Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) | Responsive | OV | Pre-clinical |
| KRAS | KRAS MUT (G12C) | Complete Match | FAK inhibitor | Responsive | L | Pre-clinical |
| KRAS | KRAS MUT (G12C) | Complete Match | EGFR inhibitor | Resistant | NSCLC | Pre-clinical |
| KRAS | KRAS MUT (G12C) | Complete Match | EZH2 inhibitor | Resistant | CANCER | Pre-clinical |
| KRAS | KRAS MUT (G12C) | Complete Match | MEK inhibitor | Responsive | BT, L | Early trials |
| KRAS | KRAS MUT (G12C) | Complete Match | MEK inhibitor;IGF1R inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | KRAS MUT (G12C) | Complete Match | MTOR inhibitor;BH3 mimetics | Responsive | COREAD | Pre-clinical |
| KRAS | KRAS MUT (G12C) | Complete Match | EGFR mAb inhibitor;MEK inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | KRAS MUT (G12C) | Complete Match | pan-RAF inhibitor | Responsive | ED | Case report |
| KRAS | KRAS MUT (G12C) | Complete Match | EGFR mAb inhibitor | Resistant | ST | Pre-clinical |
| KRAS | KRAS MUT (G12C) | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | L | Early trials |
| KRAS | KRAS MUT (G12C) | Complete Match | Selumetinib (MEK inhibitor) | No Responsive | L | Early trials |
| KRAS | KRAS MUT (G12C) | Complete Match | CDK4/6 inhibitor;MEK inhibitor | Responsive | L | Early trials |
| KRAS | KRAS MUT (G12C) | Complete Match | Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) | Responsive | LUAD | Pre-clinical |
| KRAS | KRAS MUT (G12C) | Complete Match | Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) | Resistant | COREAD | Late trials |
| KRAS | KRAS MUT (G12C) | Complete Match | pan-RAF inhibitor | Responsive | L | Early trials |
| KRAS | KRAS MUT (G12C) | Complete Match | JAK/TBK1/IKKε inhibitor | Responsive | L | Pre-clinical |
| KRAS | KRAS MUT (G12C) | Complete Match | FAS inhibitor | Responsive | L | Case report |
| KRAS | KRAS MUT (G12C) | Complete Match | HSP90 inhibitor | Responsive | L | Pre-clinical |
| KRAS | KRAS MUT (G12C) | Complete Match | ERK inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | KRAS MUT (G12C) | Complete Match | PI3K pathway inhibitor;MEK inhibitor | No Responsive | PA | Early trials |
| KRAS | KRAS MUT (G12C) | Complete Match | MEK inhibitor;BCL-XL inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | KRAS MUT (G12C) | Complete Match | Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) | Responsive | PA | Early trials |
| KRAS | KRAS MUT (G12C) | Complete Match | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | NCCN guidelines |
| KRAS | KRAS MUT (G12C) | Complete Match | PI3K pathway inhibitor | Resistant | ED | Pre-clinical |
| KRAS | KRAS MUT (G12C) | Complete Match | CDK4/6 inhibitor;MEK inhibitor | Responsive | CESC | Pre-clinical |
| KRAS | KRAS MUT (G12C) | Different Alteration | BRAF inhibitor;MEK inhibitor | Resistant | COREAD | Case report |
| KRAS | KRAS MUT (G12C) | Different Alteration | BRAF inhibitor;EGFR mAb inhibitor | Resistant | COREAD | Case report |
| PTEN | PTEN MUT (I135K) | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | PTEN MUT (I135K) | Different Mutation | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | PTEN MUT (I135K) | Different Mutation | BYL719 (PIK3CA inhibitor) | Resistant | BRCA | Case report |
| PTEN | PTEN MUT (I135K) | Complete Match | ATM inhibitor | Responsive | BRCA | Pre-clinical |
| PTEN | PTEN MUT (I135K) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA, ED, TH, CANCER, L, G, OV | Pre-clinical |
| PTEN | PTEN MUT (I135K) | Complete Match | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | PTEN MUT (I135K) | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | PTEN MUT (I135K) | Complete Match | PARP inhibitor | Responsive | ED | Case report |
| PTEN | PTEN MUT (I135K) | Complete Match | PD1 Ab inhibitor | Resistant | CM | Early trials |
| PTEN | PTEN MUT (I135K) | Complete Match | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | PTEN MUT (I135K) | Complete Match | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | PTEN MUT (I135K) | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| PTEN | PTEN MUT (I135K) | Complete Match | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | PTEN MUT (I135K) | Complete Match | AKT inhibitor | Responsive | PA | Case report |
| PTEN | PTEN MUT (I135K) | Complete Match | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | PTEN MUT (I135K) | Different Alteration | PI3K pathway inhibitor | Responsive | L, BRCA, CANCER, G, ED, TH, OV | Pre-clinical |
| PTEN | PTEN MUT (I135K) | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | PTEN MUT (I135K) | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | PTEN MUT (I135K) | Different Alteration | PARP inhibitor | Responsive | ED | Case report |
| PTEN | PTEN MUT (I135K) | Different Alteration | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | PTEN MUT (I135K) | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | PTEN MUT (I135K) | Different Alteration | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | PTEN MUT (I135K) | Different Alteration | AKT inhibitor | Responsive | PA | Case report |
| PTEN | PTEN MUT (I135K) | Different Alteration | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | PTEN MUT (I135K) | Different Alteration | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| TP53 | TP53 MUT (Y220H) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (Y220H) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (Y220H) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (Y220H) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (Y220H) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (Y220H) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (Y220H) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Y220H) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Y220H) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (Y220H) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (Y220H) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Y220H) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (Y220H) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (Y220H) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (Y220H) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| KMT2A | MLL MUT* (K3048T) | Different Alteration | EPZ-5676 (DOT1L inhibitor) | Responsive | ALL, MDS, AML | Early trials |
| KMT2A | MLL MUT* (K3048T) | Different Alteration | BET inhibitor | Responsive | ALL | Pre-clinical |
| KMT2A | MLL MUT* (K3048T) | Different Alteration | BET inhibitor | Responsive | AML | Pre-clinical |
| KMT2A | MLL MUT* (K3048T) | Different Alteration | Daunorubicin (Chemotherapy) | Responsive | AML | FDA guidelines |
| KMT2A | MLL MUT* (K3048T) | Different Alteration | Belinostat (HDAC inhibitor) | Responsive | AML | Early trials |
| KMT2A | MLL MUT* (K3048T) | Different Alteration | DOT1L inhibitor | Responsive | AML | Early trials |
| ERBB2 | ERBB2 MUT (I767M) | Different Alteration | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | ERBB2 MUT (I767M) | Different Alteration | Lapatinib (ERBB2 inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | ERBB2 MUT (I767M) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | ST, BRCA, GEJA | FDA guidelines |
| ERBB2 | ERBB2 MUT (I767M) | Different Alteration | Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | ERBB2 MUT (I767M) | Different Alteration | MK2206;Trastuzumab (allosteric AKT inhibitor;ERBB2 mAb inhibitor) | Responsive | SOLID | Early trials |
| ERBB2 | ERBB2 MUT (I767M) | Different Mutation | Lapatinib (ERBB2 inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (I767M) | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (I767M) | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | CANCER, BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (I767M) | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | CANCER | Early trials |
| ERBB2 | ERBB2 MUT (I767M) | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Case report |
| ERBB2 | ERBB2 MUT (I767M) | Different Mutation | Lapatinib (ERBB2 inhibitor) | Responsive | BRCA, LUAD | Case report |
| ERBB2 | ERBB2 MUT (I767M) | Different Mutation | Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) | Responsive | L | Early trials |
| ERBB2 | ERBB2 MUT (I767M) | Different Mutation | Neratinib (ERBB2 inhibitor) | Resistant | BRCA | Case report |
| ERBB2 | ERBB2 MUT (I767M) | Different Mutation | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (I767M) | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | LUAD | Case report |
| ERBB2 | ERBB2 MUT (I767M) | Different Mutation | Lapatinib (ERBB2 inhibitor) | Resistant | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (I767M) | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | CANCER | Pre-clinical |
| ERBB2 | ERBB2 MUT (I767M) | Complete Match | Temsirolimus (MTOR inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (I767M) | Complete Match | Dacomitinib (Pan ERBB inhibitor) | Responsive | NSCLC | Early trials |
| ERBB2 | ERBB2 MUT (I767M) | Complete Match | Neratinib (ERBB2 inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (I767M) | Different Mutation | ERBB2 inhibitor | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (I767M) | Different Mutation | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (I767M) | Different Mutation | ERBB2 mAb inhibitor | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (I767M) | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (I767M) | Different Mutation | Lapatinib (ERBB2 inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (I767M) | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (I767M) | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BRCA | Late trials |
| ERBB2 | ERBB2 MUT (I767M) | Different Alteration | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | BT | Early trials |
| ERBB2 | ERBB2 MUT (I767M) | Different Alteration | Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) | Responsive | COREAD | Late trials |
| ERBB2 | ERBB2 MUT (I767M) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | OV | Early trials |
| ERBB2 | ERBB2 MUT (I767M) | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BLCA | Case report |
| ERBB2 | ERBB2 MUT (I767M) | Different Alteration | Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) | Responsive | COREAD | Case report |
| ERBB2 | ERBB2 MUT (I767M) | Different Alteration | Rociletinib (EGFR inhibitor) | Resistant | LUAD | Case report |
| ERBB2 | ERBB2 MUT (I767M) | Different Alteration | Osimertinib (EGFR inhibitor) | Resistant | LUAD | Case report |
| ERBB2 | ERBB2 MUT (I767M) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | BT | Early trials |
| ERBB2 | ERBB2 MUT (I767M) | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Early trials |
| ERBB2 | ERBB2 MUT (I767M) | Different Alteration | Lapatinib (ERBB2 inhibitor) | Responsive | BT | Early trials |
| ERBB2 | ERBB2 MUT (I767M) | Different Alteration | Trastuzumab;HSP90 inhibitor (ERBB2 mAb inhibitor;HSP90 inhibitor) | Responsive | BRCA | Early trials |
| ERBB2 | ERBB2 MUT (I767M) | Different Alteration | HER2 inhibitor;CDK4/6 inhibitor | Responsive | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (I767M) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | ERBB2 MUT (I767M) | Different Alteration | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | ST | Early trials |
| ERBB2 | ERBB2 MUT (I767M) | Different Alteration | Trastuzumab;Everolimus;Chemotherapy (ERBB2 mAb inhibitor;MTOR inhibitor;Chemotherapy) | Responsive | BRCA | Early trials |
| ERBB2 | ERBB2 MUT (I767M) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | ST, GEJA | FDA guidelines |
| ERBB2 | ERBB2 MUT (I767M) | Different Alteration | ERBB2 inhibitor;CDK4/6 inhibitor | Responsive | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (I767M) | Different Alteration | Ado-Trastuzumab Emtansine (EGFR mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | ERBB2 MUT (I767M) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | HNC | Case report |
| ERBB2 | ERBB2 MUT (I767M) | Different Alteration | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Late trials |
| ERBB2 | ERBB2 MUT (I767M) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | No Responsive | ED | Early trials |
| ERBB2 | ERBB2 MUT (I767M) | Different Alteration | Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) | Responsive | ED | Pre-clinical |
| ERBB2 | ERBB2 MUT (I767M) | Different Alteration | Lapatinib;Chemotherapy (ERBB2 inhibitor;Chemotherapy) | Responsive | ST | Early trials |
| ERBB2 | ERBB2 MUT (I767M) | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | ST | Case report |
| ERBB2 | ERBB2 MUT (I767M) | Different Alteration | EGFR inhibitor | Resistant | LUAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (N345H) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (N345H) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (N345H) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (N345H) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (N345H) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (N345H) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (N345H) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (N345H) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (N345H) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (N345H) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (N345H) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (N345H) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (N345H) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (N345H) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| FGFR3 | FGFR3 MUT* (3-UTRSNV) | Different Alteration | FGFR inhibitor | Responsive | BLCA | Case report |
| FGFR3 | FGFR3 MUT* (3-UTRSNV) | Different Alteration | FGFR inhibitor | Responsive | G | Early trials |
| FGFR3 | FGFR3 MUT* (3-UTRSNV) | Different Alteration | FGFR inhibitor | Responsive | NSCLC | Pre-clinical |
| PTEN | PTEN MUT (Y88*) | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | PTEN MUT (Y88*) | Different Mutation | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | PTEN MUT (Y88*) | Different Mutation | BYL719 (PIK3CA inhibitor) | Resistant | BRCA | Case report |
| PTEN | PTEN MUT (Y88*) | Complete Match | ATM inhibitor | Responsive | BRCA | Pre-clinical |
| PTEN | PTEN MUT (Y88*) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA, ED, TH, CANCER, L, G, OV | Pre-clinical |
| PTEN | PTEN MUT (Y88*) | Complete Match | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | PTEN MUT (Y88*) | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | PTEN MUT (Y88*) | Complete Match | PARP inhibitor | Responsive | ED | Case report |
| PTEN | PTEN MUT (Y88*) | Complete Match | PD1 Ab inhibitor | Resistant | CM | Early trials |
| PTEN | PTEN MUT (Y88*) | Complete Match | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | PTEN MUT (Y88*) | Complete Match | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | PTEN MUT (Y88*) | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| PTEN | PTEN MUT (Y88*) | Complete Match | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | PTEN MUT (Y88*) | Complete Match | AKT inhibitor | Responsive | PA | Case report |
| PTEN | PTEN MUT (Y88*) | Complete Match | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | PTEN MUT (Y88*) | Different Alteration | PI3K pathway inhibitor | Responsive | L, BRCA, CANCER, G, ED, TH, OV | Pre-clinical |
| PTEN | PTEN MUT (Y88*) | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | PTEN MUT (Y88*) | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | PTEN MUT (Y88*) | Different Alteration | PARP inhibitor | Responsive | ED | Case report |
| PTEN | PTEN MUT (Y88*) | Different Alteration | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | PTEN MUT (Y88*) | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | PTEN MUT (Y88*) | Different Alteration | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | PTEN MUT (Y88*) | Different Alteration | AKT inhibitor | Responsive | PA | Case report |
| PTEN | PTEN MUT (Y88*) | Different Alteration | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | PTEN MUT (Y88*) | Different Alteration | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| PTEN | PTEN MUT (H93L) | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | PTEN MUT (H93L) | Different Mutation | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | PTEN MUT (H93L) | Different Mutation | BYL719 (PIK3CA inhibitor) | Resistant | BRCA | Case report |
| PTEN | PTEN MUT (H93L) | Complete Match | ATM inhibitor | Responsive | BRCA | Pre-clinical |
| PTEN | PTEN MUT (H93L) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA, ED, TH, CANCER, L, G, OV | Pre-clinical |
| PTEN | PTEN MUT (H93L) | Complete Match | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | PTEN MUT (H93L) | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | PTEN MUT (H93L) | Complete Match | PARP inhibitor | Responsive | ED | Case report |
| PTEN | PTEN MUT (H93L) | Complete Match | PD1 Ab inhibitor | Resistant | CM | Early trials |
| PTEN | PTEN MUT (H93L) | Complete Match | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | PTEN MUT (H93L) | Complete Match | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | PTEN MUT (H93L) | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| PTEN | PTEN MUT (H93L) | Complete Match | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | PTEN MUT (H93L) | Complete Match | AKT inhibitor | Responsive | PA | Case report |
| PTEN | PTEN MUT (H93L) | Complete Match | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | PTEN MUT (H93L) | Different Alteration | PI3K pathway inhibitor | Responsive | L, BRCA, CANCER, G, ED, TH, OV | Pre-clinical |
| PTEN | PTEN MUT (H93L) | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | PTEN MUT (H93L) | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | PTEN MUT (H93L) | Different Alteration | PARP inhibitor | Responsive | ED | Case report |
| PTEN | PTEN MUT (H93L) | Different Alteration | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | PTEN MUT (H93L) | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | PTEN MUT (H93L) | Different Alteration | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | PTEN MUT (H93L) | Different Alteration | AKT inhibitor | Responsive | PA | Case report |
| PTEN | PTEN MUT (H93L) | Different Alteration | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | PTEN MUT (H93L) | Different Alteration | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| TP53 | TP53 MUT (Q167*) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (Q167*) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (Q167*) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (Q167*) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (Q167*) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (Q167*) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (Q167*) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Q167*) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Q167*) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (Q167*) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (Q167*) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Q167*) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (Q167*) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (Q167*) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (Q167*) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (Q136E) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (Q136E) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (Q136E) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (Q136E) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (Q136E) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (Q136E) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (Q136E) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Q136E) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Q136E) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (Q136E) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (Q136E) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Q136E) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (Q136E) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (Q136E) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (Q136E) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| KMT2A | MLL MUT* (C2068Y) | Different Alteration | EPZ-5676 (DOT1L inhibitor) | Responsive | ALL, MDS, AML | Early trials |
| KMT2A | MLL MUT* (C2068Y) | Different Alteration | BET inhibitor | Responsive | ALL | Pre-clinical |
| KMT2A | MLL MUT* (C2068Y) | Different Alteration | BET inhibitor | Responsive | AML | Pre-clinical |
| KMT2A | MLL MUT* (C2068Y) | Different Alteration | Daunorubicin (Chemotherapy) | Responsive | AML | FDA guidelines |
| KMT2A | MLL MUT* (C2068Y) | Different Alteration | Belinostat (HDAC inhibitor) | Responsive | AML | Early trials |
| KMT2A | MLL MUT* (C2068Y) | Different Alteration | DOT1L inhibitor | Responsive | AML | Early trials |
| EGFR | EGFR MUT* (S198S) | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | L | Case report |
| EGFR | EGFR MUT* (S198S) | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | NSCLC | Case report |
| EGFR | EGFR MUT* (L792L) | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | L | Case report |
| EGFR | EGFR MUT* (L792L) | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | NSCLC | Case report |
| TP53 | TP53 MUT (R273H), TP53 MUT (D208G) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (R273H), TP53 MUT (D208G) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (R273H), TP53 MUT (D208G) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (R273H), TP53 MUT (D208G) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (R273H), TP53 MUT (D208G) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (R273H), TP53 MUT (D208G) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (R273H), TP53 MUT (D208G) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R273H), TP53 MUT (D208G) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R273H), TP53 MUT (D208G) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (R273H), TP53 MUT (D208G) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (R273H), TP53 MUT (D208G) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R273H), TP53 MUT (D208G) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (R273H), TP53 MUT (D208G) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (R273H), TP53 MUT (D208G) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (R273H), TP53 MUT (D208G) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| PIK3CA | PIK3CA MUT (H1047Y) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (H1047Y) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (H1047Y) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (H1047Y) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (H1047Y) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (H1047Y) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (H1047Y) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (H1047Y) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (H1047Y) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (H1047Y) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (H1047Y) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (H1047Y) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (H1047Y) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (H1047Y) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| KMT2A | MLL MUT* (V3015I) | Different Alteration | EPZ-5676 (DOT1L inhibitor) | Responsive | ALL, MDS, AML | Early trials |
| KMT2A | MLL MUT* (V3015I) | Different Alteration | BET inhibitor | Responsive | ALL | Pre-clinical |
| KMT2A | MLL MUT* (V3015I) | Different Alteration | BET inhibitor | Responsive | AML | Pre-clinical |
| KMT2A | MLL MUT* (V3015I) | Different Alteration | Daunorubicin (Chemotherapy) | Responsive | AML | FDA guidelines |
| KMT2A | MLL MUT* (V3015I) | Different Alteration | Belinostat (HDAC inhibitor) | Responsive | AML | Early trials |
| KMT2A | MLL MUT* (V3015I) | Different Alteration | DOT1L inhibitor | Responsive | AML | Early trials |
| NTRK3 | NTRK3 MUT* (A573V) | Different Alteration | IGF1R inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK3 | NTRK3 MUT* (A573V) | Different Alteration | PI3K pathway inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK3 | NTRK3 MUT* (A573V) | Different Alteration | Midostaurin (Pan-TK inhibitor) | Responsive | BRCA | Pre-clinical |
| PDGFRA | PDGFRA MUT* (D1075N) | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | MDPS, MDS, ECL, HES | FDA guidelines |
| RAF1 | RAF1 MUT* (intron_variant) | Different Alteration | Sorafenib (Pan-TK inhibitor) | Responsive | PRAD | Pre-clinical |
| RAF1 | RAF1 MUT* (intron_variant) | Different Alteration | Pan-RAF inhibitor | Responsive | PRAD | Pre-clinical |
| RAF1 | RAF1 MUT* (intron_variant) | Different Alteration | U0126 (MEK inhibitor) | Responsive | PRAD | Pre-clinical |
| TP53 | TP53 MUT (S183*) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (S183*) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (S183*) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (S183*) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (S183*) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (S183*) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (S183*) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (S183*) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (S183*) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (S183*) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (S183*) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (S183*) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (S183*) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (S183*) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (S183*) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| CDH1 | CDH1 MUT (R732Q) | Complete Match | Bicalutamide (AR inhibitor) | Responsive | BRCA | Pre-clinical |
| CDH1 | CDH1 MUT (Q195*) | Complete Match | Bicalutamide (AR inhibitor) | Responsive | BRCA | Pre-clinical |
| TP53 | TP53 MUT (H179Y) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (H179Y) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (H179Y) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (H179Y) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (H179Y) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (H179Y) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (H179Y) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (H179Y) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (H179Y) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (H179Y) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (H179Y) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (H179Y) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (H179Y) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (H179Y) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (H179Y) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| ALK | ALK MUT* (E1340V) | Different Alteration | ALK inhibitor;SRC inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (E1340V) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | GB, LY | Early trials |
| ALK | ALK MUT* (E1340V) | Different Alteration | Lorlatinib (ALK&ROS1 inhibitor) | Responsive | NSCLC | Early trials |
| ALK | ALK MUT* (E1340V) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | THCA, IM | Case report |
| ALK | ALK MUT* (E1340V) | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (E1340V) | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | ALK MUT* (E1340V) | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | IM, COREAD | Case report |
| ALK | ALK MUT* (E1340V) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | ALK MUT* (E1340V) | Different Alteration | Brigatinib (Pan-TK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | ALK MUT* (E1340V) | Different Alteration | Entrictinib (Pan-TK inhibitor) | Responsive | COREAD | Case report |
| ALK | ALK MUT* (E1340V) | Different Alteration | Alectinib (ALK inhibitor) | Responsive | LUAD | FDA guidelines |
| ALK | ALK MUT* (E1340V) | Different Alteration | HSP90 inhibitor (HSP90 inhibitor) | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (E1340V) | Different Alteration | ALK inhibitor;IGF1R inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (E1340V) | Different Alteration | ALK inhibitor;MEK inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (E1340V) | Different Alteration | novel ALK inhibitor | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (E1340V) | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | HEMATO | Early trials |
| ALK | ALK MUT* (E1340V) | Different Alteration | ALK inhibitor | Responsive | COREAD | Case report |
| ALK | ALK MUT* (E1340V) | Different Alteration | Alectinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | ALK MUT* (E1340V) | Different Alteration | MEK inhibitor (ALK inhibitor;MEK inhibitor) | Responsive | LUAD | Pre-clinical |
| TP53 | TP53 MUT (C176Y) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (C176Y) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (C176Y) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (C176Y) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (C176Y) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (C176Y) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (C176Y) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (C176Y) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (C176Y) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (C176Y) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (C176Y) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (C176Y) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (C176Y) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (C176Y) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (C176Y) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (E51*) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (E51*) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (E51*) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (E51*) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (E51*) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (E51*) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (E51*) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (E51*) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (E51*) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (E51*) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (E51*) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (E51*) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (E51*) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (E51*) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (E51*) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| EGFR | EGFR MUT* (Y900Y) | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | L | Case report |
| EGFR | EGFR MUT* (Y900Y) | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | NSCLC | Case report |
| STAG2 | STAG2 MUT (G540*) | Complete Match | PARP inhibitor | Responsive | G | Pre-clinical |
| MET | MET MUT* (Q830L) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | G | Case report |
| TP53 | TP53 MUT (I255S) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (I255S) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (I255S) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (I255S) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (I255S) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (I255S) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (I255S) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (I255S) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (I255S) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (I255S) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (I255S) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (I255S) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (I255S) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (I255S) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (I255S) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| ERBB4 | ERBB4 MUT* (intron_variant) | Different Alteration | Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) | Responsive | LUAD | Pre-clinical |
| BRAF | BRAF MUT* (E309*) | Different Alteration | Sorafenib (Pan-TK inhibitor) | Responsive | CM, LUAD, PRAD | Pre-clinical |
| BRAF | BRAF MUT* (E309*) | Different Alteration | MEK inhibitor | Responsive | LUAD, CM, PRAD | Pre-clinical |
| BRAF | BRAF MUT* (E309*) | Different Alteration | Selumetinib (MEK inhibitor) | Responsive | OV | Case report |
| BRAF | BRAF MUT* (E309*) | Different Alteration | BRAF inhibitor;MEK inhibitor | Responsive | LUAD | Case report |
| NOTCH2 | NOTCH2 MUT* (Y217F) | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| TP53 | TP53 MUT (T155P) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (T155P) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (T155P) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (T155P) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (T155P) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (T155P) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (T155P) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (T155P) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (T155P) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (T155P) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (T155P) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (T155P) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (T155P) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (T155P) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (T155P) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| PIK3CA | PIK3CA MUT (Q546K), PIK3CA MUT (H1047R) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (Q546K), PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (Q546K), PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (Q546K), PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (Q546K), PIK3CA MUT (H1047R) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (Q546K), PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (Q546K), PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (Q546K), PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (Q546K), PIK3CA MUT (H1047R) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (Q546K), PIK3CA MUT (H1047R) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (Q546K), PIK3CA MUT (H1047R) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (Q546K), PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (Q546K), PIK3CA MUT (H1047R) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (Q546K), PIK3CA MUT (H1047R) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| ARID1A | ARID1A MUT (R1335*) | Complete Match | EZH2 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | ARID1A MUT (R1335*) | Complete Match | PD1 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | ARID1A MUT (R1335*) | Complete Match | PARP inhibitor | Responsive | CANCER | Pre-clinical |
| ARID1A | ARID1A MUT (R1335*) | Complete Match | ATR inhibitor | Responsive | CANCER | Pre-clinical |
| PTEN | PTEN MUT (L146*) | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | PTEN MUT (L146*) | Different Mutation | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | PTEN MUT (L146*) | Different Mutation | BYL719 (PIK3CA inhibitor) | Resistant | BRCA | Case report |
| PTEN | PTEN MUT (L146*) | Complete Match | ATM inhibitor | Responsive | BRCA | Pre-clinical |
| PTEN | PTEN MUT (L146*) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA, ED, TH, CANCER, L, G, OV | Pre-clinical |
| PTEN | PTEN MUT (L146*) | Complete Match | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | PTEN MUT (L146*) | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | PTEN MUT (L146*) | Complete Match | PARP inhibitor | Responsive | ED | Case report |
| PTEN | PTEN MUT (L146*) | Complete Match | PD1 Ab inhibitor | Resistant | CM | Early trials |
| PTEN | PTEN MUT (L146*) | Complete Match | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | PTEN MUT (L146*) | Complete Match | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | PTEN MUT (L146*) | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| PTEN | PTEN MUT (L146*) | Complete Match | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | PTEN MUT (L146*) | Complete Match | AKT inhibitor | Responsive | PA | Case report |
| PTEN | PTEN MUT (L146*) | Complete Match | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | PTEN MUT (L146*) | Different Alteration | PI3K pathway inhibitor | Responsive | L, BRCA, CANCER, G, ED, TH, OV | Pre-clinical |
| PTEN | PTEN MUT (L146*) | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | PTEN MUT (L146*) | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | PTEN MUT (L146*) | Different Alteration | PARP inhibitor | Responsive | ED | Case report |
| PTEN | PTEN MUT (L146*) | Different Alteration | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | PTEN MUT (L146*) | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | PTEN MUT (L146*) | Different Alteration | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | PTEN MUT (L146*) | Different Alteration | AKT inhibitor | Responsive | PA | Case report |
| PTEN | PTEN MUT (L146*) | Different Alteration | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | PTEN MUT (L146*) | Different Alteration | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| ERBB2 | ERBB2 MUT (G309A) | Different Alteration | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | ERBB2 MUT (G309A) | Different Alteration | Lapatinib (ERBB2 inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | ERBB2 MUT (G309A) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | ST, BRCA, GEJA | FDA guidelines |
| ERBB2 | ERBB2 MUT (G309A) | Different Alteration | Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | ERBB2 MUT (G309A) | Different Alteration | MK2206;Trastuzumab (allosteric AKT inhibitor;ERBB2 mAb inhibitor) | Responsive | SOLID | Early trials |
| ERBB2 | ERBB2 MUT (G309A) | Complete Match | Lapatinib (ERBB2 inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (G309A) | Complete Match | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (G309A) | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | CANCER, BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (G309A) | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | CANCER | Early trials |
| ERBB2 | ERBB2 MUT (G309A) | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Case report |
| ERBB2 | ERBB2 MUT (G309A) | Different Mutation | Lapatinib (ERBB2 inhibitor) | Responsive | BRCA, LUAD | Case report |
| ERBB2 | ERBB2 MUT (G309A) | Different Mutation | Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) | Responsive | L | Early trials |
| ERBB2 | ERBB2 MUT (G309A) | Different Mutation | Neratinib (ERBB2 inhibitor) | Resistant | BRCA | Case report |
| ERBB2 | ERBB2 MUT (G309A) | Different Mutation | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (G309A) | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | LUAD | Case report |
| ERBB2 | ERBB2 MUT (G309A) | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (G309A) | Different Mutation | Lapatinib (ERBB2 inhibitor) | Resistant | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (G309A) | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | CANCER | Pre-clinical |
| ERBB2 | ERBB2 MUT (G309A) | Complete Match | Temsirolimus (MTOR inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (G309A) | Complete Match | Dacomitinib (Pan ERBB inhibitor) | Responsive | NSCLC | Early trials |
| ERBB2 | ERBB2 MUT (G309A) | Complete Match | Neratinib (ERBB2 inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (G309A) | Different Mutation | ERBB2 inhibitor | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (G309A) | Different Mutation | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (G309A) | Different Mutation | ERBB2 mAb inhibitor | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (G309A) | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (G309A) | Different Mutation | Lapatinib (ERBB2 inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (G309A) | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (G309A) | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BRCA | Late trials |
| ERBB2 | ERBB2 MUT (G309A) | Different Alteration | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | BT | Early trials |
| ERBB2 | ERBB2 MUT (G309A) | Different Alteration | Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) | Responsive | COREAD | Late trials |
| ERBB2 | ERBB2 MUT (G309A) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | OV | Early trials |
| ERBB2 | ERBB2 MUT (G309A) | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BLCA | Case report |
| ERBB2 | ERBB2 MUT (G309A) | Different Alteration | Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) | Responsive | COREAD | Case report |
| ERBB2 | ERBB2 MUT (G309A) | Different Alteration | Rociletinib (EGFR inhibitor) | Resistant | LUAD | Case report |
| ERBB2 | ERBB2 MUT (G309A) | Different Alteration | Osimertinib (EGFR inhibitor) | Resistant | LUAD | Case report |
| ERBB2 | ERBB2 MUT (G309A) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | BT | Early trials |
| ERBB2 | ERBB2 MUT (G309A) | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Early trials |
| ERBB2 | ERBB2 MUT (G309A) | Different Alteration | Lapatinib (ERBB2 inhibitor) | Responsive | BT | Early trials |
| ERBB2 | ERBB2 MUT (G309A) | Different Alteration | Trastuzumab;HSP90 inhibitor (ERBB2 mAb inhibitor;HSP90 inhibitor) | Responsive | BRCA | Early trials |
| ERBB2 | ERBB2 MUT (G309A) | Different Alteration | HER2 inhibitor;CDK4/6 inhibitor | Responsive | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (G309A) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | ERBB2 MUT (G309A) | Different Alteration | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | ST | Early trials |
| ERBB2 | ERBB2 MUT (G309A) | Different Alteration | Trastuzumab;Everolimus;Chemotherapy (ERBB2 mAb inhibitor;MTOR inhibitor;Chemotherapy) | Responsive | BRCA | Early trials |
| ERBB2 | ERBB2 MUT (G309A) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | ST, GEJA | FDA guidelines |
| ERBB2 | ERBB2 MUT (G309A) | Different Alteration | ERBB2 inhibitor;CDK4/6 inhibitor | Responsive | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (G309A) | Different Alteration | Ado-Trastuzumab Emtansine (EGFR mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | ERBB2 MUT (G309A) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | HNC | Case report |
| ERBB2 | ERBB2 MUT (G309A) | Different Alteration | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Late trials |
| ERBB2 | ERBB2 MUT (G309A) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | No Responsive | ED | Early trials |
| ERBB2 | ERBB2 MUT (G309A) | Different Alteration | Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) | Responsive | ED | Pre-clinical |
| ERBB2 | ERBB2 MUT (G309A) | Different Alteration | Lapatinib;Chemotherapy (ERBB2 inhibitor;Chemotherapy) | Responsive | ST | Early trials |
| ERBB2 | ERBB2 MUT (G309A) | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | ST | Case report |
| ERBB2 | ERBB2 MUT (G309A) | Different Alteration | EGFR inhibitor | Resistant | LUAD | Pre-clinical |
| ALK | ALK MUT* (G1125V), ALK MUT* (L1169L) | Different Alteration | ALK inhibitor;SRC inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (G1125V), ALK MUT* (L1169L) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | GB, LY | Early trials |
| ALK | ALK MUT* (G1125V), ALK MUT* (L1169L) | Different Alteration | Lorlatinib (ALK&ROS1 inhibitor) | Responsive | NSCLC | Early trials |
| ALK | ALK MUT* (G1125V), ALK MUT* (L1169L) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | THCA, IM | Case report |
| ALK | ALK MUT* (G1125V), ALK MUT* (L1169L) | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (G1125V), ALK MUT* (L1169L) | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | ALK MUT* (G1125V), ALK MUT* (L1169L) | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | IM, COREAD | Case report |
| ALK | ALK MUT* (G1125V), ALK MUT* (L1169L) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | ALK MUT* (G1125V), ALK MUT* (L1169L) | Different Alteration | Brigatinib (Pan-TK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | ALK MUT* (G1125V), ALK MUT* (L1169L) | Different Alteration | Entrictinib (Pan-TK inhibitor) | Responsive | COREAD | Case report |
| ALK | ALK MUT* (G1125V), ALK MUT* (L1169L) | Different Alteration | Alectinib (ALK inhibitor) | Responsive | LUAD | FDA guidelines |
| ALK | ALK MUT* (G1125V), ALK MUT* (L1169L) | Different Alteration | HSP90 inhibitor (HSP90 inhibitor) | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (G1125V), ALK MUT* (L1169L) | Different Alteration | ALK inhibitor;IGF1R inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (G1125V), ALK MUT* (L1169L) | Different Alteration | ALK inhibitor;MEK inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (G1125V), ALK MUT* (L1169L) | Different Alteration | novel ALK inhibitor | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (G1125V), ALK MUT* (L1169L) | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | HEMATO | Early trials |
| ALK | ALK MUT* (G1125V), ALK MUT* (L1169L) | Different Alteration | ALK inhibitor | Responsive | COREAD | Case report |
| ALK | ALK MUT* (G1125V), ALK MUT* (L1169L) | Different Alteration | Alectinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | ALK MUT* (G1125V), ALK MUT* (L1169L) | Different Alteration | MEK inhibitor (ALK inhibitor;MEK inhibitor) | Responsive | LUAD | Pre-clinical |
| BRD4 | BRD4 MUT* (K546N) | Different Alteration | BET inhibitor | Responsive | NMC | Case report |
| PIK3CA | PIK3CA MUT (D350G) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (D350G) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (D350G) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (D350G) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (D350G) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (D350G) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (D350G) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (D350G) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (D350G) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (D350G) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (D350G) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (D350G) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (D350G) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (D350G) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| MET | MET MUT* (V797M) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | G | Case report |
| ALK | ALK MUT* (Q286Q) | Different Alteration | ALK inhibitor;SRC inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (Q286Q) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | GB, LY | Early trials |
| ALK | ALK MUT* (Q286Q) | Different Alteration | Lorlatinib (ALK&ROS1 inhibitor) | Responsive | NSCLC | Early trials |
| ALK | ALK MUT* (Q286Q) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | THCA, IM | Case report |
| ALK | ALK MUT* (Q286Q) | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (Q286Q) | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | ALK MUT* (Q286Q) | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | IM, COREAD | Case report |
| ALK | ALK MUT* (Q286Q) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | ALK MUT* (Q286Q) | Different Alteration | Brigatinib (Pan-TK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | ALK MUT* (Q286Q) | Different Alteration | Entrictinib (Pan-TK inhibitor) | Responsive | COREAD | Case report |
| ALK | ALK MUT* (Q286Q) | Different Alteration | Alectinib (ALK inhibitor) | Responsive | LUAD | FDA guidelines |
| ALK | ALK MUT* (Q286Q) | Different Alteration | HSP90 inhibitor (HSP90 inhibitor) | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (Q286Q) | Different Alteration | ALK inhibitor;IGF1R inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (Q286Q) | Different Alteration | ALK inhibitor;MEK inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (Q286Q) | Different Alteration | novel ALK inhibitor | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (Q286Q) | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | HEMATO | Early trials |
| ALK | ALK MUT* (Q286Q) | Different Alteration | ALK inhibitor | Responsive | COREAD | Case report |
| ALK | ALK MUT* (Q286Q) | Different Alteration | Alectinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | ALK MUT* (Q286Q) | Different Alteration | MEK inhibitor (ALK inhibitor;MEK inhibitor) | Responsive | LUAD | Pre-clinical |
| NOTCH2 | NOTCH2 MUT (G476*) | Different Mutation | Mk-0752 (Gamma secretase inhibitor) | Responsive | ALL, AML, BRCA | Early trials |
| NOTCH2 | NOTCH2 MUT (G476*) | Different Mutation | OMP-59R5 (NOTCH2 inhibitor) | Responsive | SOLID | Early trials |
| NOTCH2 | NOTCH2 MUT* (S955N), NOTCH2 MUT (G476*) | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| BRD4 | BRD4 MUT* (T296P) | Different Alteration | BET inhibitor | Responsive | NMC | Case report |
| FBXW7 | FBXW7 MUT (Y545C) | Complete Match | Steroid | Responsive | ALL | Late trials |
| FBXW7 | FBXW7 MUT (Y545C) | Complete Match | Tubulin inhibitor | Resistant | CANCER | Pre-clinical |
| FBXW7 | FBXW7 MUT (Y545C) | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | COREAD | Pre-clinical |
| FBXW7 | FBXW7 MUT (Y545C) | Different Alteration | Tubulin inhibitor | Resistant | CANCER | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Mutation | Vemurafenib (BRAF inhibitor) | Resistant | CM | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Mutation | Everolimus (MTOR inhibitor) | Responsive | HNC | Case report |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Vinblastine (Chemotherapy) | Responsive | G | Early trials |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | KIT inhibitor;MTOR inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Tamoxifen (Hormonal therapy) | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Bevacizumab (VEGFR mAb inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Retinoic Acid | Resistant | NB | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Everolimus (MTOR inhibitor) | Responsive | NF | Late trials |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Trametinib (MEK inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Nilotinib (BCR-ABL inhibitor) | Responsive | MPN, PLEN | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | MEK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Everolimus (MTOR inhibitor) | Responsive | HNC, SG | Case report |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) | No Responsive | MPN | Early trials |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | PLX3397 (Pan-TK inhibitor) | Responsive | PLEN | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | MEK inhibitor | Responsive | LK, G | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Pan-RAF inhibitor;MEK inhibitor | Responsive | CM | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | AURK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | MTOR inhibitor | Responsive | LK, G, MPN | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Dasatinib (BCR-ABL inhibitor) | Resistant | L | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Everolimus;Pazopanib (MTOR inhibitor;VEGFR inhibitor) | Responsive | HC | Case report |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Everolimus (MTOR inhibitor) | No Responsive | MPN | Early trials |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Cediranib (ALK inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | PD1 Ab inhibitor | Responsive | CM | Early trials |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | No Responsive | G | Case report |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | BRD4 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Tipifarnib (Farnesyltransferase inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Selumetinib (MEK inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | MTOR inhibitor;HSP90 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Trametinib (MEK inhibitor) | Responsive | CM | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Erlotinib (EGFR inhibitor) | Resistant | L | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Trametinib (MEK inhibitor) | No Responsive | OS | Case report |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | MTOR inhibitor | Responsive | MPN, G, LK | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | PLX3397 (Pan-TK inhibitor) | Responsive | PLEN | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | Erlotinib (EGFR inhibitor) | Resistant | L | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | Trametinib (MEK inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | BRD4 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | Trametinib (MEK inhibitor) | No Responsive | OS | Case report |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | Cediranib (ALK inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | Bevacizumab (VEGFR mAb inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | MEK inhibitor | Responsive | G, LK | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | Vinblastine (Chemotherapy) | Responsive | G | Early trials |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) | No Responsive | MPN | Early trials |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Resistant | L | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | MTOR inhibitor;HSP90 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | Tamoxifen (Hormonal therapy) | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | SG, HNC | Case report |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | Pan-RAF inhibitor;MEK inhibitor | Responsive | CM | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | Tipifarnib (Farnesyltransferase inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | Selumetinib (MEK inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | Retinoic Acid | Resistant | NB | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | Everolimus (MTOR inhibitor) | No Responsive | MPN | Early trials |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | PLEN, MPN | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | Trametinib (MEK inhibitor) | Responsive | CM | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | AURK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | No Responsive | G | Case report |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | PD1 Ab inhibitor | Responsive | CM | Early trials |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | MEK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | KIT inhibitor;MTOR inhibitor | Responsive | MPN | Pre-clinical |
| NOTCH2 | NOTCH2 MUT* (S1110F) | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| MET | MET MUT* (I565M) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | G | Case report |
| TP53 | TP53 MUT (P278L) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (P278L) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (P278L) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (P278L) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (P278L) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (P278L) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (P278L) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (P278L) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (P278L) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (P278L) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (P278L) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (P278L) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (P278L) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (P278L) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (P278L) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (M133K) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (M133K) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (M133K) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (M133K) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (M133K) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (M133K) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (M133K) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (M133K) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (M133K) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (M133K) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (M133K) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (M133K) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (M133K) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (M133K) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (M133K) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| ERBB4 | ERBB4 MUT* (N278S) | Different Alteration | Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) | Responsive | LUAD | Pre-clinical |
| PTPRD | PTPRD MUT (Q193*) | Complete Match | IGF1R inhibitor | Responsive | S | Case report |
| KMT2A | MLL MUT* (I3288I) | Different Alteration | EPZ-5676 (DOT1L inhibitor) | Responsive | ALL, MDS, AML | Early trials |
| KMT2A | MLL MUT* (I3288I) | Different Alteration | BET inhibitor | Responsive | ALL | Pre-clinical |
| KMT2A | MLL MUT* (I3288I) | Different Alteration | BET inhibitor | Responsive | AML | Pre-clinical |
| KMT2A | MLL MUT* (I3288I) | Different Alteration | Daunorubicin (Chemotherapy) | Responsive | AML | FDA guidelines |
| KMT2A | MLL MUT* (I3288I) | Different Alteration | Belinostat (HDAC inhibitor) | Responsive | AML | Early trials |
| KMT2A | MLL MUT* (I3288I) | Different Alteration | DOT1L inhibitor | Responsive | AML | Early trials |
| NOTCH2 | NOTCH2 MUT* (H151Y) | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| ERBB4 | ERBB4 MUT* (L686F) | Different Alteration | Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (E576Q) | Different Alteration | ALK inhibitor;SRC inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (E576Q) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | GB, LY | Early trials |
| ALK | ALK MUT* (E576Q) | Different Alteration | Lorlatinib (ALK&ROS1 inhibitor) | Responsive | NSCLC | Early trials |
| ALK | ALK MUT* (E576Q) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | THCA, IM | Case report |
| ALK | ALK MUT* (E576Q) | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (E576Q) | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | ALK MUT* (E576Q) | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | IM, COREAD | Case report |
| ALK | ALK MUT* (E576Q) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | ALK MUT* (E576Q) | Different Alteration | Brigatinib (Pan-TK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | ALK MUT* (E576Q) | Different Alteration | Entrictinib (Pan-TK inhibitor) | Responsive | COREAD | Case report |
| ALK | ALK MUT* (E576Q) | Different Alteration | Alectinib (ALK inhibitor) | Responsive | LUAD | FDA guidelines |
| ALK | ALK MUT* (E576Q) | Different Alteration | HSP90 inhibitor (HSP90 inhibitor) | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (E576Q) | Different Alteration | ALK inhibitor;IGF1R inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (E576Q) | Different Alteration | ALK inhibitor;MEK inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (E576Q) | Different Alteration | novel ALK inhibitor | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (E576Q) | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | HEMATO | Early trials |
| ALK | ALK MUT* (E576Q) | Different Alteration | ALK inhibitor | Responsive | COREAD | Case report |
| ALK | ALK MUT* (E576Q) | Different Alteration | Alectinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | ALK MUT* (E576Q) | Different Alteration | MEK inhibitor (ALK inhibitor;MEK inhibitor) | Responsive | LUAD | Pre-clinical |
| SETD2 | SETD2 MUT (S815*) | Complete Match | WEE1 inhibitor | Responsive | CANCER | Pre-clinical |
| SETD2 | SETD2 MUT (S815*) | Different Alteration | WEE1 inhibitor | Responsive | CANCER | Pre-clinical |
| PDGFRA | PDGFRA MUT* (E556K) | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | MDPS, MDS, ECL, HES | FDA guidelines |
| EGFR | EGFR MUT* (D314G) | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | L | Case report |
| EGFR | EGFR MUT* (D314G) | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | NSCLC | Case report |
| ROS1 | ROS1 MUT* (S2326F) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | IM | Case report |
| ROS1 | ROS1 MUT* (S2326F) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ROS1 | ROS1 MUT* (S2326F) | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Case report |
| ROS1 | ROS1 MUT* (S2326F) | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Pre-clinical |
| ROS1 | ROS1 MUT* (S2326F) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Early trials |
| NOTCH2 | NOTCH2 MUT* (S801L) | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| PDGFRA | PDGFRA MUT* (R981P) | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | MDPS, MDS, ECL, HES | FDA guidelines |
| 0 | SMARCA4 MUT (E1611*) | Complete Match | EZH2 inhibitor | Responsive | OVRT | Case report |
| 0 | SMARCA4 MUT (E1611*) | Complete Match | AURKA inhibitor | Responsive | NSCLC | Pre-clinical |
| 0 | SMARCA4 MUT (E1611*) | Complete Match | EZH2 inhibitor | Responsive | OV | Case report |
| 0 | SMARCA4 MUT (E1611*) | Different Alteration | EZH2 inhibitor | Responsive | OVRT | Case report |
| 0 | SMARCA4 MUT (E1611*) | Different Alteration | EZH2 inhibitor | Responsive | OV | Case report |
| BRCA2 | BRCA2 MUT (L2926*) | Complete Match | PD1 Ab inhibitor | Responsive | CM | Case report |
| BRCA2 | BRCA2 MUT (L2926*) | Complete Match | Olaparib (PARP inhibitor) | Responsive | OV | FDA guidelines |
| BRCA2 | BRCA2 MUT (L2926*) | Complete Match | Platinum Agent (Chemotherapy) | Responsive | OV | Late trials |
| BRCA2 | BRCA2 MUT (L2926*) | Complete Match | Chemotherapy (PARP inhibitor;Chemotherapy) | Responsive | OV | Early trials |
| BRCA2 | BRCA2 MUT (L2926*) | Complete Match | PARP inhibitor;Chemotherapy | Responsive | OV | Early trials |
| BRCA2 | BRCA2 MUT (L2926*) | Complete Match | Platinum Agent (Chemotherapy) | Responsive | PA | Case report |
| BRCA2 | BRCA2 MUT (L2926*) | Complete Match | Olaparib (PARP inhibitor) | Responsive | PRAD | Early trials |
| BRCA2 | BRCA2 MUT (L2926*) | Complete Match | Rucaparib (PARP inhibitor) | Responsive | OV | FDA guidelines |
| BRCA2 | BRCA2 MUT (L2926*) | Complete Match | PD1/PDL1 inhibitor | Responsive | UTH | Early trials |
| BRCA2 | BRCA2 MUT (L2926*) | Complete Match | Veliparib;Cisplatin (PARP inhibitor;Chemotherapy) | Responsive | BRCA | Early trials |
| BRCA2 | BRCA2 MUT (L2926*) | Complete Match | Platinum Agent (Chemotherapy) | Responsive | BRCA | Early trials |
| BRCA2 | BRCA2 MUT (L2926*) | Complete Match | PARP inhibitor | Responsive | BRCA | Early trials |
| BRCA2 | BRCA2 MUT (L2926*) | Different Alteration | PD1/PDL1 inhibitor | Responsive | UTH | Early trials |
| BRCA2 | BRCA2 MUT (L2926*) | Different Alteration | PARP inhibitor | Responsive | OV | Pre-clinical |
| AKT3 | AKT3 MUT* (R66*) | Different Alteration | ATP competitive AKT inhibitor | Responsive | BRCA | Pre-clinical |
| ARID1A | ARID1A MUT (Q548*) | Complete Match | EZH2 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | ARID1A MUT (Q548*) | Complete Match | PD1 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | ARID1A MUT (Q548*) | Complete Match | PARP inhibitor | Responsive | CANCER | Pre-clinical |
| ARID1A | ARID1A MUT (Q548*) | Complete Match | ATR inhibitor | Responsive | CANCER | Pre-clinical |
| RET | RET MUT* (R330Q) | Different Alteration | Nintedanib (Pan-TK inhibitor) | Responsive | LUAD | Case report |
| RET | RET MUT* (R330Q) | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Early trials |
| RET | RET MUT* (R330Q) | Different Alteration | RET inhibitor | Responsive | LUAD | Pre-clinical |
| RET | RET MUT* (R330Q) | Different Alteration | Vandetanib (Pan-TK inhibitor) | Responsive | LUAD | Early trials |
| RET | RET MUT* (R330Q) | Different Alteration | Sunitinib (Pan-TK inhibitor) | Responsive | LUAD | Early trials |
| RET | RET MUT* (R330Q) | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | THCA | Pre-clinical |
| RET | RET MUT* (R330Q) | Different Alteration | Vandetanib (Pan-TK inhibitor) | Responsive | THCA | Pre-clinical |
| RET | RET MUT* (R330Q) | Different Alteration | Sunitinib (Pan-TK inhibitor) | Responsive | THCA | Pre-clinical |
| RET | RET MUT* (R330Q) | Different Alteration | RET inhibitor | Responsive | TH | Pre-clinical |
| PIK3CA | PIK3CA MUT (N345T) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (N345T) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (N345T) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (N345T) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (N345T) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (N345T) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (N345T) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (N345T) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (N345T) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (N345T) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (N345T) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (N345T) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (N345T) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (N345T) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (E453K), PIK3CA MUT (E545K) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (E453K), PIK3CA MUT (E545K) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (E453K), PIK3CA MUT (E545K) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (E453K), PIK3CA MUT (E545K) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (E453K), PIK3CA MUT (E545K) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (E453K), PIK3CA MUT (E545K) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (E453K), PIK3CA MUT (E545K) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (E453K), PIK3CA MUT (E545K) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (E453K), PIK3CA MUT (E545K) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (E453K), PIK3CA MUT (E545K) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (E453K), PIK3CA MUT (E545K) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (E453K), PIK3CA MUT (E545K) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (E453K), PIK3CA MUT (E545K) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (E453K), PIK3CA MUT (E545K) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| PDGFRA | PDGFRA MUT* (S1042S) | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | MDPS, MDS, ECL, HES | FDA guidelines |
| ATM | ATM MUT (splice_acceptor_variant) | Different Mutation | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| ATM | ATM MUT (splice_acceptor_variant) | Complete Match | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| ATM | ATM MUT (splice_acceptor_variant) | Complete Match | Olaparib (PARP inhibitor) | Responsive | ST, PRAD | Early trials |
| ATM | ATM MUT (splice_acceptor_variant) | Complete Match | PARP inhibitor | Responsive | ST | Early trials |
| ATM | ATM MUT (splice_acceptor_variant) | Complete Match | ATR inhibitor | Responsive | COREAD | Case report |
| ATM | ATM MUT (splice_acceptor_variant) | Complete Match | DNA-PKc inhibitor | Responsive | LY | Pre-clinical |
| ATM | ATM MUT (splice_acceptor_variant) | Complete Match | Temozolomide (Chemotherapy) | Responsive | G | Pre-clinical |
| ATM | ATM MUT (splice_acceptor_variant) | Complete Match | PD1/PDL1 inhibitor | Responsive | UTH | Early trials |
| ATM | ATM MUT (splice_acceptor_variant) | Different Alteration | PD1/PDL1 inhibitor | Responsive | UTH | Early trials |
| ATM | ATM MUT (splice_acceptor_variant) | Different Alteration | DNA-PKc inhibitor | Responsive | LY | Pre-clinical |
| ATM | ATM MUT (splice_acceptor_variant) | Different Alteration | PARP inhibitor | Responsive | ST | Early trials |
| ATM | ATM MUT (splice_acceptor_variant) | Different Alteration | ATR inhibitor | Responsive | COREAD | Case report |
| ATM | ATM MUT (splice_acceptor_variant) | Different Alteration | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| ABL1 | ABL1 MUT* (splice_acceptor_variant) | Different Alteration | Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) | Responsive | CML, ALL | FDA guidelines |
| ABL1 | ABL1 MUT* (splice_acceptor_variant) | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Responsive | ALL, CML | FDA guidelines |
| ABL1 | ABL1 MUT* (splice_acceptor_variant) | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| ABL1 | ABL1 MUT* (splice_acceptor_variant) | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | ALL, CML | FDA guidelines |
| ABL1 | ABL1 MUT* (splice_acceptor_variant) | Different Alteration | Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) | Responsive | ALL | Pre-clinical |
| ABL1 | ABL1 MUT* (splice_acceptor_variant) | Different Alteration | Bosutinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| RAF1 | RAF1 MUT* (R354W) | Different Alteration | Sorafenib (Pan-TK inhibitor) | Responsive | PRAD | Pre-clinical |
| RAF1 | RAF1 MUT* (R354W) | Different Alteration | Pan-RAF inhibitor | Responsive | PRAD | Pre-clinical |
| RAF1 | RAF1 MUT* (R354W) | Different Alteration | U0126 (MEK inhibitor) | Responsive | PRAD | Pre-clinical |
| NOTCH2 | NOTCH2 MUT* (C1342C) | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| CDH1 | CDH1 MUT (E512*) | Complete Match | Bicalutamide (AR inhibitor) | Responsive | BRCA | Pre-clinical |
| EGFR | EGFR MUT* (E97Q) | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | L | Case report |
| EGFR | EGFR MUT* (E97Q) | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | NSCLC | Case report |
| PLCG2 | PLCG2 MUT (S225*) | Different Mutation | Ibrutinib (BTK inhibitor) | Resistant | CLL | Early trials |
| GATA3 | GATA3 MUT (K347*) | Complete Match | Aromatase ihibitor | Responsive | BRCA | Pre-clinical |
| KMT2A | MLL MUT* (E1464*) | Different Alteration | EPZ-5676 (DOT1L inhibitor) | Responsive | ALL, MDS, AML | Early trials |
| KMT2A | MLL MUT* (E1464*) | Different Alteration | BET inhibitor | Responsive | ALL | Pre-clinical |
| KMT2A | MLL MUT* (E1464*) | Different Alteration | BET inhibitor | Responsive | AML | Pre-clinical |
| KMT2A | MLL MUT* (E1464*) | Different Alteration | Daunorubicin (Chemotherapy) | Responsive | AML | FDA guidelines |
| KMT2A | MLL MUT* (E1464*) | Different Alteration | Belinostat (HDAC inhibitor) | Responsive | AML | Early trials |
| KMT2A | MLL MUT* (E1464*) | Different Alteration | DOT1L inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (R280S) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (R280S) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (R280S) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (R280S) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (R280S) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (R280S) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (R280S) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R280S) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R280S) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (R280S) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (R280S) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R280S) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (R280S) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (R280S) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (R280S) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| BCR | BCR MUT* (I57I) | Different Alteration | Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) | Responsive | CML, ALL | FDA guidelines |
| BCR | BCR MUT* (I57I) | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | ALL, CML | FDA guidelines |
| BCR | BCR MUT* (I57I) | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| BCR | BCR MUT* (I57I) | Different Alteration | Bosutinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| BCR | BCR MUT* (I57I) | Different Alteration | Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) | Responsive | ALL | Pre-clinical |
| BCR | BCR MUT* (I57I) | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Responsive | ALL, CML | FDA guidelines |
| PTEN | PTEN MUT (D92E) | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | PTEN MUT (D92E) | Different Mutation | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | PTEN MUT (D92E) | Different Mutation | BYL719 (PIK3CA inhibitor) | Resistant | BRCA | Case report |
| PTEN | PTEN MUT (D92E) | Complete Match | ATM inhibitor | Responsive | BRCA | Pre-clinical |
| PTEN | PTEN MUT (D92E) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA, ED, TH, CANCER, L, G, OV | Pre-clinical |
| PTEN | PTEN MUT (D92E) | Complete Match | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | PTEN MUT (D92E) | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | PTEN MUT (D92E) | Complete Match | PARP inhibitor | Responsive | ED | Case report |
| PTEN | PTEN MUT (D92E) | Complete Match | PD1 Ab inhibitor | Resistant | CM | Early trials |
| PTEN | PTEN MUT (D92E) | Complete Match | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | PTEN MUT (D92E) | Complete Match | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | PTEN MUT (D92E) | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| PTEN | PTEN MUT (D92E) | Complete Match | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | PTEN MUT (D92E) | Complete Match | AKT inhibitor | Responsive | PA | Case report |
| PTEN | PTEN MUT (D92E) | Complete Match | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | PTEN MUT (D92E) | Different Alteration | PI3K pathway inhibitor | Responsive | L, BRCA, CANCER, G, ED, TH, OV | Pre-clinical |
| PTEN | PTEN MUT (D92E) | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | PTEN MUT (D92E) | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | PTEN MUT (D92E) | Different Alteration | PARP inhibitor | Responsive | ED | Case report |
| PTEN | PTEN MUT (D92E) | Different Alteration | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | PTEN MUT (D92E) | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | PTEN MUT (D92E) | Different Alteration | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | PTEN MUT (D92E) | Different Alteration | AKT inhibitor | Responsive | PA | Case report |
| PTEN | PTEN MUT (D92E) | Different Alteration | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | PTEN MUT (D92E) | Different Alteration | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| GATA3 | GATA3 MUT (W329*) | Complete Match | Aromatase ihibitor | Responsive | BRCA | Pre-clinical |
| NOTCH2 | NOTCH2 MUT* (T2159T) | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| RAF1 | RAF1 MUT* (V226D) | Different Alteration | Sorafenib (Pan-TK inhibitor) | Responsive | PRAD | Pre-clinical |
| RAF1 | RAF1 MUT* (V226D) | Different Alteration | Pan-RAF inhibitor | Responsive | PRAD | Pre-clinical |
| RAF1 | RAF1 MUT* (V226D) | Different Alteration | U0126 (MEK inhibitor) | Responsive | PRAD | Pre-clinical |
| ESR1 | ESR1 MUT* (Y246*) | Different Alteration | ESR1 inhibitor | Resistant | BRCA | Pre-clinical |
| ESR1 | ESR1 MUT* (P222S) | Different Alteration | ESR1 inhibitor | Resistant | BRCA | Pre-clinical |
| GATA3 | GATA3 MUT (K358*) | Complete Match | Aromatase ihibitor | Responsive | BRCA | Pre-clinical |
| PTEN | PTEN MUT (L140*) | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | PTEN MUT (L140*) | Different Mutation | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | PTEN MUT (L140*) | Different Mutation | BYL719 (PIK3CA inhibitor) | Resistant | BRCA | Case report |
| PTEN | PTEN MUT (L140*) | Complete Match | ATM inhibitor | Responsive | BRCA | Pre-clinical |
| PTEN | PTEN MUT (L140*) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA, ED, TH, CANCER, L, G, OV | Pre-clinical |
| PTEN | PTEN MUT (L140*) | Complete Match | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | PTEN MUT (L140*) | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | PTEN MUT (L140*) | Complete Match | PARP inhibitor | Responsive | ED | Case report |
| PTEN | PTEN MUT (L140*) | Complete Match | PD1 Ab inhibitor | Resistant | CM | Early trials |
| PTEN | PTEN MUT (L140*) | Complete Match | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | PTEN MUT (L140*) | Complete Match | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | PTEN MUT (L140*) | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| PTEN | PTEN MUT (L140*) | Complete Match | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | PTEN MUT (L140*) | Complete Match | AKT inhibitor | Responsive | PA | Case report |
| PTEN | PTEN MUT (L140*) | Complete Match | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | PTEN MUT (L140*) | Different Alteration | PI3K pathway inhibitor | Responsive | L, BRCA, CANCER, G, ED, TH, OV | Pre-clinical |
| PTEN | PTEN MUT (L140*) | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | PTEN MUT (L140*) | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | PTEN MUT (L140*) | Different Alteration | PARP inhibitor | Responsive | ED | Case report |
| PTEN | PTEN MUT (L140*) | Different Alteration | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | PTEN MUT (L140*) | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | PTEN MUT (L140*) | Different Alteration | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | PTEN MUT (L140*) | Different Alteration | AKT inhibitor | Responsive | PA | Case report |
| PTEN | PTEN MUT (L140*) | Different Alteration | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | PTEN MUT (L140*) | Different Alteration | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| KMT2A | MLL MUT* (P3059P) | Different Alteration | EPZ-5676 (DOT1L inhibitor) | Responsive | ALL, MDS, AML | Early trials |
| KMT2A | MLL MUT* (P3059P) | Different Alteration | BET inhibitor | Responsive | ALL | Pre-clinical |
| KMT2A | MLL MUT* (P3059P) | Different Alteration | BET inhibitor | Responsive | AML | Pre-clinical |
| KMT2A | MLL MUT* (P3059P) | Different Alteration | Daunorubicin (Chemotherapy) | Responsive | AML | FDA guidelines |
| KMT2A | MLL MUT* (P3059P) | Different Alteration | Belinostat (HDAC inhibitor) | Responsive | AML | Early trials |
| KMT2A | MLL MUT* (P3059P) | Different Alteration | DOT1L inhibitor | Responsive | AML | Early trials |
| EGFR | EGFR MUT* (E257K) | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | L | Case report |
| EGFR | EGFR MUT* (E257K) | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | NSCLC | Case report |
| PTEN | PTEN MUT (R130P) | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | PTEN MUT (R130P) | Different Mutation | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | PTEN MUT (R130P) | Different Mutation | BYL719 (PIK3CA inhibitor) | Resistant | BRCA | Case report |
| PTEN | PTEN MUT (R130P) | Complete Match | ATM inhibitor | Responsive | BRCA | Pre-clinical |
| PTEN | PTEN MUT (R130P) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA, ED, TH, CANCER, L, G, OV | Pre-clinical |
| PTEN | PTEN MUT (R130P) | Complete Match | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | PTEN MUT (R130P) | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | PTEN MUT (R130P) | Complete Match | PARP inhibitor | Responsive | ED | Case report |
| PTEN | PTEN MUT (R130P) | Complete Match | PD1 Ab inhibitor | Resistant | CM | Early trials |
| PTEN | PTEN MUT (R130P) | Complete Match | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | PTEN MUT (R130P) | Complete Match | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | PTEN MUT (R130P) | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| PTEN | PTEN MUT (R130P) | Complete Match | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | PTEN MUT (R130P) | Complete Match | AKT inhibitor | Responsive | PA | Case report |
| PTEN | PTEN MUT (R130P) | Complete Match | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | PTEN MUT (R130P) | Different Alteration | PI3K pathway inhibitor | Responsive | L, BRCA, CANCER, G, ED, TH, OV | Pre-clinical |
| PTEN | PTEN MUT (R130P) | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | PTEN MUT (R130P) | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | PTEN MUT (R130P) | Different Alteration | PARP inhibitor | Responsive | ED | Case report |
| PTEN | PTEN MUT (R130P) | Different Alteration | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | PTEN MUT (R130P) | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | PTEN MUT (R130P) | Different Alteration | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | PTEN MUT (R130P) | Different Alteration | AKT inhibitor | Responsive | PA | Case report |
| PTEN | PTEN MUT (R130P) | Different Alteration | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | PTEN MUT (R130P) | Different Alteration | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| ROS1 | ROS1 MUT* (G2148E) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | IM | Case report |
| ROS1 | ROS1 MUT* (G2148E) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ROS1 | ROS1 MUT* (G2148E) | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Case report |
| ROS1 | ROS1 MUT* (G2148E) | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Pre-clinical |
| ROS1 | ROS1 MUT* (G2148E) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Early trials |
| RB1 | RB1 MUT (Q93*) | Different Alteration | Palbociclib (CDK4/6 inhibitor) | Responsive | PRAD | Pre-clinical |
| RB1 | RB1 MUT (Q93*) | Complete Match | MDM2/MDMX inhibitor | Responsive | RB | Pre-clinical |
| RB1 | RB1 MUT (Q93*) | Complete Match | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| RB1 | RB1 MUT (Q93*) | Complete Match | HDAC inhibitor | Responsive | RB | Pre-clinical |
| RB1 | RB1 MUT (Q93*) | Different Alteration | MDM2/MDMX inhibitor | Responsive | RB | Pre-clinical |
| RB1 | RB1 MUT (Q93*) | Different Alteration | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| RB1 | RB1 MUT (Q93*) | Different Alteration | HDAC inhibitor | Responsive | RB | Pre-clinical |
| TP53 | TP53 MUT (R280T) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (R280T) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (R280T) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (R280T) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (R280T) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (R280T) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (R280T) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R280T) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R280T) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (R280T) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (R280T) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R280T) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (R280T) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (R280T) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (R280T) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (L252P) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (L252P) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (L252P) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (L252P) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (L252P) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (L252P) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (L252P) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (L252P) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (L252P) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (L252P) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (L252P) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (L252P) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (L252P) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (L252P) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (L252P) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| ESR1 | ESR1 MUT (E380Q) | Different Mutation | Fulvestrant (Hormonal therapy) | Resistant | BRCA | Pre-clinical |
| ESR1 | ESR1 MUT (E380Q) | Complete Match | novel ER degrader | Responsive | BRCA | Case report |
| ESR1 | ESR1 MUT (E380Q) | Complete Match | Tamoxifen (Hormonal therapy) | Resistant | BRCA | Early trials |
| ESR1 | ESR1 MUT (E380Q) | Complete Match | Exemestane (Hormonal therapy) | Resistant | BRCA | Late trials |
| ESR1 | ESR1 MUT (E380Q) | Complete Match | Fluvestrant (Hormonal therapy) | Responsive | BRCA | Late trials |
| ESR1 | ESR1 MUT (E380Q) | Different Alteration | ESR1 inhibitor | Resistant | BRCA | Pre-clinical |
| ALK | ALK MUT* (D525N) | Different Alteration | ALK inhibitor;SRC inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (D525N) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | GB, LY | Early trials |
| ALK | ALK MUT* (D525N) | Different Alteration | Lorlatinib (ALK&ROS1 inhibitor) | Responsive | NSCLC | Early trials |
| ALK | ALK MUT* (D525N) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | THCA, IM | Case report |
| ALK | ALK MUT* (D525N) | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (D525N) | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | ALK MUT* (D525N) | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | IM, COREAD | Case report |
| ALK | ALK MUT* (D525N) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | ALK MUT* (D525N) | Different Alteration | Brigatinib (Pan-TK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | ALK MUT* (D525N) | Different Alteration | Entrictinib (Pan-TK inhibitor) | Responsive | COREAD | Case report |
| ALK | ALK MUT* (D525N) | Different Alteration | Alectinib (ALK inhibitor) | Responsive | LUAD | FDA guidelines |
| ALK | ALK MUT* (D525N) | Different Alteration | HSP90 inhibitor (HSP90 inhibitor) | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (D525N) | Different Alteration | ALK inhibitor;IGF1R inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (D525N) | Different Alteration | ALK inhibitor;MEK inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (D525N) | Different Alteration | novel ALK inhibitor | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (D525N) | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | HEMATO | Early trials |
| ALK | ALK MUT* (D525N) | Different Alteration | ALK inhibitor | Responsive | COREAD | Case report |
| ALK | ALK MUT* (D525N) | Different Alteration | Alectinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | ALK MUT* (D525N) | Different Alteration | MEK inhibitor (ALK inhibitor;MEK inhibitor) | Responsive | LUAD | Pre-clinical |
| RAF1 | RAF1 MUT* (Q253*) | Different Alteration | Sorafenib (Pan-TK inhibitor) | Responsive | PRAD | Pre-clinical |
| RAF1 | RAF1 MUT* (Q253*) | Different Alteration | Pan-RAF inhibitor | Responsive | PRAD | Pre-clinical |
| RAF1 | RAF1 MUT* (Q253*) | Different Alteration | U0126 (MEK inhibitor) | Responsive | PRAD | Pre-clinical |
| PDGFB | PDGFB MUT* (R216C) | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | DFS | FDA guidelines |
| ARID1A | ARID1A MUT (E1726*) | Complete Match | EZH2 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | ARID1A MUT (E1726*) | Complete Match | PD1 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | ARID1A MUT (E1726*) | Complete Match | PARP inhibitor | Responsive | CANCER | Pre-clinical |
| ARID1A | ARID1A MUT (E1726*) | Complete Match | ATR inhibitor | Responsive | CANCER | Pre-clinical |
| NOTCH2 | NOTCH2 MUT* (R1604S) | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| JAK2 | JAK2 MUT* (R115I) | Different Alteration | Ruxolitinib (JAK inhibitor) | Responsive | ALL | Pre-clinical |
| TP53 | TP53 MUT (F270S) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (F270S) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (F270S) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (F270S) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (F270S) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (F270S) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (F270S) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (F270S) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (F270S) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (F270S) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (F270S) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (F270S) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (F270S) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (F270S) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (F270S) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| MET | MET MUT* (R412G) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | G | Case report |
| NTRK3 | NTRK3 MUT* (splice_donor_variant) | Different Alteration | IGF1R inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK3 | NTRK3 MUT* (splice_donor_variant) | Different Alteration | PI3K pathway inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK3 | NTRK3 MUT* (splice_donor_variant) | Different Alteration | Midostaurin (Pan-TK inhibitor) | Responsive | BRCA | Pre-clinical |
| BRCA1 | BRCA1 MUT (E272*) | Complete Match | Chemotherapy (PARP inhibitor;Chemotherapy) | Responsive | OV | Early trials |
| BRCA1 | BRCA1 MUT (E272*) | Complete Match | PARP inhibitor | Responsive | BRCA | Early trials |
| BRCA1 | BRCA1 MUT (E272*) | Complete Match | PARP inhibitor;Chemotherapy | Responsive | OV | Early trials |
| BRCA1 | BRCA1 MUT (E272*) | Complete Match | Rucaparib (PARP inhibitor) | Responsive | OV | FDA guidelines |
| BRCA1 | BRCA1 MUT (E272*) | Complete Match | Platinum Agent (Chemotherapy) | Responsive | BRCA | Early trials |
| BRCA1 | BRCA1 MUT (E272*) | Complete Match | WEE1 inhibitor | Responsive | CANCER | Case report |
| BRCA1 | BRCA1 MUT (E272*) | Complete Match | Platinum Agent (Chemotherapy) | Responsive | OV | Late trials |
| BRCA1 | BRCA1 MUT (E272*) | Complete Match | Olaparib (PARP inhibitor) | Responsive | PRAD | Early trials |
| BRCA1 | BRCA1 MUT (E272*) | Complete Match | Veliparib;Cisplatin (PARP inhibitor;Chemotherapy) | Responsive | BRCA | Early trials |
| BRCA1 | BRCA1 MUT (E272*) | Complete Match | PARP inhibitor | Responsive | PA | Case report |
| BRCA1 | BRCA1 MUT (E272*) | Complete Match | Olaparib (PARP inhibitor) | Responsive | OV | FDA guidelines |
| BRCA1 | BRCA1 MUT (E272*) | Different Alteration | PARP inhibitor | Responsive | OV | Pre-clinical |
| ROS1 | ROS1 MUT* (splice_donor_variant) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | IM | Case report |
| ROS1 | ROS1 MUT* (splice_donor_variant) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ROS1 | ROS1 MUT* (splice_donor_variant) | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Case report |
| ROS1 | ROS1 MUT* (splice_donor_variant) | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Pre-clinical |
| ROS1 | ROS1 MUT* (splice_donor_variant) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Early trials |
| MET | MET MUT* (G225D) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | G | Case report |
| NTRK3 | NTRK3 MUT* (T369N) | Different Alteration | IGF1R inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK3 | NTRK3 MUT* (T369N) | Different Alteration | PI3K pathway inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK3 | NTRK3 MUT* (T369N) | Different Alteration | Midostaurin (Pan-TK inhibitor) | Responsive | BRCA | Pre-clinical |
| TP53 | TP53 MUT (R342P) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (R342P) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (R342P) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (R342P) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (R342P) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (R342P) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (R342P) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R342P) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R342P) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (R342P) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (R342P) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R342P) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (R342P) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (R342P) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (R342P) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| BRAF | BRAF MUT* (E433K) | Different Alteration | Sorafenib (Pan-TK inhibitor) | Responsive | CM, LUAD, PRAD | Pre-clinical |
| BRAF | BRAF MUT* (E433K) | Different Alteration | MEK inhibitor | Responsive | LUAD, CM, PRAD | Pre-clinical |
| BRAF | BRAF MUT* (E433K) | Different Alteration | Selumetinib (MEK inhibitor) | Responsive | OV | Case report |
| BRAF | BRAF MUT* (E433K) | Different Alteration | BRAF inhibitor;MEK inhibitor | Responsive | LUAD | Case report |
| MET | MET MUT* (Y390Y) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | G | Case report |
| ERBB2 | ERBB2 MUT (V842I) | Different Alteration | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | ERBB2 MUT (V842I) | Different Alteration | Lapatinib (ERBB2 inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | ERBB2 MUT (V842I) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | ST, BRCA, GEJA | FDA guidelines |
| ERBB2 | ERBB2 MUT (V842I) | Different Alteration | Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | ERBB2 MUT (V842I) | Different Alteration | MK2206;Trastuzumab (allosteric AKT inhibitor;ERBB2 mAb inhibitor) | Responsive | SOLID | Early trials |
| ERBB2 | ERBB2 MUT (V842I) | Complete Match | Lapatinib (ERBB2 inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (V842I) | Complete Match | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (V842I) | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | CANCER, BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (V842I) | Complete Match | Neratinib (ERBB2 inhibitor) | Responsive | CANCER | Early trials |
| ERBB2 | ERBB2 MUT (V842I) | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | CANCER | Early trials |
| ERBB2 | ERBB2 MUT (V842I) | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Case report |
| ERBB2 | ERBB2 MUT (V842I) | Different Mutation | Lapatinib (ERBB2 inhibitor) | Responsive | BRCA, LUAD | Case report |
| ERBB2 | ERBB2 MUT (V842I) | Different Mutation | Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) | Responsive | L | Early trials |
| ERBB2 | ERBB2 MUT (V842I) | Different Mutation | Neratinib (ERBB2 inhibitor) | Resistant | BRCA | Case report |
| ERBB2 | ERBB2 MUT (V842I) | Different Mutation | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (V842I) | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | LUAD | Case report |
| ERBB2 | ERBB2 MUT (V842I) | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (V842I) | Different Mutation | Lapatinib (ERBB2 inhibitor) | Resistant | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (V842I) | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | CANCER | Pre-clinical |
| ERBB2 | ERBB2 MUT (V842I) | Complete Match | Temsirolimus (MTOR inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (V842I) | Complete Match | Dacomitinib (Pan ERBB inhibitor) | Responsive | NSCLC | Early trials |
| ERBB2 | ERBB2 MUT (V842I) | Complete Match | Neratinib (ERBB2 inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (V842I) | Different Mutation | ERBB2 inhibitor | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (V842I) | Different Mutation | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (V842I) | Different Mutation | ERBB2 mAb inhibitor | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (V842I) | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (V842I) | Different Mutation | Lapatinib (ERBB2 inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (V842I) | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | ERBB2 MUT (V842I) | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BRCA | Late trials |
| ERBB2 | ERBB2 MUT (V842I) | Different Alteration | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | BT | Early trials |
| ERBB2 | ERBB2 MUT (V842I) | Different Alteration | Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) | Responsive | COREAD | Late trials |
| ERBB2 | ERBB2 MUT (V842I) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | OV | Early trials |
| ERBB2 | ERBB2 MUT (V842I) | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BLCA | Case report |
| ERBB2 | ERBB2 MUT (V842I) | Different Alteration | Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) | Responsive | COREAD | Case report |
| ERBB2 | ERBB2 MUT (V842I) | Different Alteration | Rociletinib (EGFR inhibitor) | Resistant | LUAD | Case report |
| ERBB2 | ERBB2 MUT (V842I) | Different Alteration | Osimertinib (EGFR inhibitor) | Resistant | LUAD | Case report |
| ERBB2 | ERBB2 MUT (V842I) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | BT | Early trials |
| ERBB2 | ERBB2 MUT (V842I) | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Early trials |
| ERBB2 | ERBB2 MUT (V842I) | Different Alteration | Lapatinib (ERBB2 inhibitor) | Responsive | BT | Early trials |
| ERBB2 | ERBB2 MUT (V842I) | Different Alteration | Trastuzumab;HSP90 inhibitor (ERBB2 mAb inhibitor;HSP90 inhibitor) | Responsive | BRCA | Early trials |
| ERBB2 | ERBB2 MUT (V842I) | Different Alteration | HER2 inhibitor;CDK4/6 inhibitor | Responsive | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (V842I) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | ERBB2 MUT (V842I) | Different Alteration | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | ST | Early trials |
| ERBB2 | ERBB2 MUT (V842I) | Different Alteration | Trastuzumab;Everolimus;Chemotherapy (ERBB2 mAb inhibitor;MTOR inhibitor;Chemotherapy) | Responsive | BRCA | Early trials |
| ERBB2 | ERBB2 MUT (V842I) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | ST, GEJA | FDA guidelines |
| ERBB2 | ERBB2 MUT (V842I) | Different Alteration | ERBB2 inhibitor;CDK4/6 inhibitor | Responsive | BRCA | Pre-clinical |
| ERBB2 | ERBB2 MUT (V842I) | Different Alteration | Ado-Trastuzumab Emtansine (EGFR mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | ERBB2 MUT (V842I) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | HNC | Case report |
| ERBB2 | ERBB2 MUT (V842I) | Different Alteration | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Late trials |
| ERBB2 | ERBB2 MUT (V842I) | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | No Responsive | ED | Early trials |
| ERBB2 | ERBB2 MUT (V842I) | Different Alteration | Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) | Responsive | ED | Pre-clinical |
| ERBB2 | ERBB2 MUT (V842I) | Different Alteration | Lapatinib;Chemotherapy (ERBB2 inhibitor;Chemotherapy) | Responsive | ST | Early trials |
| ERBB2 | ERBB2 MUT (V842I) | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | ST | Case report |
| ERBB2 | ERBB2 MUT (V842I) | Different Alteration | EGFR inhibitor | Resistant | LUAD | Pre-clinical |
| ERBB4 | ERBB4 MUT* (P172R) | Different Alteration | Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (E296K) | Different Alteration | ALK inhibitor;SRC inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (E296K) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | GB, LY | Early trials |
| ALK | ALK MUT* (E296K) | Different Alteration | Lorlatinib (ALK&ROS1 inhibitor) | Responsive | NSCLC | Early trials |
| ALK | ALK MUT* (E296K) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | THCA, IM | Case report |
| ALK | ALK MUT* (E296K) | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (E296K) | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | ALK MUT* (E296K) | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | IM, COREAD | Case report |
| ALK | ALK MUT* (E296K) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | ALK MUT* (E296K) | Different Alteration | Brigatinib (Pan-TK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | ALK MUT* (E296K) | Different Alteration | Entrictinib (Pan-TK inhibitor) | Responsive | COREAD | Case report |
| ALK | ALK MUT* (E296K) | Different Alteration | Alectinib (ALK inhibitor) | Responsive | LUAD | FDA guidelines |
| ALK | ALK MUT* (E296K) | Different Alteration | HSP90 inhibitor (HSP90 inhibitor) | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (E296K) | Different Alteration | ALK inhibitor;IGF1R inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (E296K) | Different Alteration | ALK inhibitor;MEK inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (E296K) | Different Alteration | novel ALK inhibitor | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (E296K) | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | HEMATO | Early trials |
| ALK | ALK MUT* (E296K) | Different Alteration | ALK inhibitor | Responsive | COREAD | Case report |
| ALK | ALK MUT* (E296K) | Different Alteration | Alectinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | ALK MUT* (E296K) | Different Alteration | MEK inhibitor (ALK inhibitor;MEK inhibitor) | Responsive | LUAD | Pre-clinical |
| ROS1 | ROS1 MUT* (splice_acceptor_variant) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | IM | Case report |
| ROS1 | ROS1 MUT* (splice_acceptor_variant) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ROS1 | ROS1 MUT* (splice_acceptor_variant) | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Case report |
| ROS1 | ROS1 MUT* (splice_acceptor_variant) | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Pre-clinical |
| ROS1 | ROS1 MUT* (splice_acceptor_variant) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Early trials |
| CDH1 | CDH1 MUT (Q129*) | Complete Match | Bicalutamide (AR inhibitor) | Responsive | BRCA | Pre-clinical |
| PTEN | PTEN MUT (Q149*) | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | PTEN MUT (Q149*) | Different Mutation | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | PTEN MUT (Q149*) | Different Mutation | BYL719 (PIK3CA inhibitor) | Resistant | BRCA | Case report |
| PTEN | PTEN MUT (Q149*) | Complete Match | ATM inhibitor | Responsive | BRCA | Pre-clinical |
| PTEN | PTEN MUT (Q149*) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA, ED, TH, CANCER, L, G, OV | Pre-clinical |
| PTEN | PTEN MUT (Q149*) | Complete Match | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | PTEN MUT (Q149*) | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | PTEN MUT (Q149*) | Complete Match | PARP inhibitor | Responsive | ED | Case report |
| PTEN | PTEN MUT (Q149*) | Complete Match | PD1 Ab inhibitor | Resistant | CM | Early trials |
| PTEN | PTEN MUT (Q149*) | Complete Match | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | PTEN MUT (Q149*) | Complete Match | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | PTEN MUT (Q149*) | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| PTEN | PTEN MUT (Q149*) | Complete Match | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | PTEN MUT (Q149*) | Complete Match | AKT inhibitor | Responsive | PA | Case report |
| PTEN | PTEN MUT (Q149*) | Complete Match | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | PTEN MUT (Q149*) | Different Alteration | PI3K pathway inhibitor | Responsive | L, BRCA, CANCER, G, ED, TH, OV | Pre-clinical |
| PTEN | PTEN MUT (Q149*) | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | PTEN MUT (Q149*) | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | PTEN MUT (Q149*) | Different Alteration | PARP inhibitor | Responsive | ED | Case report |
| PTEN | PTEN MUT (Q149*) | Different Alteration | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | PTEN MUT (Q149*) | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | PTEN MUT (Q149*) | Different Alteration | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | PTEN MUT (Q149*) | Different Alteration | AKT inhibitor | Responsive | PA | Case report |
| PTEN | PTEN MUT (Q149*) | Different Alteration | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | PTEN MUT (Q149*) | Different Alteration | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| TP53 | TP53 MUT (S127Y) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (S127Y) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (S127Y) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (S127Y) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (S127Y) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (S127Y) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (S127Y) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (S127Y) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (S127Y) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (S127Y) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (S127Y) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (S127Y) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (S127Y) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (S127Y) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (S127Y) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| ROS1 | ROS1 MUT* (A313E) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | IM | Case report |
| ROS1 | ROS1 MUT* (A313E) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ROS1 | ROS1 MUT* (A313E) | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Case report |
| ROS1 | ROS1 MUT* (A313E) | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Pre-clinical |
| ROS1 | ROS1 MUT* (A313E) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Early trials |
| HRAS | HRAS MUT (G12C) | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | CER | Pre-clinical |
| HRAS | HRAS MUT (G12C) | Complete Match | MEK inhibitor +/- MTOR inhibitor | Responsive | AML | Pre-clinical |
| HRAS | HRAS MUT (G12C) | Complete Match | MTOR inhibitor | Responsive | CESC | Pre-clinical |
| HRAS | HRAS MUT (G12C) | Complete Match | Tipifarnib (Farnesyltransferase inhibitor) | Responsive | CANCER | Early trials |
| PTEN | PTEN MUT (Y76*) | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | PTEN MUT (Y76*) | Different Mutation | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | PTEN MUT (Y76*) | Different Mutation | BYL719 (PIK3CA inhibitor) | Resistant | BRCA | Case report |
| PTEN | PTEN MUT (Y76*) | Complete Match | ATM inhibitor | Responsive | BRCA | Pre-clinical |
| PTEN | PTEN MUT (Y76*) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA, ED, TH, CANCER, L, G, OV | Pre-clinical |
| PTEN | PTEN MUT (Y76*) | Complete Match | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | PTEN MUT (Y76*) | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | PTEN MUT (Y76*) | Complete Match | PARP inhibitor | Responsive | ED | Case report |
| PTEN | PTEN MUT (Y76*) | Complete Match | PD1 Ab inhibitor | Resistant | CM | Early trials |
| PTEN | PTEN MUT (Y76*) | Complete Match | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | PTEN MUT (Y76*) | Complete Match | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | PTEN MUT (Y76*) | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| PTEN | PTEN MUT (Y76*) | Complete Match | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | PTEN MUT (Y76*) | Complete Match | AKT inhibitor | Responsive | PA | Case report |
| PTEN | PTEN MUT (Y76*) | Complete Match | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | PTEN MUT (Y76*) | Different Alteration | PI3K pathway inhibitor | Responsive | L, BRCA, CANCER, G, ED, TH, OV | Pre-clinical |
| PTEN | PTEN MUT (Y76*) | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | PTEN MUT (Y76*) | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | PTEN MUT (Y76*) | Different Alteration | PARP inhibitor | Responsive | ED | Case report |
| PTEN | PTEN MUT (Y76*) | Different Alteration | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | PTEN MUT (Y76*) | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | PTEN MUT (Y76*) | Different Alteration | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | PTEN MUT (Y76*) | Different Alteration | AKT inhibitor | Responsive | PA | Case report |
| PTEN | PTEN MUT (Y76*) | Different Alteration | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | PTEN MUT (Y76*) | Different Alteration | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| IDH1 | IDH1 MUT (R132H) | Complete Match | Venetoclax (BCL2 inhibitor) | Responsive | AML | Early trials |
| IDH1 | IDH1 MUT (R132H) | Complete Match | IDH1 inhibitor | Responsive | AML | Early trials |
| IDH1 | IDH1 MUT (R132H) | Complete Match | AG-120 (IDH1 inhibitor) | Responsive | G | Early trials |
| IDH1 | IDH1 MUT (R132H) | Complete Match | Dasatinib (BCR-ABL inhibitor) | Responsive | CH | Early trials |
| IDH1 | IDH1 MUT (R132H) | Complete Match | Ivosidenib (IDH1 inhibitor) | Responsive | AML | Early trials |
| IDH1 | IDH1 MUT (R132H) | Complete Match | BCL2 inhibitor | Responsive | AML | Pre-clinical |
| IDH1 | IDH1 MUT (R132H) | Complete Match | BCL2 inhibitor (BCL2 inhibitor) | Responsive | AML | Pre-clinical |
| IDH1 | IDH1 MUT (R132H) | Complete Match | Dasatinib (BCR-ABL inhibitor) | Responsive | BT | Pre-clinical |
| IDH1 | IDH1 MUT (R132H) | Complete Match | PARP inhibitor | Responsive | CANCER | Pre-clinical |
| BRCA1 | BRCA1 MUT (E1329*) | Complete Match | Chemotherapy (PARP inhibitor;Chemotherapy) | Responsive | OV | Early trials |
| BRCA1 | BRCA1 MUT (E1329*) | Complete Match | PARP inhibitor | Responsive | BRCA | Early trials |
| BRCA1 | BRCA1 MUT (E1329*) | Complete Match | PARP inhibitor;Chemotherapy | Responsive | OV | Early trials |
| BRCA1 | BRCA1 MUT (E1329*) | Complete Match | Rucaparib (PARP inhibitor) | Responsive | OV | FDA guidelines |
| BRCA1 | BRCA1 MUT (E1329*) | Complete Match | Platinum Agent (Chemotherapy) | Responsive | BRCA | Early trials |
| BRCA1 | BRCA1 MUT (E1329*) | Complete Match | WEE1 inhibitor | Responsive | CANCER | Case report |
| BRCA1 | BRCA1 MUT (E1329*) | Complete Match | Platinum Agent (Chemotherapy) | Responsive | OV | Late trials |
| BRCA1 | BRCA1 MUT (E1329*) | Complete Match | Olaparib (PARP inhibitor) | Responsive | PRAD | Early trials |
| BRCA1 | BRCA1 MUT (E1329*) | Complete Match | Veliparib;Cisplatin (PARP inhibitor;Chemotherapy) | Responsive | BRCA | Early trials |
| BRCA1 | BRCA1 MUT (E1329*) | Complete Match | PARP inhibitor | Responsive | PA | Case report |
| BRCA1 | BRCA1 MUT (E1329*) | Complete Match | Olaparib (PARP inhibitor) | Responsive | OV | FDA guidelines |
| BRCA1 | BRCA1 MUT (E1329*) | Different Alteration | PARP inhibitor | Responsive | OV | Pre-clinical |
| TP53 | TP53 MUT (L257R) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (L257R) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (L257R) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (L257R) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (L257R) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (L257R) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (L257R) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (L257R) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (L257R) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (L257R) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (L257R) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (L257R) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (L257R) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (L257R) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (L257R) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (V157D) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (V157D) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (V157D) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (V157D) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (V157D) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (V157D) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (V157D) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (V157D) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (V157D) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (V157D) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (V157D) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (V157D) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (V157D) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (V157D) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (V157D) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (C275Y) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (C275Y) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (C275Y) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (C275Y) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (C275Y) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (C275Y) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (C275Y) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (C275Y) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (C275Y) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (C275Y) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (C275Y) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (C275Y) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (C275Y) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (C275Y) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (C275Y) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| MET | MET MUT* (A932A) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | G | Case report |
| PIK3CA | PIK3CA MUT (G106R) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (G106R) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (G106R) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (G106R) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (G106R) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (G106R) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (G106R) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (G106R) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (G106R) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (G106R) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (G106R) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (G106R) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (G106R) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (G106R) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| BRCA2 | BRCA2 MUT (Y3308*) | Complete Match | PD1 Ab inhibitor | Responsive | CM | Case report |
| BRCA2 | BRCA2 MUT (Y3308*) | Complete Match | Olaparib (PARP inhibitor) | Responsive | OV | FDA guidelines |
| BRCA2 | BRCA2 MUT (Y3308*) | Complete Match | Platinum Agent (Chemotherapy) | Responsive | OV | Late trials |
| BRCA2 | BRCA2 MUT (Y3308*) | Complete Match | Chemotherapy (PARP inhibitor;Chemotherapy) | Responsive | OV | Early trials |
| BRCA2 | BRCA2 MUT (Y3308*) | Complete Match | PARP inhibitor;Chemotherapy | Responsive | OV | Early trials |
| BRCA2 | BRCA2 MUT (Y3308*) | Complete Match | Platinum Agent (Chemotherapy) | Responsive | PA | Case report |
| BRCA2 | BRCA2 MUT (Y3308*) | Complete Match | Olaparib (PARP inhibitor) | Responsive | PRAD | Early trials |
| BRCA2 | BRCA2 MUT (Y3308*) | Complete Match | Rucaparib (PARP inhibitor) | Responsive | OV | FDA guidelines |
| BRCA2 | BRCA2 MUT (Y3308*) | Complete Match | PD1/PDL1 inhibitor | Responsive | UTH | Early trials |
| BRCA2 | BRCA2 MUT (Y3308*) | Complete Match | Veliparib;Cisplatin (PARP inhibitor;Chemotherapy) | Responsive | BRCA | Early trials |
| BRCA2 | BRCA2 MUT (Y3308*) | Complete Match | Platinum Agent (Chemotherapy) | Responsive | BRCA | Early trials |
| BRCA2 | BRCA2 MUT (Y3308*) | Complete Match | PARP inhibitor | Responsive | BRCA | Early trials |
| BRCA2 | BRCA2 MUT (Y3308*) | Different Alteration | PD1/PDL1 inhibitor | Responsive | UTH | Early trials |
| BRCA2 | BRCA2 MUT (Y3308*) | Different Alteration | PARP inhibitor | Responsive | OV | Pre-clinical |
| ERBB4 | ERBB4 MUT* (G500E) | Different Alteration | Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) | Responsive | LUAD | Pre-clinical |
| TP53 | TP53 MUT (C176*) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (C176*) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (C176*) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (C176*) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (C176*) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (C176*) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (C176*) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (C176*) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (C176*) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (C176*) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (C176*) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (C176*) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (C176*) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (C176*) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (C176*) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| BRAF | BRAF MUT* (L537S) | Different Alteration | Sorafenib (Pan-TK inhibitor) | Responsive | CM, LUAD, PRAD | Pre-clinical |
| BRAF | BRAF MUT* (L537S) | Different Alteration | MEK inhibitor | Responsive | LUAD, CM, PRAD | Pre-clinical |
| BRAF | BRAF MUT* (L537S) | Different Alteration | Selumetinib (MEK inhibitor) | Responsive | OV | Case report |
| BRAF | BRAF MUT* (L537S) | Different Alteration | BRAF inhibitor;MEK inhibitor | Responsive | LUAD | Case report |
| MET | MET MUT* (D414N) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | G | Case report |
| PIK3CA | PIK3CA MUT (E726K), PIK3CA MUT (E545K) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (E726K), PIK3CA MUT (E545K) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (E726K), PIK3CA MUT (E545K) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (E726K), PIK3CA MUT (E545K) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (E726K), PIK3CA MUT (E545K) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (E726K), PIK3CA MUT (E545K) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (E726K), PIK3CA MUT (E545K) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (E726K), PIK3CA MUT (E545K) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (E726K), PIK3CA MUT (E545K) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (E726K), PIK3CA MUT (E545K) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (E726K), PIK3CA MUT (E545K) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (E726K), PIK3CA MUT (E545K) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (E726K), PIK3CA MUT (E545K) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (E726K), PIK3CA MUT (E545K) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| PDGFRA | PDGFRA MUT* (3-UTRSNV) | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | MDPS, MDS, ECL, HES | FDA guidelines |
| CRLF2 | CRLF2 MUT* (S245F) | Different Alteration | MTOR inhibitor | Responsive | ALL | Pre-clinical |
| CRLF2 | CRLF2 MUT* (S245F) | Different Alteration | BET inhibitor | Responsive | ALL | Pre-clinical |
| ESR1 | ESR1 MUT* (Q17H) | Different Alteration | ESR1 inhibitor | Resistant | BRCA | Pre-clinical |
| JAK2 | JAK2 MUT* (R133P) | Different Alteration | Ruxolitinib (JAK inhibitor) | Responsive | ALL | Pre-clinical |
| BRAF | BRAF MUT* (S112C) | Different Alteration | Sorafenib (Pan-TK inhibitor) | Responsive | CM, LUAD, PRAD | Pre-clinical |
| BRAF | BRAF MUT* (S112C) | Different Alteration | MEK inhibitor | Responsive | LUAD, CM, PRAD | Pre-clinical |
| BRAF | BRAF MUT* (S112C) | Different Alteration | Selumetinib (MEK inhibitor) | Responsive | OV | Case report |
| BRAF | BRAF MUT* (S112C) | Different Alteration | BRAF inhibitor;MEK inhibitor | Responsive | LUAD | Case report |
| AKT3 | AKT3 MUT* (L151F) | Different Alteration | ATP competitive AKT inhibitor | Responsive | BRCA | Pre-clinical |
| ARID1A | ARID1A MUT (Q393*) | Complete Match | EZH2 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | ARID1A MUT (Q393*) | Complete Match | PD1 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | ARID1A MUT (Q393*) | Complete Match | PARP inhibitor | Responsive | CANCER | Pre-clinical |
| ARID1A | ARID1A MUT (Q393*) | Complete Match | ATR inhibitor | Responsive | CANCER | Pre-clinical |
| SETD2 | SETD2 MUT (S461*) | Complete Match | WEE1 inhibitor | Responsive | CANCER | Pre-clinical |
| SETD2 | SETD2 MUT (S461*) | Different Alteration | WEE1 inhibitor | Responsive | CANCER | Pre-clinical |
| PIK3CA | PIK3CA MUT (E542K), PIK3CA MUT (R88Q) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (E542K), PIK3CA MUT (R88Q) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (E542K), PIK3CA MUT (R88Q) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (E542K), PIK3CA MUT (R88Q) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (E542K), PIK3CA MUT (R88Q) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (E542K), PIK3CA MUT (R88Q) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (E542K), PIK3CA MUT (R88Q) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (E542K), PIK3CA MUT (R88Q) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (E542K), PIK3CA MUT (R88Q) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (E542K), PIK3CA MUT (R88Q) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (E542K), PIK3CA MUT (R88Q) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (E542K), PIK3CA MUT (R88Q) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (E542K), PIK3CA MUT (R88Q) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (E542K), PIK3CA MUT (R88Q) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| ERCC4 | ERCC4 MUT (R8*) | Complete Match | Cisplatin (Chemotherapy) | Responsive | OV | Pre-clinical |
| NF1 | NF1 MUT (Q535*) | Different Mutation | Vemurafenib (BRAF inhibitor) | Resistant | CM | Pre-clinical |
| NF1 | NF1 MUT (Q535*) | Different Mutation | Everolimus (MTOR inhibitor) | Responsive | HNC | Case report |
| NF1 | NF1 MUT (Q535*) | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (Q535*) | Complete Match | Vinblastine (Chemotherapy) | Responsive | G | Early trials |
| NF1 | NF1 MUT (Q535*) | Complete Match | KIT inhibitor;MTOR inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (Q535*) | Complete Match | Tamoxifen (Hormonal therapy) | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (Q535*) | Complete Match | Bevacizumab (VEGFR mAb inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (Q535*) | Complete Match | Retinoic Acid | Resistant | NB | Pre-clinical |
| NF1 | NF1 MUT (Q535*) | Complete Match | Everolimus (MTOR inhibitor) | Responsive | NF | Late trials |
| NF1 | NF1 MUT (Q535*) | Complete Match | Trametinib (MEK inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (Q535*) | Complete Match | Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (Q535*) | Complete Match | Nilotinib (BCR-ABL inhibitor) | Responsive | MPN, PLEN | Pre-clinical |
| NF1 | NF1 MUT (Q535*) | Complete Match | MEK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (Q535*) | Complete Match | Everolimus (MTOR inhibitor) | Responsive | HNC, SG | Case report |
| NF1 | NF1 MUT (Q535*) | Complete Match | Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) | No Responsive | MPN | Early trials |
| NF1 | NF1 MUT (Q535*) | Complete Match | PLX3397 (Pan-TK inhibitor) | Responsive | PLEN | Pre-clinical |
| NF1 | NF1 MUT (Q535*) | Complete Match | MEK inhibitor | Responsive | LK, G | Pre-clinical |
| NF1 | NF1 MUT (Q535*) | Complete Match | Pan-RAF inhibitor;MEK inhibitor | Responsive | CM | Pre-clinical |
| NF1 | NF1 MUT (Q535*) | Complete Match | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (Q535*) | Complete Match | AURK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (Q535*) | Complete Match | MTOR inhibitor | Responsive | LK, G, MPN | Pre-clinical |
| NF1 | NF1 MUT (Q535*) | Complete Match | Dasatinib (BCR-ABL inhibitor) | Resistant | L | Pre-clinical |
| NF1 | NF1 MUT (Q535*) | Complete Match | Everolimus;Pazopanib (MTOR inhibitor;VEGFR inhibitor) | Responsive | HC | Case report |
| NF1 | NF1 MUT (Q535*) | Complete Match | Everolimus (MTOR inhibitor) | No Responsive | MPN | Early trials |
| NF1 | NF1 MUT (Q535*) | Complete Match | Cediranib (ALK inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (Q535*) | Complete Match | PD1 Ab inhibitor | Responsive | CM | Early trials |
| NF1 | NF1 MUT (Q535*) | Complete Match | Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (Q535*) | Complete Match | Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (Q535*) | Complete Match | Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | No Responsive | G | Case report |
| NF1 | NF1 MUT (Q535*) | Complete Match | BRD4 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (Q535*) | Complete Match | Tipifarnib (Farnesyltransferase inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (Q535*) | Complete Match | Selumetinib (MEK inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (Q535*) | Complete Match | MTOR inhibitor;HSP90 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (Q535*) | Complete Match | Trametinib (MEK inhibitor) | Responsive | CM | Pre-clinical |
| NF1 | NF1 MUT (Q535*) | Complete Match | Erlotinib (EGFR inhibitor) | Resistant | L | Pre-clinical |
| NF1 | NF1 MUT (Q535*) | Complete Match | Trametinib (MEK inhibitor) | No Responsive | OS | Case report |
| NF1 | NF1 MUT (Q535*) | Different Alteration | MTOR inhibitor | Responsive | MPN, G, LK | Pre-clinical |
| NF1 | NF1 MUT (Q535*) | Different Alteration | PLX3397 (Pan-TK inhibitor) | Responsive | PLEN | Pre-clinical |
| NF1 | NF1 MUT (Q535*) | Different Alteration | Erlotinib (EGFR inhibitor) | Resistant | L | Pre-clinical |
| NF1 | NF1 MUT (Q535*) | Different Alteration | Trametinib (MEK inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (Q535*) | Different Alteration | BRD4 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (Q535*) | Different Alteration | Trametinib (MEK inhibitor) | No Responsive | OS | Case report |
| NF1 | NF1 MUT (Q535*) | Different Alteration | Cediranib (ALK inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (Q535*) | Different Alteration | Bevacizumab (VEGFR mAb inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (Q535*) | Different Alteration | MEK inhibitor | Responsive | G, LK | Pre-clinical |
| NF1 | NF1 MUT (Q535*) | Different Alteration | Vinblastine (Chemotherapy) | Responsive | G | Early trials |
| NF1 | NF1 MUT (Q535*) | Different Alteration | Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (Q535*) | Different Alteration | Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) | No Responsive | MPN | Early trials |
| NF1 | NF1 MUT (Q535*) | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Resistant | L | Pre-clinical |
| NF1 | NF1 MUT (Q535*) | Different Alteration | MTOR inhibitor;HSP90 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (Q535*) | Different Alteration | Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (Q535*) | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (Q535*) | Different Alteration | Tamoxifen (Hormonal therapy) | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (Q535*) | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | SG, HNC | Case report |
| NF1 | NF1 MUT (Q535*) | Different Alteration | Pan-RAF inhibitor;MEK inhibitor | Responsive | CM | Pre-clinical |
| NF1 | NF1 MUT (Q535*) | Different Alteration | Tipifarnib (Farnesyltransferase inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (Q535*) | Different Alteration | Selumetinib (MEK inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (Q535*) | Different Alteration | Retinoic Acid | Resistant | NB | Pre-clinical |
| NF1 | NF1 MUT (Q535*) | Different Alteration | Everolimus (MTOR inhibitor) | No Responsive | MPN | Early trials |
| NF1 | NF1 MUT (Q535*) | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (Q535*) | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | PLEN, MPN | Pre-clinical |
| NF1 | NF1 MUT (Q535*) | Different Alteration | Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (Q535*) | Different Alteration | Trametinib (MEK inhibitor) | Responsive | CM | Pre-clinical |
| NF1 | NF1 MUT (Q535*) | Different Alteration | AURK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (Q535*) | Different Alteration | Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | No Responsive | G | Case report |
| NF1 | NF1 MUT (Q535*) | Different Alteration | PD1 Ab inhibitor | Responsive | CM | Early trials |
| NF1 | NF1 MUT (Q535*) | Different Alteration | MEK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (Q535*) | Different Alteration | KIT inhibitor;MTOR inhibitor | Responsive | MPN | Pre-clinical |
| ARID1A | ARID1A MUT (Q944*) | Complete Match | EZH2 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | ARID1A MUT (Q944*) | Complete Match | PD1 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | ARID1A MUT (Q944*) | Complete Match | PARP inhibitor | Responsive | CANCER | Pre-clinical |
| ARID1A | ARID1A MUT (Q944*) | Complete Match | ATR inhibitor | Responsive | CANCER | Pre-clinical |
| CDH1 | CDH1 MUT (Q647*) | Complete Match | Bicalutamide (AR inhibitor) | Responsive | BRCA | Pre-clinical |
| TP53 | TP53 MUT (P278S) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (P278S) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (P278S) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (P278S) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (P278S) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (P278S) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (P278S) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (P278S) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (P278S) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (P278S) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (P278S) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (P278S) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (P278S) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (P278S) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (P278S) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| RB1 | RB1 MUT (Q383*) | Different Alteration | Palbociclib (CDK4/6 inhibitor) | Responsive | PRAD | Pre-clinical |
| RB1 | RB1 MUT (Q383*) | Complete Match | MDM2/MDMX inhibitor | Responsive | RB | Pre-clinical |
| RB1 | RB1 MUT (Q383*) | Complete Match | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| RB1 | RB1 MUT (Q383*) | Complete Match | HDAC inhibitor | Responsive | RB | Pre-clinical |
| RB1 | RB1 MUT (Q383*) | Different Alteration | MDM2/MDMX inhibitor | Responsive | RB | Pre-clinical |
| RB1 | RB1 MUT (Q383*) | Different Alteration | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| RB1 | RB1 MUT (Q383*) | Different Alteration | HDAC inhibitor | Responsive | RB | Pre-clinical |
| KMT2D | MLL2 MUT (W1491*) | Complete Match | Bicalutamide (AR inhibitor) | Responsive | LUSC | Pre-clinical |
| PIK3CA | PIK3CA MUT (E542K), PIK3CA MUT (M1004I) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (E542K), PIK3CA MUT (M1004I) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (E542K), PIK3CA MUT (M1004I) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (E542K), PIK3CA MUT (M1004I) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (E542K), PIK3CA MUT (M1004I) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (E542K), PIK3CA MUT (M1004I) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (E542K), PIK3CA MUT (M1004I) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (E542K), PIK3CA MUT (M1004I) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (E542K), PIK3CA MUT (M1004I) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (E542K), PIK3CA MUT (M1004I) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (E542K), PIK3CA MUT (M1004I) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (E542K), PIK3CA MUT (M1004I) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (E542K), PIK3CA MUT (M1004I) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (E542K), PIK3CA MUT (M1004I) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| FGFR2 | FGFR2 MUT* (V122M) | Different Alteration | FGFR inhibitor | Responsive | COREAD | Early trials |
| FGFR2 | FGFR2 MUT* (V122M) | Different Alteration | FGFR inhibitor | Responsive | BT | Early trials |
| PTPRD | PTPRD MUT (L1535*) | Complete Match | IGF1R inhibitor | Responsive | S | Case report |
| CHEK2 | CHEK2 MUT (Q69*) | Complete Match | Olaparib (PARP inhibitor) | Responsive | PRAD | Early trials |
| CHEK2 | CHEK2 MUT (Q69*) | Different Alteration | Olaparib (PARP inhibitor) | Responsive | PRAD | Early trials |
| BCOR | BCOR MUT (S3*) | Complete Match | Enzastaurin (PKCb inhibitor) | Responsive | ST | Pre-clinical |
| ARID1A | ARID1A MUT (splice_acceptor_variant) | Complete Match | EZH2 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | ARID1A MUT (splice_acceptor_variant) | Complete Match | PD1 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | ARID1A MUT (splice_acceptor_variant) | Complete Match | PARP inhibitor | Responsive | CANCER | Pre-clinical |
| ARID1A | ARID1A MUT (splice_acceptor_variant) | Complete Match | ATR inhibitor | Responsive | CANCER | Pre-clinical |
| KMT2A | MLL MUT* (3-UTRSNV) | Different Alteration | EPZ-5676 (DOT1L inhibitor) | Responsive | ALL, MDS, AML | Early trials |
| KMT2A | MLL MUT* (3-UTRSNV) | Different Alteration | BET inhibitor | Responsive | ALL | Pre-clinical |
| KMT2A | MLL MUT* (3-UTRSNV) | Different Alteration | BET inhibitor | Responsive | AML | Pre-clinical |
| KMT2A | MLL MUT* (3-UTRSNV) | Different Alteration | Daunorubicin (Chemotherapy) | Responsive | AML | FDA guidelines |
| KMT2A | MLL MUT* (3-UTRSNV) | Different Alteration | Belinostat (HDAC inhibitor) | Responsive | AML | Early trials |
| KMT2A | MLL MUT* (3-UTRSNV) | Different Alteration | DOT1L inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (Q136P) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (Q136P) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (Q136P) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (Q136P) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (Q136P) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (Q136P) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (Q136P) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Q136P) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Q136P) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (Q136P) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (Q136P) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Q136P) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (Q136P) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (Q136P) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (Q136P) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| EGFR | EGFR MUT (A289V) | Different Alteration | Cetuximab (EGFR mAb inhibitor) | Responsive | COREAD | FDA guidelines |
| EGFR | EGFR MUT (A289V) | Different Alteration | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | FDA guidelines |
| EGFR | EGFR MUT (A289V) | Different Mutation | Rindopepimut (Vaccine) | Responsive | GB | Late trials |
| EGFR | EGFR MUT (A289V) | Different Mutation | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | NSCLC | FDA guidelines |
| EGFR | EGFR MUT (A289V) | Different Mutation | Gefitinib (EGFR inhibitor) | Responsive | NSCLC | FDA guidelines |
| EGFR | EGFR MUT (A289V) | Different Mutation | HSP90 inhibitor | Responsive | L | Early trials |
| EGFR | EGFR MUT (A289V) | Different Mutation | Afatinib;Cetuximab (ERBB2 & EGFR inhibitor;EGFR mAb inhibitor) | Responsive | L | Early trials |
| EGFR | EGFR MUT (A289V) | Different Mutation | MEK inhibitor | Responsive | L | Pre-clinical |
| EGFR | EGFR MUT (A289V) | Different Mutation | EGFR TK inhibitor | Responsive | L | Late trials |
| EGFR | EGFR MUT (A289V) | Different Mutation | Erlotinib (EGFR inhibitor) | Responsive | NSCLC | NCCN guidelines |
| EGFR | EGFR MUT (A289V) | Different Mutation | Osimertinib (EGFR inhibitor) | Resistant | L | Early trials |
| EGFR | EGFR MUT (A289V) | Different Mutation | EGFR-TKI's (EGFR inhibitor) | Resistant | L | Late trials |
| EGFR | EGFR MUT (A289V) | Different Mutation | HSP90 inhibitor | Responsive | L | Case report |
| EGFR | EGFR MUT (A289V) | Different Mutation | EGFR inhibitor | Resistant | L | Late trials |
| EGFR | EGFR MUT (A289V) | Different Mutation | Poziotinib (EGFR inhibitor) | Responsive | L | Early trials |
| EGFR | EGFR MUT (A289V) | Different Mutation | Osimertinib (EGFR inhibitor) | Responsive | L | Pre-clinical |
| EGFR | EGFR MUT (A289V) | Different Mutation | HSP90 inhibitor (HSP90 inhibitor) | Responsive | L | Early trials |
| EGFR | EGFR MUT (A289V) | Complete Match | Erlotinib (EGFR inhibitor) | Responsive | G | Pre-clinical |
| EGFR | EGFR MUT (A289V) | Different Mutation | Erlotinib (EGFR inhibitor) | Responsive | NSCLC | FDA guidelines |
| EGFR | EGFR MUT (A289V) | Different Mutation | Osimertinib (EGFR inhibitor) | Responsive | L | Early trials |
| EGFR | EGFR MUT (A289V) | Different Mutation | Rociletinib (EGFR inhibitor) | Resistant | LUAD | Case report |
| EGFR | EGFR MUT (A289V) | Different Mutation | Panitumumab (EGFR mAb inhibitor) | Responsive | COREAD | Case report |
| EGFR | EGFR MUT (A289V) | Different Mutation | novel EGFR mAb inhibitor | Responsive | COREAD | Early trials |
| EGFR | EGFR MUT (A289V) | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| EGFR | EGFR MUT (A289V) | Different Mutation | Cetuximab;Sirolimus (EGFR mAb inhibitor;MTOR inhibitor) | Responsive | HNC | Case report |
| EGFR | EGFR MUT (A289V) | Different Mutation | Erlotinib (EGFR inhibitor) | Responsive | L | Case report |
| EGFR | EGFR MUT (A289V) | Different Mutation | Gefitinib (EGFR inhibitor) | No Responsive | HNC | Case report |
| EGFR | EGFR MUT (A289V) | Different Mutation | EGFR inhibitor | Responsive | L | Early trials |
| EGFR | EGFR MUT (A289V) | Different Mutation | Erlotinib (EGFR inhibitor) | Resistant | L | NCCN/CAP guidelines |
| EGFR | EGFR MUT (A289V) | Different Mutation | Osimertinib (EGFR inhibitor) | Responsive | NSCLC | FDA guidelines |
| EGFR | EGFR MUT (A289V) | Different Mutation | EGFR inhibitor | Responsive | NSCLC | Late trials |
| EGFR | EGFR MUT (A289V) | Different Mutation | Afatinib;Nimotuzumab (ERBB2 & EGFR inhibitor;EGFR mAb inhibitor) | Responsive | L | Early trials |
| EGFR | EGFR MUT (A289V) | Different Mutation | Afatinib (ERBB2 & EGFR inhibitor) | Resistant | L | NCCN/CAP guidelines |
| EGFR | EGFR MUT (A289V) | Different Mutation | Erlotinib (EGFR inhibitor) | Responsive | L | Early trials |
| EGFR | EGFR MUT (A289V) | Different Mutation | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | L | Late trials |
| EGFR | EGFR MUT (A289V) | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Pre-clinical |
| EGFR | EGFR MUT (A289V) | Different Mutation | Erlotinib (EGFR inhibitor) | No Responsive | L | Case report |
| EGFR | EGFR MUT (A289V) | Different Mutation | Lapatinib (ERBB2 inhibitor) | Responsive | ED | Case report |
| EGFR | EGFR MUT (A289V) | Different Mutation | EGFR inhibitor | No Responsive | G | Early trials |
| EGFR | EGFR MUT (A289V) | Different Mutation | EGFR inhibitor | Resistant | NSCLC | Case report |
| EGFR | EGFR MUT (A289V) | Different Mutation | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| EGFR | EGFR MUT (A289V) | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant;Resistant | COREAD | Pre-clinical;Case report |
| EGFR | EGFR MUT (A289V) | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Responsive | HNC | Case report |
| EGFR | EGFR MUT (A289V) | Different Alteration | Gefitinib (EGFR inhibitor) | Responsive | ED | Late trials |
| EGFR | EGFR MUT (A289V) | Different Alteration | Gefitinib (EGFR inhibitor) | No Responsive | HNC | Early trials |
| EGFR | EGFR MUT (A289V) | Different Alteration | EGFR inhibitor | Responsive | HNSC | Case report |
| EGFR | EGFR MUT (A289V) | Different Alteration | EGFR inhibitor | No Responsive | G | Early trials |
| EGFR | EGFR MUT (A289V) | Different Alteration | Erlotinib (EGFR inhibitor) | No Responsive | L | Early trials |
| EGFR | EGFR MUT (A289V) | Different Alteration | EGFR mAb inhibitor | Responsive | COREAD | Late trials |
| EGFR | EGFR MUT (A289V) | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | L | Case report |
| EGFR | EGFR MUT (A289V) | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | NSCLC | Case report |
| ERBB4 | ERBB4 MUT* (H190Y) | Different Alteration | Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) | Responsive | LUAD | Pre-clinical |
| SMARCA1 | SMARCA1 MUT (S324*) | Complete Match | EZH2 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (M169I) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (M169I) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (M169I) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (M169I) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (M169I) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (M169I) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (M169I) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (M169I) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (M169I) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (M169I) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (M169I) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (M169I) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (M169I) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (M169I) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (M169I) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| NTRK3 | NTRK3 MUT* (L146L) | Different Alteration | IGF1R inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK3 | NTRK3 MUT* (L146L) | Different Alteration | PI3K pathway inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK3 | NTRK3 MUT* (L146L) | Different Alteration | Midostaurin (Pan-TK inhibitor) | Responsive | BRCA | Pre-clinical |
| ABL1 | ABL1 MUT* (3-UTRSNV) | Different Alteration | Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) | Responsive | CML, ALL | FDA guidelines |
| ABL1 | ABL1 MUT* (3-UTRSNV) | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Responsive | ALL, CML | FDA guidelines |
| ABL1 | ABL1 MUT* (3-UTRSNV) | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| ABL1 | ABL1 MUT* (3-UTRSNV) | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | ALL, CML | FDA guidelines |
| ABL1 | ABL1 MUT* (3-UTRSNV) | Different Alteration | Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) | Responsive | ALL | Pre-clinical |
| ABL1 | ABL1 MUT* (3-UTRSNV) | Different Alteration | Bosutinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| NRG1 | NRG1 MUT* (R18Q) | Different Alteration | Lapatinib (ERBB2 inhibitor) | Responsive | LUAD | Pre-clinical |
| NRG1 | NRG1 MUT* (R18Q) | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | LUAD | Case report |
| FGFR2 | FGFR2 MUT* (H254Y) | Different Alteration | FGFR inhibitor | Responsive | COREAD | Early trials |
| FGFR2 | FGFR2 MUT* (H254Y) | Different Alteration | FGFR inhibitor | Responsive | BT | Early trials |
| CDKN1B | CDKN1B MUT (Q141*), CDKN1B MUT (Q20*) | Complete Match | CDK2/4 inhibitor | Responsive | CANCER | Pre-clinical |
| CDKN1B | CDKN1B MUT (Q141*), CDKN1B MUT (Q20*) | Different Alteration | CDK2/4 inhibitor | Responsive | CANCER | Pre-clinical |
| NOTCH2 | NOTCH2 MUT* (D1306N), NOTCH2 MUT* (3-UTRSNV) | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| CDH1 | CDH1 MUT (R335*) | Complete Match | Bicalutamide (AR inhibitor) | Responsive | BRCA | Pre-clinical |
| ARID1A | ARID1A MUT (Q1631*) | Complete Match | EZH2 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | ARID1A MUT (Q1631*) | Complete Match | PD1 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | ARID1A MUT (Q1631*) | Complete Match | PARP inhibitor | Responsive | CANCER | Pre-clinical |
| ARID1A | ARID1A MUT (Q1631*) | Complete Match | ATR inhibitor | Responsive | CANCER | Pre-clinical |
| RET | RET MUT* (L1101V) | Different Alteration | Nintedanib (Pan-TK inhibitor) | Responsive | LUAD | Case report |
| RET | RET MUT* (L1101V) | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Early trials |
| RET | RET MUT* (L1101V) | Different Alteration | RET inhibitor | Responsive | LUAD | Pre-clinical |
| RET | RET MUT* (L1101V) | Different Alteration | Vandetanib (Pan-TK inhibitor) | Responsive | LUAD | Early trials |
| RET | RET MUT* (L1101V) | Different Alteration | Sunitinib (Pan-TK inhibitor) | Responsive | LUAD | Early trials |
| RET | RET MUT* (L1101V) | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | THCA | Pre-clinical |
| RET | RET MUT* (L1101V) | Different Alteration | Vandetanib (Pan-TK inhibitor) | Responsive | THCA | Pre-clinical |
| RET | RET MUT* (L1101V) | Different Alteration | Sunitinib (Pan-TK inhibitor) | Responsive | THCA | Pre-clinical |
| RET | RET MUT* (L1101V) | Different Alteration | RET inhibitor | Responsive | TH | Pre-clinical |
| CDKN1B | CDKN1B MUT (splice_acceptor_variant) | Complete Match | CDK2/4 inhibitor | Responsive | CANCER | Pre-clinical |
| CDKN1B | CDKN1B MUT (splice_acceptor_variant) | Different Alteration | CDK2/4 inhibitor | Responsive | CANCER | Pre-clinical |
| NF1 | NF1 MUT (Q2492*) | Different Mutation | Vemurafenib (BRAF inhibitor) | Resistant | CM | Pre-clinical |
| NF1 | NF1 MUT (Q2492*) | Different Mutation | Everolimus (MTOR inhibitor) | Responsive | HNC | Case report |
| NF1 | NF1 MUT (Q2492*) | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (Q2492*) | Complete Match | Vinblastine (Chemotherapy) | Responsive | G | Early trials |
| NF1 | NF1 MUT (Q2492*) | Complete Match | KIT inhibitor;MTOR inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (Q2492*) | Complete Match | Tamoxifen (Hormonal therapy) | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (Q2492*) | Complete Match | Bevacizumab (VEGFR mAb inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (Q2492*) | Complete Match | Retinoic Acid | Resistant | NB | Pre-clinical |
| NF1 | NF1 MUT (Q2492*) | Complete Match | Everolimus (MTOR inhibitor) | Responsive | NF | Late trials |
| NF1 | NF1 MUT (Q2492*) | Complete Match | Trametinib (MEK inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (Q2492*) | Complete Match | Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (Q2492*) | Complete Match | Nilotinib (BCR-ABL inhibitor) | Responsive | MPN, PLEN | Pre-clinical |
| NF1 | NF1 MUT (Q2492*) | Complete Match | MEK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (Q2492*) | Complete Match | Everolimus (MTOR inhibitor) | Responsive | HNC, SG | Case report |
| NF1 | NF1 MUT (Q2492*) | Complete Match | Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) | No Responsive | MPN | Early trials |
| NF1 | NF1 MUT (Q2492*) | Complete Match | PLX3397 (Pan-TK inhibitor) | Responsive | PLEN | Pre-clinical |
| NF1 | NF1 MUT (Q2492*) | Complete Match | MEK inhibitor | Responsive | LK, G | Pre-clinical |
| NF1 | NF1 MUT (Q2492*) | Complete Match | Pan-RAF inhibitor;MEK inhibitor | Responsive | CM | Pre-clinical |
| NF1 | NF1 MUT (Q2492*) | Complete Match | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (Q2492*) | Complete Match | AURK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (Q2492*) | Complete Match | MTOR inhibitor | Responsive | LK, G, MPN | Pre-clinical |
| NF1 | NF1 MUT (Q2492*) | Complete Match | Dasatinib (BCR-ABL inhibitor) | Resistant | L | Pre-clinical |
| NF1 | NF1 MUT (Q2492*) | Complete Match | Everolimus;Pazopanib (MTOR inhibitor;VEGFR inhibitor) | Responsive | HC | Case report |
| NF1 | NF1 MUT (Q2492*) | Complete Match | Everolimus (MTOR inhibitor) | No Responsive | MPN | Early trials |
| NF1 | NF1 MUT (Q2492*) | Complete Match | Cediranib (ALK inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (Q2492*) | Complete Match | PD1 Ab inhibitor | Responsive | CM | Early trials |
| NF1 | NF1 MUT (Q2492*) | Complete Match | Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (Q2492*) | Complete Match | Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (Q2492*) | Complete Match | Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | No Responsive | G | Case report |
| NF1 | NF1 MUT (Q2492*) | Complete Match | BRD4 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (Q2492*) | Complete Match | Tipifarnib (Farnesyltransferase inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (Q2492*) | Complete Match | Selumetinib (MEK inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (Q2492*) | Complete Match | MTOR inhibitor;HSP90 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (Q2492*) | Complete Match | Trametinib (MEK inhibitor) | Responsive | CM | Pre-clinical |
| NF1 | NF1 MUT (Q2492*) | Complete Match | Erlotinib (EGFR inhibitor) | Resistant | L | Pre-clinical |
| NF1 | NF1 MUT (Q2492*) | Complete Match | Trametinib (MEK inhibitor) | No Responsive | OS | Case report |
| NF1 | NF1 MUT (Q2492*) | Different Alteration | MTOR inhibitor | Responsive | MPN, G, LK | Pre-clinical |
| NF1 | NF1 MUT (Q2492*) | Different Alteration | PLX3397 (Pan-TK inhibitor) | Responsive | PLEN | Pre-clinical |
| NF1 | NF1 MUT (Q2492*) | Different Alteration | Erlotinib (EGFR inhibitor) | Resistant | L | Pre-clinical |
| NF1 | NF1 MUT (Q2492*) | Different Alteration | Trametinib (MEK inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (Q2492*) | Different Alteration | BRD4 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (Q2492*) | Different Alteration | Trametinib (MEK inhibitor) | No Responsive | OS | Case report |
| NF1 | NF1 MUT (Q2492*) | Different Alteration | Cediranib (ALK inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (Q2492*) | Different Alteration | Bevacizumab (VEGFR mAb inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (Q2492*) | Different Alteration | MEK inhibitor | Responsive | G, LK | Pre-clinical |
| NF1 | NF1 MUT (Q2492*) | Different Alteration | Vinblastine (Chemotherapy) | Responsive | G | Early trials |
| NF1 | NF1 MUT (Q2492*) | Different Alteration | Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (Q2492*) | Different Alteration | Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) | No Responsive | MPN | Early trials |
| NF1 | NF1 MUT (Q2492*) | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Resistant | L | Pre-clinical |
| NF1 | NF1 MUT (Q2492*) | Different Alteration | MTOR inhibitor;HSP90 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (Q2492*) | Different Alteration | Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (Q2492*) | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (Q2492*) | Different Alteration | Tamoxifen (Hormonal therapy) | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (Q2492*) | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | SG, HNC | Case report |
| NF1 | NF1 MUT (Q2492*) | Different Alteration | Pan-RAF inhibitor;MEK inhibitor | Responsive | CM | Pre-clinical |
| NF1 | NF1 MUT (Q2492*) | Different Alteration | Tipifarnib (Farnesyltransferase inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (Q2492*) | Different Alteration | Selumetinib (MEK inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (Q2492*) | Different Alteration | Retinoic Acid | Resistant | NB | Pre-clinical |
| NF1 | NF1 MUT (Q2492*) | Different Alteration | Everolimus (MTOR inhibitor) | No Responsive | MPN | Early trials |
| NF1 | NF1 MUT (Q2492*) | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (Q2492*) | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | PLEN, MPN | Pre-clinical |
| NF1 | NF1 MUT (Q2492*) | Different Alteration | Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (Q2492*) | Different Alteration | Trametinib (MEK inhibitor) | Responsive | CM | Pre-clinical |
| NF1 | NF1 MUT (Q2492*) | Different Alteration | AURK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (Q2492*) | Different Alteration | Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | No Responsive | G | Case report |
| NF1 | NF1 MUT (Q2492*) | Different Alteration | PD1 Ab inhibitor | Responsive | CM | Early trials |
| NF1 | NF1 MUT (Q2492*) | Different Alteration | MEK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (Q2492*) | Different Alteration | KIT inhibitor;MTOR inhibitor | Responsive | MPN | Pre-clinical |
| TP53 | TP53 MUT (Q136*) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (Q136*) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (Q136*) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (Q136*) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (Q136*) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (Q136*) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (Q136*) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Q136*) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Q136*) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (Q136*) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (Q136*) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Q136*) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (Q136*) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (Q136*) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (Q136*) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| Variation | Gene | Transcript | Protein Alteration | Consequence | Tumour Driver | Oncogenic Classification |
|---|
Loading...
Drug-Gene Interactions help
Druggable categories in the cohort
No meaningful categories found
Focus the search to a gene of interest:
Loading...
| Gene | Interaction Source | Interaction Types | Drug Claim Primary Name | Drug Name | ChEMBL ID |
|---|---|---|---|---|---|
| PIK3CA | MyCancerGenome | inhibitor | INK-1117 | INK-1117 | CHEMBL3545055 |
| PIK3CA | CKB | MS417 | |||
| PIK3CA | CIViC | RAPAMYCIN (SIROLIMUS) | SIROLIMUS | CHEMBL413 | |
| PIK3CA | CGI | Chemotherapy | |||
| PIK3CA | CKB | Olaparib | OLAPARIB | CHEMBL521686 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | HS-173 | ||
| PIK3CA | CKB | Linsitinib | LINSITINIB | CHEMBL1091644 | |
| PIK3CA | CKB | ZSTK474 | ZSTK-474 | CHEMBL586701 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | AMG319 | AMG-319 | CHEMBL3545048 |
| PIK3CA | MyCancerGenome | inhibitor | BKM120 | BUPARLISIB | CHEMBL2017974 |
| PIK3CA | ClearityFoundationBiomarkers | BYL719 | ALPELISIB | CHEMBL2396661 | |
| PIK3CA | NCI | I3C | INDOLE-3-CARBINOL | CHEMBL155625 | |
| PIK3CA | CKB | GDC-0941 | PICTILISIB | CHEMBL521851 | |
| PIK3CA | CKB | Navitoclax | NAVITOCLAX | CHEMBL443684 | |
| PIK3CA | CIViC | PICTILISIB | PICTILISIB | CHEMBL521851 | |
| PIK3CA | ChemblInteractions | inhibitor | SF-1126 | SF-1126 | CHEMBL2326966 |
| PIK3CA | ClearityFoundationBiomarkers | DS-7423 | DS-7423 | CHEMBL3545248 | |
| PIK3CA | GuideToPharmacologyInteractions | allosteric modulator | PIK-108 | ||
| PIK3CA | CKB | Neratinib | NERATINIB | CHEMBL180022 | |
| PIK3CA | CGI | Cetuximab | CETUXIMAB | CHEMBL1201577 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | AZD8186 | AZD-8186 | CHEMBL3545424 |
| PIK3CA | CKB | DS-7423 | DS-7423 | CHEMBL3545248 | |
| PIK3CA | OncoKB | Copanlisib | COPANLISIB | CHEMBL3218576 | |
| PIK3CA | NCI | SERM | |||
| PIK3CA | CKB | ASN003 | |||
| PIK3CA | CIViC | PP242 | |||
| PIK3CA | CKB | AZD6482 | AZD-6482 | CHEMBL2165191 | |
| PIK3CA | CIViC | BYL719 (ALPELISIB) | |||
| PIK3CA | MyCancerGenomeClinicalTrial | inhibitor | PX-866 | SONOLISIB | CHEMBL411907 |
| PIK3CA | CKB | AZD5363 | AZD-5363 | CHEMBL2178577 | |
| PIK3CA | CKB | GDC-0980 | APITOLISIB | CHEMBL1922094 | |
| PIK3CA | CKB | Radiotherapy | |||
| PIK3CA | CKB | Palbociclib | PALBOCICLIB | CHEMBL189963 | |
| PIK3CA | CKB | LY2780301 | LY-2780301 | CHEMBL3545134 | |
| PIK3CA | NCI | RAS INHIBITOR | |||
| PIK3CA | OncoKB | AZD5363 | AZD-5363 | CHEMBL2178577 | |
| PIK3CA | NCI | HGF | |||
| PIK3CA | CIViC | EVEROLIMUS | EVEROLIMUS | CHEMBL1908360 | |
| PIK3CA | CKB | Tamoxifen | TAMOXIFEN | CHEMBL83 | |
| PIK3CA | CKB | Trametinib | TRAMETINIB | CHEMBL2103875 | |
| PIK3CA | NCI | RAPAMYCIN | SIROLIMUS | CHEMBL413 | |
| PIK3CA | CKB | TGX-221 | |||
| PIK3CA | MyCancerGenome | inhibitor | GDC-0032 | TASELISIB | CHEMBL2387080 |
| PIK3CA | ChemblInteractions | inhibitor | PILARALISIB | PILARALISIB (CHEMBL3360203) | CHEMBL3360203 |
| PIK3CA | ChemblInteractions | inhibitor | PWT-33587 | PWT-33587 | CHEMBL3545006 |
| PIK3CA | ChemblInteractions | inhibitor | RECILISIB | RECILISIB | CHEMBL2219421 |
| PIK3CA | CIViC | CETUXIMAB | CETUXIMAB | CHEMBL1201577 | |
| PIK3CA | CIViC | LAPATINIB | LAPATINIB | CHEMBL554 | |
| PIK3CA | CKB | CUDC-907 | CUDC-907 | CHEMBL3545052 | |
| PIK3CA | CKB | VS-5584 | VS-5584 | CHEMBL1079593 | |
| PIK3CA | CKB | Lapatinib | LAPATINIB | CHEMBL554 | |
| PIK3CA | CKB | Selumetinib | SELUMETINIB | CHEMBL1614701 | |
| PIK3CA | CKB | GSK2126458 | OMIPALISIB | CHEMBL1236962 | |
| PIK3CA | NCI | SELECTIVE ESTROGEN RECEPTOR MODULATOR | |||
| PIK3CA | OncoKB | Letrozole | LETROZOLE | CHEMBL1444 | |
| PIK3CA | CKB | GSK1059615 | GSK-1059615 | CHEMBL3544966 | |
| PIK3CA | ChemblInteractions | inhibitor | PA-799 | PA-799 | CHEMBL1684984 |
| PIK3CA | CKB | ARQ092 | ARQ-092 | CHEMBL3545422 | |
| PIK3CA | CKB | BGJ398 | INFIGRATINIB | CHEMBL1852688 | |
| PIK3CA | ChemblInteractions | inhibitor | TASELISIB | TASELISIB | CHEMBL2387080 |
| PIK3CA | MyCancerGenome | inhibitor | XL147 | PILARALISIB (CHEMBL3218575) | CHEMBL3218575 |
| PIK3CA | ChemblInteractions | inhibitor | VS-5584 | VS-5584 | CHEMBL1079593 |
| PIK3CA | OncoKB | MLN0128 | INK-128 | CHEMBL3545056 | |
| PIK3CA | TdgClinicalTrial | RIGOSERTIB | RIGOSERTIB | CHEMBL1241855 | |
| PIK3CA | CKB | Cisplatin | |||
| PIK3CA | ChemblInteractions | inhibitor | COPANLISIB | COPANLISIB | CHEMBL3218576 |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | PI 3-KG INHIBITOR II | CHEMBL1231533 | CHEMBL1231533 |
| PIK3CA | CIViC | PERIFOSINE | PERIFOSINE | CHEMBL372764 | |
| PIK3CA | ChemblInteractions | inhibitor | PF-04691502 | PF-04691502 | CHEMBL1234354 |
| PIK3CA | ChemblInteractions | inhibitor | SONOLISIB | SONOLISIB | CHEMBL411907 |
| PIK3CA | ChemblInteractions | inhibitor | PKI-179 | PKI-179 | CHEMBL1258517 |
| PIK3CA | MyCancerGenome | inhibitor | GDC-0980 | APITOLISIB | CHEMBL1922094 |
| PIK3CA | CKB | Demcizumab | DEMCIZUMAB | CHEMBL2109384 | |
| PIK3CA | NCI | FLAVOPIRIDOL | ALVOCIDIB | CHEMBL428690 | |
| PIK3CA | NCI | PKC412 | MIDOSTAURIN | CHEMBL608533 | |
| PIK3CA | ChemblInteractions | inhibitor | CUDC-907 | CUDC-907 | CHEMBL3545052 |
| PIK3CA | CKB | P7170 | Panulisib | CHEMBL3545322 | |
| PIK3CA | ClearityFoundationBiomarkers | GSK2126458 | OMIPALISIB | CHEMBL1236962 | |
| PIK3CA | CKB | MLN0128 | INK-128 | CHEMBL3545056 | |
| PIK3CA | CancerCommons | inhibitor | BKM120 | BUPARLISIB | CHEMBL2017974 |
| PIK3CA | OncoKB | Serabelisib | YOHIMBINE | CHEMBL15245 | |
| PIK3CA | ChemblInteractions | inhibitor | INK-1117 | INK-1117 | CHEMBL3545055 |
| PIK3CA | NCI | IL-2 | |||
| PIK3CA | CKB | Bevacizumab | BEVACIZUMAB | CHEMBL1201583 | |
| PIK3CA | MyCancerGenome | inhibitor | GSK2636771 | GSK-2636771 | CHEMBL3188551 |
| PIK3CA | CKB | PKI-179 | PKI-179 | CHEMBL1258517 | |
| PIK3CA | ClearityFoundationBiomarkers | BAY80-6946 | COPANLISIB | CHEMBL3218576 | |
| PIK3CA | CIViC | PALBOCICLIB (PD0332991) | PALBOCICLIB | CHEMBL189963 | |
| PIK3CA | CKB | Idelalisib | IDELALISIB | CHEMBL2216870 | |
| PIK3CA | ChemblInteractions | inhibitor | LY-3023414 | LY-3023414 | CHEMBL3544999 |
| PIK3CA | CIViC | TEMSIROLIMUS | TEMSIROLIMUS | CHEMBL1201182 | |
| PIK3CA | CIViC | AZD5363 | AZD-5363 | CHEMBL2178577 | |
| PIK3CA | NCI | THEAFLAVINS | |||
| PIK3CA | CIViC | IDELALISIB | IDELALISIB | CHEMBL2216870 | |
| PIK3CA | NCI | PTHRP | |||
| PIK3CA | CKB | GSK2334470 | CHEMBL1765740 | CHEMBL1765740 | |
| PIK3CA | CKB | Doxil | |||
| PIK3CA | CIViC | CISPLATIN | |||
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | LY 294002 | LY-294002 | CHEMBL98350 |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | ECF309 | ||
| PIK3CA | ClearityFoundationBiomarkers | PF-05212384 | GEDATOLISIB | CHEMBL592445 | |
| PIK3CA | ClearityFoundationBiomarkers | ZSTK474 | ZSTK-474 | CHEMBL586701 | |
| PIK3CA | NCI | RALOXIFENE | RALOXIFENE | CHEMBL81 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | PIK-75 | ||
| PIK3CA | ChemblInteractions | inhibitor | DACTOLISIB | DACTOLISIB | CHEMBL1879463 |
| PIK3CA | CKB | Ponatinib | PONATINIB | CHEMBL1171837 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | CH5132799 | PA-799 | CHEMBL1684984 |
| PIK3CA | CIViC | ANTI-EGFR MONOCLONAL ANTIBODY | |||
| PIK3CA | ClearityFoundationBiomarkers | TEMSIROLIMUS | TEMSIROLIMUS | CHEMBL1201182 | |
| PIK3CA | CKB | BAY1125976 | BAY-1125976 | CHEMBL3545049 | |
| PIK3CA | CKB | Sirolimus | SIROLIMUS | CHEMBL413 | |
| PIK3CA | CKB | GSK2141795 | UPROSERTIB | CHEMBL3137336 | |
| PIK3CA | MyCancerGenome | inhibitor | PI-103 | PI-103 | CHEMBL573339 |
| PIK3CA | CKB | Alpelisib | ALPELISIB | CHEMBL2396661 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | APITOLISIB | APITOLISIB | CHEMBL1922094 |
| PIK3CA | ChemblInteractions | inhibitor | RG-7666 | RG-7666 | CHEMBL3545324 |
| PIK3CA | CKB | Doxorubicin | DOXORUBICIN | CHEMBL53463 | |
| PIK3CA | CKB | LY294002 | LY-294002 | CHEMBL98350 | |
| PIK3CA | CKB | AT-7867 | CHEMBL428462 | CHEMBL428462 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | BGT-226 | ||
| PIK3CA | NCI | SULINDAC | SULINDAC | CHEMBL15770 | |
| PIK3CA | NCI | CAMPTOTHECIN | CAMPTOTHECIN | CHEMBL65 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | TASELISIB | TASELISIB | CHEMBL2387080 |
| PIK3CA | CKB | WEHI-539 | |||
| PIK3CA | CKB | GDC-0032 | TASELISIB | CHEMBL2387080 | |
| PIK3CA | CKB | Fluorouracil | FLUOROURACIL | CHEMBL185 | |
| PIK3CA | MyCancerGenome | inhibitor | PKI-587 | GEDATOLISIB | CHEMBL592445 |
| PIK3CA | ChemblInteractions | inhibitor | ZSTK-474 | ZSTK-474 | CHEMBL586701 |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | BUPARLISIB | BUPARLISIB | CHEMBL2017974 |
| PIK3CA | CancerCommons | inhibitor | BEZ235 | DACTOLISIB | CHEMBL1879463 |
| PIK3CA | CKB | YM-024 | |||
| PIK3CA | CKB | PKI-402 | CHEMBL589258 | CHEMBL589258 | |
| PIK3CA | CIViC | PI3K INHIBITOR | |||
| PIK3CA | ChemblInteractions | inhibitor | BGT-226 | BGT-226 (CHEMBL3545096) | CHEMBL3545096 |
| PIK3CA | CKB | Vistusertib | BENZONATATE | CHEMBL1374379 | |
| PIK3CA | CKB | Paclitaxel | PACLITAXEL | CHEMBL428647 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | LENIOLISIB | ||
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | PQR309 | ||
| PIK3CA | TdgClinicalTrial | SF1126 | SF-1126 | CHEMBL2326966 | |
| PIK3CA | CKB | FOLFOX | |||
| PIK3CA | CKB | rigosertib | RIGOSERTIB | CHEMBL1241855 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | PICTILISIB | PICTILISIB | CHEMBL521851 |
| PIK3CA | MyCancerGenomeClinicalTrial | inhibitor | BYL719 | ALPELISIB | CHEMBL2396661 |
| PIK3CA | NCI | STZ | STREPTOZOTOCIN | CHEMBL1651906 | |
| PIK3CA | NCI | HERBIMYCIN A | HERBIMYCIN | CHEMBL479533 | |
| PIK3CA | CKB | Sapanisertib | INK-128 | CHEMBL3545056 | |
| PIK3CA | CKB | A-443654 | A-443654 | CHEMBL379300 | |
| PIK3CA | CKB | AZD8055 | AZD-8055 | CHEMBL1801204 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | AZD8835 | CANDICIDIN | CHEMBL1200647 |
| PIK3CA | MyCancerGenome | inhibitor | XL-765 | VOXTALISIB | CHEMBL3545366 |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | OMIPALISIB | OMIPALISIB | CHEMBL1236962 |
| PIK3CA | OncoKB | Taselisib | TASELISIB | CHEMBL2387080 | |
| PIK3CA | OncoKB | Ribociclib | Ribociclib | CHEMBL3545110 | |
| PIK3CA | ChemblInteractions | inhibitor | GSK-1059615 | GSK-1059615 | CHEMBL3544966 |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | AZD6482 | AZD-6482 | CHEMBL2165191 |
| PIK3CA | MyCancerGenomeClinicalTrial | inhibitor | PKI-587 | GEDATOLISIB | CHEMBL592445 |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | COMPOUND 28 [PMID: 24387221] | ||
| PIK3CA | CKB | Pertuzumab | PERTUZUMAB | CHEMBL2007641 | |
| PIK3CA | MyCancerGenome | inhibitor | SF1126 | SF-1126 | CHEMBL2326966 |
| PIK3CA | CKB | Fulvestrant | FULVESTRANT | CHEMBL1358 | |
| PIK3CA | CKB | OSI-027 | OSI-027 | CHEMBL3120215 | |
| PIK3CA | ChemblInteractions | inhibitor | APITOLISIB | APITOLISIB | CHEMBL1922094 |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | PI-103 | PI-103 | CHEMBL573339 |
| PIK3CA | ChemblInteractions | inhibitor | VOXTALISIB | VOXTALISIB | CHEMBL3545366 |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | ZSTK474 | ZSTK-474 | CHEMBL586701 |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | TG-100-115 | TG100-115 | CHEMBL230011 |
| PIK3CA | CKB | PI-103 | PI-103 | CHEMBL573339 | |
| PIK3CA | MyCancerGenome | inhibitor | PWT33597 | ||
| PIK3CA | NCI | PACLITAXEL | PACLITAXEL | CHEMBL428647 | |
| PIK3CA | CKB | U0126 | U-0126 | CHEMBL100473 | |
| PIK3CA | CIViC | RADIATION | |||
| PIK3CA | CKB | Lucitanib | LUCITANIB | CHEMBL2220486 | |
| PIK3CA | OncoKB | Trastuzumab | TRASTUZUMAB | CHEMBL1201585 | |
| PIK3CA | CKB | Torin 1 | TORIN1 | CHEMBL1256459 | |
| PIK3CA | CKB | Carboxyamidotriazole Orotate | |||
| PIK3CA | CKB | ARQ 751 | |||
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | GEDATOLISIB | GEDATOLISIB | CHEMBL592445 |
| PIK3CA | CKB | AZD8835 | CANDICIDIN | CHEMBL1200647 | |
| PIK3CA | CKB | 5-FU | FLUOROURACIL | CHEMBL185 | |
| PIK3CA | ClearityFoundationBiomarkers | XL-147 | |||
| PIK3CA | NCI | RESVERATROL | RESVERATROL | CHEMBL165 | |
| PIK3CA | CKB | Letrozole | LETROZOLE | CHEMBL1444 | |
| PIK3CA | MyCancerGenomeClinicalTrial | inhibitor | GSK2126458 | OMIPALISIB | CHEMBL1236962 |
| PIK3CA | CKB | SAR245409 | VOXTALISIB | CHEMBL3545366 | |
| PIK3CA | CKB | ABT-263 | NAVITOCLAX | CHEMBL443684 | |
| PIK3CA | CKB | Cetuximab | CETUXIMAB | CHEMBL1201577 | |
| PIK3CA | MyCancerGenome | inhibitor | BGJ398 | ||
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | PILARALISIB | PILARALISIB (CHEMBL3360203) | CHEMBL3360203 |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | VS-5584 | VS-5584 | CHEMBL1079593 |
| PIK3CA | CancerCommons | inhibitor | PX-866 | SONOLISIB | CHEMBL411907 |
| PIK3CA | CKB | NVP-AEW541 | AEW-541 | CHEMBL551064 | |
| PIK3CA | CIViC | CH5132799 | PA-799 | CHEMBL1684984 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | CUDC-907 | CUDC-907 | CHEMBL3545052 |
| PIK3CA | CKB | BKM120 | BUPARLISIB | CHEMBL2017974 | |
| PIK3CA | OncoKB | Everolimus | EVEROLIMUS | CHEMBL1908360 | |
| PIK3CA | CIViC | BEZ235 (NVP-BEZ235, DACTOLISIB) | DACTOLISIB | CHEMBL1879463 | |
| PIK3CA | ChemblInteractions | inhibitor | DS-7423 | DS-7423 | CHEMBL3545248 |
| PIK3CA | CKB | CH5132799 | PA-799 | CHEMBL1684984 | |
| PIK3CA | CKB | Regorafenib | REGORAFENIB | CHEMBL1946170 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | SERABELISIB | YOHIMBINE | CHEMBL15245 |
| PIK3CA | CGI | Everolimus | EVEROLIMUS | CHEMBL1908360 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | PP121 | CHEMBL1081312 | CHEMBL1081312 |
| PIK3CA | CKB | Temsirolimus | TEMSIROLIMUS | CHEMBL1201182 | |
| PIK3CA | CKB | A-1210477 | |||
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | IDELALISIB | IDELALISIB | CHEMBL2216870 |
| PIK3CA | CKB | MLN1117 | INK-1117 | CHEMBL3545055 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | KU-0060648 | CHEMBL1086377 | CHEMBL1086377 |
| PIK3CA | NCI | DHEA | PRASTERONE | CHEMBL90593 | |
| PIK3CA | CKB | Dabrafenib | DABRAFENIB | CHEMBL2028663 | |
| PIK3CA | NCI | UROKINASE-TYPE PLASMINOGEN ACTIVATOR | |||
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | COMPOUND 11J [PMID: 23021994] | ||
| PIK3CA | ChemblInteractions | inhibitor | OMIPALISIB | OMIPALISIB | CHEMBL1236962 |
| PIK3CA | CKB | Ridaforolimus | RIDAFOROLIMUS | CHEMBL2103839 | |
| PIK3CA | MyCancerGenome | inhibitor | PF-4691502 | PF-04691502 | CHEMBL1234354 |
| PIK3CA | CKB | Copanlisib | COPANLISIB | CHEMBL3218576 | |
| PIK3CA | NCI | BCG | |||
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | PF-04691502 | PF-04691502 | CHEMBL1234354 |
| PIK3CA | OncoKB | LJM716 | |||
| PIK3CA | OncoKB | Olaparib | OLAPARIB | CHEMBL521686 | |
| PIK3CA | NCI | 17-AAG | CHEMBL126955 | CHEMBL126955 | |
| PIK3CA | NCI | NSAID | |||
| PIK3CA | MyCancerGenome | inhibitor | GDC-0941 | PICTILISIB | CHEMBL521851 |
| PIK3CA | ChemblInteractions | inhibitor | AZD-6482 | AZD-6482 | CHEMBL2165191 |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | WORTMANNIN | WORTMANNIN | CHEMBL428496 |
| PIK3CA | CKB | GS-9820 | Acalisib | CHEMBL3545397 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | NEMIRALISIB | ||
| PIK3CA | CKB | Torkinib | |||
| PIK3CA | CKB | PD-0325901 | PD-0325901 | CHEMBL507361 | |
| PIK3CA | CKB | Gemcitabine | GEMCITABINE | CHEMBL888 | |
| PIK3CA | CKB | Deguelin | DEGUELIN | CHEMBL393417 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | INK-128 | INK-128 | CHEMBL3545056 |
| PIK3CA | CKB | Dasatinib | DASATINIB | CHEMBL1421 | |
| PIK3CA | CancerCommons | inhibitor | BAY80-6946 | COPANLISIB | CHEMBL3218576 |
| PIK3CA | NCI | TRAIL | |||
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | PI 3-KG INHIBITOR | CHEMBL568150 | CHEMBL568150 |
| PIK3CA | NCI | GM-CSF | REGRAMOSTIM | CHEMBL2107881 | |
| PIK3CA | MyCancerGenome | inhibitor | BAY80-6946 | COPANLISIB | CHEMBL3218576 |
| PIK3CA | CKB | CCT128930 | CHEMBL263664 | CHEMBL263664 | |
| PIK3CA | TdgClinicalTrial | PWT33597 | |||
| PIK3CA | NCI | ZINC SULFATE | ZINC SULFATE | CHEMBL1200929 | |
| PIK3CA | CKB | trastuzumab emtansine | TRASTUZUMAB EMTANSINE | CHEMBL1743082 | |
| PIK3CA | CKB | A66 | PHENMETRAZINE | CHEMBL1201208 | |
| PIK3CA | MyCancerGenomeClinicalTrial | inhibitor | DACTOLISIB | DACTOLISIB | CHEMBL1879463 |
| PIK3CA | OncoKB | Fulvestrant | FULVESTRANT | CHEMBL1358 | |
| PIK3CA | MyCancerGenome | inhibitor | PX-866 | SONOLISIB | CHEMBL411907 |
| PIK3CA | MyCancerGenome | inhibitor | SOPHORETIN | QUERCETIN | CHEMBL50 |
| PIK3CA | CKB | BAY1082439 | BAY-1082439 | CHEMBL3545245 | |
| PIK3CA | CIViC | TRASTUZUMAB | TRASTUZUMAB | CHEMBL1201585 | |
| PIK3CA | NCI | CARBOPLATIN | CARBOPLATIN | CHEMBL1351 | |
| PIK3CA | NCI | ANTIANGIOGENIC | |||
| PIK3CA | MyCancerGenome | inhibitor | BEZ235 | DACTOLISIB | CHEMBL1879463 |
| PIK3CA | CKB | PF-05212384 | GEDATOLISIB | CHEMBL592445 | |
| PIK3CA | CKB | WYE-125132 | |||
| PIK3CA | OncoKB | GDC-0077 | PHENMETRAZINE | CHEMBL1201208 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | ALPELISIB | ALPELISIB | CHEMBL2396661 |
| PIK3CA | CIViC | CABOZANTINIB | CABOZANTINIB | CHEMBL2105717 | |
| PIK3CA | NCI | VINCRISTINE | VINCRISTINE | CHEMBL90555 | |
| PIK3CA | NCI | DOXORUBICIN | DOXORUBICIN | CHEMBL53463 | |
| PIK3CA | CKB | BEZ235 | DACTOLISIB | CHEMBL1879463 | |
| PIK3CA | ChemblInteractions | inhibitor | BAY-1082439 | BAY-1082439 | CHEMBL3545245 |
| PIK3CA | CKB | Afuresertib | AFURESERTIB | CHEMBL2219422 | |
| PIK3CA | CancerCommons | inhibitor | BYL719 | ALPELISIB | CHEMBL2396661 |
| PIK3CA | CKB | Floxuridine | FLOXURIDINE | CHEMBL917 | |
| PIK3CA | CancerCommons | inhibitor | XL765 | VOXTALISIB | CHEMBL3545366 |
| PIK3CA | ClearityFoundationBiomarkers | EVEROLIMUS | EVEROLIMUS | CHEMBL1908360 | |
| PIK3CA | NCI | RETINOID | ETRETINATE | CHEMBL464 | |
| PIK3CA | CKB | DHM25 | |||
| PIK3CA | CKB | Gedatolisib | GEDATOLISIB | CHEMBL592445 | |
| PIK3CA | CKB | PWT33597 | |||
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | LY3023414 | LY-3023414 | CHEMBL3544999 |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | COMPOUND 82 [PMID: 21332118] | ||
| PIK3CA | CKB | Camptothecin | CAMPTOTHECIN | CHEMBL65 | |
| PIK3CA | ChemblInteractions | inhibitor | WX-037 | WX-037 | CHEMBL3545385 |
| PIK3CA | CKB | Venetoclax | VENETOCLAX | CHEMBL3137309 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | QUINOSTATIN | ||
| PIK3CA | NCI | TYROSINE KINASE INHIBITORS | |||
| PIK3CA | ChemblInteractions | inhibitor | Puquitinib | Puquitinib | CHEMBL3545088 |
| PIK3CA | ChemblInteractions | inhibitor | PWT-33579 | PWT-33579 | CHEMBL3545323 |
| PIK3CA | MyCancerGenomeClinicalTrial | inhibitor | BUPARLISIB HYDROCHLORIDE | BUPARLISIB HYDROCHLORIDE | CHEMBL2364604 |
| PIK3CA | CKB | ABT-737 | CHEMBL376408 | CHEMBL376408 | |
| PIK3CA | CIViC | PANITUMUMAB | PANITUMUMAB | CHEMBL1201827 | |
| PIK3CA | ChemblInteractions | inhibitor | GEDATOLISIB | GEDATOLISIB | CHEMBL592445 |
| PIK3CA | CKB | XL147 | PILARALISIB (CHEMBL3218575) | CHEMBL3218575 | |
| PIK3CA | CIViC | MK-2206 | MK-2206 | CHEMBL1079175 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | IPI549 | OXAZEPAM | CHEMBL568 |
| PIK3CA | CKB | BYL719 | ALPELISIB | CHEMBL2396661 | |
| PIK3CA | ChemblInteractions | inhibitor | BUPARLISIB | BUPARLISIB | CHEMBL2017974 |
| PIK3CA | CKB | MK2206 | MK-2206 | CHEMBL1079175 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | DACTOLISIB | DACTOLISIB | CHEMBL1879463 |
| PIK3CA | ChemblInteractions | inhibitor | Panulisib | Panulisib | CHEMBL3545322 |
| PIK3CA | CKB | PD98509 | |||
| PIK3CA | CancerCommons | inhibitor | SAR260301 | SAR-260301 | CHEMBL3545008 |
| PIK3CA | CKB | Metformin | METFORMIN | CHEMBL1431 | |
| PIK3CA | CKB | Vemurafenib | VEMURAFENIB | CHEMBL1229517 | |
| PIK3CA | MyCancerGenomeClinicalTrial | inhibitor | BAY80-6946 | COPANLISIB | CHEMBL3218576 |
| PIK3CA | NCI | SURAMIN | SURAMIN | CHEMBL265502 | |
| PIK3CA | CKB | Capecitabine | CAPECITABINE | CHEMBL1773 | |
| PIK3CA | ClearityFoundationBiomarkers | XL765 | VOXTALISIB | CHEMBL3545366 | |
| PIK3CA | CKB | Everolimus | EVEROLIMUS | CHEMBL1908360 | |
| PIK3CA | ClearityFoundationBiomarkers | NVP-BEZ235 | DACTOLISIB | CHEMBL1879463 | |
| PIK3CA | CKB | Pimasertib | PIMASERTIB | CHEMBL2107832 | |
| PIK3CA | MyCancerGenome | inhibitor | BYL719 | ALPELISIB | CHEMBL2396661 |
| PIK3CA | CKB | PF-04691502 | PF-04691502 | CHEMBL1234354 | |
| PIK3CA | CIViC | TASELISIB (GDC-0032) | |||
| PIK3CA | NCI | MILTEFOSINE | MILTEFOSINE | CHEMBL125 | |
| PIK3CA | NCI | QUERCETIN | QUERCETIN | CHEMBL50 | |
| PIK3CA | CGI | Trastuzumab | TRASTUZUMAB | CHEMBL1201585 | |
| PIK3CA | TdgClinicalTrial | XL765 | VOXTALISIB | CHEMBL3545366 | |
| PIK3CA | CKB | AT13148 | AT-13148 | CHEMBL3544960 | |
| PIK3CA | ChemblInteractions | inhibitor | ALPELISIB | ALPELISIB | CHEMBL2396661 |
| PIK3CA | CKB | Irinotecan | IRINOTECAN | CHEMBL481 | |
| PIK3CA | CKB | CGM097 | |||
| PIK3CA | CKB | MSC2363318A | MSC-2363318A | CHEMBL3545003 | |
| PIK3CA | CKB | PW12 | |||
| PIK3CA | NCI | 17-ALLYL-AMINOGELDANAMYCIN | CHEMBL126955 | CHEMBL126955 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | GDC-0077 | PHENMETRAZINE | CHEMBL1201208 |
| PIK3CA | CKB | CC-223 | CC-223 | CHEMBL3545151 | |
| PIK3CA | CKB | cobimetinib | COBIMETINIB | CHEMBL2146883 | |
| PIK3CA | NCI | CPT-11 | IRINOTECAN | CHEMBL481 | |
| PIK3CA | OncoKB | Buparlisib | BUPARLISIB | CHEMBL2017974 | |
| PIK3CA | NCI | IL-11 | |||
| PIK3CA | CKB | Trastuzumab | TRASTUZUMAB | CHEMBL1201585 | |
| PIK3CA | OncoKB | ASN003 | |||
| PIK3CA | CKB | Sorafenib | SORAFENIB | CHEMBL1336 | |
| PIK3CA | CKB | PF-4989216 | |||
| PIK3CA | CKB | TAK-733 | TAK-733 | CHEMBL1615025 | |
| PIK3CA | CKB | LY3023414 | LY-3023414 | CHEMBL3544999 | |
| PIK3CA | CKB | PX-866 | SONOLISIB | CHEMBL411907 | |
| PIK3CA | CKB | Bortezomib | BORTEZOMIB | CHEMBL325041 | |
| PIK3CA | CKB | Carboplatin | CARBOPLATIN | CHEMBL1351 | |
| PIK3CA | ChemblInteractions | inhibitor | PICTILISIB | PICTILISIB | CHEMBL521851 |
| PIK3CA | OncoKB | Alpelisib | ALPELISIB | CHEMBL2396661 | |
| PIK3CA | CKB | Ipatasertib | IPATASERTIB | CHEMBL2177390 | |
| PIK3CA | ClearityFoundationBiomarkers | PF-04691502 | PF-04691502 | CHEMBL1234354 | |
| PIK3CA | CKB | Topotecan | TOPOTECAN | CHEMBL84 | |
| PIK3CA | CIViC | RIBOCICLIB | Ribociclib | CHEMBL3545110 | |
| PIK3CA | ChemblInteractions | inhibitor | MLN-1117 | MLN-1117 | CHEMBL3545379 |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | DUVELISIB | DUVELISIB | CHEMBL3039502 |
Phenotype
Protein
Drug
Loading...
There are patients available from the BCN Biobank that match the selected/a subset of the criteria. Explore the data available for these patients using our Cohort Browser.
Researchers can request samples from BCNB website to support their research activities.
*Based on your filtering criteria you can view the number of available patients and associated samples in BCNBIn order to apply for samples, please use the BCNB Request System to submit an Expression of interest (EOI) form.
If you require further details please contact us at tissue.bank@breastcancernow.org
| Patient ID | Age at Diagnosis | Sex | Survival Status | Survival Time | Follow up |
|---|---|---|---|---|---|
| DO1249 | 72 | female | alive | 0.05 | complete remission |
| DO1250 | 59 | female | alive | 1.76 | complete remission |
| DO1251 | 44 | male | alive | 3.08 | complete remission |
| DO1252 | 82 | female | alive | 0.04 | complete remission |
| DO1253 | 62 | female | alive | NA | complete remission |
| DO1254 | 45 | female | alive | 2.04 | complete remission |
| DO1255 | 52 | female | alive | 0.08 | complete remission |
| DO1256 | 62 | female | alive | 0.51 | complete remission |
| DO1257 | 30 | female | alive | 1.95 | complete remission |
| DO1258 | 80 | female | alive | NA | complete remission |
| DO1259 | 71 | female | alive | 1.02 | complete remission |
| DO1260 | 54 | female | alive | 0.06 | complete remission |
| DO1261 | 39 | female | alive | 3.93 | complete remission |
| DO1262 | 90 | female | alive | 0.67 | complete remission |
| DO1263 | 63 | female | alive | 0.09 | complete remission |
| DO1264 | 66 | female | alive | 1.59 | complete remission |
| DO1265 | 59 | female | alive | 6.34 | NA |
| DO1266 | 74 | female | alive | 0.22 | complete remission |
| DO1267 | 85 | female | alive | 1.02 | complete remission |
| DO1268 | 58 | female | alive | 5.19 | complete remission |
| DO1269 | 77 | female | alive | 0.7 | complete remission |
| DO1270 | 63 | female | alive | 0.81 | complete remission |
| DO1271 | 67 | female | alive | NA | complete remission |
| DO1272 | 49 | female | alive | 1.53 | complete remission |
| DO1273 | 90 | female | alive | 0.04 | complete remission |
| DO1274 | 40 | female | alive | 0.29 | complete remission |
| DO1275 | 62 | female | deceased | 3.48 | NA |
| DO1276 | 65 | female | alive | 2.28 | complete remission |
| DO1277 | 51 | female | alive | 0.83 | complete remission |
| DO1278 | 55 | female | alive | 4.24 | NA |
| DO1279 | 63 | female | alive | 0.04 | complete remission |
| DO1280 | 51 | female | alive | 0.15 | complete remission |
| DO1281 | 62 | female | alive | 3.57 | NA |
| DO1282 | 59 | female | alive | 1.41 | NA |
| DO1283 | 83 | female | deceased | 3.52 | NA |
| DO1284 | 69 | female | alive | 2.04 | complete remission |
| DO1285 | 68 | female | alive | 0.03 | complete remission |
| DO1286 | 50 | female | alive | 3.32 | NA |
| DO1287 | 38 | female | alive | 8.54 | complete remission |
| DO1288 | 56 | female | alive | 0.78 | complete remission |
| DO1289 | 63 | female | alive | 6.46 | complete remission |
| DO1290 | 71 | female | NA | NA | complete remission |
| DO1291 | 57 | female | alive | 4.31 | NA |
| DO1292 | 66 | female | alive | 0.03 | complete remission |
| DO1293 | 47 | female | alive | 0.99 | complete remission |
| DO1295 | 78 | female | alive | 4.16 | complete remission |
| DO1297 | 76 | female | alive | 0.83 | progression |
| DO1299 | 54 | female | alive | 3.06 | complete remission |
| DO1301 | 53 | female | alive | 3.29 | complete remission |
| DO1303 | 40 | female | alive | 0.23 | NA |
| DO1305 | 49 | female | alive | 1.16 | complete remission |
| DO1307 | 53 | female | alive | 0.02 | complete remission |
| DO1310 | 66 | female | deceased | 0.7 | NA |
| DO1313 | 53 | female | alive | 3.58 | complete remission |
| DO1316 | 52 | female | alive | 0.04 | complete remission |
| DO1319 | 51 | female | alive | 0.47 | complete remission |
| DO1322 | 54 | female | deceased | 4.65 | NA |
| DO1325 | 69 | female | alive | 0.03 | NA |
| DO1328 | 78 | female | alive | 3.21 | complete remission |
| DO1331 | 59 | female | alive | 1.03 | complete remission |
| DO1334 | 54 | female | alive | 2.34 | complete remission |
| DO1337 | 84 | male | alive | 4.16 | complete remission |
| DO1340 | 43 | female | alive | 6.9 | NA |
| DO1342 | 54 | female | alive | 4.01 | complete remission |
| DO1345 | 74 | female | NA | NA | complete remission |
| DO1348 | 66 | female | alive | 0.5 | complete remission |
| DO1351 | 47 | female | alive | 7.54 | complete remission |
| DO1354 | 55 | female | alive | 2.21 | complete remission |
| DO1357 | 45 | female | alive | 1.37 | complete remission |
| DO1360 | 54 | female | deceased | 10.8 | NA |
| DO1364 | 44 | female | deceased | 3.8 | NA |
| DO1368 | 51 | female | alive | 6.29 | complete remission |
| DO1372 | 56 | female | alive | 0.46 | complete remission |
| DO1376 | 41 | female | alive | 0.96 | progression |
| DO1380 | 59 | female | alive | 0.4 | complete remission |
| DO1384 | 38 | female | alive | 0.37 | complete remission |
| DO1388 | 51 | female | alive | 1.25 | complete remission |
| DO1392 | 46 | female | alive | 0.73 | complete remission |
| DO1396 | 59 | female | alive | 4.09 | complete remission |
| DO1398 | 80 | female | alive | 0.32 | complete remission |
| DO1402 | 75 | female | alive | 10.5 | complete remission |
| DO1406 | 62 | female | alive | 2.9 | NA |
| DO1410 | 50 | female | alive | 0.89 | complete remission |
| DO1414 | 61 | female | alive | 5.17 | NA |
| DO1419 | 63 | female | alive | 0.12 | complete remission |
| DO1424 | 63 | female | alive | 3.53 | complete remission |
| DO1429 | 48 | female | alive | 2.01 | progression |
| DO1434 | 60 | female | alive | 1.3 | complete remission |
| DO1436 | 28 | female | NA | NA | complete remission |
| DO1440 | 58 | female | deceased | 1.53 | NA |
| DO1445 | 43 | female | alive | 0.13 | complete remission |
| DO1449 | 52 | female | alive | 0.03 | complete remission |
| DO1454 | 71 | female | NA | NA | complete remission |
| DO1459 | 44 | female | alive | 4.3 | complete remission |
| DO1464 | 53 | female | alive | 0.01 | complete remission |
| DO1468 | 56 | female | alive | 0.04 | complete remission |
| DO1473 | 79 | female | deceased | 5.5 | NA |
| DO1476 | 70 | female | alive | 0.08 | NA |
| DO1481 | 53 | female | alive | 2.11 | complete remission |
| DO1486 | 58 | female | NA | NA | complete remission |
| DO1491 | 80 | female | deceased | 2.15 | NA |
| DO1496 | 65 | female | alive | 0.33 | NA |
| DO1497 | 50 | female | alive | 7.57 | complete remission |
| DO1502 | 42 | female | alive | 0.27 | complete remission |
| DO1507 | 60 | female | alive | 1.77 | complete remission |
| DO1512 | 90 | female | deceased | 2.05 | NA |
| DO1517 | 64 | female | alive | 0.85 | complete remission |
| DO1522 | 58 | female | NA | NA | complete remission |
| DO1527 | 60 | female | NA | NA | complete remission |
| DO1532 | 39 | female | deceased | 5.26 | NA |
| DO1537 | 40 | female | deceased | 1.75 | NA |
| DO1542 | 54 | female | alive | 1.01 | complete remission |
| DO1547 | 69 | female | alive | 0.04 | complete remission |
| DO1550 | 56 | female | alive | 1.43 | complete remission |
| DO1555 | 62 | female | alive | 3.95 | complete remission |
| DO1559 | 41 | female | alive | 0.81 | complete remission |
| DO1564 | 43 | female | alive | 1.23 | complete remission |
| DO1569 | 49 | female | alive | 1.23 | complete remission |
| DO1574 | 51 | female | alive | 1.6 | complete remission |
| DO1579 | 83 | female | alive | 2.08 | progression |
| DO1584 | 35 | female | alive | 0.99 | complete remission |
| DO1589 | 46 | female | deceased | 7.57 | NA |
| DO1594 | 73 | female | deceased | 4.5 | NA |
| DO1599 | 49 | female | alive | 1.03 | complete remission |
| DO1604 | 68 | female | alive | 8.45 | complete remission |
| DO1608 | 76 | female | alive | 0.61 | complete remission |
| DO1613 | 50 | female | deceased | 12.2 | NA |
| DO1618 | 58 | female | NA | NA | complete remission |
| DO1623 | 27 | female | alive | 4.11 | complete remission |
| DO1628 | 48 | female | alive | 1.02 | complete remission |
| DO1633 | 66 | female | deceased | 5.28 | NA |
| DO1638 | 63 | female | alive | 4.01 | complete remission |
| DO1643 | 52 | female | alive | 1.07 | complete remission |
| DO1648 | 34 | female | alive | 0.87 | complete remission |
| DO1653 | 58 | female | alive | 1.0 | complete remission |
| DO1658 | 31 | female | alive | 2.34 | complete remission |
| DO1663 | 64 | female | alive | 0.04 | NA |
| DO1668 | 49 | female | alive | 0.44 | complete remission |
| DO1673 | 59 | female | alive | 7.87 | complete remission |
| DO1678 | 48 | female | alive | 5.97 | complete remission |
| DO1683 | 80 | female | alive | 0.65 | complete remission |
| DO1688 | 81 | female | alive | 1.25 | progression |
| DO1693 | 50 | female | alive | 0.78 | complete remission |
| DO1697 | 41 | female | alive | 0.75 | complete remission |
| DO1702 | 70 | female | alive | 0.61 | NA |
| DO1707 | 58 | female | alive | 1.51 | complete remission |
| DO1712 | 54 | female | alive | 0.03 | NA |
| DO1717 | 52 | female | NA | NA | complete remission |
| DO1722 | 54 | female | alive | 5.68 | NA |
| DO1727 | 63 | female | alive | 5.38 | complete remission |
| DO1732 | 55 | female | alive | 0.7 | NA |
| DO1737 | 41 | female | alive | 1.81 | complete remission |
| DO1743 | 51 | female | NA | NA | complete remission |
| DO1749 | 77 | female | alive | 1.99 | complete remission |
| DO1755 | 65 | female | alive | 1.13 | complete remission |
| DO1761 | 67 | female | alive | 0.79 | complete remission |
| DO1767 | 56 | female | alive | 0.2 | complete remission |
| DO1773 | 54 | female | alive | 0.03 | NA |
| DO1774 | 52 | female | alive | 1.74 | complete remission |
| DO1780 | 42 | female | alive | 0.07 | progression |
| DO1786 | 68 | female | alive | 2.52 | progression |
| DO1792 | 70 | female | alive | 0.18 | complete remission |
| DO1797 | 45 | female | deceased | 1.0 | NA |
| DO1802 | 58 | female | alive | 4.68 | complete remission |
| DO1808 | 61 | female | alive | 1.36 | complete remission |
| DO1814 | 61 | female | alive | 3.67 | progression |
| DO1820 | 56 | female | alive | 0.41 | complete remission |
| DO1826 | 67 | female | alive | 3.63 | complete remission |
| DO1830 | 57 | female | alive | 6.38 | complete remission |
| DO1836 | 62 | female | alive | 0.63 | complete remission |
| DO1842 | 67 | female | alive | 1.81 | complete remission |
| DO1848 | 54 | female | alive | 3.15 | NA |
| DO1854 | 78 | female | alive | 1.48 | complete remission |
| DO1860 | 58 | female | alive | 2.21 | complete remission |
| DO1866 | 57 | female | alive | 4.46 | complete remission |
| DO1872 | 79 | female | alive | 0.44 | complete remission |
| DO1873 | 36 | female | alive | 0.47 | NA |
| DO1879 | 76 | female | alive | 0.08 | complete remission |
| DO1885 | 45 | female | alive | 10.48 | complete remission |
| DO1890 | 60 | female | deceased | 10.05 | NA |
| DO1896 | 40 | female | alive | 0.66 | complete remission |
| DO1902 | 63 | female | deceased | 1.56 | NA |
| DO1908 | 73 | female | alive | 7.55 | complete remission |
| DO1914 | 63 | female | deceased | 2.26 | NA |
| DO1920 | 56 | female | alive | 0.3 | complete remission |
| DO1922 | 50 | female | alive | 0.36 | complete remission |
| DO1925 | 50 | female | NA | NA | complete remission |
| DO1926 | 65 | female | NA | NA | complete remission |
| DO1927 | 41 | female | alive | 0.08 | complete remission |
| DO1932 | 69 | female | alive | 10.71 | NA |
| DO1937 | 40 | female | alive | 1.73 | complete remission |
| DO1943 | 50 | female | alive | 2.02 | NA |
| DO1948 | 58 | female | alive | 0.02 | complete remission |
| DO1954 | 40 | female | alive | 19.35 | complete remission |
| DO1960 | 62 | female | alive | 4.27 | complete remission |
| DO1966 | 68 | female | alive | 0.89 | complete remission |
| DO1972 | 50 | female | alive | 10.79 | complete remission |
| DO1978 | 64 | female | alive | 0.09 | complete remission |
| DO1984 | 65 | female | alive | 1.92 | complete remission |
| DO1990 | 79 | female | NA | NA | complete remission |
| DO1996 | 45 | female | alive | 0.03 | complete remission |
| DO2002 | 62 | female | alive | 0.61 | complete remission |
| DO2008 | 58 | male | alive | 3.82 | complete remission |
| DO2014 | 73 | female | alive | 1.33 | complete remission |
| DO2020 | 67 | female | alive | 2.33 | complete remission |
| DO2026 | 66 | female | alive | 0.64 | complete remission |
| DO2032 | 55 | female | alive | 0.04 | complete remission |
| DO2037 | 54 | female | alive | 4.44 | complete remission |
| DO2043 | 56 | female | alive | 3.21 | complete remission |
| DO2049 | 38 | female | alive | 5.45 | NA |
| DO2055 | 67 | female | NA | NA | complete remission |
| DO2061 | 58 | female | alive | 0.09 | complete remission |
| DO2067 | 48 | female | alive | 0.68 | complete remission |
| DO2072 | 52 | female | alive | 2.78 | complete remission |
| DO2078 | 50 | female | deceased | 3.17 | NA |
| DO2084 | 82 | female | alive | 2.05 | complete remission |
| DO2090 | 49 | female | alive | 0.05 | complete remission |
| DO2096 | 61 | female | deceased | 5.74 | NA |
| DO2102 | 75 | female | alive | 3.47 | complete remission |
| DO2108 | 55 | female | alive | 0.03 | complete remission |
| DO2114 | 69 | female | alive | 1.26 | complete remission |
| DO2120 | 61 | female | alive | 1.19 | NA |
| DO2125 | 47 | female | NA | NA | complete remission |
| DO2131 | 56 | female | NA | NA | complete remission |
| DO2137 | 48 | female | alive | 0.08 | complete remission |
| DO2143 | 70 | female | alive | 0.34 | complete remission |
| DO2149 | 46 | female | deceased | 2.05 | NA |
| DO2155 | 37 | female | alive | 5.0 | complete remission |
| DO2156 | 78 | female | deceased | 3.21 | NA |
| DO2162 | 51 | female | alive | 15.74 | complete remission |
| DO2168 | 44 | female | alive | 1.13 | complete remission |
| DO2174 | 87 | female | alive | 0.06 | complete remission |
| DO2180 | 49 | female | alive | 0.35 | complete remission |
| DO2186 | 89 | female | alive | 1.08 | complete remission |
| DO2192 | 64 | female | alive | 0.58 | complete remission |
| DO219588 | 55 | female | alive | 10.31 | progression |
| DO219589 | 50 | female | alive | 10.41 | complete remission |
| DO219590 | 62 | female | alive | 3.36 | complete remission |
| DO219591 | 52 | female | alive | 3.33 | complete remission |
| DO219592 | 50 | female | alive | 0.43 | complete remission |
| DO219593 | 42 | female | alive | 4.04 | complete remission |
| DO219594 | 63 | female | alive | 4.03 | progression |
| DO219595 | 51 | female | alive | 0.2 | complete remission |
| DO219597 | 56 | female | alive | 0.0 | complete remission |
| DO219599 | 71 | female | alive | 0.19 | complete remission |
| DO219605 | 44 | female | deceased | 1.57 | NA |
| DO219607 | 51 | female | alive | 0.27 | complete remission |
| DO219608 | 63 | female | alive | 0.62 | complete remission |
| DO219609 | 46 | female | alive | 0.8 | complete remission |
| DO219611 | 61 | female | alive | 0.44 | complete remission |
| DO219613 | 87 | female | deceased | 0.81 | NA |
| DO219615 | 58 | female | alive | 0.39 | complete remission |
| DO219617 | 54 | female | alive | 0.55 | complete remission |
| DO219619 | 53 | female | alive | 0.51 | complete remission |
| DO219621 | 59 | female | alive | 0.02 | complete remission |
| DO219623 | 53 | female | alive | 0.03 | complete remission |
| DO219625 | 49 | female | alive | 0.03 | complete remission |
| DO219627 | 49 | female | alive | 0.02 | complete remission |
| DO219629 | 88 | female | alive | 1.35 | progression |
| DO219631 | 79 | female | alive | 0.67 | NA |
| DO219633 | 53 | female | alive | 1.01 | complete remission |
| DO219635 | 34 | female | alive | 1.27 | complete remission |
| DO219636 | 59 | male | alive | 1.4 | complete remission |
| DO219637 | 56 | female | alive | 0.22 | complete remission |
| DO219638 | 45 | female | alive | 5.06 | progression |
| DO219639 | 48 | female | alive | 2.32 | complete remission |
| DO219640 | 67 | female | alive | 0.53 | complete remission |
| DO219641 | 72 | female | deceased | 3.92 | NA |
| DO219642 | 64 | female | alive | 5.35 | complete remission |
| DO219643 | 41 | female | alive | 5.08 | complete remission |
| DO219644 | 73 | female | alive | 1.17 | complete remission |
| DO219645 | 63 | female | deceased | 0.32 | NA |
| DO219646 | 55 | female | alive | 4.24 | complete remission |
| DO219647 | 77 | female | alive | 2.17 | complete remission |
| DO2198 | 56 | female | alive | 3.35 | complete remission |
| DO2204 | 62 | female | alive | 0.07 | NA |
| DO2210 | 62 | female | alive | 1.08 | complete remission |
| DO2216 | 29 | female | alive | 3.98 | complete remission |
| DO2222 | 58 | female | alive | 0.14 | complete remission |
| DO2228 | 48 | female | alive | 0.21 | complete remission |
| DO2234 | 64 | female | alive | 0.06 | complete remission |
| DO223927 | 54 | female | alive | 0.09 | complete remission |
| DO223930 | 63 | female | alive | 0.42 | complete remission |
| DO223931 | 76 | female | alive | 0.17 | complete remission |
| DO223932 | 88 | female | NA | NA | complete remission |
| DO223933 | 74 | female | alive | 0.03 | complete remission |
| DO223934 | 62 | female | alive | 2.08 | complete remission |
| DO223935 | 60 | female | alive | 2.61 | complete remission |
| DO223936 | 32 | female | alive | 2.77 | complete remission |
| DO223937 | 75 | female | alive | 4.35 | complete remission |
| DO2240 | 50 | female | alive | 2.67 | complete remission |
| DO2246 | 53 | female | alive | 4.74 | NA |
| DO2252 | 41 | female | alive | 1.6 | complete remission |
| DO2258 | 63 | female | alive | 5.21 | complete remission |
| DO2264 | 46 | female | alive | 1.51 | complete remission |
| DO2269 | 55 | female | deceased | 1.69 | NA |
| DO2275 | 63 | female | NA | NA | NA |
| DO2281 | 63 | female | alive | 1.84 | complete remission |
| DO2287 | 43 | female | alive | 6.34 | NA |
| DO2293 | 50 | female | alive | 0.2 | complete remission |
| DO2299 | 50 | female | alive | 0.38 | complete remission |
| DO2305 | 58 | female | alive | 6.44 | complete remission |
| DO2311 | 45 | female | alive | 2.58 | progression |
| DO2317 | 49 | female | alive | 3.34 | NA |
| DO2323 | 56 | female | alive | 0.04 | complete remission |
| DO2329 | 60 | female | alive | 14.4 | complete remission |
| DO2335 | 67 | female | alive | 4.79 | complete remission |
| DO2341 | 61 | female | alive | 0.63 | complete remission |
| DO2347 | 43 | female | alive | 2.83 | complete remission |
| DO2353 | 26 | female | alive | 5.7 | complete remission |
| DO2359 | 56 | female | alive | 0.0 | complete remission |
| DO2365 | 68 | female | alive | 0.1 | complete remission |
| DO2371 | 53 | female | alive | 2.09 | complete remission |
| DO2377 | 58 | female | alive | 1.42 | complete remission |
| DO2383 | 46 | female | alive | 1.73 | NA |
| DO2389 | 54 | female | alive | 4.14 | complete remission |
| DO2395 | 61 | female | alive | 0.03 | complete remission |
| DO2401 | 90 | female | alive | 0.22 | complete remission |
| DO2407 | 51 | female | alive | 2.03 | complete remission |
| DO2413 | 45 | female | alive | 2.07 | complete remission |
| DO2419 | 50 | female | alive | 0.38 | complete remission |
| DO2425 | 64 | female | alive | 0.04 | complete remission |
| DO2431 | 71 | female | alive | 0.72 | complete remission |
| DO2437 | 67 | female | alive | 2.51 | complete remission |
| DO2443 | 41 | female | alive | 2.43 | complete remission |
| DO2449 | 50 | female | alive | 3.38 | NA |
| DO2455 | 79 | female | alive | 1.33 | complete remission |
| DO2461 | 52 | female | alive | 0.46 | complete remission |
| DO2467 | 73 | female | alive | 2.07 | complete remission |
| DO2473 | 80 | female | alive | 1.08 | complete remission |
| DO2479 | 45 | female | alive | 4.78 | NA |
| DO2485 | 52 | female | alive | 5.16 | complete remission |
| DO2491 | 65 | female | alive | 4.22 | complete remission |
| DO2497 | 59 | female | alive | 0.65 | complete remission |
| DO2503 | 41 | female | alive | 3.2 | complete remission |
| DO2509 | 65 | female | alive | 1.68 | NA |
| DO2515 | 37 | female | alive | 3.7 | complete remission |
| DO2521 | 51 | female | alive | 4.77 | complete remission |
| DO2527 | 78 | female | alive | 1.44 | complete remission |
| DO2533 | 68 | female | alive | 0.97 | complete remission |
| DO2539 | 69 | female | alive | 2.75 | complete remission |
| DO2545 | 64 | female | alive | 4.02 | complete remission |
| DO2551 | 52 | female | alive | 0.34 | complete remission |
| DO2557 | 60 | female | alive | 0.35 | complete remission |
| DO2563 | 60 | female | alive | 6.83 | complete remission |
| DO2569 | 58 | female | NA | NA | complete remission |
| DO2575 | 59 | female | alive | 0.04 | complete remission |
| DO2581 | 73 | female | deceased | 8.56 | NA |
| DO2587 | 48 | male | alive | 0.14 | complete remission |
| DO2593 | 75 | female | NA | NA | complete remission |
| DO2599 | 89 | female | alive | 0.08 | complete remission |
| DO2605 | 57 | female | alive | 0.6 | complete remission |
| DO2611 | 44 | female | alive | 18.61 | progression |
| DO2617 | 66 | female | alive | 4.5 | complete remission |
| DO2623 | 74 | female | alive | 9.24 | complete remission |
| DO2629 | 40 | female | alive | 1.42 | complete remission |
| DO2635 | 39 | female | alive | 0.88 | complete remission |
| DO2641 | 47 | female | alive | 4.74 | complete remission |
| DO2647 | 62 | female | deceased | 1.17 | NA |
| DO2653 | 38 | female | deceased | 4.64 | NA |
| DO2659 | 62 | female | alive | 0.79 | complete remission |
| DO2665 | 68 | female | alive | 0.1 | complete remission |
| DO2671 | 51 | female | deceased | 8.12 | NA |
| DO2676 | 45 | female | alive | 3.23 | complete remission |
| DO2682 | 66 | female | alive | 0.47 | complete remission |
| DO2688 | 62 | female | alive | 2.6 | complete remission |
| DO2694 | 73 | female | alive | 2.78 | complete remission |
| DO2700 | 65 | female | alive | 0.12 | complete remission |
| DO2706 | 39 | female | alive | 0.71 | complete remission |
| DO2712 | 69 | female | alive | 1.17 | complete remission |
| DO2713 | 49 | female | alive | 3.59 | complete remission |
| DO2719 | 84 | female | deceased | 0.73 | NA |
| DO2725 | 79 | female | deceased | 1.47 | NA |
| DO2731 | 36 | female | alive | 0.25 | complete remission |
| DO2737 | 52 | female | deceased | 3.09 | NA |
| DO2743 | 63 | female | alive | 1.62 | complete remission |
| DO2749 | 81 | female | deceased | 9.36 | NA |
| DO2755 | 52 | female | alive | 3.57 | complete remission |
| DO2761 | 57 | female | alive | 1.99 | complete remission |
| DO2764 | 71 | female | alive | 13.5 | complete remission |
| DO2770 | 63 | female | alive | 1.12 | complete remission |
| DO2776 | 47 | female | alive | 1.84 | complete remission |
| DO2777 | 45 | female | alive | 1.52 | complete remission |
| DO2783 | 62 | female | alive | 0.03 | complete remission |
| DO2788 | 53 | female | alive | 0.6 | complete remission |
| DO2794 | 67 | female | deceased | 6.62 | NA |
| DO2796 | 59 | female | alive | 1.2 | NA |
| DO2802 | 68 | female | alive | 1.59 | complete remission |
| DO2808 | 50 | female | alive | 1.41 | complete remission |
| DO2813 | 42 | female | alive | 14.74 | complete remission |
| DO2819 | 60 | female | alive | 0.05 | complete remission |
| DO2825 | 67 | female | alive | 0.03 | complete remission |
| DO2831 | 51 | female | alive | 3.1 | complete remission |
| DO2836 | 61 | female | alive | 0.91 | complete remission |
| DO2842 | 58 | female | deceased | 0.65 | NA |
| DO2848 | 52 | female | alive | 4.51 | NA |
| DO2854 | 61 | female | alive | 2.69 | complete remission |
| DO2860 | 59 | female | alive | 4.96 | complete remission |
| DO2866 | 39 | female | alive | 1.14 | complete remission |
| DO2870 | 65 | female | alive | 1.58 | complete remission |
| DO2874 | 57 | female | alive | 0.52 | complete remission |
| DO2879 | 56 | female | alive | 3.62 | complete remission |
| DO2885 | 74 | female | alive | 0.03 | complete remission |
| DO2891 | 36 | female | alive | 4.03 | complete remission |
| DO2897 | 82 | female | alive | 1.02 | complete remission |
| DO2903 | 48 | female | alive | 0.73 | complete remission |
| DO2909 | 61 | female | alive | 0.76 | complete remission |
| DO2913 | 67 | female | alive | 0.44 | NA |
| DO2919 | 43 | female | alive | 1.36 | complete remission |
| DO2925 | 80 | female | alive | 0.13 | complete remission |
| DO2931 | 63 | female | alive | 3.17 | complete remission |
| DO2937 | 53 | female | alive | 0.71 | complete remission |
| DO2943 | 80 | female | NA | NA | complete remission |
| DO2949 | 72 | female | alive | 8.27 | complete remission |
| DO2955 | 40 | female | alive | 0.83 | progression |
| DO2961 | 62 | female | alive | 3.16 | complete remission |
| DO2966 | 59 | female | alive | 4.47 | complete remission |
| DO2972 | 84 | female | alive | 0.4 | complete remission |
| DO2978 | 31 | female | deceased | 4.91 | NA |
| DO2983 | 80 | female | alive | 1.8 | complete remission |
| DO2989 | 76 | female | alive | 0.87 | complete remission |
| DO2995 | 60 | female | alive | 1.76 | complete remission |
| DO3001 | 63 | female | alive | 8.16 | complete remission |
| DO3007 | 55 | female | alive | 3.07 | progression |
| DO3013 | 39 | female | alive | 0.89 | complete remission |
| DO3019 | 48 | female | NA | NA | complete remission |
| DO3025 | 60 | female | alive | 4.066 | complete remission |
| DO3031 | 46 | female | alive | 3.64 | complete remission |
| DO3037 | 77 | male | alive | 0.66 | complete remission |
| DO3043 | 65 | female | alive | 9.13 | NA |
| DO3049 | 61 | female | alive | 0.69 | complete remission |
| DO3055 | 38 | female | deceased | 5.46 | NA |
| DO3061 | 81 | female | alive | 0.33 | complete remission |
| DO3067 | 66 | female | alive | 9.17 | complete remission |
| DO3070 | 67 | female | alive | 1.41 | complete remission |
| DO3076 | 40 | female | alive | 1.6 | complete remission |
| DO3082 | 56 | female | alive | 3.07 | complete remission |
| DO3083 | 53 | female | alive | 0.5 | NA |
| DO3089 | 75 | female | alive | 3.42 | complete remission |
| DO3095 | 69 | female | alive | 0.48 | complete remission |
| DO3101 | 44 | female | alive | 8.13 | complete remission |
| DO3107 | 61 | female | alive | 0.34 | complete remission |
| DO3110 | 89 | female | deceased | 0.83 | NA |
| DO3116 | 62 | female | alive | 6.55 | complete remission |
| DO3122 | 45 | female | alive | 3.73 | complete remission |
| DO3128 | 57 | female | deceased | 6.5 | NA |
| DO3134 | 60 | female | alive | 1.07 | complete remission |
| DO3140 | 71 | female | alive | 1.59 | complete remission |
| DO3146 | 68 | female | alive | 2.5 | complete remission |
| DO3152 | 72 | female | deceased | 2.71 | NA |
| DO3158 | 69 | female | alive | 2.36 | complete remission |
| DO3164 | 59 | female | alive | 1.27 | complete remission |
| DO3170 | 38 | female | NA | NA | complete remission |
| DO3176 | 62 | female | deceased | 7.43 | NA |
| DO3182 | 78 | female | alive | 0.01 | complete remission |
| DO3188 | 84 | female | alive | 2.75 | complete remission |
| DO3194 | 62 | female | alive | 3.48 | complete remission |
| DO3200 | 46 | female | alive | 4.44 | NA |
| DO3204 | 37 | female | alive | 1.36 | complete remission |
| DO3209 | 72 | female | alive | 0.04 | complete remission |
| DO3215 | 42 | female | alive | 3.25 | complete remission |
| DO3221 | 61 | female | alive | 3.44 | progression |
| DO3227 | 42 | female | alive | 1.17 | complete remission |
| DO3233 | 53 | female | alive | 0.87 | complete remission |
| DO3239 | 46 | female | alive | 3.15 | complete remission |
| DO3245 | 65 | female | alive | 1.58 | complete remission |
| DO3251 | 70 | female | NA | NA | complete remission |
| DO3257 | 61 | female | alive | 14.77 | complete remission |
| DO3263 | 51 | female | alive | 18.4 | complete remission |
| DO3269 | 42 | female | alive | 4.75 | complete remission |
| DO3275 | 55 | female | alive | 0.52 | complete remission |
| DO3281 | 51 | female | alive | 0.05 | complete remission |
| DO3287 | 77 | female | alive | 0.29 | complete remission |
| DO3293 | 48 | female | deceased | 4.82 | NA |
| DO3299 | 46 | female | alive | 2.12 | complete remission |
| DO3305 | 64 | female | alive | 7.75 | progression |
| DO3311 | 85 | female | alive | 2.34 | complete remission |
| DO3317 | 58 | female | alive | 3.52 | complete remission |
| DO3322 | 63 | female | alive | 0.03 | NA |
| DO3328 | 51 | female | alive | 0.06 | complete remission |
| DO3334 | 73 | female | alive | 2.58 | progression |
| DO3340 | 61 | female | alive | 1.2 | complete remission |
| DO3346 | 60 | female | deceased | 2.52 | NA |
| DO3352 | 58 | female | alive | 0.09 | complete remission |
| DO3358 | 69 | female | alive | 0.09 | NA |
| DO3364 | 68 | female | deceased | 2.76 | NA |
| DO3370 | 56 | female | alive | 2.14 | complete remission |
| DO3376 | 65 | female | alive | 0.46 | complete remission |
| DO3382 | 41 | female | alive | 3.18 | complete remission |
| DO3388 | 84 | female | alive | 1.0 | complete remission |
| DO3394 | 40 | female | alive | 4.03 | complete remission |
| DO3400 | 53 | female | deceased | 2.63 | NA |
| DO3406 | 72 | female | alive | 0.73 | complete remission |
| DO3412 | 55 | female | alive | 0.03 | NA |
| DO3418 | 42 | female | alive | 5.5 | complete remission |
| DO3424 | 40 | female | deceased | 9.48 | NA |
| DO3430 | 53 | female | alive | 3.85 | complete remission |
| DO3436 | 46 | female | alive | 0.65 | complete remission |
| DO3442 | 47 | female | alive | 0.33 | complete remission |
| DO3448 | 73 | female | alive | 0.67 | progression |
| DO3454 | 46 | female | alive | 0.54 | complete remission |
| DO3458 | 34 | female | alive | 6.69 | complete remission |
| DO3464 | 78 | female | alive | 0.04 | NA |
| DO3470 | 79 | female | alive | 2.01 | complete remission |
| DO3476 | 56 | female | alive | 0.3 | complete remission |
| DO3482 | 61 | female | alive | 17.62 | complete remission |
| DO3488 | 42 | female | alive | 2.02 | complete remission |
| DO3494 | 78 | female | deceased | 5.82 | NA |
| DO3500 | 55 | female | alive | 0.99 | complete remission |
| DO3506 | 69 | female | alive | 3.41 | complete remission |
| DO3512 | 77 | female | alive | 6.88 | complete remission |
| DO3518 | 51 | female | alive | 0.29 | complete remission |
| DO3524 | 49 | female | alive | 5.5 | NA |
| DO3530 | 57 | female | alive | 4.67 | complete remission |
| DO3536 | 79 | female | alive | 3.18 | complete remission |
| DO3542 | 82 | female | alive | 0.75 | complete remission |
| DO3548 | 53 | female | alive | 2.05 | complete remission |
| DO3554 | 74 | female | alive | 0.13 | complete remission |
| DO3560 | 36 | female | alive | 0.42 | complete remission |
| DO3566 | 62 | female | deceased | 2.36 | NA |
| DO3572 | 47 | female | alive | 1.52 | complete remission |
| DO3578 | 54 | female | alive | 2.97 | complete remission |
| DO3584 | 64 | female | alive | 1.75 | complete remission |
| DO3590 | 81 | female | alive | 0.47 | complete remission |
| DO3596 | 48 | female | alive | 9.2 | complete remission |
| DO3602 | 47 | female | alive | 0.87 | complete remission |
| DO3608 | 53 | female | alive | 1.0 | complete remission |
| DO3614 | 62 | female | alive | 1.33 | complete remission |
| DO3620 | 36 | female | alive | 6.48 | complete remission |
| DO3626 | 62 | female | alive | 0.08 | NA |
| DO3632 | 62 | female | alive | 0.41 | complete remission |
| DO3638 | 39 | female | alive | 7.8 | complete remission |
| DO3644 | 60 | female | deceased | 6.76 | NA |
| DO3650 | 53 | female | alive | 5.38 | complete remission |
| DO3656 | 57 | female | alive | 9.12 | complete remission |
| DO3662 | 71 | female | alive | 0.97 | complete remission |
| DO3668 | 62 | female | deceased | 4.88 | NA |
| DO3674 | 70 | female | deceased | 0.61 | NA |
| DO3680 | 60 | female | alive | 1.08 | complete remission |
| DO3686 | 81 | female | alive | 0.17 | NA |
| DO3692 | 63 | female | alive | 0.23 | complete remission |
| DO3698 | 53 | female | alive | 2.4 | complete remission |
| DO3703 | 71 | female | alive | 0.06 | complete remission |
| DO3709 | 59 | female | alive | 0.01 | complete remission |
| DO3715 | 64 | female | alive | 0.9 | complete remission |
| DO3721 | 64 | female | alive | 1.28 | complete remission |
| DO3727 | 54 | female | alive | 3.76 | complete remission |
| DO3733 | 85 | female | alive | 0.22 | complete remission |
| DO3739 | 73 | female | alive | 1.08 | complete remission |
| DO3745 | 68 | female | alive | 0.03 | complete remission |
| DO3751 | 62 | female | NA | NA | complete remission |
| DO3757 | 40 | female | alive | 0.058 | complete remission |
| DO3763 | 41 | female | alive | 1.66 | complete remission |
| DO3769 | 46 | female | alive | 0.08 | complete remission |
| DO3775 | 84 | female | alive | 0.63 | complete remission |
| DO3781 | 87 | female | deceased | 2.17 | NA |
| DO3787 | 80 | female | deceased | 6.94 | NA |
| DO3793 | 45 | female | alive | 0.04 | complete remission |
| DO3799 | 59 | female | alive | 1.74 | complete remission |
| DO3804 | 52 | female | alive | 0.01 | complete remission |
| DO3810 | 50 | female | alive | 0.94 | complete remission |
| DO3816 | 54 | female | alive | 5.97 | complete remission |
| DO3822 | 62 | female | alive | 2.31 | complete remission |
| DO3828 | 61 | female | alive | 0.6 | complete remission |
| DO3834 | 56 | female | alive | 2.58 | complete remission |
| DO3840 | 53 | female | alive | 3.56 | complete remission |
| DO3846 | 70 | female | alive | 4.27 | complete remission |
| DO3852 | 75 | female | alive | 1.25 | complete remission |
| DO3856 | 45 | female | alive | 0.08 | complete remission |
| DO3862 | 88 | female | alive | 0.58 | complete remission |
| DO3868 | 63 | female | alive | 0.5 | complete remission |
| DO3874 | 55 | female | alive | 1.9 | complete remission |
| DO3880 | 90 | female | alive | 0.3 | NA |
| DO3886 | 37 | female | alive | 1.25 | complete remission |
| DO3892 | 36 | female | alive | 0.4 | complete remission |
| DO3898 | 59 | female | alive | 0.18 | NA |
| DO3904 | 74 | female | alive | 0.02 | complete remission |
| DO3910 | 29 | female | alive | 8.0 | complete remission |
| DO3916 | 54 | female | alive | 4.61 | NA |
| DO3922 | 41 | female | alive | 0.54 | complete remission |
| DO3928 | 26 | female | alive | 6.08 | NA |
| DO3934 | 38 | female | alive | 0.71 | complete remission |
| DO3940 | 45 | female | alive | 3.5 | complete remission |
| DO3946 | 47 | female | deceased | 2.83 | NA |
| DO3952 | 38 | female | alive | 0.01 | complete remission |
| DO3958 | 76 | female | alive | 2.15 | complete remission |
| DO3964 | 63 | female | alive | 0.06 | complete remission |
| DO3970 | 56 | female | alive | 0.39 | complete remission |
| DO3976 | 62 | female | alive | 0.55 | complete remission |
| DO3982 | 60 | female | alive | 2.38 | complete remission |
| DO3988 | 59 | female | alive | 3.61 | complete remission |
| DO3994 | 71 | female | deceased | 2.41 | NA |
| DO4000 | 55 | female | NA | NA | complete remission |
| DO4006 | 49 | female | alive | 0.19 | progression |
| DO4012 | 38 | female | deceased | 8.39 | NA |
| DO4018 | 50 | female | alive | 0.96 | complete remission |
| DO4024 | 62 | female | alive | 0.1 | complete remission |
| DO4030 | 57 | female | alive | 7.53 | complete remission |
| DO4036 | 63 | female | alive | 1.11 | complete remission |
| DO4038 | 46 | female | alive | 1.23 | complete remission |
| DO4044 | 55 | female | NA | NA | complete remission |
| DO4050 | 29 | female | alive | 0.02 | complete remission |
| DO4056 | 76 | female | alive | 4.06 | complete remission |
| DO4062 | 83 | female | alive | 4.39 | complete remission |
| DO4068 | 32 | female | alive | 0.47 | complete remission |
| DO4074 | 50 | female | alive | 0.73 | complete remission |
| DO4080 | 57 | female | alive | 0.7 | complete remission |
| DO4086 | 49 | female | alive | 0.02 | complete remission |
| DO4092 | 84 | female | alive | 0.09 | NA |
| DO4098 | 44 | female | alive | 0.54 | complete remission |
| DO4104 | 73 | female | alive | 0.02 | NA |
| DO4110 | 40 | female | NA | NA | complete remission |
| DO4116 | 51 | female | alive | 1.27 | complete remission |
| DO4122 | 59 | female | alive | 0.92 | complete remission |
| DO4128 | 37 | female | alive | 0.44 | complete remission |
| DO4134 | 69 | female | deceased | 6.8 | NA |
| DO4138 | 73 | female | deceased | 6.46 | NA |
| DO4143 | 54 | female | deceased | 2.65 | NA |
| DO4149 | 53 | female | alive | 1.04 | complete remission |
| DO4155 | 45 | female | deceased | 7.81 | NA |
| DO4161 | 61 | female | alive | 1.5 | complete remission |
| DO4167 | 42 | female | alive | 13.11 | complete remission |
| DO4173 | 77 | female | alive | 0.46 | complete remission |
| DO4179 | 75 | female | alive | 0.09 | complete remission |
| DO4185 | 42 | female | alive | 1.42 | complete remission |
| DO4191 | 56 | female | alive | 0.01 | complete remission |
| DO4197 | 65 | female | alive | 1.42 | NA |
| DO4203 | 35 | female | alive | 1.0 | complete remission |
| DO4209 | 51 | female | alive | 5.86 | complete remission |
| DO4215 | 55 | female | alive | 4.49 | complete remission |
| DO4221 | 64 | female | alive | 1.42 | progression |
| DO4227 | 70 | female | alive | 1.63 | complete remission |
| DO4233 | 61 | female | alive | 2.12 | complete remission |
| DO4239 | 47 | female | alive | 4.01 | complete remission |
| DO4245 | 39 | female | deceased | 6.04 | NA |
| DO4251 | 69 | female | alive | 0.75 | complete remission |
| DO4257 | 67 | female | deceased | 4.13 | NA |
| DO4263 | 45 | female | alive | 0.27 | complete remission |
| DO4269 | 48 | female | alive | 3.57 | complete remission |
| DO4275 | 35 | female | alive | 3.67 | complete remission |
| DO4281 | 78 | male | alive | 2.28 | complete remission |
| DO4287 | 47 | female | alive | 0.03 | complete remission |
| DO4293 | 42 | female | NA | NA | complete remission |
| DO4299 | 50 | female | alive | 3.27 | complete remission |
| DO4305 | 62 | female | alive | 0.05 | complete remission |
| DO4311 | 80 | female | alive | 0.59 | complete remission |
| DO4317 | 46 | female | alive | 3.12 | NA |
| DO4323 | 51 | female | alive | 2.33 | complete remission |
| DO4329 | 66 | female | alive | 8.63 | complete remission |
| DO4335 | 36 | female | alive | 0.95 | progression |
| DO4341 | 62 | female | alive | 0.98 | complete remission |
| DO4347 | 45 | female | alive | 0.01 | NA |
| DO4353 | 36 | female | alive | 5.84 | NA |
| DO4359 | 50 | female | alive | 0.58 | NA |
| DO4365 | 48 | female | alive | 2.7 | complete remission |
| DO4371 | 76 | female | alive | 0.9 | complete remission |
| DO4377 | 67 | female | alive | 0.83 | complete remission |
| DO4383 | 35 | female | alive | 1.88 | complete remission |
| DO4389 | 80 | female | alive | 0.75 | NA |
| DO4395 | 52 | female | alive | 2.74 | complete remission |
| DO4401 | 47 | female | alive | 4.44 | NA |
| DO4407 | 45 | female | deceased | 7.05 | NA |
| DO44099 | 54 | female | alive | 1.21 | complete remission |
| DO44101 | 69 | female | alive | 0.6 | complete remission |
| DO44103 | 49 | female | alive | 3.2 | complete remission |
| DO44105 | 41 | female | alive | 0.02 | complete remission |
| DO44107 | 68 | female | alive | 0.61 | complete remission |
| DO44109 | 40 | female | alive | 0.63 | complete remission |
| DO44111 | 49 | female | alive | 4.7 | complete remission |
| DO44113 | 70 | female | alive | 3.88 | complete remission |
| DO44115 | 62 | female | alive | 0.58 | complete remission |
| DO44117 | 68 | female | alive | 0.019 | complete remission |
| DO44119 | 49 | female | alive | 0.99 | NA |
| DO44121 | 61 | female | alive | 3.72 | complete remission |
| DO44123 | 90 | female | alive | 0.14 | complete remission |
| DO44125 | 84 | female | alive | 0.58 | complete remission |
| DO44127 | 62 | female | alive | 0.59 | complete remission |
| DO44129 | 41 | female | alive | 0.75 | complete remission |
| DO4413 | 76 | female | alive | 3.21 | complete remission |
| DO44131 | 46 | female | alive | 0.96 | NA |
| DO44133 | 60 | female | alive | 0.0 | complete remission |
| DO44135 | 68 | female | deceased | 0.88 | NA |
| DO44137 | 46 | female | alive | 2.66 | complete remission |
| DO44138 | 79 | female | alive | 0.78 | complete remission |
| DO44140 | 46 | female | alive | 1.17 | complete remission |
| DO44141 | 54 | female | alive | 1.02 | complete remission |
| DO44143 | 71 | female | alive | 1.05 | complete remission |
| DO44145 | 85 | female | alive | 9.33 | complete remission |
| DO44146 | 65 | female | alive | 1.51 | complete remission |
| DO44147 | 50 | female | alive | 0.63 | NA |
| DO44148 | 88 | female | alive | 0.39 | progression |
| DO44150 | 56 | female | alive | 0.55 | complete remission |
| DO44152 | 49 | female | alive | 2.15 | complete remission |
| DO44153 | 80 | female | alive | 4.54 | complete remission |
| DO44155 | 66 | female | alive | 0.82 | complete remission |
| DO44157 | 77 | female | alive | 0.74 | NA |
| DO44159 | 74 | female | alive | 1.13 | complete remission |
| DO44161 | 62 | female | alive | 3.94 | complete remission |
| DO44163 | 54 | female | alive | 8.09 | complete remission |
| DO44165 | 84 | female | alive | 0.49 | complete remission |
| DO44166 | 64 | female | alive | 0.46 | NA |
| DO44168 | 67 | female | alive | 4.8 | complete remission |
| DO44170 | 45 | female | alive | 6.13 | complete remission |
| DO44172 | 71 | female | alive | 2.59 | complete remission |
| DO44174 | 51 | female | alive | 0.21 | complete remission |
| DO44175 | 54 | female | alive | 1.2 | complete remission |
| DO44177 | 48 | female | alive | 0.06 | complete remission |
| DO44178 | 44 | female | alive | 0.69 | complete remission |
| DO44180 | 56 | female | alive | 8.27 | complete remission |
| DO44182 | 75 | female | alive | 0.16 | NA |
| DO44184 | 62 | female | alive | 0.56 | complete remission |
| DO44186 | 52 | female | alive | 5.21 | complete remission |
| DO44188 | 60 | female | alive | 10.46 | complete remission |
| DO4419 | 48 | female | NA | NA | complete remission |
| DO44190 | 42 | female | alive | 3.31 | complete remission |
| DO44192 | 60 | female | alive | 0.03 | complete remission |
| DO44194 | 48 | female | alive | 1.85 | complete remission |
| DO44196 | 63 | female | alive | 2.3 | complete remission |
| DO44198 | 78 | female | alive | 0.09 | complete remission |
| DO44200 | 47 | female | alive | 1.5 | complete remission |
| DO44202 | 51 | female | alive | 0.88 | complete remission |
| DO44204 | 61 | female | alive | 1.51 | complete remission |
| DO44206 | 63 | female | alive | 1.13 | complete remission |
| DO44208 | 66 | female | alive | 0.11 | complete remission |
| DO44210 | 70 | female | alive | 0.8 | NA |
| DO44212 | 51 | female | alive | 1.41 | complete remission |
| DO44214 | 49 | female | alive | 0.61 | complete remission |
| DO44216 | 66 | female | alive | 1.0 | complete remission |
| DO44218 | 63 | female | alive | 0.019 | complete remission |
| DO44220 | 65 | female | alive | 0.02 | complete remission |
| DO44222 | 35 | female | deceased | 2.5 | NA |
| DO44224 | 43 | female | alive | 2.01 | complete remission |
| DO44226 | 67 | female | alive | 0.75 | NA |
| DO44228 | 57 | female | alive | 0.86 | complete remission |
| DO44230 | 72 | female | alive | 2.8 | complete remission |
| DO44232 | 62 | female | deceased | 2.83 | NA |
| DO44234 | 85 | female | NA | NA | complete remission |
| DO44236 | 74 | female | alive | 0.13 | NA |
| DO44238 | 40 | female | alive | 2.18 | complete remission |
| DO44240 | 44 | female | alive | 4.49 | complete remission |
| DO44242 | 45 | female | alive | 0.46 | complete remission |
| DO44243 | 80 | female | alive | 9.1 | NA |
| DO44245 | 68 | female | alive | 1.08 | complete remission |
| DO44246 | 47 | female | alive | 0.1 | complete remission |
| DO44247 | 44 | female | alive | 0.23 | progression |
| DO44248 | 59 | female | alive | 0.29 | complete remission |
| DO44249 | 63 | female | NA | NA | complete remission |
| DO4425 | 62 | female | alive | 13.25 | NA |
| DO44250 | 59 | female | alive | 1.13 | complete remission |
| DO44252 | 46 | female | alive | 0.73 | complete remission |
| DO44254 | 46 | female | alive | 2.69 | complete remission |
| DO44256 | 51 | male | alive | 1.82 | complete remission |
| DO44258 | 36 | female | alive | 1.96 | complete remission |
| DO44260 | 56 | female | alive | 0.51 | complete remission |
| DO44262 | 75 | female | alive | 0.08 | complete remission |
| DO44264 | 52 | female | alive | 1.18 | progression |
| DO44266 | 75 | female | alive | 0.85 | complete remission |
| DO44268 | 33 | female | alive | 0.05 | complete remission |
| DO44270 | 61 | female | alive | 0.06 | complete remission |
| DO44272 | 39 | female | alive | 0.6 | complete remission |
| DO44273 | 57 | female | alive | 2.35 | complete remission |
| DO4431 | 54 | female | alive | 2.09 | progression |
| DO4437 | 73 | female | alive | 6.29 | complete remission |
| DO4443 | 47 | female | alive | 3.63 | complete remission |
| DO4449 | 56 | female | alive | 1.61 | progression |
| DO4455 | 53 | female | alive | 0.32 | complete remission |
| DO4461 | 41 | female | alive | 2.66 | complete remission |
| DO4467 | 74 | female | alive | 2.49 | complete remission |
| DO4473 | 38 | female | alive | 0.12 | complete remission |
| DO4479 | 41 | female | alive | 5.12 | complete remission |
| DO4485 | 48 | female | alive | 0.69 | complete remission |
| DO4491 | 82 | female | deceased | 3.74 | NA |
| DO4497 | 62 | female | alive | 0.9 | complete remission |
| DO4503 | 52 | female | alive | 0.72 | complete remission |
| DO4509 | 65 | female | alive | 0.73 | complete remission |
| DO4515 | 80 | female | deceased | 2.42 | NA |
| DO4521 | 58 | female | deceased | 8.12 | NA |
| DO4527 | 56 | female | deceased | 1.68 | NA |
| DO4533 | 64 | female | alive | 3.02 | NA |
| DO4539 | 72 | female | alive | 2.03 | complete remission |
| DO4545 | 38 | female | alive | 0.77 | complete remission |
| DO4551 | 61 | female | alive | 0.03 | complete remission |
| DO4557 | 49 | female | deceased | 2.71 | NA |
| DO4563 | 79 | female | alive | 3.08 | complete remission |
| DO4569 | 46 | female | alive | 16.18 | progression |
| DO4575 | 71 | female | alive | 1.15 | complete remission |
| DO4581 | 50 | female | alive | 3.48 | complete remission |
| DO4587 | 47 | female | alive | 0.07 | NA |
| DO4593 | 68 | female | alive | 0.91 | complete remission |
| DO4599 | 54 | female | alive | 0.75 | complete remission |
| DO4605 | 35 | female | deceased | 9.48 | NA |
| DO4611 | 54 | female | alive | 1.0 | complete remission |
| DO4617 | 65 | male | alive | 3.26 | complete remission |
| DO4623 | 48 | female | alive | 0.08 | complete remission |
| DO4629 | 34 | female | alive | 0.09 | complete remission |
| DO4635 | 52 | female | alive | 3.23 | complete remission |
| DO4641 | 58 | female | alive | 1.27 | complete remission |
| DO4647 | 70 | female | NA | NA | complete remission |
| DO4653 | 62 | female | alive | 0.21 | complete remission |
| DO4659 | 68 | male | alive | 3.55 | NA |
| DO4665 | 60 | female | alive | 0.06 | NA |
| DO4671 | 59 | female | alive | 1.08 | complete remission |
| DO4677 | 50 | female | NA | NA | complete remission |
| DO4683 | 64 | female | alive | 0.75 | complete remission |
| DO4689 | 47 | female | alive | 5.15 | complete remission |
| DO4695 | 70 | female | alive | 1.67 | complete remission |
| DO4701 | 74 | female | alive | 2.62 | complete remission |
| DO4707 | 43 | female | alive | 5.33 | complete remission |
| DO4713 | 57 | female | alive | 1.59 | complete remission |
| DO4719 | 70 | female | alive | 3.52 | complete remission |
| DO4725 | 47 | female | alive | 2.37 | complete remission |
| DO4731 | 55 | female | alive | 0.03 | complete remission |
| DO4737 | 61 | female | NA | NA | complete remission |
| DO4743 | 48 | female | deceased | 4.26 | NA |
| DO4749 | 55 | female | alive | 0.89 | complete remission |
| DO4756 | 56 | female | alive | 0.0 | complete remission |
| DO4763 | 68 | female | deceased | 0.44 | NA |
| DO4766 | 64 | female | alive | 3.21 | NA |
| DO4773 | 64 | female | alive | 5.62 | complete remission |
| DO4780 | 71 | female | alive | 5.25 | complete remission |
| DO4787 | 50 | female | alive | 5.25 | complete remission |
| DO4794 | 34 | female | NA | NA | complete remission |
| DO4796 | 48 | female | alive | 1.33 | complete remission |
| DO4803 | 52 | female | alive | 0.12 | complete remission |
| DO4810 | 69 | female | deceased | 4.96 | NA |
| DO4817 | 60 | female | alive | 2.67 | complete remission |
| DO4824 | 74 | female | NA | NA | complete remission |
| DO4830 | 31 | female | deceased | 6.22 | NA |
| DO4837 | 66 | female | alive | 3.14 | complete remission |
| DO4844 | 47 | female | alive | 2.2 | complete remission |
| DO4847 | 40 | female | alive | 10.6 | complete remission |
| DO4854 | 48 | female | alive | 15.54 | complete remission |
| DO4861 | 69 | female | alive | 0.03 | complete remission |
| DO4866 | 59 | female | alive | 0.47 | complete remission |
| DO4872 | 66 | female | alive | 2.17 | complete remission |
| DO4879 | 66 | female | alive | 2.48 | complete remission |
| DO4886 | 43 | female | alive | 0.59 | complete remission |
| DO4893 | 50 | female | deceased | 1.44 | NA |
| DO4900 | 63 | female | alive | 0.21 | complete remission |
| DO49021 | 79 | female | alive | 0.15 | complete remission |
| DO49022 | 44 | female | alive | 1.66 | complete remission |
| DO49023 | 71 | female | alive | 0.57 | complete remission |
| DO49024 | 65 | female | alive | 0.15 | complete remission |
| DO49025 | 79 | female | alive | 0.56 | progression |
| DO49026 | 55 | female | alive | 4.16 | complete remission |
| DO49027 | 54 | female | alive | 0.38 | complete remission |
| DO4907 | 71 | female | alive | 0.54 | complete remission |
| DO4914 | 58 | female | NA | NA | complete remission |
| DO4921 | 61 | male | alive | 0.48 | complete remission |
| DO4928 | 90 | female | deceased | 4.22 | NA |
| DO4935 | 49 | female | alive | 1.7 | complete remission |
| DO4942 | 80 | female | alive | 1.49 | complete remission |
| DO4949 | 71 | female | alive | 0.41 | complete remission |
| DO4956 | 61 | female | NA | NA | complete remission |
| DO4963 | 36 | female | deceased | 1.5 | NA |
| DO4970 | 61 | female | alive | 1.59 | complete remission |
| DO4977 | 76 | female | alive | 0.83 | NA |
| DO4984 | 74 | female | alive | 0.17 | complete remission |
| DO4991 | 40 | female | alive | 4.62 | complete remission |
| DO4998 | 79 | female | alive | 3.73 | complete remission |
| DO50012 | 52 | female | alive | 0.03 | NA |
| DO50013 | 47 | female | alive | 0.37 | complete remission |
| DO50014 | 48 | female | alive | 0.36 | complete remission |
| DO50015 | 51 | female | alive | 0.5 | complete remission |
| DO50017 | 48 | female | alive | 0.48 | complete remission |
| DO50019 | 68 | female | alive | 0.46 | complete remission |
| DO50021 | 48 | female | alive | 0.34 | complete remission |
| DO50023 | 74 | female | alive | 0.13 | complete remission |
| DO50024 | 58 | male | alive | 0.01 | progression |
| DO50026 | 72 | female | alive | 0.09 | complete remission |
| DO50028 | 73 | female | alive | 0.06 | complete remission |
| DO50030 | 49 | female | alive | 0.04 | complete remission |
| DO50032 | 72 | female | alive | 0.15 | complete remission |
| DO50034 | 72 | female | alive | 0.09 | complete remission |
| DO50036 | 75 | female | alive | 0.11 | complete remission |
| DO50038 | 55 | female | alive | 0.83 | complete remission |
| DO50040 | 47 | female | alive | 5.45 | complete remission |
| DO50041 | 47 | female | alive | 4.52 | progression |
| DO50043 | 76 | female | alive | 6.9 | complete remission |
| DO50045 | 51 | female | alive | 4.58 | complete remission |
| DO50047 | 72 | female | alive | 2.28 | complete remission |
| DO50048 | 45 | female | alive | 0.25 | NA |
| DO50049 | 46 | female | alive | 0.3 | NA |
| DO5005 | 56 | female | alive | 1.7 | complete remission |
| DO50050 | 50 | female | alive | 0.27 | complete remission |
| DO50052 | 49 | female | alive | 0.27 | NA |
| DO50054 | 77 | female | alive | 0.22 | NA |
| DO50056 | 50 | female | alive | 0.32 | complete remission |
| DO50058 | 67 | female | alive | 0.35 | complete remission |
| DO50060 | 55 | female | alive | 0.38 | progression |
| DO50062 | 61 | female | alive | 0.38 | complete remission |
| DO50064 | 49 | female | alive | 0.47 | complete remission |
| DO50066 | 70 | female | alive | 0.27 | NA |
| DO50068 | 61 | female | alive | 0.52 | NA |
| DO50070 | 69 | female | alive | 0.61 | NA |
| DO50072 | 66 | female | alive | 0.44 | complete remission |
| DO5012 | 52 | female | alive | 1.92 | complete remission |
| DO5018 | 46 | female | alive | 0.48 | complete remission |
| DO5025 | 62 | female | alive | 2.13 | complete remission |
| DO5032 | 55 | female | alive | 0.88 | complete remission |
| DO5039 | 44 | female | NA | NA | complete remission |
| DO5046 | 61 | female | alive | 1.32 | complete remission |
| DO5053 | 49 | female | alive | 12.46 | complete remission |
| DO5060 | 59 | female | alive | 0.66 | complete remission |
| DO5067 | 47 | female | deceased | 6.98 | NA |
| DO5074 | 77 | female | deceased | 2.58 | NA |
| DO5081 | 57 | female | alive | 0.09 | complete remission |
| DO5088 | 61 | female | alive | 2.56 | complete remission |
| DO5095 | 62 | female | alive | 0.75 | complete remission |
| DO5102 | 55 | female | deceased | 6.9 | NA |
| DO5109 | 52 | female | alive | 2.44 | complete remission |
| DO5116 | 44 | female | alive | 3.59 | complete remission |
| DO51206 | 43 | female | alive | 0.14 | complete remission |
| DO51207 | 40 | female | alive | 3.72 | NA |
| DO51208 | 69 | female | alive | 1.58 | complete remission |
| DO51209 | 90 | female | alive | 0.77 | complete remission |
| DO51210 | 52 | female | alive | 0.34 | progression |
| DO51211 | 73 | female | alive | 0.73 | complete remission |
| DO51212 | 90 | female | alive | 0.96 | complete remission |
| DO51213 | 43 | female | alive | 1.31 | complete remission |
| DO51214 | 49 | female | alive | 0.63 | complete remission |
| DO51215 | 54 | female | NA | NA | progression |
| DO51216 | 35 | female | alive | 0.01 | progression |
| DO51217 | 30 | female | alive | 0.02 | progression |
| DO51218 | 29 | female | alive | 0.32 | complete remission |
| DO51219 | 64 | female | alive | 0.58 | complete remission |
| DO51220 | 29 | female | alive | 0.72 | complete remission |
| DO51221 | 63 | female | alive | 0.88 | complete remission |
| DO51222 | 65 | female | alive | 0.66 | complete remission |
| DO51223 | 67 | female | alive | 0.46 | complete remission |
| DO51224 | 82 | female | alive | 0.71 | complete remission |
| DO51225 | 47 | female | alive | 0.6 | complete remission |
| DO51226 | 51 | female | alive | 0.57 | complete remission |
| DO51227 | 64 | female | alive | 0.33 | complete remission |
| DO51228 | 46 | female | alive | 0.8 | complete remission |
| DO51229 | 68 | female | alive | 0.76 | complete remission |
| DO5123 | 58 | female | alive | 0.49 | complete remission |
| DO51230 | 61 | female | alive | 8.33 | complete remission |
| DO51231 | 46 | female | alive | 7.67 | complete remission |
| DO5130 | 71 | female | alive | 0.21 | complete remission |
| DO5137 | 52 | female | alive | 0.52 | complete remission |
| DO5144 | 63 | female | alive | 0.75 | complete remission |
| DO5151 | 65 | female | alive | 2.94 | NA |
| DO5158 | 65 | female | alive | 0.91 | complete remission |
| DO5165 | 69 | female | alive | 1.5 | complete remission |
| DO5172 | 43 | female | alive | 1.37 | complete remission |
| DO5179 | 62 | female | alive | 4.42 | complete remission |
| DO5186 | 39 | female | alive | 2.26 | complete remission |
| DO5193 | 39 | female | alive | 3.86 | NA |
| DO5200 | 72 | female | deceased | 4.28 | NA |
| DO5207 | 45 | female | alive | 2.96 | complete remission |
| DO5214 | 34 | female | deceased | 6.0 | NA |
| DO5221 | 69 | female | deceased | 4.58 | NA |
| DO5228 | 70 | female | alive | 0.03 | complete remission |
| DO5235 | 74 | female | alive | 1.26 | complete remission |
| DO5242 | 71 | female | alive | 0.2 | complete remission |
| DO5249 | 34 | female | alive | 3.69 | complete remission |
| DO5256 | 70 | female | alive | 11.19 | complete remission |
| DO5263 | 54 | female | alive | 0.06 | complete remission |
| DO5270 | 58 | female | alive | 0.51 | complete remission |
| DO5277 | 64 | female | alive | 4.24 | complete remission |
| DO5284 | 58 | female | alive | 0.03 | complete remission |
| DO5291 | 66 | female | alive | 0.83 | complete remission |
| DO5298 | 70 | female | alive | 2.58 | complete remission |
| DO5305 | 66 | female | alive | 0.31 | complete remission |
| DO5312 | 45 | female | alive | 0.44 | complete remission |
| DO5319 | 48 | female | alive | 0.19 | complete remission |
| DO5326 | 61 | female | alive | 7.88 | complete remission |
| DO5333 | 56 | female | alive | 3.91 | complete remission |
| DO5340 | 56 | female | deceased | 1.98 | NA |
| DO5347 | 37 | female | alive | 1.36 | complete remission |
| DO5354 | 67 | female | alive | 0.06 | complete remission |
| DO5361 | 48 | female | alive | 3.53 | progression |
| DO5368 | 81 | female | alive | 1.67 | complete remission |
| DO5375 | 39 | female | alive | 7.45 | complete remission |
| DO5382 | 54 | female | alive | 0.02 | complete remission |
| DO5389 | 41 | female | alive | 3.21 | complete remission |
| DO5396 | 59 | female | alive | 3.07 | complete remission |
| DO5403 | 72 | female | alive | 0.18 | NA |
| DO5410 | 43 | female | alive | 3.4 | complete remission |
| DO5417 | 62 | female | alive | 7.17 | NA |
| DO5424 | 52 | female | alive | 1.31 | complete remission |
| DO5431 | 63 | female | alive | 1.08 | complete remission |
| DO5438 | 66 | female | NA | NA | complete remission |
| DO5445 | 46 | female | alive | 4.24 | NA |
| DO5452 | 56 | female | deceased | 4.63 | NA |
| DO5459 | 68 | female | deceased | 7.66 | NA |
| DO5465 | 75 | female | alive | 0.58 | complete remission |
| DO5472 | 66 | female | alive | 1.04 | complete remission |
| DO5479 | 50 | female | alive | 3.15 | complete remission |
| DO5486 | 64 | female | alive | 4.3 | complete remission |
| DO5493 | 44 | female | alive | 0.93 | complete remission |
| DO5500 | 80 | female | alive | 0.69 | complete remission |
| DO5507 | 43 | female | NA | NA | complete remission |
| DO5514 | 40 | female | alive | 0.31 | NA |
| DO5521 | 83 | female | NA | NA | progression |
| DO5528 | 77 | female | alive | 1.49 | complete remission |
| DO5535 | 68 | female | deceased | 11.68 | NA |
| DO5542 | 64 | female | alive | 1.14 | complete remission |
| DO5549 | 58 | female | alive | 0.03 | complete remission |
| DO5556 | 34 | female | alive | 6.88 | complete remission |
| DO5563 | 66 | female | NA | NA | complete remission |
| DO5569 | 51 | female | alive | 1.09 | complete remission |
| DO5576 | 59 | female | alive | 0.73 | complete remission |
| DO5583 | 79 | female | alive | 0.15 | complete remission |
| DO5590 | 77 | female | deceased | 10.84 | NA |
| DO5597 | 34 | female | alive | 0.75 | complete remission |
| DO5604 | 78 | female | alive | 0.46 | complete remission |
| DO5611 | 76 | female | alive | 0.96 | complete remission |
| DO5618 | 56 | female | alive | 3.8 | complete remission |
| DO5625 | 29 | female | alive | 0.02 | NA |
| DO5626 | 40 | female | alive | 5.0 | complete remission |
| DO5633 | 54 | female | alive | 7.05 | progression |
| DO5640 | 61 | female | alive | 0.86 | complete remission |
| DO5647 | 51 | female | alive | 0.58 | NA |
| DO5654 | 59 | female | NA | NA | complete remission |
| DO5661 | 78 | female | deceased | 9.51 | NA |
| DO5668 | 69 | female | alive | 0.8 | complete remission |
| DO5675 | 63 | female | alive | 0.0 | complete remission |
| DO5682 | 40 | female | deceased | 2.06 | NA |
| DO5689 | 64 | female | deceased | 10.79 | NA |
| DO5696 | 62 | female | alive | 5.34 | complete remission |
| DO5703 | 43 | female | alive | 1.54 | complete remission |
| DO5710 | 63 | female | alive | 1.51 | complete remission |
| DO5717 | 81 | female | alive | 0.49 | complete remission |
| DO5724 | 51 | female | alive | 3.76 | NA |
| DO5731 | 64 | female | alive | 0.34 | NA |
| DO5738 | 70 | female | deceased | 0.47 | NA |
| DO5745 | 58 | female | alive | 1.95 | complete remission |
| DO5752 | 79 | female | alive | 0.57 | complete remission |
| DO5759 | 43 | female | alive | 5.47 | complete remission |
| DO5766 | 56 | female | alive | 0.66 | complete remission |
| DO5773 | 88 | female | deceased | 10.23 | NA |
| DO5780 | 75 | female | NA | NA | complete remission |
| DO5787 | 62 | female | alive | 0.16 | complete remission |
| DO5794 | 88 | female | deceased | 3.14 | NA |
| DO5801 | 78 | female | alive | 1.7 | complete remission |
| DO5808 | 59 | female | alive | 4.5 | progression |
| DO5815 | 66 | female | alive | 0.08 | complete remission |
| DO5822 | 50 | female | deceased | 2.22 | NA |
| DO5829 | 70 | female | alive | 0.71 | complete remission |
| DO5836 | 47 | female | alive | 0.07 | complete remission |
| DO5843 | 67 | female | alive | 2.05 | complete remission |
| DO5850 | 41 | female | alive | 0.01 | complete remission |
| DO5857 | 73 | female | alive | 0.46 | NA |
| DO5863 | 62 | female | deceased | 0.99 | NA |
| DO5870 | 62 | female | alive | 1.02 | complete remission |
| DO5877 | 54 | female | alive | 1.42 | complete remission |
| DO5884 | 84 | female | alive | 0.12 | NA |
| DO5891 | 54 | female | alive | 2.27 | complete remission |
| DO5898 | 37 | female | NA | NA | complete remission |
| DO5905 | 47 | female | alive | 1.08 | complete remission |
| DO5912 | 61 | female | alive | 0.53 | complete remission |
| DO5920 | 49 | female | alive | 1.04 | NA |
| DO5928 | 58 | female | alive | 1.5 | complete remission |
| DO5936 | 57 | female | alive | 0.08 | complete remission |
| DO5944 | 46 | female | NA | NA | complete remission |
| DO5952 | 40 | female | alive | 1.06 | complete remission |
| DO5960 | 53 | female | alive | 0.37 | complete remission |
| DO5968 | 65 | female | alive | 1.67 | complete remission |
| DO5976 | 77 | female | alive | 1.0 | complete remission |
| DO5984 | 57 | female | alive | 0.94 | NA |
| DO5992 | 63 | female | alive | 0.62 | NA |
| DO6000 | 39 | female | alive | 0.65 | complete remission |
| DO6008 | 34 | female | alive | 4.26 | complete remission |
| DO6016 | 78 | female | alive | 0.89 | complete remission |
| DO6024 | 76 | female | alive | 3.33 | complete remission |
| DO6032 | 80 | female | alive | 3.33 | complete remission |
| DO6040 | 79 | female | alive | 0.67 | complete remission |
| DO6048 | 62 | female | alive | 0.2 | complete remission |
| DO6056 | 59 | female | alive | 0.49 | complete remission |
| DO6064 | 83 | female | alive | 3.17 | complete remission |
| DO6072 | 45 | female | alive | 2.08 | complete remission |
| DO6080 | 46 | female | alive | 3.67 | complete remission |
| DO6088 | 68 | female | alive | 2.58 | complete remission |
| DO6096 | 71 | female | alive | 1.42 | complete remission |
| DO6104 | 66 | female | alive | 3.7 | complete remission |
| DO6112 | 73 | female | NA | NA | complete remission |
| DO6120 | 74 | female | alive | 2.29 | complete remission |
| DO6128 | 44 | female | deceased | 4.62 | NA |
| DO6136 | 73 | female | deceased | 0.43 | NA |
| DO6144 | 59 | female | alive | 0.62 | complete remission |
| DO6152 | 59 | female | alive | 1.5 | complete remission |
| DO6160 | 48 | female | alive | 1.62 | complete remission |
| DO6168 | 62 | female | alive | 0.25 | complete remission |
| DO6177 | 48 | female | alive | 2.96 | complete remission |
| DO6186 | 45 | female | alive | 0.03 | complete remission |
| DO6195 | 45 | female | NA | NA | complete remission |
| DO6204 | 79 | female | alive | 0.26 | complete remission |
| DO6213 | 86 | female | alive | 0.21 | complete remission |
| DO6222 | 52 | female | alive | 4.01 | NA |
| DO6231 | 66 | female | alive | 0.51 | complete remission |
| DO6240 | 65 | female | alive | 1.0 | complete remission |